"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtAU_IN","meanArtPer_AU_IN_FIRST","meanArtPer_AU_IN_LAST","meanArtPer_AU_IN_CORR","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","InternCoauthorship","AffCoauthorship","meanCitationTrend","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"IRCCS_SANMARTINO",2000,61,8.81967213114754,3.24590163934426,0.308080808080808,0.540983606557377,0.262295081967213,0.0983606557377049,0.311475409836066,4,29,9,7,11,0.48,0.15,0.11,0.18,38.23,0.843341798550548,0.229508196721311,0.688524590163934,NA,0.415635067527801,0.384971693257849,0.406015037593985,0.333333333333333,"ANDREA BACIGALUPO;FRANCESCO FRASSONI;ANGELO MICHELE CARELLA;O FIGARI;ANNA MARIA RAIOLA;STEFANIA BREGANTE;FRANCESCA GUALANDI;TERESA LAMPARELLI;M. VALBONESI;GIOVANNA PIAGGIO;ENRICA LERMA;C TROISE;GINO SANTINI;ARSENIO CORRADO NEGRINI;SUSANNA VOLTOLINI;ANNA DEJANA;GIOVANNI BERISSO;MARINA PODESTÀ;CÁRMINO ANTÔNIO DE SOUZA;NICOLA MORDINI","8;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","ALBERTO M. MARMONT;ANGELO MICHELE CARELLA;A CARELLA;ANDREA BACIGALUPO;FRANCESCO FRASSONI;PAOLO TANGANELLI;ALBERTO ZANELLA;GIOVANNI REGESTA;A MARMONT;C TROISE;M. VALBONESI;ARSENIO CORRADO NEGRINI;SUSANNA VOLTOLINI;O FIGARI;GIOVANNA PIAGGIO;SHIMON SLAVIN;DONATELLA BIGNARDI;GINO SANTINI;CÁRMINO ANTÔNIO DE SOUZA;MAURIZIO RAITERI","2.04;1.55;1;0.6;0.55;0.5;0.5;0.5;0.5;0.45;0.44;0.4;0.4;0.39;0.39;0.38;0.34;0.34;0.34;0.33","ANDREA BACIGALUPO;FRANCESCO FRASSONI;ANGELO MICHELE CARELLA;O FIGARI;ANNA MARIA RAIOLA;STEFANIA BREGANTE;FRANCESCA GUALANDI;TERESA LAMPARELLI;M. VALBONESI;GIOVANNA PIAGGIO;ENRICA LERMA;C TROISE;GINO SANTINI;ARSENIO CORRADO NEGRINI;SUSANNA VOLTOLINI;ANNA DEJANA;GIOVANNI BERISSO;MARINA PODESTÀ;CÁRMINO ANTÔNIO DE SOUZA;NICOLA MORDINI","8;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","ALBERTO M. MARMONT;ANGELO MICHELE CARELLA;A CARELLA;ANDREA BACIGALUPO;FRANCESCO FRASSONI;GIOVANNI REGESTA;A MARMONT;C TROISE;M. VALBONESI;ARSENIO CORRADO NEGRINI;SUSANNA VOLTOLINI;O FIGARI;GIOVANNA PIAGGIO;GINO SANTINI;CÁRMINO ANTÔNIO DE SOUZA;E TOGNONI;FRANCA MOCCIA;MARINA PODESTÀ;ANNA MARIA RAIOLA;STEFANIA BREGANTE","2.04;1.55;1;0.6;0.55;0.5;0.5;0.45;0.44;0.4;0.4;0.39;0.39;0.34;0.34;0.33;0.33;0.32;0.31;0.31","ANDREA BACIGALUPO;ALOÏS GRATWOHL;WILLIAM ARCESE;TAPANI RUUTU;THÉO DE WITTE;FRANCESCO FRASSONI;PIETRO LEONI;BENEDETTO BRUNO;A. FERSTER;A. GABBAS;ANNA LOCASCIULLI;CARLO DUFOUR;E. DI BONA;FRANCESCO LOCATELLI;G BROCCIA;GABRIELE TESTI;M CAROTENUTO;P COSER;PAOLA SARACCO;TIZIANO BARBUI","910;424;375;363;363;344;325;287;267;267;267;267;267;267;267;267;267;267;267;267","ANDREA BACIGALUPO;BENEDETTO BRUNO;A. FERSTER;A. GABBAS;ANNA LOCASCIULLI;CARLO DUFOUR;E. DI BONA;FRANCESCO LOCATELLI;G BROCCIA;GABRIELE TESTI;M CAROTENUTO;P COSER;PAOLA SARACCO;PIETRO LEONI;TIZIANO BARBUI;WILLIAM ARCESE;FRANCESCO FRASSONI;ALBERTO M. MARMONT;MAURO TRUINI;MARINA PODESTÀ","848;287;267;267;267;267;267;267;267;267;267;267;267;267;267;267;231;212;148;134","ANDREA BACIGALUPO;ANGELO MICHELE CARELLA;FRANCESCO FRASSONI;M. VALBONESI;O FIGARI;GIOVANNA PIAGGIO;MARINA PODESTÀ;ALBERTO M. MARMONT;ANNA DEJANA;ANNA MARIA RAIOLA;ENRICA LERMA;SUSANNA VOLTOLINI;ANNA PITTO;ARSENIO CORRADO NEGRINI;BENEDETTO BRUNO;C TROISE;C. PARODI;ENZO ANDORNO;F. VASSALLO;FRANCESCA GUALANDI","8;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY;BUSINESS;COMPUTER SCIENCE;GEOGRAPHY;HISTORY;SOCIOLOGY","54;29;10;3;2;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;SURGERY;GENETICS;GASTROENTEROLOGY;BIOCHEMISTRY;ONCOLOGY;PATHOLOGY;PHARMACOLOGY;ENDOCRINOLOGY;BOTANY;DERMATOLOGY;MOLECULAR BIOLOGY;PEDIATRICS;ANESTHESIA;CARDIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;ORGANIC CHEMISTRY;RADIOLOGY","42;25;24;17;16;13;8;8;6;5;4;4;4;4;3;3;3;3;3;3","TRANSPLANTATION;CHEMOTHERAPY;LEUKEMIA;BONE MARROW;STEM CELL;ANTIBODY;DISEASE;GENE;METHOTREXATE;CANCER;MYELOID;POLLEN;RECEPTOR;ANEMIA;ANTIGEN;CALCIUM;CELL CULTURE;ENZYME;IN VITRO;PLATELET;POPULATION","18;11;11;10;10;7;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3","CYCLOPHOSPHAMIDE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PROGENITOR CELL;APLASTIC ANEMIA;CD34;CHRONIC LYMPHOCYTIC LEUKEMIA;HAEMATOPOIESIS;ALLERGEN;AMIFOSTINE;ANTAGONIST;APHERESIS;BREAKPOINT CLUSTER REGION;BREAST CANCER;CHROMOSOMAL TRANSLOCATION;CHRONIC MYELOGENOUS LEUKEMIA;COOMBS TEST;GESTATION;GRAFT-VERSUS-HOST DISEASE;GRANULOCYTE COLONY-STIMULATING FACTOR;LYMPHOBLASTIC LEUKEMIA;MINIMAL RESIDUAL DISEASE;MUCOSITIS;PLACEBO;T CELL;TRANSFECTION;TYROSINE KINASE;VIRAL DISEASE","5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BUSULFAN;ABL;ACUTE LYMPHOCYTIC LEUKEMIA;FLUDARABINE;PHILADELPHIA CHROMOSOME;RECEPTOR ANTAGONIST;TOTAL BODY IRRADIATION;5-HT RECEPTOR;ABSOLUTE NEUTROPHIL COUNT;ANAPLASTIC LYMPHOMA KINASE;ANTIGEN PRESENTATION;ANTIRETROVIRAL THERAPY;DEBULKING;DRUGS IN PREGNANCY;GANCICLOVIR;GENE PRODUCT;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HERPESVIRIDAE;LARGE CELL;LEUKAPHERESIS;LYMPHEDEMA;MHC CLASS II;NASAL PROVOCATION TEST;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER;PRAZOSIN;PURINE ANALOGUE;REED–STERNBERG CELL;RETINOID;SIDA;TAMOXIFEN;TERATOLOGY;THIOTEPA;URINE CYTOLOGY;VERATRIDINE;WINDOW PERIOD","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MIDDLE AGED;MALE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;;BONE MARROW TRANSPLANTATION;ADOLESCENT;HEMATOPOIETIC STEM CELLS;ANTINEOPLASTIC AGENTS;CYCLOPHOSPHAMIDE;AGED;CELL DIVISION;RECOMBINANT PROTEINS;GRAFT VS HOST DISEASE;HEMATOLOGIC NEOPLASMS;IMMUNOSUPPRESSIVE AGENTS;TRANSPLANTATION CONDITIONING;TRANSPLANTATION, HOMOLOGOUS","47;26;25;23;22;15;14;14;13;11;10;10;9;9;9;8;8;8;8;8","HEMATOPOIETIC STEM CELL BIOLOGY;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ACUTE MYELOID LEUKEMIA;DISEASES RELATED TO BLOOD GROUP VARIANTS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CEREBROSPINAL FLUID DISORDERS AND HEMATOMAS;DIAGNOSIS AND MANAGEMENT OF ABDOMINAL TUBERCULOSIS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSTIC APPROACH TO FEVER OF UNKNOWN ORIGIN;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;EVOLUTION AND USAGE OF ANATOMICAL NOMENCLATURE;GENETIC DISORDERS CAUSING TISSUE MINERALIZATION ABNORMALITIES;GLOBAL BURDEN OF ANTIMICROBIAL RESISTANCE;HEPATITIS C INFECTION AND TREATMENT","8;5;4;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","HEMATOPOIETIC CELL TRANSPLANTATION;POLLEN ALLERGY;TREATMENT;APLASTIC ANEMIA;ABL;ACUTE LYMPHOCYTIC LEUKEMIA;AMIFOSTINE;BREAKPOINT CLUSTER REGION;CHRONIC MYELOGENOUS LEUKEMIA;COOMBS TEST;GROUP B;HEMATOLOGIC MALIGNANCIES;HEMATOPOIETIC PROGENITOR CELLS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOSUPPRESSION;INTRATHECAL;LIVER TRANSPLANTATION;MINIMAL RESIDUAL DISEASE;MOLECULAR RESPONSE;MUCOSITIS","4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MARROW TRANSPLANTATION;BONE MARROW;ACUTE MYELOID;CHRONIC LYMPHOCYTIC;STEM CELL;ALLOGENEIC BONE;B-CELL CHRONIC;BCR-ABL POSITIVE;BLOOD CELL;CELL TRANSPLANTATION;CHRONIC MYELOGENOUS;COLONY-STIMULATING FACTOR;CYTOGENETIC RESPONSE;HUMAN NEOCORTEX;INTRATHECAL METHOTREXATE;LEUKEMIA CORRELATES;LEUKEMIA RESOLUTION;LEUKEMIC MENINGITIS;LYMPHOCYTIC LEUKEMIA;MYELOGENOUS LEUKEMIA;MYELOID LEUKAEMIA;PERIPHERAL BLOOD;POSITIVE CELLS;TRANSPLANTATION EBMT;UNDERGOING ALLOGENEIC;ABNORMAL ARACHIDONIC;ABO INCOMPATIBLE;ACID CONTENT;ACNE ROSACEA;ACTIVE ANTIRETROVIRAL","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","STEM CELL;CELL TRANSPLANTATION;ARTERIAL HYPERTENSION;AUTOLOGOUS STEM;ARACHIDONIC ACID;CLASS II;ACID CONTENT;BCR-ABLABL RATIO;BLOOD CELL;MARROW TRANSPLANTATION;PROGENITOR CELLS;RED BLOOD;STEM CELLS;BONE MARROW;CYTOGENETIC RESPONSE;HUMAN NEOCORTEX;LT GY;MGKG CYA;MONTHS RANGE;PATIENTS RECEIVED;PERIPHERAL BLOOD;RECEPTOR ANTAGONIST;TAT MUTANTS;TETANUS TOXIN;UNRELATED DONORS;ALLERGIC RHINITIS;ALLOGENEIC BONE;BETAAM CELLS;BLOOD PROGENITOR;BP MONITORING","16;9;8;8;7;7;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3",3,0.05,3,5,0,0,0,0,7,0,1,5,0,0,0,0,0,0,0,0,0,0,0,22,22,1,1,1,0,0,0,0,0,0,0,0,0,2,0,0,0,2,2.02,2,0,1,2,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CANCEDDA RANIERI;DOZIN BEATRICE","2;2","CONSORZIO PER LA GESTIONE DEL CENTRO DI BIOTECNOLOGIA AVANZATA;INDIVIDUAL;ISTITUTO NAZ PER LA RICERCA SUL CANCRO;ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO","1;1;1;1","40 ENGINEERING;32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;4003 BIOMEDICAL ENGINEERING","3;1;1;1","PEDIATRIC;REGENERATIVE MEDICINE;STEM CELL RESEARCH","1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.2 CELLULAR AND GENE THERAPIES","1;1","A61K35/12;C12N5/00;C12N5/02;C12N5/077;C12N5/0775;C12R1/91","2;2;2;2;2;2","A61K35/12;C12N2500/25;C12N2500/36;C12N2500/38;C12N2500/90;C12N2501/105;C12N2501/11;C12N2501/115;C12N2501/125;C12N2501/135","2;2;2;2;2;2;2;2;2;2",4,0,651.25,3.17,0,0,47.5,0,0,1,0,3,0,0,0,0,4,0,0,0,0,0,0,0,3,1,0,4,0,0,0,0,0,0,0,0,0,"Belgium","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY","4;4;2","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;LUNG CANCER;ORPHAN DRUG;PATIENT SAFETY;RARE DISEASES;AGING;BREAST CANCER;COMPARATIVE EFFECTIVENESS RESEARCH","4;4;3;2;2;2;2;2;1;1;1","CANCER","4","6.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","4;1;1","LUNG CANCER;BREAST CANCER;MELANOMA","2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","4;2;1;1",2,2066101.5,269233.38,4.5,8,5,1,24,118960.883333333,0.512773596587001,"OSPEDALE POLICLINICO SAN MARTINO;AARHUS UNIVERSITY HOSPITAL;BABRAHAM INSTITUTE;DANISH TECHNOLOGICAL INSTITUTE;DÉLÉGATION PARIS 11;FINCERAMICA (ITALY);GERMAN INSTITUTE OF HUMAN NUTRITION;MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH;NATIONAL POLYTECHNIC INSTITUTE OF TOULOUSE;NOVARTIS (SWITZERLAND);OTTO-VON-GUERICKE UNIVERSITY MAGDEBURG;QUEEN MARY UNIVERSITY OF LONDON;UNIVERSITY OF CRETE;UNIVERSITY OF PISA;UNIVERSITÄT HAMBURG","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);FP5-GROWTH - PROGRAMME FOR RESEARCH TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""COMPETITIVE AND SUSTAINABLE GROWTH 1998-2002"" (PROGRAMME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME)","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","2;1;1;1;1","BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;BRAIN DISORDERS;DENTAL/ORAL AND CRANIOFACIAL DISEASE;MENTAL HEALTH;NEUROSCIENCES;REGENERATIVE MEDICINE;TRANSPLANTATION","1;1;1;1;1;1;1;1;1","MENTAL HEALTH;MUSCULOSKELETAL;NEUROLOGICAL","1;1;1","5.2 CELLULAR AND GENE THERAPIES;5.3 MEDICAL DEVICES","1;1",NA,NA,NA,NA,"A04 PSYCHOLOGY, PSYCHIATRY AND NEUROSCIENCE;B12 ENGINEERING","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMARTINO",2001,78,7.48717948717949,3.47435897435897,0.287822878228782,0.666666666666667,0.41025641025641,0.0769230769230769,0.230769230769231,4,26,10,22,17,0.33,0.13,0.28,0.22,39.32,0.860547658814772,0.17948717948718,0.551282051282051,NA,0.477456555257084,0.389561975768872,0.463912630579297,0.133333333333333,"RENATO BRUNI;M. VALBONESI;FRANCESCO FRASSONI;P. CARLIER;G. FLORIO;ANDREA BACIGALUPO;M.C. DE LUIGI;IVANA PIERRI;TERESA LAMPARELLI;LETIZIA CANEPA;UMBERTO VALENTE;B. SANFILIPPO;MARINO CLAVIO;PAOLA STURA;ALESSANDRA BÒ;GIUSEPPE SANGUINETI;GINO SANTINI;ANNA MARIA RAIOLA;G. LERCARI;STEFANIA BREGANTE","12;12;8;6;6;6;5;4;4;4;4;4;4;4;4;3;3;3;3;3","M. VALBONESI;RENATO BRUNI;A. PRIMAVERA;G. FLORIO;A GENZONE;P. CARLIER;GIANNI TESTINO;CHIERCHIA SL;SERGIO CAPURRO;SERGIO CHIERCHIA;PAOLO FIALLO;FRANCESCO FRASSONI;M.C. DE LUIGI;B. SANFILIPPO;PAOLA STURA;ALESSANDRA BÒ;ANDREA BACIGALUPO;UMBERTO VALENTE;M CORNAGGIA;MARCO GUAZZI","2.49;2.47;1.33;1.23;1.1;1.08;1.03;1;1;1;1;0.77;0.7;0.6;0.55;0.55;0.53;0.51;0.5;0.5","RENATO BRUNI;M. VALBONESI;FRANCESCO FRASSONI;P. CARLIER;G. FLORIO;ANDREA BACIGALUPO;M.C. DE LUIGI;IVANA PIERRI;TERESA LAMPARELLI;UMBERTO VALENTE;B. SANFILIPPO;MARINO CLAVIO;PAOLA STURA;ALESSANDRA BÒ;GINO SANTINI;ANNA MARIA RAIOLA;G. LERCARI;STEFANIA BREGANTE;FRANCESCA GUALANDI;MANOLO BEELKE","12;12;8;6;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3","M. VALBONESI;RENATO BRUNI;A. PRIMAVERA;G. FLORIO;A GENZONE;P. CARLIER;GIANNI TESTINO;CHIERCHIA SL;SERGIO CAPURRO;SERGIO CHIERCHIA;PAOLO FIALLO;FRANCESCO FRASSONI;M.C. DE LUIGI;B. SANFILIPPO;PAOLA STURA;ALESSANDRA BÒ;ANDREA BACIGALUPO;UMBERTO VALENTE;C VECCHIO;G. LERCARI","2.49;2.47;1.33;1.23;1.1;1.08;1.03;1;1;1;1;0.77;0.7;0.6;0.55;0.55;0.53;0.51;0.5;0.49","ANDREA BACIGALUPO;FRANCESCO FRASSONI;TERESA LAMPARELLI;MARIA TERESA VAN LINT;ALBERTO BOSI;BARBARA BRUNO;M. BARBANTI;NICOLETTA SACCHI;P ALESSANDRINO;PAOLO BRUZZI;PAOLO DI BARTOLOMEO;ROSA ONETO;STEFANO GUIDI;MT VAN LINT;ALBERT D. M. E. OSTERHAUS;ANTON M. VAN LOON;BOB LÖWENBERG;BRONNO VAN DER HOLT;ELLEN MEIJER;HUBERT G.M. NIESTERS","1212;825;707;656;511;511;511;511;511;511;511;511;511;453;371;371;371;371;371;371","ANDREA BACIGALUPO;FRANCESCO FRASSONI;TERESA LAMPARELLI;MARIA TERESA VAN LINT;ALBERTO BOSI;BARBARA BRUNO;M. BARBANTI;NICOLETTA SACCHI;P ALESSANDRINO;PAOLO BRUZZI;PAOLO DI BARTOLOMEO;ROSA ONETO;STEFANO GUIDI;MT VAN LINT;ALBERT D. M. E. OSTERHAUS;ANTON M. VAN LOON;BOB LÖWENBERG;BRONNO VAN DER HOLT;ELLEN MEIJER;HUBERT G.M. NIESTERS","1172;825;707;656;511;511;511;511;511;511;511;511;511;453;371;371;371;371;371;371","RENATO BRUNI;M. VALBONESI;ANDREA BACIGALUPO;FRANCESCO FRASSONI;G. FLORIO;P. CARLIER;M.C. DE LUIGI;ALESSANDRA BÒ;B. SANFILIPPO;MT VAN LINT;PAOLA STURA;TERESA LAMPARELLI;ANNA MARIA RAIOLA;FRANCESCA GUALANDI;G. LERCARI;STEFANIA BREGANTE;ALESSANDRA DORCARATTO;ALIDA DOMINIETTO;ANNA PITTO;ANTONIO DI BIAGIO","12;12;9;8;6;6;5;4;4;4;4;4;3;3;3;3;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;PHILOSOPHY;MATHEMATICS;PSYCHOLOGY;ECONOMICS;MATERIALS SCIENCE;SOCIOLOGY;ART;BUSINESS;ENGINEERING;GEOLOGY","72;25;10;9;4;4;3;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;GENETICS;PATHOLOGY;RADIOLOGY;CARDIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;ONCOLOGY;OPTICS;UROLOGY;CELL BIOLOGY;CHROMATOGRAPHY;DERMATOLOGY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;PALEONTOLOGY;PSYCHIATRY","51;29;20;18;14;12;8;7;6;6;5;5;5;4;4;4;4;4;4;4","TRANSPLANTATION;CHEMOTHERAPY;BONE MARROW;DISEASE;PLATELET;STEM CELL;ANTIGEN;CANCER;POPULATION;ANTIBODY;GENE;LYMPHOMA;RADIATION THERAPY;RECEPTOR;ALTERNATIVE MEDICINE;BACTERIA;BLOOD COLLECTION;BLOOD TRANSFUSION;CARCINOMA;INCIDENCE (GEOMETRY);MYELOID;MYOCARDIAL INFARCTION;REGIMEN;STAGE (STRATIGRAPHY);VIRUS;WHOLE BLOOD","15;11;9;9;9;7;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","CYCLOPHOSPHAMIDE;GRAFT-VERSUS-HOST DISEASE;APHERESIS;PROGENITOR CELL;ANGINA;CUMULATIVE INCIDENCE;HAEMATOPOIESIS;HEAD AND NECK CANCER;LIVER TRANSPLANTATION;CHEMORADIOTHERAPY;GROWTH FACTOR;LYMPHOPROLIFERATIVE DISORDERS;MATRIGEL;MINIMAL RESIDUAL DISEASE;MITOXANTRONE;MUTATION;MYELOFIBROSIS;T CELL;VASCULITIS;VIRAL DISEASE","7;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","FLUDARABINE;TOTAL BODY IRRADIATION;ATROPHIC GASTRITIS;BASIC FIBROBLAST GROWTH FACTOR;C2C12;CAGA;CEFTAZIDIME;CFU-GM;CHRONIC GASTRITIS;COLONOSCOPY;CORONARY ARTERY ANEURYSM;FLAVIVIRIDAE;HAPLOTYPE;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HEPACIVIRUS;HERPESVIRIDAE;HIATAL HERNIA;HIBERNATING MYOCARDIUM;HISTOCOMPATIBILITY;IMIPENEM;JOINT INFECTIONS;LIVE DONOR;LIVING DONOR LIVER TRANSPLANTATION;MEGAKARYOCYTE;MEROPENEM;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MINOR HISTOCOMPATIBILITY ANTIGEN;PERIPHERAL BLOOD STEM CELLS;PLATELETPHERESIS;PLEURAL DISEASE;PNEUMOCYSTIS CARINII;PROSTATE-SPECIFIC ANTIGEN;PROSTATECTOMY;RIGHT CORONARY ARTERY;SINGLE-STRAND CONFORMATION POLYMORPHISM;SLEEP SPINDLE;T-CELL RECEPTOR;THIOLASE;THYMOGLOBULIN;VANCOMYCIN;WINDOW PERIOD","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;GRAFT VS HOST DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOSUPPRESSIVE AGENTS;BONE MARROW TRANSPLANTATION;HEMATOLOGIC NEOPLASMS;TRANSPLANTATION, HOMOLOGOUS;ADOLESCENT;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BLOOD COMPONENT REMOVAL;BLOOD SPECIMEN COLLECTION;GRANULOCYTE COLONY-STIMULATING FACTOR;VASCULITIS;VIDARABINE","65;36;35;32;29;17;15;15;14;13;13;13;12;11;11;11;9;9;9;9","HEMATOPOIETIC STEM CELL BIOLOGY;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;EFFECTS OF BLOOD TRANSFUSION IN CLINICAL PRACTICE;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENETIC BASIS OF NEUROPATHIES AND RELATED DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HIP ARTHROPLASTY TECHNIQUES AND MATERIALS;MANAGEMENT AND OPTIMIZATION OF BLOOD SUPPLY CHAIN;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;TUBEROUS SCLEROSIS COMPLEX AND RELATED DISORDERS;ACUTE MYELOID LEUKEMIA;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ANALYSIS OF ELECTROCARDIOGRAM SIGNALS;BODY CONTOURING TECHNIQUES AND PROCEDURES;CHOLINESTERASE INHIBITORS IN NEURODEGENERATIVE DISEASES;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;CLINICAL IMPLICATIONS OF UTERINE ANOMALIES AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE","7;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","GRAFT-VERSUS-HOST DISEASE;HEMATOPOIETIC CELL TRANSPLANTATION;BLOOD COLLECTION;CUMULATIVE INCIDENCE;PLATELET TRANSFUSION;REGIMEN;ANGIOFIBROMA;BLOOD DONATION;BLOOD PRODUCT;CARDIAC METABOLISM;CHARCOT-MARIE-TOOTH DISEASE;CHEMORADIOTHERAPY;CONCOMITANT;CRYOSURGERY;CURETTAGE;DERMABRASION;ELECTROSURGERY;EPILEPSY DETECTION;FECAL INCONTINENCE;FILTRATION (MATHEMATICS)","4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BONE MARROW;CASCADE FILTRATION;CELL TRANSPLANTATION;MARROW TRANSPLANTATION;PERIPHERAL BLOOD;SQUAMOUS CELL;STEM CELL;ACCELERATED RADIOTHERAPY;ADVANCED SQUAMOUS;ALLOGENEIC BONE;ALTERNATING CHEMORADIOTHERAPY;ANTITHYMOCYTE GLOBULIN;BLOOD CELL;CELL CARCINOMA;CELL THERAPY;CHEMORADIOTHERAPY VERSUS;CORONARY ARTERY;DIDECO EXCEL;ECTOPIC SKELETAL;EXCEL PRO;FACTOR SUPPLEMENTED;FECAL INCONTINENCE;FILTRATION CF;FORMATIONA CELL;GRAFT-VERSUS-HOST DISEASE;GRAFTVERSUSHOST DISEASE;GROWTH FACTOR;HELICOBACTER PYLORI;IMPROVES ECTOPIC;LEFT VENTRICULAR","5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CANCER RESEARCH;GENOA ITALYSEARCH;BONE MARROW;INSTITUTE GENOA;NATIONAL CANCER;RESEARCH INSTITUTE;MD ONCOLOGIA;FREE SURVIVAL;PROGRESSION FREE;LOCOREGIONAL CONTROL;ONCOLOGIA RADIOTERAPICA;ACCELERATED RADIOTHERAPY;PATIENTS TREATED;PARTLY ACCELERATED;PERIPHERAL BLOOD;RADIOTERAPICA NATIONAL;COMPLETE RESPONSE;CONVENTIONAL RADIOTHERAPY;PA-RT ARM;ALT ARM;ALTERNATING CHEMORADIOTHERAPY;CD CELLS;CELL CARCINOMA;CELL LINES;GY PATIENTS;LOCALLY ADVANCED;MNC NA;ONCOLOGIA MEDICA;PATIENTS PATIENTS;PATIENTS RECEIVED","20;18;16;16;16;16;14;13;13;12;10;9;9;8;8;8;7;7;7;6;6;6;6;6;6;6;6;6;6;6",9,0.12,6,2,0,0,0,0,2,0,1,2,0,0,22,0,5,0,0,22,0,0,0,50,50,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,9,796.08,7.36,2,0.17,88.33,0,0,1,0,10,0,0,1,0,12,0,0,0,0,0,0,0,7,2,3,11,0,0,1,0,0,0,0,0,0,"Belgium;Italy;United States;Canada","5;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;4403 DEMOGRAPHY","12;9;5;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;ORPHAN DRUG;UROLOGIC DISEASES;AGING;BRAIN CANCER;BRAIN DISORDERS;PROSTATE CANCER;BREAST CANCER;COLO-RECTAL CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;LUNG;LUNG CANCER;NEUROSCIENCES;OVARIAN CANCER;PREVENTION","10;9;8;7;6;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;REPRODUCTIVE HEALTH AND CHILDBIRTH","9;1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","11;4","PROSTATE CANCER;BRAIN TUMOR;BLADDER CANCER;BREAST CANCER;COLON AND RECTAL CANCER;LUNG CANCER;MELANOMA;OVARIAN CANCER","3;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","6;3;2;1",6,1493560,150656.36,3.66666666666667,12,7.16666666666667,1,31.5,365585.329433551,0.213356482659891,"OSPEDALE POLICLINICO SAN MARTINO;NATIONAL INSTITUTE OF PUBLIC HEALTH;VILNIUS UNIVERSITY;ARISTOTLE UNIVERSITY OF THESSALONIKI;ASSOCIATION OF EUROPEAN RENEWABLE ENERGY RESEARCH CENTRES;BAYER (GERMANY);BELGIAN FEDERAL SCIENCE POLICY OFFICE;CAB INTERNATIONAL;CENTRE LÉON BÉRARD;CHARITÉ - UNIVERSITY MEDICINE BERLIN;CORVINUS UNIVERSITY OF BUDAPEST;D'APPOLONIA (ITALY);DÉLÉGATION PARIS 11;ETH ZURICH;FINNISH INSTITUTE OF OCCUPATIONAL HEALTH;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;FRENCH RESEARCH INSTITUTE FOR EXPLOITATION OF THE SEA;GERMAN CANCER RESEARCH CENTER;GHENT UNIVERSITY;HELIOS KLINIKUM ERFURT","6;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","6","COALITION S;EC & ERC - EUROPEAN UNION","6;6","CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);FP5-IST - PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON A ""USER-FRIENDLY INFORMATION SOCIETY, 1998-2002"" (PROGRAMME);ACM - PREPARATORY, ACCOMPANYING AND SUPPORT MEASURES (FUNDING SCHEME);DEM - DEMONSTRATION CONTRACTS (FUNDING SCHEME);FP5-EESD - PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""ENERGY, ENVIRONMENT AND SUSTAINABLE DEVELOPMENT, 1998-2002"" (PROGRAMME);THN - THEMATIC NETWORK CONTRACTS (FUNDING SCHEME)","3;3;2;1;1;1;1","46 INFORMATION AND COMPUTING SCIENCES;31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3103 ECOLOGY;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;41 ENVIRONMENTAL SCIENCES;4104 ENVIRONMENTAL MANAGEMENT;4105 POLLUTION AND CONTAMINATION;4610 LIBRARY AND INFORMATION STUDIES","3;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD);PREVENTION;BIOTECHNOLOGY;CANCER;GENETIC TESTING;GENETICS;HEALTH SERVICES;HUMAN GENOME;RURAL HEALTH","2;2;2;1;1;1;1;1;1;1","CANCER","2","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);5.1 PHARMACEUTICALS","2;1;1;1","NOT SITE-SPECIFIC CANCER;LUNG CANCER","2;1","2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1;1;1","B11 COMPUTER SCIENCE AND INFORMATICS;A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B07 EARTH SYSTEMS AND ENVIRONMENTAL SCIENCES;D34 COMMUNICATION, CULTURAL AND MEDIA STUDIES, LIBRARY AND INFORMATION MANAGEMENT","2;1;1;1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMARTINO",2002,72,7.55555555555556,2.52777777777778,0.395604395604396,0.569444444444444,0.333333333333333,0.125,0.291666666666667,5,33,10,3,21,0.46,0.14,0.04,0.29,96.69,1.75270445038697,0.236111111111111,0.666666666666667,NA,0.434395688765102,0.407075873827792,0.433551198257081,0.251207729468599,"ANDREA BACIGALUPO;FRANCESCO FRASSONI;MARIA TERESA VAN LINT;CARMEN DI GRAZIA;ANNA MARIA RAIOLA;STEFANIA BREGANTE;FRANCESCA GUALANDI;TERESA LAMPARELLI;PAOLO GIORGI ROSSI;G. CARMIGNANI;MARCO GOBBI;ERNESTO PAOLETTI;ALIDA DOMINIETTO;GIUSEPPE SARTORI;RICCARDO GHIO;NORBERT SCHMITZ;ENRICO BALLEARI;G. CORBUCCI;M. MORANDO;GIUSEPPE CANNELLA","15;6;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","ERNESTO PAOLETTI;ANDREA BACIGALUPO;PAOLO GIORGI ROSSI;GIANNI TESTINO;NORBERT SCHMITZ;ALBERTO M. MARMONT;G. CARMIGNANI;FRANCESCO FRASSONI;GIORGIO CIPRANDI;GIUSEPPE CANNELLA;PAOLO TANGANELLI;GIOVANNI REGESTA;MARIA ANGELA TOSCA;FABIO DE IACO;FABIO CAMPODONICO;M CORNAGGIA;DANIELA GADA;GIUSEPPE SARTORI;MARIA TERESA VAN LINT;ADELIA CAMPOSTANO","1.79;1.72;1.38;1.25;1.12;1;0.9;0.83;0.81;0.79;0.75;0.75;0.5;0.5;0.5;0.5;0.5;0.48;0.47;0.45","ANDREA BACIGALUPO;FRANCESCO FRASSONI;MARIA TERESA VAN LINT;CARMEN DI GRAZIA;ANNA MARIA RAIOLA;STEFANIA BREGANTE;FRANCESCA GUALANDI;TERESA LAMPARELLI;PAOLO GIORGI ROSSI;G. CARMIGNANI;MARCO GOBBI;ERNESTO PAOLETTI;ALIDA DOMINIETTO;GIUSEPPE SARTORI;RICCARDO GHIO;NORBERT SCHMITZ;ENRICO BALLEARI;GIUSEPPE CANNELLA;GIORGIO CIPRANDI;MARINO CLAVIO","15;6;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","ERNESTO PAOLETTI;ANDREA BACIGALUPO;PAOLO GIORGI ROSSI;GIANNI TESTINO;NORBERT SCHMITZ;ALBERTO M. MARMONT;G. CARMIGNANI;FRANCESCO FRASSONI;GIORGIO CIPRANDI;GIUSEPPE CANNELLA;GIOVANNI REGESTA;MARIA ANGELA TOSCA;GIUSEPPE SARTORI;MARIA TERESA VAN LINT;ADELIA CAMPOSTANO;TERESA LAMPARELLI;MATTEO GIGLIO;A MARMONT;FRANCESCA GUALANDI;CARLO TONCINI","1.79;1.72;1.38;1.25;1.12;1;0.9;0.83;0.81;0.79;0.75;0.5;0.48;0.47;0.45;0.39;0.37;0.37;0.36;0.33","FRANCESCO FRASSONI;ANDREA VELARDI;ANTONELLÁ TOSTI;DANIELA ROGAIA;ELENA URBANI;FRANCO AVERSA;KATIA PERRUCCIO;LOREDANA RUGGERI;MARIA PAOLA MARTELLI;MARUSCA CAPANNI;SABRINA POSATI;WARREN D. SHLOMCHIK;NORBERT SCHMITZ;ANGELO MICHELE CARELLA;ANDREAS LOHRI;ANTHONY H. GOLDSTONE;BEATE PFISTNER;BETTINA KOCH;DIRK HASENCLEVER;F. BOISSEVAIN","3529;3252;3252;3252;3252;3252;3252;3252;3252;3252;3252;3252;1413;1089;1072;1072;1072;1072;1072;1072","FRANCESCO FRASSONI;ANGELO MICHELE CARELLA;ANDREA BACIGALUPO;A MARMONT;MARIA TERESA VAN LINT;FRANCESCA GUALANDI;NORBERT SCHMITZ;GIANLUIGI MANCARDI;S CHIODI;S SPINELLI;CONCETTA VIOLA;F COPELLO;ALIDA DOMINIETTO;ANNA MARIA RAIOLA;CARMEN DI GRAZIA;STEFANIA BREGANTE;TERESA LAMPARELLI;GIOVANNI BERISSO;JEAN LOUIS RAVETTI;ANNA PITTO","3516;1072;743;357;310;286;270;263;212;212;188;188;175;175;175;175;170;120;102;89","ANDREA BACIGALUPO;FRANCESCO FRASSONI;MARIA TERESA VAN LINT;PAOLO GIORGI ROSSI;FRANCESCA GUALANDI;ALIDA DOMINIETTO;ANNA MARIA RAIOLA;CARMEN DI GRAZIA;ERNESTO PAOLETTI;GIANNI TESTINO;STEFANIA BREGANTE;TERESA LAMPARELLI;GIUSEPPE SARTORI;A MARMONT;ADELIA CAMPOSTANO;ANTONIO FERRAZIN;BENEDETTO BRUNO;E BORGO;ENRICO BALLEARI;G. CARMIGNANI","12;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;MATHEMATICS;CHEMISTRY;COMPUTER SCIENCE;MATERIALS SCIENCE;PSYCHOLOGY;ART;ECONOMICS;ENGINEERING;PHILOSOPHY","68;22;13;7;5;4;3;3;1;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;GENETICS;CARDIOLOGY;ONCOLOGY;OPTICS;PATHOLOGY;PSYCHIATRY;BIOCHEMISTRY;PEDIATRICS;ENDOCRINOLOGY;UROLOGY;ANESTHESIA;CANCER RESEARCH;CELL BIOLOGY;COMPOSITE MATERIAL;ENVIRONMENTAL HEALTH;MICROBIOLOGY;MOLECULAR BIOLOGY;OPHTHALMOLOGY;PALEONTOLOGY;QUANTUM MECHANICS;RADIOLOGY","54;26;21;18;14;11;8;8;8;8;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3","TRANSPLANTATION;CHEMOTHERAPY;BONE MARROW;DISEASE;STEM CELL;INCIDENCE (GEOMETRY);LEUKEMIA;ATRIAL FIBRILLATION;BLOOD PRESSURE;CANCER;RECEPTOR;REGIMEN;ASTHMA;COMPRESSION (PHYSICS);CONCOMITANT;HEART FAILURE;HEMODIALYSIS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;LUNG;OBESITY;POPULATION;PROSPECTIVE COHORT STUDY","18;11;10;10;9;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","HEMATOPOIETIC STEM CELL TRANSPLANTATION;CYCLOPHOSPHAMIDE;GRAFT-VERSUS-HOST DISEASE;HAEMATOPOIESIS;ATRIAL FLUTTER;LEFT VENTRICULAR HYPERTROPHY;SINUS RHYTHM;T CELL;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BINGE EATING;BULIMIA NERVOSA;CYTARABINE;ETOPOSIDE;GRANULOCYTE COLONY-STIMULATING FACTOR;MELPHALAN;NEURORADIOLOGY;NORMAL SINUS RHYTHM;VIRAL LOAD;WEIGHT LOSS;ACUTE LEUKEMIA;ACUTE SCROTUM;AGE OF ONSET;AIRWAY MANAGEMENT;ALLERGIC INFLAMMATION;AMPHOTERICIN B;ANGINA;ANGIOTENSIN-CONVERTING ENZYME;ANTI-THYMOCYTE GLOBULIN;APLASTIC ANEMIA;ATOPY;BACTEREMIA;BONE MARROW TRANSPLANTATION;CARCINOGENESIS;CATHETER ABLATION;CD34;CD36;CD8;CENTRAL VENOUS CATHETER;CHEMOKINE;CHEMOTAXIS;CHRONIC MYELOGENOUS LEUKEMIA;CIRCUMFLEX;CLOCKWISE;COMPLETE REMISSION;CROHN'S DISEASE;CYTOTOXIC T CELL;DIGOXIN;DNA REPAIR;DOXAZOSIN;EATING BEHAVIOR;EJECTION FRACTION;EPIDIDYMIS;EXON;FETUS;FIBRILLATION;FIBRIN TISSUE ADHESIVE;FILARIASIS;FLAG (LINEAR ALGEBRA);FLUORESCEIN;GALACTOMANNAN;GASTRIC MUCOSA;GLUTAMATE RECEPTOR;HAZARD RATIO;HERNIA REPAIR;HIGH RISK PREGNANCY;HORMONE REPLACEMENT THERAPY (FEMALE-TO-MALE);HUMAN LEUKOCYTE ANTIGEN;IMMUNOASSAY;INFERTILITY;INFLAMMATORY BOWEL DISEASE;INGUINAL HERNIA;INTERLEUKIN;ITRACONAZOLE;KI-67;LAPAROSCOPIC SURGERY;LEPTIN;LINOLEIC ACID;LIPOPROTEIN;LYMPHOBLASTIC LEUKEMIA;MAGNETIZATION TRANSFER;MAJOR HISTOCOMPATIBILITY COMPLEX;MINIMAL RESIDUAL DISEASE;MITOXANTRONE;NEUTROPENIA;NICOTINIC AGONIST;NON-HODGKIN'S LYMPHOMA;OCCUPATIONAL ASTHMA;OVEREATING;OVERWEIGHT;PLACEBO;POLYUNSATURATED FATTY ACID;PROGENITOR CELL;PULSE (MUSIC);PULSE PRESSURE;RESPIRATORY DISEASE;RESTING ENERGY EXPENDITURE;SPERM MOTILITY;SPLENECTOMY;STAT3;TEMPORAL LOBE;THROMBOCYTOPENIC PURPURA;TRACHEAL INTUBATION;TUMOR MARKER;ULCERATIVE COLITIS;VAGUS NERVE;VASCULAR SMOOTH MUSCLE;VASCULITIS;VORICONAZOLE","8;7;5;5;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TOTAL BODY IRRADIATION;HEMATOPOIETIC CELL;ANTIRETROVIRAL THERAPY;BINGE-EATING DISORDER;THIOTEPA;ABSOLUTE NEUTROPHIL COUNT;ACE INHIBITOR;ACUTE LYMPHOCYTIC LEUKEMIA;ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY;ANTIGEN PRESENTATION;AZOOSPERMIA;BASE EXCISION REPAIR;BUSULFAN;CANADIAN CARDIOVASCULAR SOCIETY;CARMUSTINE;CD3;CHEMOKINE RECEPTOR;CXCR4;CYTOLYSIS;DIETHYLCARBAMAZINE;DONOR LYMPHOCYTE INFUSION;DRUGS IN PREGNANCY;FETAL GROWTH;FLUDARABINE;FOAM CELL;FOVEOLAR CELL;GAMMA-LINOLENIC ACID;GLUTAMATERGIC;IDARUBICIN;INTERLEUKIN 12;INTERLEUKIN 21;INTERLEUKIN 5;MECAMYLAMINE;METHACHOLINE;MHC CLASS II;MORBIDLY OBESE;NATURAL KILLER CELL;NICOTINIC ACETYLCHOLINE RECEPTOR;NICOTINIC ANTAGONIST;SCAVENGER RECEPTOR;SEMEN ANALYSIS;SEMEN CRYOPRESERVATION;STAT;VAGUS NERVE STIMULATION;VINCRISTINE;WUCHERERIA BANCROFTI","5;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;BONE MARROW TRANSPLANTATION;ADOLESCENT;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;TRANSPLANTATION CONDITIONING;TRANSPLANTATION, HOMOLOGOUS;GRAFT VS HOST DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;RETROSPECTIVE STUDIES;;CHILD;CYTARABINE;ETOPOSIDE;FOLLOW-UP STUDIES;HEMATOLOGIC NEOPLASMS","62;43;42;40;35;31;19;17;17;17;17;16;16;11;10;10;9;9;9;9","HEMATOPOIETIC STEM CELL BIOLOGY;ANALYSIS OF ELECTROCARDIOGRAM SIGNALS;LYMPHOID NEOPLASMS;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;NATURAL KILLER CELLS IN IMMUNITY;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN MEDICAL SCIENCE AND PRACTICE;APPLICATIONS OF PLATELET-RICH PLASMA IN REGENERATIVE MEDICINE;ASTHMA;BIOMECHANICAL PROPERTIES OF THE CORNEA AND RELATED DISEASES;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CHRONIC RHINOSINUSITIS AND NASAL POLYPS;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF DRY EYE DISEASE;DIAGNOSIS AND MANAGEMENT OF IGG4-RELATED DISEASE","10;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","HEMATOPOIETIC CELL TRANSPLANTATION;STEM CELL AGING;TOTAL BODY IRRADIATION;ARRHYTHMIA DETECTION;CARDIAC ELECTROPHYSIOLOGY;HEARTBEAT CLASSIFICATION;REGIMEN;CONCOMITANT;EEG ANALYSIS;GRAFT-VERSUS-HOST DISEASE;HEMATOPOIETIC STEM CELLS;INFLAMMATION;STEM CELL MOBILIZATION;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BINGE EATING;BINGE-EATING DISORDER;EPILEPSY DETECTION;GASTRIC METAPLASIA;HEMODIALYSIS;HIV EPIDEMIOLOGY","10;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2","BONE MARROW;STEM CELL;CELL TRANSPLANTATION;MARROW TRANSPLANTATION;LEFT VENTRICULAR;ALLOGENEIC BONE;ELECTROGRAM COMPRESSION;HEMATOPOIETIC STEM;NATURAL KILLER;ACQUIRED HIV;ADOLESCENTS SURVIVING;AUTOIMMUNE DISEASES;BODY IRRADIATION;CANCER PATIENTS;CONGESTIVE HEART;EPITHELIAL GASTRIC;GASTRIC DYSPLASIA;HEART FAILURE;HEMODIALYSIS PATIENTS;HIV INFECTION;KILLER CELLS;LUNG CANCER;MARROW TRANSPLANT;MULTIPLE SCLEROSIS;PERIPHERAL BLOOD;RENAL FAILURE;TOTAL BODY;VENTRICULAR HYPERTROPHY;VERTICALLY ACQUIRED;ACE INHIBITORS","8;7;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","CELL DOSE;SEVERE APLASTIC;ANTIRETROVIRAL THERAPY;APLASTIC ANAEMIA;CONCOMITANT AID;NK CELLS;CELL TRANSPLANTATION;CHILDREN INFECTED;CONDITIONING REGIMEN;ESOPHAGEAL COMBITUBE;IMMUNOSUPPRESSIVE THERAPY;INFECTED VERTICALLY;PATIENTS RECEIVING;STEM CELL;TRACHEAL ESOPHAGEAL;ALLOGENEIC SCTX;BONE MARROW;CELLS INFUSED;CEREBRAL ASPERGILLOSIS;CEREBROSPINAL FLUID;CHRONIC GVHD;HIV INFECTION;HUMAN NEOCORTEX;NEUTROPHIL RESPONSE;NK CELL;PEAK METHOD;UNMAINTAINED REMISSION;VERSUS VERSUS;ADDITIONAL SERVICES;ADOLESCENCE ADDITIONAL","6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2",13,0.18,4,3,0,0,0,1.75,5.5,0,1,3,0,1,2,0,0,0,0,1,1.75,0,0,64,65,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,20,2,1.1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"カンチェッダ，ラニエリ;ドツィン，ベアトリス","1;1","ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;40 ENGINEERING","1;1;1","PEDIATRIC;REGENERATIVE MEDICINE;STEM CELL RESEARCH","1;1;1","5.2 CELLULAR AND GENE THERAPIES","1","A61K35/12;C12N5/00;C12N5/02;C12N5/06;C12N5/077;C12N5/0775;C12R1/91","1;1;1;1;1;1;1","A61K35/12;C12N2500/25;C12N2500/36;C12N2500/38;C12N2500/90;C12N2501/105;C12N2501/11;C12N2501/115;C12N2501/125;C12N2501/135","1;1;1;1;1;1;1;1;1;1",5,2,1381,4.24,2,0.4,121.2,0,0,2,0,2,0,0,1,0,5,0,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"Germany;United States;Belgium","2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","5;2;2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;PREVENTION;RARE DISEASES;TRANSPLANTATION;AUTOIMMUNE DISEASE;CANCER;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;HEMATOLOGY;INFECTIOUS DISEASES;ORPHAN DRUG;PATIENT SAFETY;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","5;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1","INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY;CANCER;INFECTION","2;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","4;2","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;HODGKIN'S DISEASE;MYELOMA","2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",3,1545281.33,233773.44,3.33333333333333,8,5,1,5.5,593415.412766885,0.121331530073157,"OSPEDALE POLICLINICO SAN MARTINO;AYUNTAMIENTO DE MADRID;FINNISH INSTITUTE OF OCCUPATIONAL HEALTH;HOSPITAL CLÍNIC DE BARCELONA;INSERM;INTERNATIONAL AGENCY FOR RESEARCH ON CANCER;KAROLINSKA INSTITUTET;KLINIČKA BOLNICA MERKUR;POLICLINICO SAN MATTEO FONDAZIONE;PSA PEUGEOT CITROËN (FRANCE);ROBOTIKER;SOFTECO SISMAT (ITALY);TECHNICAL UNIVERSITY OF MADRID;TELEFÓNICA (SPAIN);UNIVERSITY OF BORDEAUX;UNIVERSITY OF BRESCIA;UNIVERSITY OF COLOGNE;UNIVERSITY OF GENOA;UNIVERSITY OF SHEFFIELD;UNIVERSITY OF ULM","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","3","COALITION S;EC & ERC - EUROPEAN UNION","3;3","CON - COORDINATION OF RESEARCH ACTIONS (FUNDING SCHEME);CSC - COST-SHARING CONTRACTS (FUNDING SCHEME);DEM - DEMONSTRATION CONTRACTS (FUNDING SCHEME);FP5-IST - PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON A ""USER-FRIENDLY INFORMATION SOCIETY, 1998-2002"" (PROGRAMME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);IS-ECONTENT - MULTIANNUAL COMMUNITY PROGRAMME TO STIMULATE THE DEVELOPMENT AND USE OF EUROPEAN DIGITAL CONTENT ON THE GLOBAL NETWORKS AND TO PROMOTE LINGUISTIC DIVERSITY IN THE INFORMATION SOCIETY 2001-2005 (PROGRAMME)","1;1;1;1;1;1","46 INFORMATION AND COMPUTING SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;4604 CYBERSECURITY AND PRIVACY;4605 DATA MANAGEMENT AND DATA SCIENCE","2;1;1;1;1","CLINICAL RESEARCH;HEALTH SERVICES","1;1",NA,NA,NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;B11 COMPUTER SCIENCE AND INFORMATICS","1;1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMARTINO",2003,80,7.95,2.375,0.421052631578947,0.4625,0.3375,0.0625,0.2125,5,37,14,4,20,0.46,0.17,0.05,0.25,43.46,0.821164236497136,0.3,0.8,NA,0.477950083870246,0.390584132519616,0.4,0.461538461538462,"GIORGIO CIPRANDI;ANDREA BACIGALUPO;FRANCESCO FRASSONI;MARIA ANGELA TOSCA;MANLIO MILANESE;RITA MACCARIO;NICOLA RAGNI;ANDREA VIZZACCARO;UMBERTO VALENTE;E PALLESTRINI;IGNAZIO CIRILLO;RAFFAELLA ROSSO;ANTONIO DI BIAGIO;FRANCO LOCATELLI;FRANCESCA GUALANDI;SIMONE FERRERO;JOHN REX;MATTEO BASSETTI;WILLIAM E. DISMUKES;RAOUL HERBRECHT","8;8;7;6;6;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","ANDREA BACIGALUPO;GIORGIO CIPRANDI;MARIA ANGELA TOSCA;CLAUDIO DOGLIONI;MANLIO MILANESE;M CANEPA;ALBERTO F. SOBRERO;P. DE BELLIS;ANDREA VIZZACCARO;IGNAZIO CIRILLO;NICOLA RAGNI;FRANCESCO BOCCARDO;C. CAMPISI;FRANCESCO FRASSONI;LUCA CANNAVÒ;F PIPINO;ANDREA PALERMO;ÁLVARO URBANO-ISPÍZUA;ENZO ANDORNO;E PALLESTRINI","2.16;1.52;1.15;1.08;1.02;1;1;1;0.9;0.9;0.83;0.83;0.83;0.7;0.67;0.67;0.67;0.64;0.6;0.53","GIORGIO CIPRANDI;ANDREA BACIGALUPO;FRANCESCO FRASSONI;MARIA ANGELA TOSCA;RITA MACCARIO;NICOLA RAGNI;ANDREA VIZZACCARO;UMBERTO VALENTE;E PALLESTRINI;IGNAZIO CIRILLO;RAFFAELLA ROSSO;ANTONIO DI BIAGIO;FRANCESCA GUALANDI;SIMONE FERRERO;MATTEO BASSETTI;PAOLO GIORGI ROSSI;DANTE BASSETTI;GIUSEPPE SARTORI;CLAUDIO VISCOLI;MARIA TERESA VAN LINT","8;8;7;6;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","ANDREA BACIGALUPO;GIORGIO CIPRANDI;MARIA ANGELA TOSCA;CLAUDIO DOGLIONI;M CANEPA;ALBERTO F. SOBRERO;P. DE BELLIS;ANDREA VIZZACCARO;IGNAZIO CIRILLO;NICOLA RAGNI;FRANCESCO BOCCARDO;C. CAMPISI;FRANCESCO FRASSONI;LUCA CANNAVÒ;F PIPINO;ANDREA PALERMO;ENZO ANDORNO;E PALLESTRINI;RAFFAELLA ROSSO;ANTONIO DI BIAGIO","2.16;1.52;1.15;1.08;1;1;1;0.9;0.9;0.83;0.83;0.83;0.7;0.67;0.67;0.67;0.6;0.53;0.52;0.5","CORINNA GIACHERO;PAOLO RUBARTELLI;ALESSANDRO FONTANELLI;CARLO DI MARIO;FEDERICA ETTORI;FEDERICO PISCIONE;FRANCESCO BEDOGNI;GABRIELE GABRIELLI;LEONARDO SPEDICATO;LUIGI SALEMME;ZORAN OLIVARI;FRANCESCO FRASSONI;ANDREA BACIGALUPO;FRANCO LOCATELLI;RITA MACCARIO;A. LUCENTI;CLAUDIO DOGLIONI;D ALDOVINI;ENZO GALLIGIONI;FRANCESCO MAURI","553;553;486;486;486;486;486;486;486;486;486;424;413;304;304;230;230;230;230;230","CORINNA GIACHERO;PAOLO RUBARTELLI;FRANCESCO FRASSONI;ANDREA BACIGALUPO;CLAUDIO DOGLIONI;LORENZA PECCIARINI;MARIA GIULIA CANGI;RAFFAELLA ROSSO;FRANCESCA GUALANDI;MARIA TERESA VAN LINT;MARIA TERESA VALLE;E PALLESTRINI;ARCANGELO NOCERA;ALBERTO SOBRERO;ALIDA DOMINIETTO;ANNA MARIA RAIOLA;BENEDETTO BRUNO;TERESA LAMPARELLI;MARINA PODESTÀ;GIANNI TESTINO","553;553;424;413;230;230;230;217;186;186;173;166;162;159;126;126;126;126;111;106","ANDREA BACIGALUPO;FRANCESCO FRASSONI;E PALLESTRINI;GIORGIO CIPRANDI;GIUSEPPE SARTORI;PAOLO GIORGI ROSSI;RAFFAELLA ROSSO;CLAUDIO VISCOLI;FRANCESCA GUALANDI;MARIA TERESA VAN LINT;MATTEO BASSETTI;NICOLA RAGNI;A MARMONT;ALIDA DOMINIETTO;ANNA MARIA RAIOLA;ANTONIO DI BIAGIO;ANTONIO FERRAZIN;ARCANGELO NOCERA;B CIRAVEGNA;BENEDETTO BRUNO","8;7;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;PSYCHOLOGY;MATHEMATICS;PHILOSOPHY;ECONOMICS;MATERIALS SCIENCE","77;21;13;7;4;4;3;2;2;1;1","INTERNAL MEDICINE;IMMUNOLOGY;SURGERY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;ONCOLOGY;OPTICS;ANESTHESIA;BIOCHEMISTRY;DERMATOLOGY;RADIOLOGY;CARDIOLOGY;PEDIATRICS;VIROLOGY;CANCER RESEARCH;CELL BIOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;PSYCHIATRY;UROLOGY","54;25;23;19;14;13;9;9;8;7;7;7;6;6;6;5;5;5;4;4;4","TRANSPLANTATION;BONE MARROW;CANCER;INCIDENCE (GEOMETRY);STEM CELL;ASTHMA;CHEMOTHERAPY;GENE;IMMUNE SYSTEM;IN VITRO;CLINICAL TRIAL;DISEASE;POPULATION;ALTERNATIVE MEDICINE;ANTIBODY;LUNG;RANDOMIZED CONTROLLED TRIAL;VIRUS;ALLERGY;ANTIFUNGAL;ANTIGEN;CYTOKINE;IMMUNOSUPPRESSION;MULTIVARIATE ANALYSIS;NEUROLOGY;SINUSITIS","16;8;8;8;8;6;6;6;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","HEMATOPOIETIC STEM CELL TRANSPLANTATION;BREAST CANCER;PLACEBO;SPIROMETRY;CD34;CYTOTOXIC T CELL;GRAFT-VERSUS-HOST DISEASE;HAEMATOPOIESIS;KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION;NEURORADIOLOGY;PROGENITOR CELL;RESPIRATORY DISEASE;AUTOIMMUNE DISEASE;CD8;COLORECTAL CANCER;FLUTICASONE;HAZARD RATIO;IMMUNOTHERAPY;NASAL SPRAY;PERCUTANEOUS CORONARY INTERVENTION;STAPHYLOCOCCUS AUREUS;T CELL;VAGUS NERVE","5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","BK VIRUS;LYMPHEDEMA;MACE;MASTECTOMY;VAGUS NERVE STIMULATION;ACROMEGALY;ADOPTIVE CELL TRANSFER;ADULT STEM CELL;ANTIRETROVIRAL THERAPY;AZOOSPERMIA;BILATERAL NEPHRECTOMY;BRONCHIAL HYPERREACTIVITY;BRONCHIAL HYPERRESPONSIVENESS;BUSULFAN;CANDIDATUS;CASPOFUNGIN;CD40;CHEMOKINE RECEPTOR;CROSSOVER STUDY;CTL*;CXCL10;DEEP BRAIN STIMULATION;DESIGN FOR SIX SIGMA;DIFFUSING CAPACITY;DMAIC;DONOR LYMPHOCYTE INFUSION;ESTROGEN RECEPTOR;EVANS SYNDROME;FEBRILE NEUTROPENIA;FILGRASTIM;HEMORRHAGIC CYSTITIS;HOUSE DUST MITE;IL-2 RECEPTOR;IMMUNOGLOBULIN A;INTERLEUKIN 13;INTERLEUKIN 21;INTERLEUKIN 5;KAPOSI'S SARCOMA;METHACHOLINE;MYELOPOIESIS;PERIPHERAL MYELIN PROTEIN 22;POINT MUTATION;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SINGLE-STRAND CONFORMATION POLYMORPHISM;SOMATOSTATIN RECEPTOR 2;SUMATRIPTAN;TAXANE;TERLIPRESSIN;THIOBARBITURIC ACID;THYMIDYLATE SYNTHASE;TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;VANCOMYCIN","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;;ASTHMA;ADOLESCENT;BONE MARROW TRANSPLANTATION;RHINITIS, ALLERGIC, PERENNIAL;LYMPHEDEMA;HEMATOPOIETIC STEM CELL TRANSPLANTATION;INTERFERON-GAMMA;LUNG NEOPLASMS;SINUSITIS;TREATMENT OUTCOME;CHILD;GRAFT VS HOST DISEASE;ITALY","63;39;39;30;24;17;15;15;14;13;13;12;11;11;10;10;10;9;9;9","HEMATOPOIETIC STEM CELL BIOLOGY;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;HEPATITIS C INFECTION AND TREATMENT;HIP ARTHROPLASTY TECHNIQUES AND MATERIALS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MANAGEMENT AND QUALITY IN REHABILITATION MEDICINE;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;MULTIPOTENT MESENCHYMAL STEM CELLS;NEURO-IMMUNE MODULATION VIA VAGUS NERVE STIMULATION;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ANALYSIS OF ELECTROCARDIOGRAM SIGNALS;ASTHMA;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS","6;5;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","TREATMENT;HEMATOPOIETIC CELL TRANSPLANTATION;ASTHMA;ANTIFUNGAL THERAPY;CARDIAC ELECTROPHYSIOLOGY;EEG ANALYSIS;HEMATOPOIETIC STEM CELLS;IMMUNOSUPPRESSION;NEURORADIOLOGY;RENAL TRANSPLANTATION;STEM CELL AGING;TRANSPLANTATION;;ADOPTIVE CELL TRANSFER;ARRHYTHMIA DETECTION;BONE REMODELING;DEEP LEARNING FOR EEG;EPILEPSY TREATMENT;FLUTICASONE;GRAFT-VERSUS-HOST DISEASE","6;5;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","STEM CELL;BONE MARROW;ALLERGIC RHINITIS;CELL TRANSPLANTATION;FORUM REPORT;LIVER TRANSPLANTATION;ACUTE LYMPHOBLASTIC;ALLERGIC CHILDREN;ANTEGA CONSERVATIVE;ASTHMATIC CHILDREN;CARDIOVERTER DEFIBRILLATOR;CELL DOSE;CHRONIC RHINOSINUSITIS;CHRONIC VAGUS;CLINICAL TRIALS;CONSERVATIVE HIP;CYTOKINE PATTERN;HAEMOPOIETIC STEM;HIP SYSTEM;IMMUNE RESPONSE;IMPLANTABLE CARDIOVERTER;ITALIAN CONSCRIPTS;LYMPHOBLASTIC LEUKAEMIA;MARROW TRANSPLANTATION;NERVE STIMULATION;ORTHOTOPIC LIVER;PATIENTS AFFECTED;PERENNIAL ALLERGIC;PILOT STUDY;PLEURAL MESOTHELIOMA","7;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PROTEIN SPOTS;LACTIC ACIDOSIS;ANTIRETROVIRAL THERAPY;CLINICAL TRIALS;AML PATIENTS;KS DIAGNOSIS;MM HG;SEVERE LACTIC;GUILLAIN-BARRÉ SYNDROME;INFERTILE CONTROLS;KSHAART PATIENTS;PROTEOMIC PATTERNS;RECEIVING HAART;SIGNIFICANTLY INCREASED;STAGE III;STAGE IIIIV;STENT IMPLANTATION;TRANSPLANT RATES;VERTICAL TRANSMISSION;CELL SOURCE;COLORECTAL CANCER;DEEP MYCOSES;FAILURE MIMICKING;HIV INFECTION;KAPOSI SARCOMA;KIDNEY TRANSPLANTATION;NEUROMUSCULAR WEAKNESS;PATIENTS COMPARED;PRELIMINARY DATA;RESPIRATORY FAILURE","16;12;8;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3",15,0.19,6,7.5,0,0,0,1,9.5,0,1.75,7.5,0,0,2,0,0,0,1,1,0,0,0,60.5,60.5,2,0,1,0,0,0,0,1,0,1,0,0,1,2,0,35,3,4.74,2,0,3,2,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CANCEDDA RANIERI;DOZIN BEATRICE;ALBINI ADRIANA;BENELLI ROBERTO;CARROZZINO FABIO;NOONAN DOUGLAS;SANTI LEONARDO","2;2;1;1;1;1;1","CONSORZIO PER LA GESTIONE DEL CENTRO DI BIOTECNOLOGIA AVANZATA;ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO","3;3","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;40 ENGINEERING;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","3;2;2;1;1","PEDIATRIC;REGENERATIVE MEDICINE;STEM CELL RESEARCH","2;2;2","5.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS","2;1","A61K35/12;C12N5/00;C12N5/02;C12N5/077;C12N5/0775;C12R1/91;A61K38/17;A61K38/48;C12N5/08","2;2;2;2;2;2;1;1;1","A61K35/12;C12N2500/25;C12N2500/36;C12N2500/38;C12N2500/90;C12N2501/105;C12N2501/11;C12N2501/115;C12N2501/125;C12N2501/135","2;2;2;2;2;2;2;2;2;2",4,11,911.33,3.45,3,0.75,74.75,0,0,0,0,4,0,0,0,0,4,0,0,0,0,0,0,0,1,2,1,4,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY","4;4;2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BREAST CANCER;AGING;COMPARATIVE EFFECTIVENESS RESEARCH;CONTRACEPTION/REPRODUCTION;ESTROGEN;HEMATOLOGY;LYMPHOMA;PATIENT SAFETY;PREVENTION;PROSTATE CANCER;RARE DISEASES;UROLOGIC DISEASES","4;4;4;2;1;1;1;1;1;1;1;1;1;1;1","CANCER","3","6.1 PHARMACEUTICALS","4","BREAST CANCER;NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER","2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1",4,1947425.5,97516.89,4,26.5,13.5,1,10,683732.878675975,0.117004757991041,"OSPEDALE POLICLINICO SAN MARTINO;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;INSTITUTE OF BOTANY;UNIVERSITY OF COPENHAGEN;AGRUICULTURAL RESEARCH INSTITUTE;ANTHONY NOLAN;AUTONOMOUS UNIVERSITY OF BARCELONA;AYUNTAMIENTO DE MADRID;BANC DE SANG I TEIXITS;BIOVERSITY INTERNATIONAL;CAB INTERNATIONAL;CENTRE HOSPITALIER UNIVERSITAIRE DE NANCY;CHARLES UNIVERSITY;DÉLÉGATION PARIS 11;ECOLOGICAL CONSULTANCY SERVICES (IRELAND);EMPRESA PÚBLICA DE EMERGENCIAS SANITARIAS;FEDERAL OFFICE FOR FOOD AND AGRICULTURE;FREIE UNIVERSITÄT BERLIN;FRESHWATER BIOLOGICAL ASSOCIATION;FRÉDÉRIC JOLIOT-CURIE NATIONAL RESEARCH INSTITUTE FOR RADIOBIOLOGY AND RADIOHYGIENE","4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","4","COALITION S;EC & ERC - EUROPEAN UNION","4;4","FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);THN - THEMATIC NETWORK CONTRACTS (FUNDING SCHEME);CA - COORDINATION ACTION (FUNDING SCHEME);CON - COORDINATION OF RESEARCH ACTIONS (FUNDING SCHEME);ERA-NET/1/CA-SSA (CALL FOR PROPOSAL);FP5-EESD - PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""ENERGY, ENVIRONMENT AND SUSTAINABLE DEVELOPMENT, 1998-2002"" (PROGRAMME);FP6-COORDINATION - SUPPORT FOR THE COORDINATION OF ACTIVITIES: SPECIFIC PROGRAMME STRENGTHENING THE FOUNDATIONS OF THE EUROPEAN RESEARCH AREA UNDER THE SIXTH FRAMEWORK PROGRAMME 2002-2006 (FP6) (PROGRAMME)","2;2;1;1;1;1;1","42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;4202 EPIDEMIOLOGY;4206 PUBLIC HEALTH;46 INFORMATION AND COMPUTING SCIENCES;4610 LIBRARY AND INFORMATION STUDIES","2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;GENETICS;PEDIATRIC;PREVENTION;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;STEM CELL RESEARCH - UMBILICAL CORD BLOOD/ PLACENTA;STEM CELL RESEARCH - UMBILICAL CORD BLOOD/ PLACENTA - HUMAN;TRANSPLANTATION","1;1;1;1;1;1;1;1;1;1;1",NA,NA,NA,NA,"HODGKIN'S DISEASE;LEUKEMIA / LEUKAEMIA;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER","1;1;1;1;1",NA,NA,"A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A05 BIOLOGICAL SCIENCES;C17 BUSINESS AND MANAGEMENT STUDIES","1;1;1;1","15 LIFE ON LAND","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMARTINO",2004,121,8.98347107438017,2.23140495867769,0.448148148148148,0.537190082644628,0.305785123966942,0.256198347107438,0.31404958677686,12,62,20,14,16,0.51,0.17,0.12,0.13,46.79,0.99429397512227,0.256198347107438,0.727272727272727,NA,0.545764088428478,0.514293567894447,0.538461538461538,0.536231884057971,"ANDREA BACIGALUPO;GIORGIO CIPRANDI;UMBERTO VALENTE;FRANCESCO FRASSONI;ANGELO MICHELE CARELLA;SIMONE FERRERO;ANDREA VIZZACCARO;IGNAZIO CIRILLO;MANLIO MILANESE;NICOLA RAGNI;MARIA ANGELA TOSCA;ALBERTO SOBRERO;PAOLA ANSERINI;VALENTINO REMORGIDA;MARIA TERESA CORSETTI;MYRIAM LABOPIN;MARINA PODESTÀ;GERMANA BELTRAMI;VANDERSON ROCHA;ATTILIO OLIVIERI","17;15;11;11;10;8;8;8;7;7;6;6;6;6;6;5;5;5;4;4","GIORGIO CIPRANDI;ANDREA BACIGALUPO;SIMONE FERRERO;ANDREA VIZZACCARO;IGNAZIO CIRILLO;ANGELO MICHELE CARELLA;MANLIO MILANESE;UMBERTO VALENTE;GIANNI TESTINO;NICOLA RAGNI;MARIA ANGELA TOSCA;VALENTINO REMORGIDA;FRANCESCO FRASSONI;PAOLA ANSERINI;GIAN PAOLO GUELFI;RAFAEL SALES;NATALE R. MUSSO;ERNESTO PAOLETTI;DOMENICO PALOMBO;MARIA TERESA CORSETTI","5.53;3.42;2.23;1.85;1.85;1.39;1.33;1.27;1.25;1.23;1.22;1.07;1.04;1.03;1;1;1;1;1;0.98","ANDREA BACIGALUPO;GIORGIO CIPRANDI;UMBERTO VALENTE;FRANCESCO FRASSONI;ANGELO MICHELE CARELLA;SIMONE FERRERO;MANLIO MILANESE;NICOLA RAGNI;ALBERTO SOBRERO;PAOLA ANSERINI;VALENTINO REMORGIDA;MARIA TERESA CORSETTI;MARINA PODESTÀ;GERMANA BELTRAMI;GIOVANNA PIAGGIO;MARIA ANGELA TOSCA;PAOLO RUBARTELLI;I. FONTANA;EZIO FULCHERI;FRANCESCA GUALANDI","17;15;11;11;10;8;7;7;6;6;6;6;5;5;4;4;3;3;3;3","GIORGIO CIPRANDI;ANDREA BACIGALUPO;SIMONE FERRERO;ANGELO MICHELE CARELLA;MANLIO MILANESE;UMBERTO VALENTE;GIANNI TESTINO;NICOLA RAGNI;VALENTINO REMORGIDA;FRANCESCO FRASSONI;PAOLA ANSERINI;GIAN PAOLO GUELFI;RAFAEL SALES;NATALE R. MUSSO;ERNESTO PAOLETTI;DOMENICO PALOMBO;MARIA TERESA CORSETTI;GERMANA BELTRAMI;ALBERTO SOBRERO;MARIA ANGELA TOSCA","5.53;3.42;2.23;1.39;1.33;1.27;1.25;1.23;1.07;1.04;1.03;1;1;1;1;1;0.98;0.87;0.75;0.73","FRANCESCO FRASSONI;WILLIAM ARCESE;MYRIAM LABOPIN;VANDERSON ROCHA;ÉLIANE GLUCKMAN;JÜRGEN FINKE;TAPANI RUUTU;ALBERTO BOSI;GUILLERMO SANZ;MARCOS DE LIMA;N JACOBSEN;RAINER SCHWERDTFEGER;GIORGIO WALTER CANONICA;H. FOX;JEAN BOUSQUET;JEAN‐LOUIS HÉBERT;JON G. AYRES;K. SURREY;K.M. BEEH;MARC HUMBERT","1300;1141;1109;1107;1104;1097;1097;1095;1095;1095;1095;1095;1073;1073;1073;1073;1073;1073;1073;1073","FRANCESCO FRASSONI;GIORGIO WALTER CANONICA;ANDREA BACIGALUPO;UMBERTO VALENTE;GIORGIO CIPRANDI;A MARMONT;MARIA TERESA VAN LINT;PAOLO RUBARTELLI;FRANCESCO BOCCARDO;CORRADINO CAMPISI;I. FONTANA;DEBORA ARICÒ;FRANCO FERRILLO;LINO NOBILI;MANOLO BEELKE;PAOLA CANOVARO;PIERPAOLO RIZZO;SERGIO GARBARINO;TSUYOSHI WATANABE;CLAUDIO DOGLIONI","1122;1073;613;470;422;263;247;219;147;146;115;103;103;103;103;103;103;103;103;101","ANDREA BACIGALUPO;GIORGIO CIPRANDI;FRANCESCO FRASSONI;SIMONE FERRERO;ANGELO MICHELE CARELLA;NICOLA RAGNI;VALENTINO REMORGIDA;ALBERTO SOBRERO;PAOLA ANSERINI;UMBERTO VALENTE;A MARMONT;FRANCESCO BOCCARDO;PAOLO RUBARTELLI;MARINA PODESTÀ;ADALBERTO IBATICI;ALESSANDRO ARRIGO;ANDREA GIANELLI CASTIGLIONE;ANGELA RITA SEMENTA;ANNA PITTO;C. SONAGLIO","16;14;9;8;7;7;6;6;6;6;3;3;3;3;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;CHEMISTRY;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;BUSINESS;ECONOMICS;HISTORY;PHILOSOPHY","115;35;9;8;5;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;PATHOLOGY;ONCOLOGY;GENETICS;RADIOLOGY;CARDIOLOGY;BIOCHEMISTRY;CANCER RESEARCH;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;ANESTHESIA;CELL BIOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;OPTICS;UROLOGY","99;48;37;36;26;18;15;14;13;10;9;9;7;7;6;6;5;5;5;5","TRANSPLANTATION;CHEMOTHERAPY;CANCER;DISEASE;ALLERGY;STEM CELL;ASTHMA;BONE MARROW;GENE;REGIMEN;ALTERNATIVE MEDICINE;DIABETES MELLITUS;IMMUNOHISTOCHEMISTRY;IMMUNOSUPPRESSION;LEUKEMIA;LUNG;BLOOD PRESSURE;ENDOMETRIOSIS;MAGNETIC RESONANCE IMAGING;POPULATION;PROSPECTIVE COHORT STUDY","34;27;18;17;14;13;12;12;10;10;7;7;7;7;6;6;5;5;5;5;5","CYCLOPHOSPHAMIDE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HAEMATOPOIESIS;ALLERGIC INFLAMMATION;COLORECTAL CANCER;GRAFT-VERSUS-HOST DISEASE;KIDNEY TRANSPLANTATION;SPIROMETRY;GEMCITABINE;IMATINIB;NASAL LAVAGE;PLACEBO;PROGRESSIVE DISEASE;CDKN2A;EOSINOPHIL;FOLLICULAR LYMPHOMA;HEART RATE;MELPHALAN;NEPHROPATHY;NEUTROPENIA;RESPIRATORY DISEASE;RESTENOSIS;RHINOMANOMETRY","11;9;8;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","FLUDARABINE;THIOTEPA;IMATINIB MESYLATE;BRONCHIAL HYPERREACTIVITY;BUSULFAN;BK VIRUS;BRONCHIAL HYPERRESPONSIVENESS;CEREBRAL AUTOREGULATION;CETUXIMAB;DONOR LYMPHOCYTE INFUSION;GERMLINE MUTATION;MEAN ARTERIAL PRESSURE;METHACHOLINE;OXALIPLATIN;ACUTE LYMPHOCYTIC LEUKEMIA;ADULT STEM CELL;ALPHA (FINANCE);ANTIRETROVIRAL THERAPY;ATHERECTOMY;ATROPHIC GASTRITIS;BASILIXIMAB;CAPECITABINE;CHROMOPHOBE CELL;CHRONIC ALLOGRAFT NEPHROPATHY;CUTTING BALLOON;CYCLIN-DEPENDENT KINASE;DIABETIC CARDIOMYOPATHY;DIASTOLIC HEART FAILURE;EVANS SYNDROME;EXTERNAL BEAM RADIOTHERAPY;FAS LIGAND;FEBRILE NEUTROPENIA;FRACTIONAL ANISOTROPY;FRACTIONAL FLOW RESERVE;FRATAXIN;FULMINANT HEPATIC FAILURE;HEART RATE VARIABILITY;HEMOPHAGOCYTOSIS;HEMORRHAGIC CYSTITIS;IDARUBICIN;IL-2 RECEPTOR;IMMUNOPEROXIDASE;INEFFECTIVE ERYTHROPOIESIS;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;LEUKOTRIENE C4;LYMPHANGIOGENESIS;LYMPHEDEMA;MAASTRICHT TREATY;MACE;MIXED LYMPHOCYTE REACTION;NEUROPSYCHOLOGICAL TEST;OMALIZUMAB;PDGFRA;PEMETREXED;PERIPHERAL BLOOD STEM CELLS;PIPERACILLIN;POLYMORPHISM (COMPUTER SCIENCE);PRIMARY TUMOR;PROSTATECTOMY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SENTINEL LYMPH NODE;SENTINEL NODE;SOMATOSTATIN RECEPTOR 2;TARGET LESION;TOTAL BODY IRRADIATION;TRINUCLEOTIDE REPEAT EXPANSION;UROTHELIAL CELL;VINORELBINE","10;5;4;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;MALE;FEMALE;ADULT;MIDDLE AGED;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ASTHMA;RHINITIS, ALLERGIC, SEASONAL;HEMATOPOIETIC STEM CELL TRANSPLANTATION;ADOLESCENT;GRAFT VS HOST DISEASE;TREATMENT OUTCOME;LUNG NEOPLASMS;BONE MARROW TRANSPLANTATION;CORONARY RESTENOSIS;CYTOKINES;NASAL OBSTRUCTION;HEART FAILURE","72;48;48;45;36;33;24;24;21;20;16;14;14;13;12;11;11;11;11;10","HEMATOPOIETIC STEM CELL BIOLOGY;ASTHMA;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MULTIPOTENT MESENCHYMAL STEM CELLS;ACUTE MYELOID LEUKEMIA;KIDNEY TRANSPLANTATION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EFFICACY AND RESISTANCE IN CML TREATMENT;GASTRIC CANCER RESEARCH AND TREATMENT;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;LYMPHOID NEOPLASMS;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY","10;8;6;6;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2","HEMATOPOIETIC CELL TRANSPLANTATION;REGIMEN;IMMUNOSUPPRESSION;TREATMENT;ALLERGIC INFLAMMATION;STEM CELL AGING;POLLEN ALLERGY;THIOTEPA;ASTHMA;COUGH REFLEX SENSITIVITY;IMATINIB MESYLATE;NASAL LAVAGE;BRONCHIAL HYPERREACTIVITY;CORONARY STENTS;FEXOFENADINE;FOLLICULAR LYMPHOMA;GRAFT-VERSUS-HOST DISEASE;IMATINIB;MELANOMA;MELPHALAN","12;10;7;7;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3","STEM CELL;CELL TRANSPLANTATION;ALLERGIC RHINITIS;SEASONAL ALLERGIC;BONE MARROW;INTENSITY CONDITIONING;REDUCED INTENSITY;STEM CELLS;HEMATOPOIETIC STEM;ACUTE LEUKAEMIA;ALLOGENEIC STEM;BRONCHIAL HYPERREACTIVITY;CONDITIONING REGIMEN;HEART FAILURE;IN-STENT RESTENOSIS;LUNG CANCER;MARROW TRANSPLANTATION;MESENCHYMAL STEM;NON-HODGKINS LYMPHOMA;SPIROMETRIC IMPAIRMENT;ACUTE LEUKEMIA;ADVANCED OVARIAN;ALLOGENEIC HEMATOPOIETIC;AOC PATIENTS;ASTHMATIC CHILDREN;BALLOON ANGIOPLASTY;BALLOON VERSUS;CANCER AOC;CELL CARCINOMA;CELL LUNG","13;12;9;6;5;5;5;5;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;TP PCR;MW KD;DE FLORA;POLLEN SEASON;SIGNIFICANT DIFFERENCE;BIOL CHEM;CHEM -ABSTRACT;DE MICHELE;FRIEDREICHS ATAXIA;BONE MARROW;ENDOMETRIOTIC LESIONS;FRIEDREICH ATAXIA;TRIPLET REPEAT;AUTOSOMAL RECESSIVE;GAA TRIPLET;GENET -CROSSREF;SOUTHERN BLOTTING;ALLERGIC RHINITIS;BILATERAL USLE;CB MNC;EXPANDED ALLELES;MENSTRUAL CYCLE;STROMAL CELLS;DI DONATO;STEM CELLS;BIDICHANDANI SI;GAA EXPANSION;MD PIANESE","72;61;32;27;26;19;17;15;15;15;15;14;14;13;13;12;12;12;12;11;11;11;11;11;11;10;10;9;9;9",21,0.17,6,3,2,0,0,0,2,0,1,3,0,0,1,0,3.5,0,0,1,0,0,0,46,47,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,7.25,382.5,3.94,2,0.4,27.6,0,0,1,0,3,0,0,1,0,4,0,0,0,0,0,0,0,4,1,0,3,1,0,1,0,0,0,0,0,0,"Italy","6","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","5;3;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;AGING;BREAST CANCER;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;ESTROGEN;HEMATOLOGY;LUNG;LYMPHOMA;ORPHAN DRUG;RARE DISEASES","3;3;2;1;1;1;1;1;1;1;1;1","CANCER;RESPIRATORY","3;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","3;1","BLADDER CANCER;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER","1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD","2;1;1",1,6e+06,38709.68,8,155,31,1,4,549674.308723765,0.220130353701518,"AARHUS UNIVERSITY HOSPITAL;ACADEMIC MEDICAL CENTER;AIX-MARSEILLE UNIVERSITY;ANKARA UNIVERSITY;ANTWERP UNIVERSITY HOSPITAL;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AZIENDA OSPEDALIERA SAN CAMILLO-FORLANINI;BELARUSIAN RESEARCH CENTER FOR PEDIATRIC ONCOLOGY AND HEMATOLOGY;CARDIFF UNIVERSITY;CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY;CATHOLIC UNIVERSITY OF THE SACRED HEART;CEINGE BIOTECNOLOGIE AVANZATE (ITALY);CENTRE HOSPITALIER RÉGIONAL ET UNIVERSITAIRE DE LILLE;CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS;CENTRE HOSPITALIER UNIVERSITAIRE DE CAEN;CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES;CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE;CHARITÉ - UNIVERSITY MEDICINE BERLIN;COLLEGIO GHISLIERI;DÉLÉGATION PARIS 11","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP6-2002-LIFESCIHEALTH (CALL FOR PROPOSAL);FP6-LIFESCIHEALTH - LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH: THEMATIC PRIORITY 1 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);NOE - NETWORK OF EXCELLENCE (FUNDING SCHEME)","1;1;1","31 BIOLOGICAL SCIENCES;3105 GENETICS","1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;ORPHAN DRUG;RARE DISEASES","1;1;1;1;1;1","CANCER","1","6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)","1","LEUKEMIA / LEUKAEMIA","1","5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1","A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMARTINO",2005,104,9.75961538461539,3.22115384615385,0.31044776119403,0.509615384615385,0.307692307692308,0.230769230769231,0.307692307692308,3,61,15,11,13,0.59,0.14,0.11,0.12,72.61,1.37137619699826,0.336538461538462,0.826923076923077,NA,0.583483360390758,0.569980506822612,0.523508771929824,0.493827160493827,"SIMONE FERRERO;NICOLA RAGNI;ANDREA BACIGALUPO;GIORGIO CIPRANDI;VALENTINO REMORGIDA;PAOLA ANSERINI;FRANCESCO FRASSONI;ANDREA VIZZACCARO;IGNAZIO CIRILLO;UMBERTO VALENTE;MARIA ANGELA TOSCA;FABRIZIO GINEVRI;GIAN LUIGI MARSEGLIA;LUIZA HELENA ABBAMONTE;ANGELO MICHELE CARELLA;MARINA PODESTÀ;GIANLUIGI MANCARDI;FRANCO LOCATELLI;FRANCESCA GUALANDI;ANTONIO UCCELLI","15;15;15;14;14;13;12;11;9;8;6;6;6;6;5;5;5;4;4;4","GIORGIO CIPRANDI;NICOLA RAGNI;SIMONE FERRERO;VALENTINO REMORGIDA;PAOLA ANSERINI;ANDREA VIZZACCARO;IGNAZIO CIRILLO;ANDREA BACIGALUPO;M GIPPONI;MARIA ANGELA TOSCA;LUIZA HELENA ABBAMONTE;FRANCESCO FRASSONI;GIAN LUIGI MARSEGLIA;GIANNI TESTINO;UMBERTO VALENTE;CATHERINE KLERSY;ANGELO MICHELE CARELLA;GIANLUIGI MANCARDI;DAVID J. GILLOTT;EZIO FULCHERI","3.48;2.64;2.6;2.3;2.14;1.98;1.56;1.34;1.25;1.24;1.13;1.12;1.08;1;0.87;0.79;0.79;0.64;0.6;0.58","SIMONE FERRERO;NICOLA RAGNI;ANDREA BACIGALUPO;GIORGIO CIPRANDI;VALENTINO REMORGIDA;PAOLA ANSERINI;FRANCESCO FRASSONI;ANDREA VIZZACCARO;IGNAZIO CIRILLO;UMBERTO VALENTE;LUIZA HELENA ABBAMONTE;ANGELO MICHELE CARELLA;MARINA PODESTÀ;GIANLUIGI MANCARDI;FRANCO LOCATELLI;FRANCESCA GUALANDI;ANTONIO UCCELLI;MAURO SPRIANO;SARAH POZZI;MARIA TERESA VAN LINT","15;15;15;14;14;13;12;11;9;8;6;5;5;5;4;4;4;4;4;4","GIORGIO CIPRANDI;NICOLA RAGNI;SIMONE FERRERO;VALENTINO REMORGIDA;PAOLA ANSERINI;ANDREA VIZZACCARO;IGNAZIO CIRILLO;ANDREA BACIGALUPO;M GIPPONI;LUIZA HELENA ABBAMONTE;FRANCESCO FRASSONI;GIANNI TESTINO;UMBERTO VALENTE;ANGELO MICHELE CARELLA;GIANLUIGI MANCARDI;DAVID J. GILLOTT;EZIO FULCHERI;GIORGIO WALTER CANONICA;J. G. GRUDZINSKAS;MARINA PODESTÀ","3.48;2.64;2.6;2.3;2.14;1.98;1.56;1.34;1.25;1.13;1.12;1;0.87;0.79;0.64;0.6;0.58;0.52;0.45;0.43","GIANLUIGI MANCARDI;ANTONIO UCCELLI;DEBORA GIUNTI;FEDERICA BENVENUTO;FRANCESCO CAZZANTI;FRANCESCA GUALANDI;FRANCESCO FRASSONI;ANNA CORCIONE;ELISA FERRETTI;MARCO RISSO;VALENTINA CAPPIELLO;VITO PISTOIA;ANDREA BACIGALUPO;ANTONELLA CERAVOLO;EMANUELA ZAPPIA;ENRICO PEDEMONTE;EZIO GERDONI;IVAN BONANNI;SIMONA CASAZZA;ANNEMARIE MOSELEY","3211;3207;3107;3107;3107;1804;1804;1704;1704;1704;1704;1704;1529;1403;1403;1403;1403;1403;1403;792","GIANLUIGI MANCARDI;ANTONIO UCCELLI;DEBORA GIUNTI;FEDERICA BENVENUTO;FRANCESCO CAZZANTI;FRANCESCA GUALANDI;FRANCESCO FRASSONI;ANNA CORCIONE;ELISA FERRETTI;MARCO RISSO;VALENTINA CAPPIELLO;VITO PISTOIA;ANDREA BACIGALUPO;ANTONELLA CERAVOLO;EMANUELA ZAPPIA;ENRICO PEDEMONTE;EZIO GERDONI;IVAN BONANNI;SIMONA CASAZZA;GIORGIO CIPRANDI","3111;3107;3107;3107;3107;1804;1804;1704;1704;1704;1704;1704;1529;1403;1403;1403;1403;1403;1403;706","ANDREA BACIGALUPO;GIORGIO CIPRANDI;SIMONE FERRERO;NICOLA RAGNI;VALENTINO REMORGIDA;PAOLA ANSERINI;FRANCESCO FRASSONI;LUIZA HELENA ABBAMONTE;FRANCESCA GUALANDI;MARIA TERESA VAN LINT;MAURO SPRIANO;DAVID J. GILLOTT;ALIDA DOMINIETTO;ANNA MARIA RAIOLA;GIANLUIGI MANCARDI;MARINA PODESTÀ;S NATI;TERESA LAMPARELLI;M GIPPONI;A CONGIU","15;14;14;14;13;12;10;6;4;4;4;3;3;3;3;3;3;3;3;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;ECONOMICS;POLITICAL SCIENCE;BUSINESS;CHEMISTRY;GEOGRAPHY;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;PHILOSOPHY","100;31;6;5;4;3;3;2;2;2;2;2;2;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;GENETICS;ONCOLOGY;GYNECOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;RADIOLOGY;BIOCHEMISTRY;CARDIOLOGY;PALEONTOLOGY;UROLOGY;CANCER RESEARCH;OBSTETRICS;INTENSIVE CARE MEDICINE;PEDIATRICS;ANDROLOGY;ANESTHESIA;PHARMACOLOGY;PSYCHIATRY","79;42;39;30;19;17;13;13;12;9;9;7;7;7;7;6;6;5;5;4;4;4;4","TRANSPLANTATION;CHEMOTHERAPY;BONE MARROW;POPULATION;ASTHMA;ENDOMETRIOSIS;STEM CELL;CANCER;ALLERGY;REGIMEN;IMMUNE SYSTEM;MESENCHYMAL STEM CELL;ANTIBODY;CREATININE;DISEASE;LUNG;PREGNANCY;RENAL FUNCTION;STAGE (STRATIGRAPHY);GENE;KIDNEY;LYMPHOMA;NOSE","31;15;14;13;12;12;11;10;9;8;7;7;6;6;6;6;6;6;6;5;5;5;5","HEMATOPOIETIC STEM CELL TRANSPLANTATION;CYCLOPHOSPHAMIDE;GRAFT-VERSUS-HOST DISEASE;NASAL LAVAGE;BREAST CANCER;HAEMATOPOIESIS;RESPIRATORY DISEASE;RHINOMANOMETRY;ALLERGEN;APLASTIC ANEMIA;EOSINOPHIL;INFERTILITY;KIDNEY TRANSPLANTATION;RITUXIMAB;SPIROMETRY;ANTI-THYMOCYTE GLOBULIN;CD8;COLORECTAL CANCER;FERTILITY;HEPATITIS C VIRUS;MELPHALAN;METASTASIS;PLACEBO;PROGRESSIVE DISEASE;UNIVARIATE ANALYSIS","14;9;7;6;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","FLUDARABINE;BRONCHIAL HYPERREACTIVITY;TOTAL BODY IRRADIATION;BUSULFAN;SENTINEL LYMPH NODE;SENTINEL NODE;ABL;CTL*;IMATINIB MESYLATE;LYMPHOVASCULAR INVASION;METHACHOLINE;THIOTEPA;ACUTE LYMPHOCYTIC LEUKEMIA;AGGRESSIVE LYMPHOMA;AIRBORNE ALLERGEN;ALLERGEN IMMUNOTHERAPY;ANTIRETROVIRAL THERAPY;AROMATASE;AXILLA;BRONCHIAL HYPERRESPONSIVENESS;BRONCHUS;CANCER IMMUNOTHERAPY;CAPECITABINE;CHEMOIMMUNOTHERAPY;CHEMOKINE RECEPTOR;COLONOSCOPY;CXCR4;DONOR LYMPHOCYTE INFUSION;DOPAMINE AGONIST;DUST MITES;EFFECTIVE RENAL PLASMA FLOW;EOSINOPHIL CATIONIC PROTEIN;ESOPHAGOGASTRIC JUNCTION;FAMILY PLANNING;FENOLDOPAM;FILGRASTIM;FLAVIVIRIDAE;FOLINIC ACID;GASTROESOPHAGEAL JUNCTION;GONADOTROPIN-RELEASING HORMONE;GP41;GRANZYME B;HEMORRHAGIC CYSTITIS;HOUSE DUST MITE;HYDROSALPINX;HYPERURICOSURIA;IMMUNOGLOBULIN D;IMMUNOGLOBULIN M;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;LEYDIG CELL;METASTATIC BREAST CANCER;MICROMETASTASIS;MYELIN OLIGODENDROCYTE GLYCOPROTEIN;OXALIPLATIN;PERFORIN;PERIPHERAL BLOOD STEM CELLS;PHILADELPHIA CHROMOSOME;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER;RENAL ISCHEMIA;SUBLINGUAL IMMUNOTHERAPY;TRYPSINIZATION;VINCRISTINE;WINDOW PERIOD","6;4;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;;MIDDLE AGED;ADOLESCENT;RHINITIS, ALLERGIC, PERENNIAL;RHINITIS, ALLERGIC, SEASONAL;HEMATOPOIETIC STEM CELL TRANSPLANTATION;NASAL OBSTRUCTION;ENDOMETRIOSIS;EOSINOPHILS;KIDNEY TRANSPLANTATION;AGED;INFLAMMATION;CHILD;GRAFT VS HOST DISEASE;COLORECTAL NEOPLASMS;HEPATITIS C","65;45;41;40;38;25;24;21;18;16;16;13;13;13;12;12;11;11;10;10","ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;HEMATOPOIETIC STEM CELL BIOLOGY;MULTIPOTENT MESENCHYMAL STEM CELLS;KIDNEY TRANSPLANTATION;EFFICACY AND RESISTANCE IN CML TREATMENT;;ACUTE MYELOID LEUKEMIA;ASTHMA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HEPATITIS C INFECTION AND TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;LYMPHOID NEOPLASMS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BRANCHIAL ANOMALIES AND THYROID ABNORMALITIES;CANCER OF UNKNOWN PRIMARY SITE;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES","12;11;7;6;4;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1","HEMATOPOIETIC CELL TRANSPLANTATION;REGIMEN;MESENCHYMAL STEM CELLS;TREATMENT;NASAL LAVAGE;POLLEN ALLERGY;STEM CELL AGING;GRAFT-VERSUS-HOST DISEASE;RHINOMANOMETRY;APLASTIC ANEMIA;BRONCHIAL HYPERREACTIVITY;COUGH REFLEX SENSITIVITY;TOTAL BODY IRRADIATION;TRANSPLANTATION;ANTI-THYMOCYTE GLOBULIN;ENDOMETRIAL RECEPTIVITY;HEPATITIS C;IMMUNOSUPPRESSION;MELPHALAN;PERITONEAL FLUID","12;8;7;7;6;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3","STEM CELL;CELL TRANSPLANTATION;STEM CELLS;ALLERGIC RHINITIS;MESENCHYMAL STEM;HEMATOPOIETIC STEM;APLASTIC ANEMIA;PERIPHERAL BLOOD;ALLERGIC INFLAMMATION;ANTI-THYMOCYTE GLOBULIN;AUTOLOGOUS STEM;BLOOD STEM;HLA-IDENTICAL SIBLING;LYMPH NODE;MARROW TRANSPLANTATION;MULTIPLE SCLEROSIS;PEDIATRIC KIDNEY;PERSISTENT ALLERGIC;PILOT STUDY;REDUCED INTENSITY;SEVERE APLASTIC;SEX LIFE;AUTOLOGOUS HEMATOPOIETIC;BREAST CANCER;BRONCHIAL HYPERREACTIVITY;CADAVERIC DONOR;CML PATIENTS;COLORECTAL CANCER;DONOR TRANSPLANTS;GRAFT FUNCTION","14;13;10;9;7;6;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","SIGNIFICANT DIFFERENCE;THYROID DISORDERS;UTERINE MYOMAS;AUTOLOGOUS EBV-SPECIFIC;RAFS STAGE;ALLERGIC RHINITIS;PERIPHERAL BLOOD;SEXUAL FUNCTION;CTL LINES;IRCCS POLICLINICO;MATTEO PAVIA;EBV DNA;SEXUAL SATISFACTION;TRANSPLANT IMMUNOLOGY;ALLERGOLOGIA-UO ORL;BENZI GENOA;E-MAIL EMAIL;EBV-SPECIFIC CTL;EBV-SPECIFIC CTLS;EMAIL PROTECTEDSEARCH;FAX E-MAIL;GENOA ITALY;HEMATOLOGYONCOLOGY IRCCS;ITALY TEL;LOST DUE;MARTINO LARGO;ORL PADIGLIONE;OSPEDALE SAN;PADIGLIONE SPECIALITÀ;PAVIA ITALYSEARCH","29;19;18;13;12;11;11;11;10;10;10;9;9;9;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8;8",14,0.13,13.5,6,1,0,0,1.75,11.25,1,2,6,0,0,2.5,1,2,0,1,3,0,0,0,180.5,180.5,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,17,2,0.6,2,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CANCEDDA RANIERI;DOZIN BEATRICE","1;1","CONSORZIO PER LA GESTIONE DEL CENTRO DI BIOTECNOLOGIA AVANZATA;ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;40 ENGINEERING","1;1;1",NA,NA,NA,NA,"A61K35/12;C12N5/00;C12N5/02;C12N5/077;C12N5/0775;C12N5/08;C12R1/91","1;1;1;1;1;1;1","A61K35/12;C12N2500/25;C12N2500/36;C12N2500/38;C12N2500/90;C12N2501/105;C12N2501/11;C12N2501/115;C12N2501/125;C12N2501/135","1;1;1;1;1;1;1;1;1;1",10,7.14,1014.5,5.38,2,0.2,37,0,0,3,1,4,0,1,1,0,7,1,0,0,0,0,0,0,8,2,0,8,2,0,0,0,0,0,0,0,0,"Belgium;Italy;United States","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","9;5;3;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES;CANCER;ORPHAN DRUG;AGING;BRAIN DISORDERS;HEMATOLOGY;NEUROSCIENCES;TRANSPLANTATION;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BREAST CANCER;DEMENTIA;ESTROGEN;LUNG;LUNG CANCER;NEURODEGENERATIVE","7;7;6;5;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;STROKE","5;1","6.1 PHARMACEUTICALS;3.4 VACCINES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","7;1;1;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;BLOOD CANCER;HODGKIN'S DISEASE;LUNG CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;STOMACH CANCER","2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","6;1;1;1",3,964934,160467,3.33333333333333,5,3.33333333333333,1,1,258186.758919844,0.402809192985329,"OSPEDALE POLICLINICO SAN MARTINO;BEN-GURION UNIVERSITY OF THE NEGEV;D'APPOLONIA (ITALY);DELFT UNIVERSITY OF TECHNOLOGY;FRAUNHOFER INSTITUTE FOR MICROENGINEERING AND MICROSYSTEMS;KING'S COLLEGE LONDON;LAVISION (GERMANY);MILTENYI BIOTEC (GERMANY);SPANISH NATIONAL RESEARCH COUNCIL;STAZIONE ZOOLOGICA ANTON DOHRN;TECHNICAL UNIVERSITY OF DENMARK;UNIVERSITY OF BARCELONA;UPPSALA UNIVERSITY","3;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;MEDICAL RESEARCH COUNCIL","2;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","3;2;1;1","STREP - SPECIFIC TARGETED RESEARCH PROJECT (FUNDING SCHEME);FP6-2003-NEST-A (CALL FOR PROPOSAL);FP6-NMP - NANOTECHNOLOGIES AND NANOSCIENCES, KNOWLEDGE-BASED MULTIFUNCTIONAL MATERIALS AND NEW PRODUCTION PROCESSES AND DEVICES: THEMATIC PRIORITY 3 UNDER THE 'FOCUSING AND INTEGRATING COMMUNITY RESEARCH' OF THE 'INTEGRATING AND STRENGTHENING THE EUROPEAN RESEARCH AREA' SPECIFIC PROGRAMME 2002-2006. (PROGRAMME);FP6-POLICIES - POLICY SUPPORT: SPECIFIC ACTIVITIES COVERING WIDER FIELD OF RESEARCH UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);RESEARCH GRANT (PROJECT CATEGORY)","2;1;1;1;1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY","2;1;1;1;1","BIOENGINEERING;GENETICS","1;1",NA,NA,"4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","1;1","NOT SITE-SPECIFIC CANCER","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","1","A01 CLINICAL MEDICINE;B12 ENGINEERING","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMARTINO",2006,107,9.14018691588785,3.2803738317757,0.304843304843305,0.542056074766355,0.401869158878505,0.336448598130841,0.308411214953271,5,64,20,8,7,0.6,0.19,0.07,0.07,56.02,1.09672391967299,0.233644859813084,0.766355140186916,NA,0.504368070448022,0.467763282283986,0.51265306122449,0.434824434824435,"NICOLA RAGNI;ANDREA BACIGALUPO;GIORGIO CIPRANDI;FRANCESCO FRASSONI;SIMONE FERRERO;VALENTINO REMORGIDA;IGNAZIO CIRILLO;MARIA TERESA VAN LINT;GIAN LUIGI MARSEGLIA;GÈRARD SOCIÉ;DAVIDE LIJOI;EMANUELA MISTRANGELO;CINZIA TOMOLILLO;JAKOB PASSWEG;FRANCO LOCATELLI;GIOVANNA LEONCINI;VALERIA FALQUI;FRANCESCA VIAZZI;ANDREA VIZZACCARO;UMBERTO VALENTE","14;12;10;10;9;8;8;8;7;6;6;6;5;5;5;5;5;5;5;5","NICOLA RAGNI;FRANCESCO FRASSONI;GIORGIO CIPRANDI;SIMONE FERRERO;IGNAZIO CIRILLO;CLAUDIO VISCOLI;VALENTINO REMORGIDA;ANDREA BACIGALUPO;EMANUELA MISTRANGELO;DAVIDE LIJOI;GIAN LUIGI MARSEGLIA;ALBERTO SOBRERO;M. VALBONESI;GIANNI TESTINO;NULL AUTHOR_ID;FRANCO ALESSANDRI;LUIZA HELENA ABBAMONTE;MARIA TERESA VAN LINT;MATTEO BASSETTI;ANDREA VIZZACCARO","2.47;1.82;1.81;1.49;1.39;1.32;1.29;1.19;1.13;1.1;1.08;1;1;1;1;0.91;0.83;0.83;0.82;0.82","NICOLA RAGNI;ANDREA BACIGALUPO;GIORGIO CIPRANDI;FRANCESCO FRASSONI;SIMONE FERRERO;VALENTINO REMORGIDA;IGNAZIO CIRILLO;MARIA TERESA VAN LINT;DAVIDE LIJOI;EMANUELA MISTRANGELO;CINZIA TOMOLILLO;GIOVANNA LEONCINI;VALERIA FALQUI;FRANCESCA VIAZZI;UMBERTO VALENTE;VALENTINA VACCARO;LUIZA HELENA ABBAMONTE;GIACOMO DEFERRARI;ROBERTO PONTREMOLI;ELENA RATTO","14;12;10;10;9;8;8;8;6;6;5;5;5;5;5;5;5;5;5;5","NICOLA RAGNI;FRANCESCO FRASSONI;GIORGIO CIPRANDI;SIMONE FERRERO;IGNAZIO CIRILLO;CLAUDIO VISCOLI;VALENTINO REMORGIDA;ANDREA BACIGALUPO;EMANUELA MISTRANGELO;DAVIDE LIJOI;ALBERTO SOBRERO;M. VALBONESI;GIANNI TESTINO;NULL AUTHOR_ID;FRANCO ALESSANDRI;LUIZA HELENA ABBAMONTE;MARIA TERESA VAN LINT;MATTEO BASSETTI;ANNAMARIA NICOLETTI;S. COSTANTINI","2.47;1.82;1.81;1.49;1.39;1.32;1.29;1.19;1.13;1.1;1;1;1;1;0.91;0.83;0.83;0.82;0.73;0.7","MARIA TERESA VAN LINT;ANDREA BACIGALUPO;GÈRARD SOCIÉ;NICOLA RAGNI;UMBERTO VALENTE;ANDRÉ TICHELLI;ALBERTO GIANNETTI;ANDREA CONTI;CHIARA BONINI;FRANCESCA DI NUNZIO;FULVIO MAVILIO;GIULIETTA MARUGGI;GRAZIELLA PELLEGRINI;MICHELE DE LUCA;SERGIO CAPURRO;STEFANO FERRARI;ALESSANDRA RECCHIA;CRISTINA MAGNONI;ELENA PROVASI;ENZO DI IORIO","771;754;739;704;665;663;637;637;637;637;637;637;637;637;637;637;635;635;635;635","MARIA TERESA VAN LINT;ANDREA BACIGALUPO;NICOLA RAGNI;UMBERTO VALENTE;SERGIO CAPURRO;SIMONE FERRERO;M BEATINI;VALENTINO REMORGIDA;F. BOBBIO PALLAVICINI;R. FASCE;TERESA LAMPARELLI;ALESSANDRO COSTA;M.P. MOLINARI;ALBERTO BOSI;BARBARA BRUNO;GIOVANNI BARISIONE;PAOLO BRUZZI;ROSI ONETO;FRANCO ALESSANDRI;GIORGIO CIPRANDI","771;754;704;649;637;596;474;429;341;341;339;338;338;329;329;329;329;329;322;316","NICOLA RAGNI;ANDREA BACIGALUPO;FRANCESCO FRASSONI;GIORGIO CIPRANDI;SIMONE FERRERO;MARIA TERESA VAN LINT;VALENTINO REMORGIDA;EMANUELA MISTRANGELO;DAVIDE LIJOI;LUIZA HELENA ABBAMONTE;ROBERTO PONTREMOLI;FRANCO ALESSANDRI;ADALBERTO IBATICI;ANNAMARIA NICOLETTI;CINZIA TOMOLILLO;ELENA RATTO;FRANCESCA VIAZZI;GIACOMO DEFERRARI;GIOVANNA LEONCINI;UMBERTO VALENTE","14;12;10;10;9;8;8;6;5;5;5;5;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;ECONOMICS;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;POLITICAL SCIENCE;ART;ENVIRONMENTAL SCIENCE;HISTORY;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY","103;42;11;4;3;3;3;3;2;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;IMMUNOLOGY;GASTROENTEROLOGY;CARDIOLOGY;PATHOLOGY;INTENSIVE CARE MEDICINE;ANESTHESIA;ONCOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;OBSTETRICS;OPTICS;DERMATOLOGY;ENDOCRINOLOGY;GYNECOLOGY;MICROBIOLOGY;BIOCHEMISTRY;CANCER RESEARCH;CELL BIOLOGY;PALEONTOLOGY","84;45;29;29;23;14;13;12;11;11;9;8;7;7;6;6;6;6;5;5;5;5","TRANSPLANTATION;STEM CELL;DISEASE;CANCER;BONE MARROW;POPULATION;BLOOD PRESSURE;INCIDENCE (GEOMETRY);ASTHMA;ENDOMETRIOSIS;GENE;LEUKEMIA;MYELOID LEUKEMIA;PROSPECTIVE COHORT STUDY;CHEMOTHERAPY;CONFIDENCE INTERVAL;NOSE;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;RECEPTOR","28;18;13;11;10;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5","HAEMATOPOIESIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;GRAFT-VERSUS-HOST DISEASE;RHINOMANOMETRY;CD34;COLORECTAL CANCER;LIVER TRANSPLANTATION;MICROALBUMINURIA;APLASTIC ANEMIA;BREAST CANCER;HAZARD RATIO;HUMAN LEUKOCYTE ANTIGEN;IMATINIB;KIDNEY TRANSPLANTATION;RESPIRATORY DISEASE;SPIROMETRY;ADENOCARCINOMA;ALBUMINURIA;AMBULATORY BLOOD PRESSURE;ARTERIAL STIFFNESS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BONE MARROW TRANSPLANTATION;BREAKPOINT CLUSTER REGION;CARCINOGENESIS;CHEMOKINE;CHRONIC MYELOGENOUS LEUKEMIA;CUMULATIVE INCIDENCE;GENETIC ENHANCEMENT;INFERTILITY;INTERLEUKIN 6;LAMININ;LAPAROSCOPIC SURGERY;LEFT VENTRICULAR HYPERTROPHY;LEVOBUPIVACAINE;MELPHALAN;MYOMA;PROGENITOR CELL;RELATIVE RISK;REPERFUSION INJURY;SINUS RHYTHM;TYROSINE KINASE;UTERINE CAVITY;VASCULITIS","9;9;5;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ABL;BONE MARROW TRANSPLANT;BRONCHIAL HYPERREACTIVITY;CHEMOKINE RECEPTOR;GIANT CELL ARTERITIS;HEMATOPOIETIC CELL;IMATINIB MESYLATE;JUNCTIONAL EPIDERMOLYSIS BULLOSA (VETERINARY MEDICINE);METHACHOLINE;ADJUVANT CHEMOTHERAPY;ANTIRETROVIRAL THERAPY;ATROPHIC GASTRITIS;BRONCHIAL HYPERRESPONSIVENESS;BRONCHUS;CARMUSTINE;CAROTID STENTING;CASPOFUNGIN;CD146;CD38;CD90;CEFTAZIDIME;CMIN;CTL*;CXCR4;CYTOGENETICS;DIFFUSING CAPACITY;ENOS;ESTROGEN RECEPTOR;EXTRACORPOREAL PHOTOPHERESIS;FLUDARABINE;FRACTIONAL ANISOTROPY;GASTRIC ADENOCARCINOMA;GASTROINTESTINAL CANCER;GERMLINE MUTATION;IFOSFAMIDE;INTRAEPITHELIAL NEOPLASIA;LEGIONNAIRES' DISEASE;LIVING DONOR LIVER TRANSPLANTATION;LOWER SEGMENT CAESAREAN SECTION;MEDIAL LONGITUDINAL FASCICULUS;MULTIPOTENT STEM CELL;OSTEOPENIA;OXALIPLATIN;PANEL REACTIVE ANTIBODY;PATIENT HEALTH QUESTIONNAIRE;PHILADELPHIA CHROMOSOME;SUBLINGUAL IMMUNOTHERAPY;TAMOXIFEN;TELEDERMATOLOGY;THYMOGLOBULIN;TOBRAMYCIN;TRACTOGRAPHY;TUMOR SUPPRESSOR GENE;UTERINE MYOMECTOMY","2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;;AGED;HEMATOPOIETIC STEM CELL TRANSPLANTATION;GRAFT VS HOST DISEASE;RHINITIS, ALLERGIC, PERENNIAL;RHINITIS, ALLERGIC, SEASONAL;TREATMENT OUTCOME;LIVER TRANSPLANTATION;HYPERTENSION;ADOLESCENT;BONE MARROW TRANSPLANTATION;ITALY;ALBUMINURIA;ENDOMETRIOSIS;KIDNEY TRANSPLANTATION","84;56;50;47;37;22;20;19;18;18;16;15;14;13;11;11;11;10;10;10","HEMATOPOIETIC STEM CELL BIOLOGY;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EFFICACY AND RESISTANCE IN CML TREATMENT;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MULTIPOTENT MESENCHYMAL STEM CELLS;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;ASTHMA;BIOLOGY AND PATHOLOGY OF KERATINS AND RELATED DISORDERS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF URTICARIA;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;UTERINE CONDITIONS AND TREATMENTS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BIOMECHANICAL PROPERTIES OF THE CORNEA AND RELATED DISEASES;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH","11;7;7;4;4;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1","HEMATOPOIETIC CELL TRANSPLANTATION;HYPERTENSION;GRAFT-VERSUS-HOST DISEASE;RHINOMANOMETRY;MICROALBUMINURIA;POSTOPERATIVE PAIN;REGIMEN;STEM CELL AGING;TRANSPLANTATION;ACOUSTIC RHINOMETRY;ALBUMINURIA;APLASTIC ANEMIA;BLOOD PRESSURE;BRACHIAL ARTERY ASSESSMENT;DIAGNOSIS;LIVING DONOR LIVER TRANSPLANTATION;MESENCHYMAL STEM CELLS;POLLEN ALLERGY;TREATMENT;ABL","12;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2","CELL TRANSPLANTATION;MARROW TRANSPLANTATION;STEM CELL;PRIMARY HYPERTENSION;ALLERGIC RHINITIS;GRAFT-VERSUS-HOST DISEASE;HEMATOPOIETIC STEM;STEM CELLS;BONE MARROW;DECONGESTION TEST;MARROW TRANSPLANT;PERIPHERAL BLOOD;WOUND PAIN;ACUTE GRAFT-VERSUS-HOST;ALLOGENEIC HEMATOPOIETIC;AMBULATORY ARTERIAL;AMERICAN SOCIETY;APLASTIC ANEMIA;ARTERIAL STIFFNESS;BLOOD STEM;BRONCHIAL HYPERREACTIVITY;CARDIOVASCULAR RISK;CELL TRANSPLANT;CHRONIC GRAFT-VERSUS-HOST;COMPLETE CYTOGENETIC;CORD BLOOD;CT ENTEROCLYSIS;CYTOGENETIC RESPONSE;EPIDERMAL STEM;EPIDERMOLYSIS BULLOSA","9;8;8;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CD CD;PAIN SYMPTOMS;ARTERIAL STIFFNESS;INCREASED RISK;STEM CELL;AMBULATORY ARTERIAL;CD CTL;EBV-SERONEGATIVE CHILDREN;HEMATOPOIETIC STEM;STIFFNESS INDEX;BOWEL WALL;PEDIATRIC PATIENTS;PRIMARY HYPERTENSION;SPLIT LIVER;STEM CELLS;SYMPATHETIC NERVE;BM TRANSPLANTATION;CAROTID ABNORMALITIES;CELL TRANSPLANTATION;CHRONIC GVHD;CTL ENDOWED;DONORRECIPIENT ORIGIN;EBV-SPECIFIC CD;LCL STIMULATION;LEFT VENTRICULAR;LIVER TRANSPLANTATION;MENTAL DISORDERS;ORGAN DAMAGE;PATIENTS UNDERGOING;RELATIVE RISK","14;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4",22,0.21,3.8,2.75,1.5,3,0,10,2,0,1,2.75,0,1,3,1,2,1,1,2.5,1.75,0,0,89.25,89.25,1,0,0,0,0,0,0,2,0,0,0,0,0,2,0,45,2,1.14,2,0,2,2,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CANCEDDA RANIERI;DOZIN BEATRICE","2;2","CONSORZIO PER LA GESTIONE DEL CENTRO DI BIOTECNOLOGIA AVANZATA;ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO","2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;40 ENGINEERING","2;2;2","REGENERATIVE MEDICINE;STEM CELL RESEARCH;PEDIATRIC","2;2;1","5.2 CELLULAR AND GENE THERAPIES","2","A61K35/12;C12N5/00;C12N5/02;C12N5/077;C12N5/0775;C12R1/91","2;2;2;2;2;2","A61K35/12;C12N2500/25;C12N2500/36;C12N2500/38;C12N2500/90;C12N2501/105;C12N2501/11;C12N2501/115;C12N2501/125;C12N2501/135","2;2;2;2;2;2;2;2;2;2",16,6.25,1150.75,9.14,3,0.19,54.38,1,1,7,0,5,0,1,1,0,11,1,0,0,0,0,0,0,16,0,0,12,4,0,0,0,0,0,0,0,0,"United States;Canada;Italy;Switzerland","3;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3206 MEDICAL BIOTECHNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","16;10;7;4;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;LUNG;LUNG CANCER;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION;COLO-RECTAL CANCER;DIGESTIVE DISEASES;LYMPHOMA;ATHEROSCLEROSIS;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;HEALTH SERVICES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE","13;11;10;6;4;3;3;3;3;3;3;2;2;2;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","9;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","12;3;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;LUNG CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;KIDNEY CANCER;MYELOMA","4;3;3;2;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","12;3;2",2,2693669,57395.02,8,154.5,26,1,24.5,221572.951247964,0.482910930225665,"HOSPITAL BASE;OSPEDALE POLICLINICO SAN MARTINO;ADDENBROOKE'S HOSPITAL;ALEXANDER FLEMING BIOMEDICAL SCIENCES RESEARCH CENTER;ALL INDIA INSTITUTE OF MEDICAL SCIENCES;ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY;ANHUI PROVINCIAL HOSPITAL;ANKARA ONKOLOJI EĞITIM VE ARAŞTIRMA HASTANESI;ANTONI VAN LEEUWENHOEK HOSPITAL;ARGERICH HOSPITAL;ASSOCIATION FOR CANCER SURGERY;ASTRAZENECA (UNITED KINGDOM);AUSTRIAN BREAST & COLORECTAL CANCER STUDY GROUP;AUTONOMOUS UNIVERSITY OF BARCELONA;BETH ISRAEL DEACONESS MEDICAL CENTER;BIRMINGHAM CHILDREN'S HOSPITAL;BOX HILL HOSPITAL;BRADFORD ROYAL INFIRMARY;CAIRO UNIVERSITY;CANCER CARE ONTARIO","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;MEDICAL RESEARCH COUNCIL","1;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","2;1;1;1","CA - COORDINATION ACTION (FUNDING SCHEME);FP6-2005-GLOBAL-4 (CALL FOR PROPOSAL);FP6-SUSTDEV - SUSTAINABLE DEVELOPMENT, GLOBAL CHANGE AND ECOSYSTEMS: THEMATIC PRIORITY 6 UNDER THE FOCUSING AND INTEGRATING COMMUNITY RESEARCH PROGRAMME 2002-2006. (PROGRAMME);INTRAMURAL (PROJECT CATEGORY)","1;1;1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4206 PUBLIC HEALTH","2;2;1;1;1","BREAST CANCER;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES","1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","1;1;1","BREAST CANCER","1","5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;C13 ARCHITECTURE, BUILT ENVIRONMENT AND PLANNING","1;1","3 GOOD HEALTH AND WELL BEING","1",1,"PUBLIC LIBRARY OF SCIENCE","1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY","2;1","GENETICS","1","GENERIC HEALTH RELEVANCE","1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","1","BIOMEDICAL","1","BASIC SCIENCE","1","NOT SITE-SPECIFIC CANCER","1",NA,NA
"IRCCS_SANMARTINO",2007,132,9.18181818181818,2.93939393939394,0.34020618556701,0.424242424242424,0.295454545454545,0.356060606060606,0.356060606060606,4,65,24,17,16,0.49,0.18,0.13,0.12,47.33,0.896872469664588,0.212121212121212,0.818181818181818,NA,0.499508111462618,0.512753677155092,0.511869918699187,0.474725274725275,"ANDREA BACIGALUPO;FRANCESCO FRASSONI;GIORGIO CIPRANDI;GIAN LUIGI MARSEGLIA;NICOLA RAGNI;IGNAZIO CIRILLO;MARINA PODESTÀ;ANGELO MICHELE CARELLA;ANNA MARIA RAIOLA;FRANCESCA GUALANDI;CATHERINE KLERSY;MARCO GOBBI;GIOVANNA PIAGGIO;SARAH POZZI;ADALBERTO IBATICI;MARIA TERESA VAN LINT;EZIO FULCHERI;MICHELE MUSSAP;SIMONE FERRERO;BENEDETTO BRUNO","20;18;16;12;9;9;8;7;7;7;7;7;7;7;6;6;5;5;5;5","GIORGIO CIPRANDI;FRANCESCO FRASSONI;IGNAZIO CIRILLO;GIAN LUIGI MARSEGLIA;ANGELO MICHELE CARELLA;ANDREA BACIGALUPO;NICOLA RAGNI;FRANCESCA VIAZZI;CATHERINE KLERSY;MATTEO BASSETTI;S VOLTOLINI;SIMONE FERRERO;EZIO FULCHERI;GIACOMO DEFERRARI;MARINA PODESTÀ;VALENTINO REMORGIDA;SARAH POZZI;GIOVANNA PIAGGIO;MICHELE MUSSAP;ENRICA LERMA","2.97;1.97;1.96;1.93;1.93;1.48;1.44;1.43;1.23;1.19;1;0.84;0.84;0.77;0.73;0.68;0.62;0.62;0.6;0.6","ANDREA BACIGALUPO;FRANCESCO FRASSONI;GIORGIO CIPRANDI;GIAN LUIGI MARSEGLIA;NICOLA RAGNI;MARINA PODESTÀ;ANGELO MICHELE CARELLA;ANNA MARIA RAIOLA;FRANCESCA GUALANDI;MARCO GOBBI;GIOVANNA PIAGGIO;SARAH POZZI;ADALBERTO IBATICI;MARIA TERESA VAN LINT;EZIO FULCHERI;MICHELE MUSSAP;SIMONE FERRERO;BENEDETTO BRUNO;FRANCESCA VIAZZI;GIACOMO DEFERRARI","20;18;16;12;9;8;7;7;7;7;7;7;6;6;5;5;5;5;5;5","GIORGIO CIPRANDI;FRANCESCO FRASSONI;GIAN LUIGI MARSEGLIA;ANGELO MICHELE CARELLA;ANDREA BACIGALUPO;NICOLA RAGNI;FRANCESCA VIAZZI;MATTEO BASSETTI;S VOLTOLINI;SIMONE FERRERO;EZIO FULCHERI;GIACOMO DEFERRARI;MARINA PODESTÀ;VALENTINO REMORGIDA;SARAH POZZI;GIOVANNA PIAGGIO;MICHELE MUSSAP;ENRICA LERMA;ALESSANDRA GUGLIELMI;FRANCESCA GUALANDI","2.97;1.97;1.93;1.93;1.48;1.44;1.43;1.19;1;0.84;0.84;0.77;0.73;0.68;0.62;0.62;0.6;0.6;0.58;0.57","ANDREA BACIGALUPO;FRANCESCO FRASSONI;GIANLUIGI MANCARDI;ANTONIO UCCELLI;EZIO GERDONI;ATTILIO OLIVIERI;ANNA LOCASCIULLI;JUDITH MARSH;GIORGIO CIPRANDI;BARBARA GALLO;ENRICO PEDEMONTE;IVAN BONANNI;RENATO MANTEGAZZA;ROSETTA PEDOTTI;SILVIA MUSIO;SIMONA CASAZZA;FRANCO LOCATELLI;GIAN LUIGI MARSEGLIA;FABRIZIO GINEVRI;MICHELA CIONI","1535;1081;737;733;733;556;545;519;510;478;478;478;478;478;478;478;408;391;384;384","ANDREA BACIGALUPO;FRANCESCO FRASSONI;GIORGIO CIPRANDI;ROSI ONETO;MARCO GOBBI;MARIA TERESA VAN LINT;ANNALISA KUNKL;FRANCESCA GUALANDI;JEAN LOUIS RAVETTI;I. FONTANA;MICHELE MUSSAP;F. BOBBIO PALLAVICINI;L. BARUTTA;PAOLO DURANDO;NICOLA RAGNI;SIMONE FERRERO;VALENTINO REMORGIDA;SARAH POZZI;M. CENTANARO;FILIPPO ANSALDI","1535;1081;454;371;367;329;286;283;243;240;208;204;197;194;191;179;170;165;160;159","ANDREA BACIGALUPO;FRANCESCO FRASSONI;GIORGIO CIPRANDI;MARINA PODESTÀ;GIOVANNA PIAGGIO;MARCO GOBBI;ANGELO MICHELE CARELLA;SARAH POZZI;ADALBERTO IBATICI;ANNA MARIA RAIOLA;FRANCESCA GUALANDI;MARIA TERESA VAN LINT;NICOLA RAGNI;MAURO SPRIANO;NADIA SESSAREGO;SIMONE FERRERO;ALIDA DOMINIETTO;BENEDETTO BRUNO;VALENTINO REMORGIDA;ALESSIA PARODI","20;18;15;8;7;7;7;7;6;6;6;5;5;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;PSYCHOLOGY;PHILOSOPHY;POLITICAL SCIENCE;ECONOMICS;GEOGRAPHY;BUSINESS;ENGINEERING;GEOLOGY;MATHEMATICS;SOCIOLOGY","125;47;11;8;7;5;3;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;IMMUNOLOGY;GENETICS;PATHOLOGY;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;BIOCHEMISTRY;CANCER RESEARCH;RADIOLOGY;MICROBIOLOGY;ONCOLOGY;ANESTHESIA;PHARMACOLOGY;INTENSIVE CARE MEDICINE;CARDIOLOGY;OPTICS;PEDIATRICS;GYNECOLOGY;PSYCHIATRY","92;50;30;30;26;18;13;12;11;11;11;10;10;9;9;8;7;7;7;6;6","TRANSPLANTATION;BONE MARROW;CHEMOTHERAPY;CANCER;GENE;POPULATION;ALLERGY;STEM CELL;ANTIBIOTICS;LEUKEMIA;ADVERSE EFFECT;ASTHMA;MYELOID LEUKEMIA;REGIMEN;IMMUNE SYSTEM;IN VITRO;INCIDENCE (GEOMETRY);MULTIVARIATE ANALYSIS;BODY MASS INDEX;DIABETES MELLITUS;MULTIPLE MYELOMA","21;17;17;13;12;12;11;11;10;10;9;8;8;8;7;7;7;7;6;6;6","CYCLOPHOSPHAMIDE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CUMULATIVE INCIDENCE;GRAFT-VERSUS-HOST DISEASE;BREAST CANCER;ACUTE LEUKEMIA;CD34;ESCHERICHIA COLI;IMATINIB;IMMUNOTHERAPY;MELPHALAN;PROGENITOR CELL;PSEUDOMONAS AERUGINOSA;RHINOMANOMETRY;T CELL;UNIVARIATE ANALYSIS;ALBUMINURIA;ALLERGIC INFLAMMATION;ANTIBIOTIC RESISTANCE;CARBAPENEM;CD8;CLINICAL ENDPOINT;CYTOTOXIC T CELL;ESSENTIAL HYPERTENSION;LIVER TRANSPLANTATION;MINIMAL RESIDUAL DISEASE;MYELOFIBROSIS;PERIPHERAL BLOOD MONONUCLEAR CELL;TYPE 2 DIABETES","11;11;9;6;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","FLUDARABINE;LYMPHEDEMA;THIOTEPA;TOTAL BODY IRRADIATION;BUSULFAN;CETUXIMAB;DIFFUSING CAPACITY;ENTEROBACTERIACEAE;IMATINIB MESYLATE;IMIPENEM;INTEGRON;KLEBSIELLA PNEUMONIAE;MONOCLONAL;PIOGLITAZONE;SUBLINGUAL IMMUNOTHERAPY;TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;VINCRISTINE;ACINETOBACTER BAUMANNII;ACROMEGALY;ACUTE PROMYELOCYTIC LEUKEMIA;ADOPTIVE CELL TRANSFER;ADULT STEM CELL;ANTIRETROVIRAL THERAPY;AROMATASE;AXILLA;BASIC FIBROBLAST GROWTH FACTOR;BETA-LACTAMASE;BIGUANIDE;BK VIRUS;BODY CONTOURING;BROTH MICRODILUTION;CD28;CD33;CD40;CENTROSOME;CHORIOAMNIONITIS;CLASTOGEN;COGNITIVE DECLINE;CTL*;CYCLIN;CYCLIN D1;EGFR INHIBITORS;ENDOTHELIAL PROGENITOR CELL;ESTROGEN RECEPTOR;EXTRACORPOREAL PHOTOPHERESIS;FIMBRIA;FOVEOLAR CELL;FRAMINGHAM HEART STUDY;GASTRIC BYPASS;GASTRIC VARICES;GEFITINIB;HEMOLYSIN;HMG-COA REDUCTASE;HOMEOSTATIC MODEL ASSESSMENT;IDARUBICIN;IL-2 RECEPTOR;IRINOTECAN;KARYOTYPE;MEROPENEM;MIGRAINE WITH AURA;MIXED LYMPHOCYTE REACTION;MORBID OBESITY;MORBIDLY OBESE;MULTICENTER TRIAL;MULTIPOTENT STEM CELL;NILOTINIB;NORETHISTERONE;NORFLOXACIN;OSTEOPROTEGERIN;OXALIPLATIN;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;PORTOSYSTEMIC SHUNT;PROTEUS MIRABILIS;SENTINEL LYMPH NODE;SINGLE-NUCLEOTIDE POLYMORPHISM;SOMATOSTATIN RECEPTOR 2;TRANSRECTAL ULTRASONOGRAPHY;TUMOR-INFILTRATING LYMPHOCYTES;VASCULOGENIC MIMICRY","7;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;;RHINITIS, ALLERGIC, PERENNIAL;ADOLESCENT;ASTHMA;ITALY;ANTINEOPLASTIC AGENTS;GRAFT VS HOST DISEASE;TREATMENT OUTCOME;ANTI-BACTERIAL AGENTS;RHINITIS, ALLERGIC, SEASONAL;CHILD;HYPERTENSION;PROSPECTIVE STUDIES;AGED, 80 AND OVER","99;78;67;54;48;35;29;25;21;21;21;20;20;19;17;16;15;14;14;13","HEMATOPOIETIC STEM CELL BIOLOGY;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ASTHMA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;EFFICACY AND RESISTANCE IN CML TREATMENT;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;MULTIPOTENT MESENCHYMAL STEM CELLS;ACUTE MYELOID LEUKEMIA;CHRONIC RHINOSINUSITIS AND NASAL POLYPS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CLINICAL IMPLICATIONS OF UTERINE ANOMALIES AND TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;LYMPHANGIOGENESIS IN CANCER METASTASIS AND DISEASE;LYMPHOID NEOPLASMS;MANAGEMENT OF DIABETES MELLITUS AND CARDIOVASCULAR RISK;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS","9;8;6;5;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2","CUMULATIVE INCIDENCE;HEMATOPOIETIC CELL TRANSPLANTATION;REGIMEN;HYPERTENSION;MESENCHYMAL STEM CELLS;TRANSPLANTATION;TREATMENT OUTCOMES;ASTHMA;LIVING DONOR LIVER TRANSPLANTATION;MELPHALAN;REFRACTORY (PLANETARY SCIENCE);RHINOMANOMETRY;TREATMENT;UNIVARIATE ANALYSIS;ALBUMINURIA;ALLERGIC INFLAMMATION;CARBAPENEM;CLINICAL ENDPOINT;COUGH REFLEX SENSITIVITY;ESSENTIAL HYPERTENSION","9;9;8;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3","ALLERGIC RHINITIS;STEM CELL;BONE MARROW;CELL TRANSPLANTATION;MESENCHYMAL STEM;MULTIPLE MYELOMA;STEM CELLS;ALLOGENEIC STEM;CARE UNIT;CD CELL;DECONGESTION TEST;HUMAN MESENCHYMAL;INTENSIVE CARE;MARROW TRANSPLANTATION;MYELOID LEUKEMIA;PILOT STUDY;PRIMARY HYPERTENSION;PROGENITOR CELLS;RESPIRATORY INFECTIONS;ACUTE LEUKEMIA;ACUTE MYELOID;ACUTE RHINOSINUSITIS;ADVANCED COLORECTAL;ALLOGENEIC BONE;ALLOGENEIC HEMOPOIETIC;APLASTIC ANEMIA;ARIA CLASSIFICATION;BASED CONDITIONING;BLOOD CELLS;CELL COUNT","7;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","BONE MARROW;STEM CELLS;NIGO DEVICE;STEM CELL;ALLERGIC RHINITIS;CD CELL;HISTOLOGICAL EVALUATION;SUDDEN DEATH;CB CELLS;CENTROSOME ABERRATIONS;CUMULATIVE INCIDENCE;ECCRINE CARCINOMA;ENDOTHELIAL CELLS;GROWTH FACTOR;MESENCHYMAL STEM;PATIENTS UNDERGOING;PERIPHERAL BLOOD;SIGNIFICANT DIFFERENCE;SUPSUPF-FDG UPTAKE;SYRINGOID ECCRINE;ADEQUATE BIOPSY;ADVERSE EVENTS;BKV DNA;BKV REPLICATION;BKV-SPECIFIC CELLULAR;BUCCAL MUCOSA;CANCER PATIENTS;CELL DEATH;CELL TRANSPLANTATION;CELLULAR IMMUNITY","11;11;10;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4",26,0.2,4.54,2,1.75,1,1,0,2.5,0,1,2,0,1,2,0,2.5,1,1,1,0,0,0,81.75,81.75,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,2,7,1.8,2,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBINI ADRIANA;BENELLI ROBERTO;BRIGATI CLAUDIO;DELL EVA RAFFAELLA;MINGHELLI SIMONA;MORINI MONICA;NOONAN DOUGLAS M","1;1;1;1;1;1;1","ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO;ISTITUTO NAZIONALE PER LA RICERCE SUL CANCRO","1;1","34 CHEMICAL SCIENCES;48 LAW AND LEGAL STUDIES;4806 PRIVATE LAW AND CIVIL OBLIGATIONS","1;1;1",NA,NA,"5.1 PHARMACEUTICALS","1","A61K38/10;C07K14/78;C07K7/08","1;1;1","A61K38/00;A61P27/02;A61P27/06;A61P29/00;A61P43/00;A61P9/00;A61P9/10;C12N9/6435;C12Y304/21007","1;1;1;1;1;1;1;1;1",20,5.94,944.65,10.1,5,0.25,68.1,0,0,8,0,9,0,0,3,0,15,2,0,0,0,0,0,0,17,3,0,17,3,0,0,0,0,0,0,0,0,"Italy;United States","11;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3209 NEUROSCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","20;12;11;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;HEMATOLOGY;COLO-RECTAL CANCER;ORPHAN DRUG;BREAST CANCER;LUNG;LYMPHOMA;AGING;ASTHMA;BIOMEDICAL IMAGING;BRAIN DISORDERS;COMPARATIVE EFFECTIVENESS RESEARCH;CONTRACEPTION/REPRODUCTION;DIABETES;EPILEPSY","16;14;11;6;5;5;4;3;3;2;2;2;1;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL;INFECTION;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;RESPIRATORY","11;2;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","14;1;1;1","BREAST CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PANCREATIC CANCER","3;3;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","10;2;1;1",1,1206670,19781.48,4,61,19,1,156,162234.486767089,0.813637116438164,"ACADEMIC MEDICAL CENTER;ACADEMY OF ATHENS;ALLEANZA CONTRO IL CANCRO;ASTRAZENECA (UNITED KINGDOM);AUTONOMOUS UNIVERSITY OF MADRID;BABRAHAM BIOSCIENCE TECHNOLOGIES (UNITED KINGDOM);BAYER (UNITED KINGDOM);BOEHRINGER INGELHEIM (GERMANY);DECODE GENETICS (ICELAND);ERASMUS MC;EUROPEAN BIOINFORMATICS INSTITUTE;FEDERAL MINISTRY OF EDUCATION AND RESEARCH;FEDERAL MINISTRY OF SCIENCE, RESEARCH AND ECONOMICS;FRAUNHOFER SOCIETY;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;GLAXOSMITHKLINE (UNITED KINGDOM);GOVERNMENT OF ESTONIA;GOVERNMENT OF FRANCE;GOVERNMENT OF NETHERLANDS;HEALTH RESEARCH BOARD","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICAL RESEARCH COUNCIL","1","COALITION S;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","1;1;1","RESEARCH GRANT (PROJECT CATEGORY)","1","31 BIOLOGICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","GENETICS;HUMAN GENOME","1;1",NA,NA,"1.5 RESOURCES AND INFRASTRUCTURE (UNDERPINNING);2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY)","1;1","NOT SITE-SPECIFIC CANCER","1","1.5 RESOURCES AND INFRASTRUCTURE;2.4 RESOURCES AND INFRASTRUCTURE RELATED TO ETIOLOGY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1;1;1;1","A01 CLINICAL MEDICINE","1",NA,NA,1,"PUBLIC LIBRARY OF SCIENCE","1","31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS","2;1;1","BIOTECHNOLOGY;GENETICS;HUMAN GENOME","1;1;1","GENERIC HEALTH RELEVANCE","1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","1","BIOMEDICAL","1","BASIC SCIENCE","1",NA,NA,NA,NA
"IRCCS_SANMARTINO",2008,157,9.63694267515924,2.47133757961783,0.404639175257732,0.420382165605096,0.337579617834395,0.203821656050955,0.261146496815287,4,78,40,9,22,0.5,0.25,0.06,0.14,53.71,0.97888727179786,0.286624203821656,0.815286624203822,NA,0.489896285271551,0.522692307692308,0.537822671156004,0.52234993614304,"ANDREA BACIGALUPO;GIORGIO CIPRANDI;FRANCESCO FRASSONI;ENZO SILVESTRI;FRANCESCA LACELLI;GIACOMO GARLASCHI;GIAN LUIGI MARSEGLIA;LM SCONFIENZA;MARIO DI GIOACCHINO;IGNAZIO CIRILLO;ANGELA PISTORIO;SIMONE FERRERO;MAURO SPRIANO;ADALBERTO IBATICI;MARIA TERESA VAN LINT;ANGELO MICHELE CARELLA;FORTUNATO MORABITO;FRANCESCA GUALANDI;MYRIAM LABOPIN;MARINA PODESTÀ","21;19;16;11;10;7;7;7;7;7;6;6;6;6;6;5;5;5;5;5","GIORGIO CIPRANDI;ANDREA BACIGALUPO;ENZO SILVESTRI;IGNAZIO CIRILLO;FRANCESCO FRASSONI;FRANCESCA LACELLI;ANGELA PISTORIO;GIACOMO GARLASCHI;LM SCONFIENZA;CLAUDIO VISCOLI;SIMONE FERRERO;A. SOBRERO;C. BALDINI;DAVIDE ROLLA;A. FASCIOLO;ALBERTO F. SOBRERO;GIAN LUIGI MARSEGLIA;ALBERTO SOBRERO;MARIO DI GIOACCHINO;LM SCONFIENZA","3.53;2.7;1.83;1.71;1.68;1.67;1.57;1.17;1.17;1.12;1.01;1;1;1;1;1;0.9;0.9;0.89;0.83","ANDREA BACIGALUPO;GIORGIO CIPRANDI;FRANCESCO FRASSONI;ENZO SILVESTRI;SIMONE FERRERO;MAURO SPRIANO;ADALBERTO IBATICI;MARIA TERESA VAN LINT;ANGELO MICHELE CARELLA;FRANCESCA GUALANDI;MARINA PODESTÀ;CLAUDIO VISCOLI;ANNA MARIA RAIOLA;GIOVANNA LEONCINI;FRANCESCA VIAZZI;ANDREA BRUGNOLO;NICOLA RAGNI;GIACOMO DEFERRARI;ROBERTO PONTREMOLI;ALIDA DOMINIETTO","21;19;16;11;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4","GIORGIO CIPRANDI;ANDREA BACIGALUPO;ENZO SILVESTRI;FRANCESCO FRASSONI;CLAUDIO VISCOLI;SIMONE FERRERO;A. SOBRERO;C. BALDINI;DAVIDE ROLLA;A. FASCIOLO;ALBERTO F. SOBRERO;ALBERTO SOBRERO;GIOVANNA LEONCINI;FRANCESCA VIAZZI;ROBERTO PONTREMOLI;ELENA RATTO;VALENTINO REMORGIDA;NICOLA RAGNI;GIUSEPPE M. MARINARI;MATTEO BASSETTI","3.53;2.7;1.83;1.68;1.12;1.01;1;1;1;1;1;0.9;0.71;0.71;0.71;0.71;0.7;0.64;0.62;0.61","ANDREA BACIGALUPO;FRANCESCO FRASSONI;FRANCO LOCATELLI;KATARINA LE BLANC;OLLE RINGDÉN;WILLEM E. FIBBE;BERIT SUNDBERG;EDOARDO LANINO;GIORGIO DINI;HELENE ROELOFS;IAN A. LEWIS;LYNNE M. BALL;MARIA ESTER BERNARDO;MATS REMBERGER;R. MAARTEN EGELER;MYRIAM LABOPIN;ANTONIO DAGA;DANIELA MARUBBI;FABRIZIO GRIFFERO;GIAN LUIGI RAVETTI","3812;3573;2609;2609;2609;2609;2607;2607;2607;2607;2607;2607;2607;2607;2607;553;552;552;552;552","ANDREA BACIGALUPO;FRANCESCO FRASSONI;GIAN LUIGI RAVETTI;GIORGIO CIPRANDI;ADALBERTO IBATICI;NADIA SESSAREGO;FRANCESCA GUALANDI;ANNA MARIA RAIOLA;MARIA TERESA VAN LINT;MARINA PODESTÀ;GIOVANNA PIAGGIO;BENEDETTO BRUNO;DANIELA VERZOLA;PAOLO STRADA;NICOLA RAGNI;ROSI ONETO;FRANCO FERRILLO;MARTA ALLENA;ENRICO BALLEARI;SIMONE FERRERO","3812;3404;552;459;449;429;397;392;328;265;262;251;247;226;207;188;180;180;179;178","ANDREA BACIGALUPO;GIORGIO CIPRANDI;FRANCESCO FRASSONI;ENZO SILVESTRI;ADALBERTO IBATICI;MARIA TERESA VAN LINT;ANGELO MICHELE CARELLA;MAURO SPRIANO;ALIDA DOMINIETTO;FRANCESCA GUALANDI;MARINA PODESTÀ;NICOLA RAGNI;SIMONE FERRERO;VALENTINO REMORGIDA;SARAH POZZI;ALBERTO SOBRERO;ANNA MARIA RAIOLA;GIACOMO DEFERRARI;MASSIMO VISCHI;SAMIR GIUSEPPE SUKKAR","21;19;15;11;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;GEOLOGY;ECONOMICS;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY","148;49;12;10;7;6;4;3;2;2;2;2;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;GENETICS;ONCOLOGY;RADIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;PATHOLOGY;ANESTHESIA;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;CELL BIOLOGY;CANCER RESEARCH;CARDIOLOGY;ANATOMY;PEDIATRICS;DERMATOLOGY;GYNECOLOGY;MICROBIOLOGY;NEUROSCIENCE;NUCLEAR MEDICINE;PALEONTOLOGY;PHYSICAL THERAPY;PSYCHIATRY;UROLOGY","107;63;41;33;22;20;19;16;13;13;12;12;12;11;10;10;9;8;6;5;5;5;5;5;5;5;5","TRANSPLANTATION;BONE MARROW;CHEMOTHERAPY;CANCER;STEM CELL;ALLERGY;POPULATION;ANTIBODY;ULTRASOUND;DISEASE;GENE;REGIMEN;ASTHMA;BLOOD PRESSURE;LEUKEMIA;ADVERSE EFFECT;IMMUNE SYSTEM;COHORT;LYMPHOMA;MAGNETIC RESONANCE IMAGING;NOSE","31;20;18;17;17;13;13;11;11;10;10;10;9;9;9;8;8;7;7;7;7","HEMATOPOIETIC STEM CELL TRANSPLANTATION;CYCLOPHOSPHAMIDE;GRAFT-VERSUS-HOST DISEASE;RHINOMANOMETRY;APLASTIC ANEMIA;COLORECTAL CANCER;HAEMATOPOIESIS;ALLERGEN;BREAST CANCER;CUMULATIVE INCIDENCE;EPITOPE;LEFT VENTRICULAR HYPERTROPHY;RITUXIMAB;T CELL;TYPE 2 DIABETES;ALEMTUZUMAB;CD34;CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL ENDPOINT;FOLLICULAR LYMPHOMA;IMMUNOTHERAPY;INSULIN RESISTANCE;MELPHALAN;MICROALBUMINURIA;MYELODYSPLASTIC SYNDROMES;VIRAL LOAD;WEIGHT LOSS","10;9;9;7;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","FLUDARABINE;BUSULFAN;ANTIRETROVIRAL THERAPY;CD38;DONOR LYMPHOCYTE INFUSION;GASTRIC BYPASS;SUBLINGUAL IMMUNOTHERAPY;THIOTEPA;ADIPONECTIN;ADULT STEM CELL;ELISPOT;EXTRACORPOREAL PHOTOPHERESIS;IGHV@;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;OXALIPLATIN;ABCIXIMAB;ABSOLUTE NEUTROPHIL COUNT;ACINETOBACTER BAUMANNII;ACUTE LYMPHOCYTIC LEUKEMIA;ALLELE FREQUENCY;ALLERGEN IMMUNOTHERAPY;ALLERGIC RESPONSE;ALPHA (FINANCE);AMNIOTIC FLUID;ARTERY DISSECTION;BODY CONTOURING;BONE MARROW FAILURE;BREAKPOINT;BRONCHIAL HYPERRESPONSIVENESS;BRONCHODILATION;CAMPESTEROL;CAPECITABINE;CEFOXITIN;CETUXIMAB;CHLORAMBUCIL;CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER;COPY-NUMBER VARIATION;CUNEUS;DNA FRAGMENTATION;ECULIZUMAB;ENDOTHELIAL PROGENITOR CELL;ENOS;EPISCLERITIS;EPTIFIBATIDE;FEBRILE NEUTROPENIA;FILGRASTIM;FISETIN;GASTROPARESIS;GENE DOSAGE;GENE EXPRESSION PROFILING;GLYCATED HEMOGLOBIN;GP41;HEMATOPOIETIC STEM CELL;HEME OXYGENASE;HOUSE DUST MITE;ICE CALVING;IL-2 RECEPTOR;IMMUNOGLOBULIN A;ISOPROSTANE;JAK2 V617F;KRAS;LENTIVIRUS;LYME BORRELIOSIS;MAMMOGRAPHY;MAMMOTOME;MEMORY CELL;METHACHOLINE;MILAN CRITERIA;MINI–MENTAL STATE EXAMINATION;MONOCLONAL;MORBID OBESITY;MULTICENTER TRIAL;MULTIPOTENT STEM CELL;NEOADJUVANT THERAPY;NICOTINIC ACETYLCHOLINE RECEPTOR;OVARIAN TUMOR;PLANT STEROLS;RADIOIMMUNOTHERAPY;RESPIRATORY ALLERGY;RETINAL VASCULITIS;RIGHT-TO-LEFT SHUNT;SECONDARY HYPERPARATHYROIDISM;SEROPREVALENCE;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;SOX2;STENOTROPHOMONAS MALTOPHILIA;TAKOTSUBO SYNDROME;TAMOXIFEN;THIAMPHENICOL;THROMBOMODULIN;THYMOGLOBULIN;TICLOPIDINE;TOTAL BODY IRRADIATION;TOTAL MESORECTAL EXCISION;TYMPANOMETRY;UNDERWEIGHT;VANCOMYCIN;VARIMAX ROTATION;VINCRISTINE","7;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;;MALE;ADULT;MIDDLE AGED;AGED;RHINITIS, ALLERGIC, PERENNIAL;ADOLESCENT;RHINITIS, ALLERGIC, SEASONAL;GRAFT VS HOST DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HYPERTENSION;KIDNEY DISEASES;TREATMENT OUTCOME;NASAL OBSTRUCTION;ASTHMA;PROSPECTIVE STUDIES;CARDIOVASCULAR DISEASES;ENDOMETRIOSIS","89;67;65;55;49;42;32;32;23;22;19;19;19;18;18;15;14;14;13;12","ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;HEMATOPOIETIC STEM CELL BIOLOGY;ACUTE MYELOID LEUKEMIA;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;MULTIPOTENT MESENCHYMAL STEM CELLS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ASTHMA;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;SHOULDER PATHOLOGY AND TREATMENT OUTCOMES;ANKLE INJURIES AND DISORDERS IN SPORTS MEDICINE;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND MANAGEMENT OF CARPAL TUNNEL SYNDROME;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES;ENGINEERING BACTERIA FOR CANCER TREATMENT","16;15;6;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2","HEMATOPOIETIC CELL TRANSPLANTATION;REGIMEN;POLLEN ALLERGY;RHINOMANOMETRY;APLASTIC ANEMIA;TREATMENT OUTCOMES;CUMULATIVE INCIDENCE;GRAFT-VERSUS-HOST DISEASE;HYPERTENSION;MESENCHYMAL STEM CELLS;ALLERGEN-SPECIFIC IMMUNOTHERAPY;ASTHMA;CLINICAL ENDPOINT;DONOR LYMPHOCYTE INFUSION;FOLLICULAR LYMPHOMA;HOUSE DUST MITE ALLERGENS;INTERNATIONAL MYELOMA WORKING GROUP;MELPHALAN;MICROALBUMINURIA;RELAPSE RISK","12;10;9;7;6;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3","CELL TRANSPLANTATION;STEM CELL;ALLERGIC RHINITIS;STEM CELLS;HEMATOPOIETIC STEM;MESENCHYMAL STEM;PATIENTS AFFECTED;PHASE II;ULTRASOUND HR-US;ACUTE LEUKEMIA;APLASTIC ANEMIA;BONE MARROW;CARDIOVASCULAR RISK;DECONGESTION TEST;DI MIDOLLO;GRAFT-VERSUS-HOST DISEASE;GRUPPO ITALIANO;HIGH-RESOLUTION ULTRASOUND;ITALIANO TRAPIANTO;LEFT VENTRICULAR;MIDOLLO OSSEO;MULTIPLE MYELOMA;MYELOID LEUKEMIA;NASAL DECONGESTION;OSSEO GITMO;OXIDATIVE STRESS;RESOLUTION ULTRASOUND;STROMAL CELLS;SUBLINGUAL IMMUNOTHERAPY;TRAPIANTO DI","10;9;7;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;GROWTH HORMONE;CROSSREF PUBMED;STEM CELLS;PLASMA POTASSIUM;GRAFT-VERSUS-HOST DISEASE;STEM CELL;STROMAL CELLS;CELL TRANSPLANTATION;CKD PATIENTS;INT -ABSTRACT;BOWEL ENDOMETRIOTIC;GH INFUSION;COMPLETE REMISSION;EXTENSIVE FIBROSIS;MESENCHYMAL STEM;MESENCHYMAL STROMAL;ALLERGIC RHINITIS;PUBMED GOOGLE;ACUTE GRAFT-VERSUS-HOST;ALLERGIC DISEASES;AMINO ACIDS;C-REACTIVE PROTEIN;ENDOCRINOL METAB;GH RESPONSE;INSULIN-LIKE GROWTH;MAGNETIC RESONANCE;PROTEIN BALANCE;WORLD ALLERGY;AMNIOTIC FLUID","55;40;31;19;17;15;15;14;13;13;13;12;12;11;11;11;11;10;10;9;8;8;8;8;8;8;8;8;8;7",27,0.17,4.38,4.5,0,1.75,0,2,5,1,1,5,0,1,2.75,0,1,1,1,2,1,0,0,68.5,68.5,3,0,0,0,1,0,0,0,2,0,0,0,3,0,0,1,5.33333333333333,4.12,2,0,2,2,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBINI ADRIANA;BENELLI ROBERTO;BIASOTTI BARBARA;BRIGATI CLAUDIO;DELL EVA RAFFAELLA;NIEDDU ERIKA;NOONAN DOUGLAS M;PARODI SILVIO;PONASSI RAFFAELLA;アルビーニ，アドリアーナ","1;1;1;1;1;1;1;1;1;1","ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO;ISTITUTO NAZIONALE PER LA RICERCE SUL CANCRO;UNIVERSITA DEGLI STUDI DI GENOVA","3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3206 MEDICAL BIOTECHNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;48 LAW AND LEGAL STUDIES","4;2;1;1;1;1;1;1","CANCER","1","5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2;1","C07K14/47;A61K38/00;A61K38/16;A61K38/17;A61P27/02;A61P27/06;A61P29/00;A61P43/00;A61P9/00;A61P9/10","2;1;1;1;1;1;1;1;1;1","A61K38/00;A61P27/02;A61P27/06;A61P29/00;A61P9/00;A61P9/10;C12N9/6435;C12Y304/21007;A61P19/02;A61P19/04","3;2;2;2;2;2;2;2;1;1",16,5.07,704.67,7.88,4,0.25,53.88,1,0,5,1,4,0,2,3,0,14,1,0,0,0,0,0,0,15,1,0,14,1,0,1,0,0,0,0,0,0,"Italy;United Kingdom;United States","3;3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;40 ENGINEERING;4012 FLUID MECHANICS AND THERMAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","15;8;7;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;CARDIOVASCULAR;DIGESTIVE DISEASES;LUNG;RARE DISEASES;BIOTECHNOLOGY;COLO-RECTAL CANCER;LUNG CANCER;NEUROSCIENCES;PREVENTION;ANTIMICROBIAL RESISTANCE;ATHEROSCLEROSIS;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;BRAIN DISORDERS;BREAST CANCER","12;9;7;6;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;EYE;INFECTION;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;RESPIRATORY;STROKE","7;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES;6.4 SURGERY;6.7 PHYSICAL","11;3;2;1;1;1;1","LUNG CANCER;COLON AND RECTAL CANCER;BREAST CANCER;HODGKIN'S DISEASE;KIDNEY CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;RESPIRATORY SYSTEM","3;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","7;2;1",3,6284850.67,304183.39,4.33333333333333,26,10,1,19.6666666666667,368832.695100422,0.425667252620469,"OSPEDALE POLICLINICO SAN MARTINO;ERASMUS MC;KAROLINSKA INSTITUTET;UPPSALA UNIVERSITY;ALLEANZA CONTRO IL CANCRO;BABRAHAM BIOSCIENCE TECHNOLOGIES (UNITED KINGDOM);BAYER (GERMANY);BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS;CARDIFF UNIVERSITY;DECODE GENETICS (ICELAND);DÉLÉGATION PARIS 11;ETH ZURICH;EUROPEAN MOLECULAR BIOLOGY LABORATORY;FEDERAL MINISTRY OF EDUCATION AND RESEARCH;FINNISH INSTITUTE FOR HEALTH AND WELFARE;FRAUNHOFER SOCIETY;FRENCH NATIONAL CANCER INSTITUTE;FÉDÉRATION HOSPITALIÈRE DE FRANCE;GOETHE UNIVERSITY FRANKFURT;HEALTH RESEARCH BOARD","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","3","COALITION S;EC & ERC - EUROPEAN UNION","3;3","CP-CSA-INFRA - COMBINATION OF CP AND CSA (FUNDING SCHEME);CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);CSA-CA - COORDINATION (OR NETWORKING) ACTIONS (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2007-A (CALL FOR PROPOSAL);FP7-INFRASTRUCTURES - SPECIFIC PROGRAMME ""CAPACITIES"": RESEARCH INFRASTRUCTURES (PROGRAMME);FP7-INFRASTRUCTURES-2007-1 (CALL FOR PROPOSAL);FP7-NMP - SPECIFIC PROGRAMME ""COOPERATION"": NANOSCIENCES, NANOTECHNOLOGIES, MATERIALS AND NEW PRODUCTION TECHNOLOGIES (PROGRAMME);FP7-NMP-2007-LARGE-1 (CALL FOR PROPOSAL)","1;1;1;1;1;1;1;1;1","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;48 LAW AND LEGAL STUDIES;4807 PUBLIC LAW","1;1;1;1;1;1;1;1;1","BIOENGINEERING;BIOTECHNOLOGY;CANCER;GENETICS;HUMAN GENOME;REGENERATIVE MEDICINE","1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","1;1","1.5 RESOURCES AND INFRASTRUCTURE (UNDERPINNING);2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);5.2 CELLULAR AND GENE THERAPIES;8.1 ORGANISATION AND DELIVERY OF SERVICES","1;1;1;1","NOT SITE-SPECIFIC CANCER","1","6.4 COST ANALYSES AND HEALTH CARE DELIVERY","1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;C21 SOCIOLOGY","2;1",NA,NA,4,"PUBLIC LIBRARY OF SCIENCE","4","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY","4;4;2;2;2","GENETICS;CLINICAL RESEARCH;HIV/AIDS;INFECTIOUS DISEASES","2;1;1;1","INFECTION","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","2;1","BIOMEDICAL","2","BASIC SCIENCE","2","NOT SITE-SPECIFIC CANCER","2","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SANMARTINO",2009,167,9.55089820359281,2.83233532934132,0.353065539112051,0.467065868263473,0.317365269461078,0.37125748502994,0.305389221556886,3,78,23,25,27,0.47,0.14,0.15,0.16,50.77,1.09761141397351,0.227544910179641,0.802395209580838,NA,0.493529274312526,0.488372093023256,0.463865546218487,0.528713811105838,"ANDREA BACIGALUPO;ALCHIEDE SIMONATO;G. CARMIGNANI;GIORGIO CIPRANDI;SIMONE FERRERO;VALENTINO REMORGIDA;ANNA GARUTI;ALBERTO BALLESTRERO;ANGELO MICHELE CARELLA;VIRGINIA VARCA;CLAUDIO VISCOLI;ALBERTO SOBRERO;NICOLA RAGNI;GIAN LUIGI MARSEGLIA;GABRIELLA CIRMENA;R. PIZZORNO;GIOVANNI CAMERINI;FRANCO PATRONE;MARIA PIA SORMANI;MARIO VALENZANO MENADA","25;14;13;11;10;10;9;9;8;8;8;7;7;7;6;6;6;6;6;5","ANDREA BACIGALUPO;GIORGIO CIPRANDI;ALCHIEDE SIMONATO;G. CARMIGNANI;ALBERTO SOBRERO;SIMONE FERRERO;VALENTINO REMORGIDA;GIAN LUIGI MARSEGLIA;PAOLO FIALLO;VIRGINIA VARCA;GIOVANNI CAMERINI;NICOLA RAGNI;GIUSEPPE APRILE;ALBERTO F. SOBRERO;GIANNI TESTINO;R. PIZZORNO;MARA DE AMICI;CLAUDIO VISCOLI;GIUSEPPE CANNELLA;ALBERTO BALLESTRERO","2.95;2.36;2.11;1.94;1.87;1.71;1.71;1.22;1.2;1.17;1.1;1.1;1;1;1;0.94;0.93;0.87;0.87;0.83","ANDREA BACIGALUPO;ALCHIEDE SIMONATO;G. CARMIGNANI;GIORGIO CIPRANDI;SIMONE FERRERO;VALENTINO REMORGIDA;ANNA GARUTI;ALBERTO BALLESTRERO;ANGELO MICHELE CARELLA;VIRGINIA VARCA;CLAUDIO VISCOLI;ALBERTO SOBRERO;NICOLA RAGNI;GIAN LUIGI MARSEGLIA;GABRIELLA CIRMENA;R. PIZZORNO;GIOVANNI CAMERINI;FRANCO PATRONE;MARIA PIA SORMANI;MARIO VALENZANO MENADA","25;14;13;11;10;10;9;9;8;8;8;7;7;7;6;6;6;6;6;5","ANDREA BACIGALUPO;GIORGIO CIPRANDI;ALCHIEDE SIMONATO;G. CARMIGNANI;ALBERTO SOBRERO;SIMONE FERRERO;VALENTINO REMORGIDA;GIAN LUIGI MARSEGLIA;PAOLO FIALLO;VIRGINIA VARCA;GIOVANNI CAMERINI;NICOLA RAGNI;ALBERTO F. SOBRERO;GIANNI TESTINO;R. PIZZORNO;MARA DE AMICI;CLAUDIO VISCOLI;GIUSEPPE CANNELLA;ALBERTO BALLESTRERO;T. MONTANARO","2.95;2.36;2.11;1.94;1.87;1.71;1.71;1.22;1.2;1.17;1.1;1.1;1;1;0.94;0.93;0.87;0.87;0.83;0.83","ANDREA BACIGALUPO;KAREN K. BALLEN;VINCENT T. HO;HILLARD M. LAZARUS;MARCELO C. PASQUINI;BRENDA M. SANDMAIER;DIDIER BLAISE;DOUG RIZZO;JANE F. APPERLEY;JOHN BARRETT;MARY M. HOROWITZ;ROBERT LOWSKI;SERGIO GIRALT;SHIMON SLAVIN;FLAVIO NOBILI;ANDREA VARRONE;JACQUES DARCOURT;JAN BOOIJ;KJELL NÅGREN;KLAUS TATSCH","2927;1591;1588;1567;1567;1564;1564;1564;1564;1564;1564;1564;1564;1564;915;801;801;801;801;801","ANDREA BACIGALUPO;FLAVIO NOBILI;ALBERTO SOBRERO;ANNA MARIA RAIOLA;FRANCESCO FRASSONI;A MARMONT;SIMONE FERRERO;BARBARA BRUNO;VALENTINO REMORGIDA;GIORGIO CIPRANDI;ROSI ONETO;FRANCESCA GUALANDI;ADALBERTO IBATICI;MARIA TERESA VAN LINT;NICOLA RAGNI;PAOLA MINALE;CLAUDIO VISCOLI;SARAH POZZI;UMBERTO VALENTE;MAURIZIO SANTO","2927;915;716;524;448;432;384;362;353;351;314;303;294;294;290;282;270;231;227;221","ANDREA BACIGALUPO;SIMONE FERRERO;GIORGIO CIPRANDI;VALENTINO REMORGIDA;ALCHIEDE SIMONATO;ANGELO MICHELE CARELLA;G. CARMIGNANI;ALBERTO SOBRERO;NICOLA RAGNI;CLAUDIO VISCOLI;FLAVIO NOBILI;FRANCESCO FRASSONI;GIAN-MATTEO PICA;MICHELE MUSSAP;T. MONTANARO;VIRGINIA VARCA;ANNA MARIA RAIOLA;ALBERTO BALLESTRERO;E. RIKANI;FRANCESCA GUALANDI","25;10;10;9;9;8;8;7;6;5;5;5;5;5;5;5;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;POLITICAL SCIENCE;BUSINESS;ECONOMICS;MATHEMATICS;SOCIOLOGY;COMPUTER SCIENCE;HISTORY;MATERIALS SCIENCE;PHILOSOPHY;ENGINEERING","158;62;16;11;8;7;4;4;4;3;2;2;2;2;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GENETICS;ONCOLOGY;GASTROENTEROLOGY;PATHOLOGY;UROLOGY;RADIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;PEDIATRICS;PSYCHIATRY;INTENSIVE CARE MEDICINE;OPTICS;GYNECOLOGY;NURSING;PALEONTOLOGY;GENERAL SURGERY;VIROLOGY","121;65;45;36;26;24;18;15;14;13;11;10;10;10;9;9;8;8;8;7;7","TRANSPLANTATION;CANCER;STEM CELL;CHEMOTHERAPY;GENE;BONE MARROW;DISEASE;ALLERGY;ADVERSE EFFECT;ENDOMETRIOSIS;POPULATION;REGIMEN;ANTIBODY;CLINICAL TRIAL;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);MAGNETIC RESONANCE IMAGING;MYELOID LEUKEMIA;URINARY SYSTEM;ANTIGEN;BLOOD PRESSURE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);KIDNEY;LEUKEMIA;PELVIC PAIN;REFRACTORY (PLANETARY SCIENCE)","31;26;20;19;18;12;12;11;10;9;9;9;8;8;8;8;7;7;7;6;6;6;6;6;6;6","HEMATOPOIETIC STEM CELL TRANSPLANTATION;COLORECTAL CANCER;HAEMATOPOIESIS;CD34;IMATINIB;ALLERGEN;CYCLOPHOSPHAMIDE;GRAFT-VERSUS-HOST DISEASE;APLASTIC ANEMIA;BLADDER CANCER;MUTATION;NEUTROPENIA;VIRAL LOAD;BREAST CANCER;HUMAN LEUKOCYTE ANTIGEN;IMMUNOGLOBULIN E;UNIVARIATE ANALYSIS;AORTIC DISSECTION;BEVACIZUMAB;CD8;CLINICAL ENDPOINT;DYSURIA;GENE EXPRESSION;KIDNEY TRANSPLANTATION;LENALIDOMIDE;NORETHISTERONE ACETATE;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;SPIROMETRY","18;11;10;7;7;6;6;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","IMATINIB MESYLATE;CYSTECTOMY;ANTIRETROVIRAL THERAPY;CETUXIMAB;FLUDARABINE;HEMATOPOIETIC CELL;SUBLINGUAL IMMUNOTHERAPY;CD38;DASATINIB;NILOTINIB;OXALIPLATIN;AROMATASE;ASYMPTOMATIC BACTERIURIA;CASPOFUNGIN;ENTEROCOCCUS FAECALIS;HOUSE DUST MITE;MISSENSE MUTATION;NORETHISTERONE;PHILADELPHIA CHROMOSOME;PROPIDIUM IODIDE;PROSTATECTOMY;SAVIOR SIBLING;THIOTEPA","6;5;4;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;ADULT;;MIDDLE AGED;AGED;ITALY;HEMATOPOIETIC STEM CELL TRANSPLANTATION;TREATMENT OUTCOME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RHINITIS, ALLERGIC, SEASONAL;YOUNG ADULT;ADOLESCENT;RETROSPECTIVE STUDIES;RISK FACTORS;COLORECTAL NEOPLASMS;ENDOMETRIOSIS;AGED, 80 AND OVER;CHILD","113;79;72;60;54;50;38;30;28;25;21;21;21;19;19;16;15;15;14;14","HEMATOPOIETIC STEM CELL BIOLOGY;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;EFFICACY AND RESISTANCE IN CML TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EPIDEMIOLOGY AND TREATMENT OF URINARY TRACT INFECTIONS;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;HEPATOCELLULAR CARCINOMA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;LYMPHOID NEOPLASMS;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;RENAL CELL CARCINOMA;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF CARPAL TUNNEL SYNDROME;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY","13;10;9;6;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2","HEMATOPOIETIC CELL TRANSPLANTATION;REGIMEN;IMATINIB MESYLATE;METASTATIC COLORECTAL CANCER;REFRACTORY (PLANETARY SCIENCE);ANTIRETROVIRAL THERAPY;APLASTIC ANEMIA;BLADDER CANCER;ETIOLOGY;HIV;HYPERTENSION;IMATINIB;IMMUNOSUPPRESSION;SLIT;SUBLINGUAL IMMUNOTHERAPY;UNIVARIATE ANALYSIS;AORTIC DISSECTION;AORTIC ROOT REPLACEMENT;ASTHMA;CANCER RISK","11;9;7;7;6;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3","STEM CELL;CELL TRANSPLANTATION;ALLERGIC RHINITIS;HEMATOPOIETIC STEM;BONE MARROW;COLORECTAL CANCER;SUBLINGUAL IMMUNOTHERAPY;ADULT PATIENTS;ALLOGENEIC HEMATOPOIETIC;ALLOGENEIC STEM;AORTIC DISSECTION;APLASTIC ANEMIA;AUTOIMMUNE DISEASES;CHRONIC MYELOID;DISEASE PROGRESSION;MYELOID LEUKEMIA;NORETHISTERONE ACETATE;PHASE II;PILOT STUDY;TRANSPLANT RECIPIENTS;ABSCISIC ACID;ACUTE LYMPHOBLASTIC;ADI NUTRITIONAL;ALZHEIMERS DISEASE;ANTIRETROVIRAL THERAPY;BLADDER CANCER;BLADDER ENDOMETRIOSIS;BLADDER TUMORS;CELL COLLECTION;CHRONIC PHASE","15;12;8;7;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;UTERINE ARTERY;STEM CELL;LEFT UTERINE;SMOOTH MUSCLE;ΜM ABA;DE FLORA;ACAD SCI;HEMATOPOIETIC STEM;NATL ACAD;PROC NATL;HUMAN MONOCYTES;PAIN SYMPTOMS;PUBMED GOOGLE;ADVERSE EVENTS;NUCLEAR TRANSLOCATION;WAITING LISTS;ABA-INDUCED CAI;ALLERGIC RHINITIS;CT ANGIOGRAPHY;MULTIDETECTOR CT;ALLOGENEIC HSCT;ANTI-ABA MAB;ANTIRETROVIRAL THERAPY;CELL TRANSPLANTATION;MUSCLE CELLS;SMC MEDIUM;ΜGML ANTI-ABA;AUTOIMMUNE DISEASES","38;30;15;13;12;12;12;11;10;10;10;10;9;9;9;8;8;8;7;7;7;7;6;6;6;6;6;6;6;5",28,0.17,3.25,2,1,1,1,1,2,0,1,2,0,1,2.25,0,1,1,1,1.25,0,0,0,82.25,82.25,2,0,0,0,1,0,0,0,1,0,0,0,2,0,0,0,4.5,1.91,1.5,0,1,2,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BOFFA LIDIA C;CUTRONA GIOVANNA;FERRARINI MANLIO;アルビーニ，アドリアーナ;デレヴァ，ラファエッラ;ニエドゥ，エリカ;ヌーナン，ダグラス・エム;ブリガティ，クラウディオ;ベネリ，ロベルト","1;1;1;1;1;1;1;1;1","ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO;ISTITUTO NAZIONALE PER LA RICERCE SUL CANCRO","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","4;2;1","CANCER;AGING;GENETICS;HEMATOLOGY;LYMPHOMA;RARE DISEASES","2;1;1;1;1;1","5.1 PHARMACEUTICALS","1","A61K31/7125;A61K38/00;A61P19/02;A61P19/04;A61P27/02;A61P27/06;A61P29/00;A61P3/10;A61P35/00;A61P35/02","1;1;1;1;1;1;1;1;1;1","A61K38/00;A61P19/02;A61P19/04;A61P27/02;A61P27/06;A61P29/00;A61P3/10;A61P35/00;A61P35/02;A61P9/00","1;1;1;1;1;1;1;1;1;1",21,6.11,349.16,8.97,3,0.14,38,1,0,8,1,5,0,2,4,0,17,2,0,0,0,0,0,0,16,4,1,19,2,0,0,0,0,0,0,0,0,"United States;Italy;Japan","6;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;44 HUMAN SOCIETY;4403 DEMOGRAPHY;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","19;12;7;7;3;2;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LYMPHOMA;COLO-RECTAL CANCER;DIGESTIVE DISEASES;DIABETES;LUNG;OBESITY;ORPHAN DRUG;PATIENT SAFETY;PREVENTION;AGING;BIODEFENSE;BIOMEDICAL IMAGING;BIOTECHNOLOGY;BRAIN DISORDERS;BREAST CANCER","19;15;13;9;6;5;3;3;2;2;2;2;2;2;1;1;1;1;1;1","CANCER;METABOLIC AND ENDOCRINE;CARDIOVASCULAR;INFECTION;REPRODUCTIVE HEALTH AND CHILDBIRTH","13;2;1;1;1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","15;3;2;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;BLADDER CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","4;3;2;2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.6 END-OF-LIFE CARE","10;2;2;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMARTINO",2010,167,9.7125748502994,2.64071856287425,0.378684807256236,0.479041916167665,0.305389221556886,0.335329341317365,0.383233532934132,8,82,24,19,27,0.49,0.14,0.11,0.16,30.9,0.683863369317836,0.287425149700599,0.802395209580838,NA,0.539290437752927,0.48364107547781,0.485495040239566,0.454929577464789,"ANDREA BACIGALUPO;SIMONE FERRERO;FRANCESCO FRASSONI;GIORGIO CIPRANDI;VALENTINO REMORGIDA;ANGELO MICHELE CARELLA;C. CAMPISI;GIOVANNA LEONCINI;MYRIAM LABOPIN;PIER LUIGI VENTURINI;VANDERSON ROCHA;ALBERTO SOBRERO;GÈRARD SOCIÉ;FORTUNATO MORABITO;STEFANO SCABINI;FRANCESCA VIAZZI;UMBERTO VALENTE;GIAN LUIGI MARSEGLIA;GIACOMO DEFERRARI;ROBERTO PONTREMOLI","14;13;13;10;10;7;7;6;6;6;5;5;5;5;5;5;5;5;5;5","SIMONE FERRERO;GIORGIO CIPRANDI;VALENTINO REMORGIDA;GIANNI TESTINO;STEFANO SCABINI;PIER LUIGI VENTURINI;C. CAMPISI;ANDREA BACIGALUPO;FRANCO MIGLIORI;GIAN LUIGI MARSEGLIA;GIOVANNA LEONCINI;FRANCESCO FRASSONI;SIMONE FERRERO;AOU SAN;ANDREA CARIATI;L. MEMO;ANGELO MICHELE CARELLA;FRANCESCA VIAZZI;ROBERTO PONTREMOLI;IGNAZIO CIRILLO","3.19;3.06;2.49;1.98;1.6;1.53;1.34;1.27;1.25;1.16;1.13;1.07;1;1;1;1;0.92;0.88;0.88;0.75","ANDREA BACIGALUPO;SIMONE FERRERO;FRANCESCO FRASSONI;GIORGIO CIPRANDI;VALENTINO REMORGIDA;ANGELO MICHELE CARELLA;C. CAMPISI;GIOVANNA LEONCINI;PIER LUIGI VENTURINI;ALBERTO SOBRERO;FORTUNATO MORABITO;STEFANO SCABINI;FRANCESCA VIAZZI;UMBERTO VALENTE;GIACOMO DEFERRARI;ROBERTO PONTREMOLI;CLAUDIO VISCOLI;R SCORDAMAGLIA;FRANCESCA GUALANDI;EMANUELE ROMAIRONE","14;13;13;10;10;7;7;6;6;5;5;5;5;5;5;5;5;4;4;4","SIMONE FERRERO;GIORGIO CIPRANDI;VALENTINO REMORGIDA;GIANNI TESTINO;STEFANO SCABINI;PIER LUIGI VENTURINI;C. CAMPISI;ANDREA BACIGALUPO;FRANCO MIGLIORI;GIOVANNA LEONCINI;FRANCESCO FRASSONI;SIMONE FERRERO;AOU SAN;ANDREA CARIATI;L. MEMO;ANGELO MICHELE CARELLA;FRANCESCA VIAZZI;ROBERTO PONTREMOLI;ALBERTO SOBRERO;GIOACCHINO CATANIA","3.19;3.06;2.49;1.98;1.6;1.53;1.34;1.27;1.25;1.13;1.07;1;1;1;1;0.92;0.88;0.88;0.73;0.73","ANDREA BACIGALUPO;FRANCESCO FRASSONI;SIMONE FERRERO;GIORGINA SPECCHIA;MASSIMO BRECCIA;VALENTINO REMORGIDA;ALBERTO SOBRERO;ANGELO MICHELE CARELLA;ALBERTO BOSI;FRANCESCO DI RAIMONDO;MARCO VIGNETTI;ALESSANDRO RAMBALDI;ANTONIO PETA;DANIELA DIVERIO;ENRICO MARIA POGLIANI;ERIKA BORLENGHI;EROS DI BONA;EUGENIO GALLO;FELICETTO FERRARA;FRANCESCA PAOLONI","666;588;338;337;335;333;329;319;309;307;307;305;305;305;305;305;305;305;305;305","ANDREA BACIGALUPO;FRANCESCO FRASSONI;ALBERTO SOBRERO;SIMONE FERRERO;ANGELO MICHELE CARELLA;VALENTINO REMORGIDA;FLAVIO NOBILI;GIACOMO DEFERRARI;BARBARA DESSI;JAKOB PASSWEG;M. T. VAN LINT;ROSA ONETO;SAVVAS DYNAMIDIS;MARINA PODESTÀ;PIER LUIGI VENTURINI;PAOLA STRAMESI;FRANCESCA VIAZZI;GIOVANNA LEONCINI;ROBERTO PONTREMOLI;C. MARCHINI","629;588;329;322;319;314;251;240;207;204;204;204;192;186;174;173;172;172;172;143","FRANCESCO FRASSONI;ANDREA BACIGALUPO;SIMONE FERRERO;GIORGIO CIPRANDI;VALENTINO REMORGIDA;ANGELO MICHELE CARELLA;C. CAMPISI;GIACOMO DEFERRARI;PIER LUIGI VENTURINI;STEFANO SCABINI;ALBERTO SOBRERO;GIOVANNA LEONCINI;FRANCESCA VIAZZI;G. CARMIGNANI;GIANNI TESTINO;MARINA PODESTÀ;ROBERTO PONTREMOLI;ANTONIO DI BIAGIO;DOMENICO PALOMBO;FRANCESCO BOCCARDO","13;13;12;10;8;7;7;5;5;5;5;5;4;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;GEOGRAPHY;HISTORY;MATERIALS SCIENCE;PHILOSOPHY","161;50;17;9;7;4;4;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;ONCOLOGY;CARDIOLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;GYNECOLOGY;ENDOCRINOLOGY;OPTICS;VIROLOGY;ANATOMY;CELL BIOLOGY;PSYCHIATRY;DERMATOLOGY;PEDIATRICS","118;65;36;35;31;28;21;16;15;14;13;13;12;10;10;10;9;9;9;8;8","TRANSPLANTATION;CANCER;CHEMOTHERAPY;GENE;STEM CELL;BONE MARROW;DISEASE;IMMUNE SYSTEM;POPULATION;LEUKEMIA;ENDOMETRIOSIS;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;BLOOD PRESSURE;CONFIDENCE INTERVAL;PREGNANCY;ALLERGY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);LUNG;MYELOID LEUKEMIA","29;28;17;14;13;11;11;11;11;10;9;9;9;8;8;8;7;7;7;7","HEMATOPOIETIC STEM CELL TRANSPLANTATION;BREAST CANCER;COLORECTAL CANCER;HAZARD RATIO;CD8;CHRONIC LYMPHOCYTIC LEUKEMIA;CUMULATIVE INCIDENCE;HAEMATOPOIESIS;ALLERGEN;CHROMOSOME;CYCLOPHOSPHAMIDE;GENOTYPE;LENALIDOMIDE;NEUTROPENIA;T CELL;APLASTIC ANEMIA;CD34;CELL THERAPY;GRAFT-VERSUS-HOST DISEASE;IMATINIB;IMMUNOGLOBULIN E;INFERTILITY;LYMPHADENECTOMY;METABOLIC SYNDROME;MICROALBUMINURIA;PHASES OF CLINICAL RESEARCH;PLACEBO;PROSTATE;PROSTATE CANCER;PROTEINURIA;SALVAGE THERAPY;TYPE 2 DIABETES;UNIVARIATE ANALYSIS","14;11;9;7;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ANEUPLOIDY;FLUDARABINE;IMATINIB MESYLATE;LYMPHEDEMA;ALLERGIC RESPONSE;ANDROGEN RECEPTOR;ANTIRETROVIRAL THERAPY;BRONCHODILATION;CD90;ENDOREDUPLICATION;FAMILY PLANNING;FINASTERIDE;GONADOTROPIN-RELEASING HORMONE;HEMATOPOIETIC CELL;HEMATOPOIETIC STEM CELL;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;OXALIPLATIN;PERIPHERAL T-CELL LYMPHOMA;PNEUMOCOCCAL INFECTIONS;SENTINEL LYMPH NODE;SENTINEL NODE;SUBLINGUAL IMMUNOTHERAPY;TAMOXIFEN;TOTAL BODY IRRADIATION;TRANSRECTAL ULTRASONOGRAPHY;UTERINE MYOMECTOMY","3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;TREATMENT OUTCOME;ITALY;HYPERTENSION;ADOLESCENT;COLORECTAL NEOPLASMS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;RHINITIS, ALLERGIC, SEASONAL;AGED, 80 AND OVER;RHINITIS, ALLERGIC, PERENNIAL;ASTHMA;YOUNG ADULT;CARDIOVASCULAR DISEASES;CHILD","102;71;67;60;51;47;44;29;25;22;19;18;17;16;15;15;14;14;13;13","DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;HEMATOPOIETIC STEM CELL BIOLOGY;MULTIPOTENT MESENCHYMAL STEM CELLS;ACUTE MYELOID LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT AND EPIDEMIOLOGY OF PNEUMONIA;COLORECTAL CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ASTHMA;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFECTS OF KETOGENIC DIET ON HEALTH;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GENETIC BASIS OF PRIMARY IMMUNODEFICIENCY DISORDERS;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA","10;8;8;5;4;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2","HEMATOPOIETIC CELL TRANSPLANTATION;REGIMEN;CUMULATIVE INCIDENCE;MESENCHYMAL STEM CELLS;METASTATIC COLORECTAL CANCER;TRANSPLANTATION;ENDOMETRIAL POLYPS;HIV;HYPERTENSION;TREATMENT;ALLERGEN-SPECIFIC IMMUNOTHERAPY;APLASTIC ANEMIA;CELL THERAPY;IMATINIB MESYLATE;LYMPHADENECTOMY;MICROALBUMINURIA;SALVAGE THERAPY;SKIN SENSITIZATION;STROKE (ENGINE);TREATMENT OUTCOMES","11;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3","CELL TRANSPLANTATION;STEM CELL;COLORECTAL CANCER;HEMATOPOIETIC STEM;ALLERGIC RHINITIS;RISK FACTORS;STEM CELLS;BONE MARROW;II STUDY;MESENCHYMAL STEM;PERIPHERAL BLOOD;PHASE II;ACUTE LEUKEMIA;CHRONIC LYMPHOCYTIC;CONTROLLED TRIAL;CORD BLOOD;KIDNEY TRANSPLANTATION;LYMPHOCYTIC LEUKEMIA;MAGNETIC RESONANCE;MYELOID LEUKEMIA;ORAL LENALIDOMIDE;RANDOMIZED CONTROLLED;VERSUS CONTINUOUS;ACUTE MYELOID;ADI-AMD RECOMMENDATIONS;ALLOGENEIC HEMATOPOIETIC;APLASTIC ANAEMIA;APLASTIC ANEMIA;ARTIFICIAL NUTRITION;B-CELL CHRONIC","8;8;7;7;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","CLINICAL PREGNANCY;PREGNANCY RATE;UTERINE WALL;STUDY INCLUDED;ALLERGIC RHINITIS;BARBED SUTURE;CLINICAL PREGNANCIES;GNRH AGONIST;GRAFT FAILURE;HAZARD RATIO;SIGNIFICANT DIFFERENCE;WALL DEFECTS;ALLERGIC PATIENTS;INCLUDED WOMEN;RECTOSIGMOID ENDOMETRIOSIS;CELL TRANSPLANTATION;CONFIDENCE INTERVAL;CONTINUOUS SUTURE;GNRH ANTAGONIST;HZ NA;INTRACORPOREAL KNOTS;INTRAOPERATIVE BLOOD;KNOTLESS BARBED;PATIENTS RECEIVED;PATIENTS UNDERGOING;PRIMARY GRAFT;UNIDIRECTIONAL KNOTLESS;VAGINAL DANAZOL;ADVERSE EVENTS;BLOOD LOSS","12;12;12;10;8;8;8;8;8;8;8;8;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6;6;5;5",17,0.1,3,2,0,1.75,0,1,2.5,0,1,2,0,1,2.5,0,2,0,0,2.25,1,0,0,76,76,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,5.76,315.61,7.25,5,0.25,42.75,0,0,6,0,7,0,1,6,0,15,3,0,0,0,0,0,0,18,2,0,18,2,0,0,0,0,0,0,0,0,"United States;Italy;Japan;Sweden","7;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4203 HEALTH SERVICES AND SYSTEMS","20;10;8;4;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;STEM CELL RESEARCH;TRANSPLANTATION;AUTOIMMUNE DISEASE;LUNG;PEDIATRIC;ARTHRITIS;BRAIN DISORDERS;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;COMPLEMENTARY AND INTEGRATIVE HEALTH;HEART DISEASE;LYMPHOMA;NEUROSCIENCES;ORPHAN DRUG","17;12;9;8;6;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;CARDIOVASCULAR;RESPIRATORY;BLOOD;NEUROLOGICAL","8;3;2;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","13;2;1;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;BREAST CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LUNG CANCER;MELANOMA;SARCOMA","5;3;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","12;2;2",2,3592318.5,560638.21,4.5,6.5,5.5,1,21,485592.96284934,0.343909431924394,"OSPEDALE POLICLINICO SAN MARTINO;AO FOUNDATION;DÉLÉGATION PARIS 11;ERASMUS MC;KING'S COLLEGE LONDON;LANCASTER UNIVERSITY;NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY;OZ BIOSCIENCES (FRANCE);RECHTS DER ISAR HOSPITAL;UNIVERSITY OF GALWAY;VRIJE UNIVERSITEIT AMSTERDAM;VRIJE UNIVERSITEIT BRUSSEL","2;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-NMP - SPECIFIC PROGRAMME ""COOPERATION"": NANOSCIENCES, NANOTECHNOLOGIES, MATERIALS AND NEW PRODUCTION TECHNOLOGIES (PROGRAMME);FP7-NMP-2009-SMALL-3 (CALL FOR PROPOSAL);FP7-PEOPLE - SPECIFIC PROGRAMME ""PEOPLE"" IMPLEMENTING THE SEVENTH FRAMEWORK PROGRAMME OF THE EUROPEAN COMMUNITY FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ACTIVITIES (2007 TO 2013) (PROGRAMME);FP7-PEOPLE-2010-ITN (CALL FOR PROPOSAL);MC-ITN - NETWORKS FOR INITIAL TRAINING (ITN) (FUNDING SCHEME)","1;1;1;1;1;1","40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","ARTHRITIS;BIOENGINEERING;BIOTECHNOLOGY;GENE THERAPY;GENETICS;NANOTECHNOLOGY;PAIN RESEARCH;REGENERATIVE MEDICINE","1;1;1;1;1;1;1;1","MUSCULOSKELETAL","1","5.2 CELLULAR AND GENE THERAPIES;7.2 END OF LIFE CARE","1;1",NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B12 ENGINEERING","1;1",NA,NA,2,"PUBLIC LIBRARY OF SCIENCE","2","31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES","4;2;2","GENETICS;BIOTECHNOLOGY;BRAIN DISORDERS;BREAST CANCER;CANCER;ESTROGEN;PREVENTION;RARE DISEASES","2;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1;1","BIOMEDICAL","2","BASIC SCIENCE","2","BREAST CANCER","1",NA,NA
"IRCCS_SANMARTINO",2011,189,10.6296296296296,2.49206349206349,0.401273885350318,0.412698412698413,0.338624338624339,0.375661375661376,0.380952380952381,6,94,25,30,26,0.5,0.13,0.16,0.14,37.5,0.88157947766858,0.328042328042328,0.841269841269841,NA,0.52307448219426,0.48202614379085,0.496126255380201,0.433140763702973,"GIORGIO CIPRANDI;ANGELO MICHELE CARELLA;CLAUDIO VISCOLI;ANDREA BACIGALUPO;FRANCESCO FRASSONI;FRANCESCO DI RAIMONDO;MARIA ANGELA TOSCA;ALESSIO SIGNORI;GIAN LUIGI MARSEGLIA;MARCO GOBBI;ANTONIO DI BIAGIO;MICHELE MUSSAP;FILIPPO CADEMARTIRI;SIMONE FERRERO;IGNAZIO CIRILLO;RAFFAELLA ROSSO;MARIA TERESA VAN LINT;MARA DE AMICI;BIANCA PANE;FRANCESCA GUALANDI","22;17;13;12;9;8;7;7;7;7;6;6;6;6;6;6;6;5;5;5","GIORGIO CIPRANDI;SAMIR GIUSEPPE SUKKAR;MARIA ANGELA TOSCA;ALESSIO SIGNORI;CLAUDIO VISCOLI;IGNAZIO CIRILLO;SERGIO CLAUDIO SACCÀ;ANGELO MICHELE CARELLA;GIANNI TESTINO;SIMONE FERRERO;GIAN LUIGI MARSEGLIA;STEFANO SCABINI;STEFANIA SCIALLERO;ANTONIO ZINGARELLI;GIUSEPPE FORNARINI;FRANCESCO FRASSONI;MARA DE AMICI;ANDREA BACIGALUPO;VALENTINO REMORGIDA;RAFFAELLA ROSSO","4.84;2.5;1.95;1.87;1.77;1.67;1.62;1.34;1.33;1.29;1.2;1.14;1.05;1;1;0.94;0.93;0.92;0.89;0.86","GIORGIO CIPRANDI;ANGELO MICHELE CARELLA;CLAUDIO VISCOLI;ANDREA BACIGALUPO;FRANCESCO FRASSONI;MARIA ANGELA TOSCA;MARCO GOBBI;ANTONIO DI BIAGIO;MICHELE MUSSAP;SIMONE FERRERO;RAFFAELLA ROSSO;MARIA TERESA VAN LINT;BIANCA PANE;FRANCESCA GUALANDI;MATTEO BASSETTI;GIOVANNI SPINELLA;SILVIA MORBELLI;GIAN-MATTEO PICA;IVANA PIERRI;GIANCARLO ICARDI","22;17;13;12;9;7;7;6;6;6;6;6;5;5;5;5;5;5;4;4","GIORGIO CIPRANDI;SAMIR GIUSEPPE SUKKAR;MARIA ANGELA TOSCA;CLAUDIO VISCOLI;SERGIO CLAUDIO SACCÀ;ANGELO MICHELE CARELLA;GIANNI TESTINO;SIMONE FERRERO;STEFANO SCABINI;STEFANIA SCIALLERO;ANTONIO ZINGARELLI;GIUSEPPE FORNARINI;FRANCESCO FRASSONI;ANDREA BACIGALUPO;VALENTINO REMORGIDA;RAFFAELLA ROSSO;ANTONIO DI BIAGIO;PIER LUIGI VENTURINI;GIOACCHINO CATANIA;MICHELE MUSSAP","4.84;2.5;1.95;1.77;1.62;1.34;1.33;1.29;1.14;1.05;1;1;0.94;0.92;0.89;0.86;0.85;0.79;0.73;0.7","FRANCESCO FRASSONI;ADRIANO GIACOMIN;ANDREA SANTARELLI;ARRIGO ARRIGONI;B. ANDREONI;C. CROSTA;CARLO SENORE;CARMEN BEATRIZ VISIOLI;CLAUDIA CASELLA;F FERRERO;FABIO FALCINI;L BISANTI;L BONELLI;MARCO ZAPPA;MAURO RISIO;NEREO SEGNAN;ORIETTA GIULIANI;PAOLA ARMAROLI;ROBERTO ZANETTI;STEFANIA SCIALLERO","709;590;590;590;590;590;590;590;590;590;590;590;590;590;590;590;590;590;590;590","FRANCESCO FRASSONI;ADRIANO GIACOMIN;ANDREA SANTARELLI;ARRIGO ARRIGONI;B. ANDREONI;C. CROSTA;CARLO SENORE;CARMEN BEATRIZ VISIOLI;CLAUDIA CASELLA;F FERRERO;FABIO FALCINI;L BISANTI;L BONELLI;MARCO ZAPPA;MAURO RISIO;NEREO SEGNAN;ORIETTA GIULIANI;PAOLA ARMAROLI;ROBERTO ZANETTI;STEFANIA SCIALLERO","675;590;590;590;590;590;590;590;590;590;590;590;590;590;590;590;590;590;590;590","GIORGIO CIPRANDI;ANGELO MICHELE CARELLA;ANDREA BACIGALUPO;CLAUDIO VISCOLI;FRANCESCO FRASSONI;MARIA TERESA VAN LINT;SIMONE FERRERO;GIAN-MATTEO PICA;MARCO GOBBI;ANTONIO DI BIAGIO;DOMENICO PALOMBO;MARCO COMASCHI;MARINA PODESTÀ;MAŁGORZATA MIKULSKA;MICHELE MUSSAP;PAOLA MINALE;PAOLA SCARUFFI;RAFFAELLA ROSSO;SARA SEITUN;SERGIO CLAUDIO SACCÀ","21;17;10;8;8;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PSYCHOLOGY;ECONOMICS;GEOGRAPHY;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY;HISTORY","174;69;17;13;7;7;6;6;3;2;2;2;2;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GENETICS;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;BIOCHEMISTRY;PATHOLOGY;PEDIATRICS;CARDIOLOGY;ENDOCRINOLOGY;RADIOLOGY;CELL BIOLOGY;DERMATOLOGY;CANCER RESEARCH;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;OPTICS;NURSING;PHYSICAL THERAPY;UROLOGY","125;55;51;34;29;27;22;21;20;19;16;16;16;13;13;12;12;12;10;8;8;8","TRANSPLANTATION;CANCER;POPULATION;GENE;CHEMOTHERAPY;ASTHMA;ALLERGY;ANTIBODY;BONE MARROW;DISEASE;LYMPHOMA;REGIMEN;STEM CELL;LUNG;ADVERSE EFFECT;INCIDENCE (GEOMETRY);CLINICAL TRIAL;COHORT;DIABETES MELLITUS;LEUKEMIA","25;24;23;21;18;16;13;13;12;11;11;11;11;10;9;9;8;8;8;8","HEMATOPOIETIC STEM CELL TRANSPLANTATION;CYCLOPHOSPHAMIDE;SPIROMETRY;BREAST CANCER;COLORECTAL CANCER;CUMULATIVE INCIDENCE;IMMUNOGLOBULIN E;RITUXIMAB;TOLERABILITY;VIRAL LOAD;ALLERGEN;CLINICAL ENDPOINT;HAEMATOPOIESIS;LUNG FUNCTION;MICROALBUMINURIA;MUTATION;RESPIRATORY DISEASE;BRONCHODILATOR;CHROMOSOME;CORONARY ANGIOGRAPHY;LENALIDOMIDE;PROSTATE CANCER","14;10;9;8;8;7;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4","BRONCHODILATION;COLONOSCOPY;DIFFUSING CAPACITY;FLUDARABINE;METHACHOLINE;ANTIRETROVIRAL THERAPY;BRONCHIAL HYPERREACTIVITY;BRONCHIAL HYPERRESPONSIVENESS;CANDIDA KRUSEI;TOTAL BODY IRRADIATION;BENDAMUSTINE;BUSULFAN;CD3;CXCR4;IMATINIB MESYLATE;NATURAL KILLER CELL;NKG2D;OFATUMUMAB;PROSTATE-SPECIFIC ANTIGEN;ABL;ACINETOBACTER BAUMANNII;AFLIBERCEPT;AGATSTON SCORE;AMSACRINE;ANDROGEN RECEPTOR;ANEUPLOIDY;ANTHRACYCLINE;ANTIANDROGEN;AORTIC VALVULOPLASTY;AROMATASE;AXILLA;AXILLARY LYMPH NODES;BONE MARROW FAILURE;BREAST CARCINOMA;BRONCHODILATATION;BROTH MICRODILUTION;CANNABINOID RECEPTOR;CAREGIVER BURDEN;CASPOFUNGIN;CD38;CD52;CENTER FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE;CENTROSOME;CHEMOKINE RECEPTOR;CHROMOSOME 17 (HUMAN);CHROMOSOME INSTABILITY;COGNITIVE DECLINE;COPY-NUMBER VARIATION;CORONAVIRUS DISEASE 2019 (COVID-19);CROSS-REACTIVITY;CTLA-4;CYTOLYSIS;CYTOMEGALOVIRUS INFECTION;DASATINIB;DISINTEGRIN;DNA GLYCOSYLASE;DOPPLER ECHOCARDIOGRAPHY;DORZOLAMIDE;DRY-POWDER INHALER;DYNAMIC HYPERINFLATION;DYSKERATOSIS CONGENITA;ECULIZUMAB;EMBRYO QUALITY;EPILEPSIA PARTIALIS CONTINUA;FAMILY PLANNING;FEBRILE NEUTROPENIA;FERTILITY PRESERVATION;FINASTERIDE;FIRST TRIMESTER;FOOD HYPERSENSITIVITY;FORMOTEROL;GASTROINTESTINAL CANCER;GENEXPERT MTB/RIF;GENOME INSTABILITY;GENOTYPING;GERIATRIC DEPRESSION SCALE;GONADOTROPIN-RELEASING HORMONE;HBSAG;HEMATOPOIETIC CELL;HEMATOPOIETIC STEM CELL;HEPADNAVIRIDAE;HEPATITIS B VIRUS DNA POLYMERASE;HERPESVIRIDAE;HISTONE DEACETYLASE;HOUSE DUST MITE;INTERLEUKIN 21;INTERNATIONAL PROGNOSTIC INDEX;INVASIVE CANDIDIASIS;IRINOTECAN;KARYOTYPE;LAMIVUDINE;MAMMOGRAPHY;METERED-DOSE INHALER;MILK ALLERGY;MISSENSE MUTATION;MOLECULAR EPIDEMIOLOGY;MULTILOCUS SEQUENCE TYPING;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;NEOADJUVANT THERAPY;NEUROENDOCRINE DIFFERENTIATION;NILOTINIB;NORETHISTERONE;ONCOGENE;PARAHIPPOCAMPAL GYRUS;POINT MUTATION;POLYMORPHISM (COMPUTER SCIENCE);POMALIDOMIDE;POSACONAZOLE;PRENATAL DIAGNOSIS;PRESENILIN;PROPIDIUM IODIDE;PROSTATECTOMY;RADICAL HYSTERECTOMY;RADIOIMMUNOTHERAPY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;REVERSE TRANSCRIPTASE;RIBAVIRIN;RIGHT BREAST;SCORAD;SECOND TRIMESTER;SENTINEL LYMPH NODE;SEROSTATUS;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;SIRTUIN;STAPHYLOCOCCAL INFECTIONS;STREPTOCOCCUS BOVIS;SYSTOLE;TAQMAN;THIOTEPA;TLR2;TOLL-LIKE RECEPTOR;TOTAL MESORECTAL EXCISION;TRACHELECTOMY;TUMOR SUPPRESSOR GENE;VIRAL VECTOR;VIRIDANS STREPTOCOCCI;VIROTHERAPY","4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;;AGED;ITALY;RHINITIS, ALLERGIC, PERENNIAL;RHINITIS, ALLERGIC, SEASONAL;ASTHMA;ADOLESCENT;YOUNG ADULT;TREATMENT OUTCOME;HIV INFECTIONS;RISK FACTORS;AGED, 80 AND OVER;CHILD;FOLLOW-UP STUDIES;ANTI-HIV AGENTS","127;106;92;69;59;57;52;45;43;36;29;26;26;24;19;19;17;17;17;16","ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ASTHMA;HEMATOPOIETIC STEM CELL BIOLOGY;LYMPHOID NEOPLASMS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MULTIPOTENT MESENCHYMAL STEM CELLS;ACUTE MYELOID LEUKEMIA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;NATURAL KILLER CELLS IN IMMUNITY;PROSTATE CANCER RESEARCH AND TREATMENT;ATOPIC DERMATITIS AND SKIN MICROBIOME;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY","15;7;7;7;5;5;4;4;4;4;4;4;3;3;3;3;3;3;2;2","REGIMEN;ASTHMA;HEMATOPOIETIC CELL TRANSPLANTATION;CUMULATIVE INCIDENCE;TOLERABILITY;CARDIOVASCULAR RISK ASSESSMENT;CLINICAL ENDPOINT;MICROALBUMINURIA;POLLEN ALLERGY;TREATMENT;AIRWAY AFFERENT NERVES;ANTIRETROVIRAL THERAPY;BRONCHODILATION;CARDIAC IMAGING;COMPUTED TOMOGRAPHY ANGIOGRAPHY;COUGH REFLEX SENSITIVITY;HOUSE DUST MITE ALLERGENS;MANTLE CELL LYMPHOMA;METHACHOLINE;VITAL CAPACITY","11;10;8;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","ALLERGIC RHINITIS;STEM CELL;CELL TRANSPLANTATION;HEMATOPOIETIC STEM;COMPUTED TOMOGRAPHY;APLASTIC ANEMIA;BRONCHIAL HYPERREACTIVITY;CANCER SCREENING;CORONARY ANGIOGRAPHY;MARROW TRANSPLANTATION;MULTICENTER STUDY;MULTIPLE MYELOMA;PHASE II;TOMOGRAPHY CORONARY;ALLOGENEIC HEMATOPOIETIC;ALLOGENEIC STEM;BONE MARROW;CHRONIC KIDNEY;CONDITIONING REGIMEN;DIAGNOSTIC ACCURACY;KIDNEY DISEASE;LYMPH NODE;MYELOID LEUKEMIA;NEWLY DIAGNOSED;PREDICTIVE FACTOR;PROSTATE CANCER;RANDOMIZED CONTROLLED;REGISTRY DATA;RETROSPECTIVE STUDY;REVASCULARISATION REGISTRY","13;13;11;6;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ANTI-APOA- IGG;RISK FACTORS;STEM CELL;TRABECULAR MESHWORK;CMV INFECTION;CELL TRANSPLANTATION;MEDIAN FOLLOW-UP;SECONDARY AD;CELL LINES;CRC INCIDENCE;FOOD ALLERGY;GASTRIC CANCER;LAF UNIT;LYMPH NODES;NK CELLS;NVC PATTERN;STEM CELLS;ALLERGIC RHINITIS;ALTERNATIVE DONOR;FLEXIBLE SIGMOIDOSCOPY;GENE EXPRESSION;LEUKEMIA CELLS;PATIENTS RECEIVED;SCREENING PROGRAM;SERUM LEVELS;VIROLOGIC FAILURE;ADVERSE EFFECTS;ANALYZED PATIENTS;ANTIFUNGAL SUSCEPTIBILITY;ANTIMICROBIAL THERAPY","11;11;11;11;9;8;7;7;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4",51,0.27,5.14,4,1,1,0,1,2,0,1,4,0,0,4.5,0,1,1,1,3.5,2,0,0,79,79,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,2,7,1.49,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBINI ADRIANA;BENELLI ROBERTO;BRIGATI CLAUDIO;DELL EVA RAFFAELLA;MINGHELLI SIMONA;MORINI MONICA;NOONAN DOUGLAS M","1;1;1;1;1;1;1","ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO","1","34 CHEMICAL SCIENCES;48 LAW AND LEGAL STUDIES;4806 PRIVATE LAW AND CIVIL OBLIGATIONS","1;1;1",NA,NA,"5.1 PHARMACEUTICALS","1","A61K38/10;C07K7/08","1;1","A61K38/00;A61P27/02;A61P27/06;A61P29/00;A61P43/00;A61P9/00;A61P9/10;C12N9/6435;C12Y304/21007","1;1;1;1;1;1;1;1;1",34,5.79,833,13.71,13,0.38,95.47,1,0,8,0,12,0,4,9,0,28,6,0,0,0,0,0,0,31,3,0,34,0,0,0,0,0,0,0,0,0,"United States;Italy;Belgium;Denmark;Germany;Japan;Netherlands;Sweden;Switzerland","5;3;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","32;17;13;5;3;3;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;HEMATOLOGY;LUNG;LUNG CANCER;CARDIOVASCULAR;ORPHAN DRUG;AGING;BEHAVIORAL AND SOCIAL SCIENCE;DIGESTIVE DISEASES;HEART DISEASE;LYMPHOMA;NEUROSCIENCES;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;BRAIN DISORDERS","31;22;18;13;6;5;5;5;4;4;3;3;3;3;3;3;2;2;2;2","CANCER;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;GENERIC HEALTH RELEVANCE;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","14;3;2;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;3.4 VACCINES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","25;5;4;2;1;1;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA;MELANOMA;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LIVER CANCER;MYELOMA;OVARIAN CANCER;SKIN CANCER","5;4;2;2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","16;1",1,1000620,250155,6,4,1,1,4,500943.240663548,0.377288252756243,"ALLEANZA CONTRO IL CANCRO;ISTITUTO SUPERIORE DI SANITÀ;OSPEDALE POLICLINICO SAN MARTINO;UNIVERSITY OF GENOA","1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP7-PEOPLE - SPECIFIC PROGRAMME ""PEOPLE"" IMPLEMENTING THE SEVENTH FRAMEWORK PROGRAMME OF THE EUROPEAN COMMUNITY FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ACTIVITIES (2007 TO 2013) (PROGRAMME);FP7-PEOPLE-COFUND-2008 (CALL FOR PROPOSAL);MC-COFUND - CO-FUNDING OF REGIONAL, NATIONAL AND INTERNATIONAL PROGRAMMES (COFUND) (FUNDING SCHEME)","1;1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1","CANCER","1",NA,NA,NA,NA,NA,NA,NA,NA,"D26 MODERN LANGUAGES AND LINGUISTICS","1",NA,NA,10,"PUBLIC LIBRARY OF SCIENCE","10","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3202 CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;4904 PURE MATHEMATICS","12;8;3;2;2;1;1;1;1;1","HEMATOLOGY;RARE DISEASES;CANCER;CLINICAL RESEARCH;GENETICS;DIGESTIVE DISEASES;LYMPHOMA;NUTRITION","4;4;3;2;2;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM","2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","2;1;1","BIOMEDICAL","4","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","4;3","LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER","5;1",NA,NA
"IRCCS_SANMARTINO",2012,337,11.2581602373887,2.69139465875371,0.371554575523705,0.388724035608309,0.359050445103858,0.293768545994065,0.448071216617211,10,188,61,34,26,0.56,0.18,0.1,0.08,58.95,1.4112745404347,0.338278931750742,0.878338278931751,5.79243243243245,0.478031482337909,0.419502719502719,0.424576534921976,0.388513037350247,"ANDREA BACIGALUPO;ANGELO MICHELE CARELLA;GIORGIO CIPRANDI;LORENZO MORETTA;GIORGIO WALTER CANONICA;ALESSANDRO RAMBALDI;DOMENICO FRANCO MERLO;ALDO PAGANO;PAOLO BRUZZI;MARIA CRISTINA MINGARI;FULVIO BRAIDO;ALBERTO BOSI;TERESA LAMPARELLI;FRANCO PATRONE;PAOLA QUEIROLO;ALBERTO BALLESTRERO;MARIA TERESA VAN LINT;PAOLO ROMANO;ANTONIO DAGA;BIANCA BRUZZONE","21;15;15;10;9;9;7;7;7;7;7;7;7;7;7;7;7;6;6;6","GIORGIO CIPRANDI;ANDREA CARIATI;SAMIR GIUSEPPE SUKKAR;PAOLO ROMANO;ANGELO MICHELE CARELLA;ANDREA BACIGALUPO;ACHILLE ZAPPA;ELISA PIROMALLI;LORENZO MORETTA;GIORGIO WALTER CANONICA;STEFANO SCABINI;GABRIELE ZOPPOLI;MARIA CRISTINA MINGARI;A. SOBRERO;UMBERTO ROSSI;FULVIO BRAIDO;SARA SEITUN;ALDO PAGANO;ANDREA DE MARIA;PIER LUIGI VENTURINI","3.77;3.33;3.2;2.87;2.02;1.75;1.53;1.33;1.3;1.3;1.27;1.26;1.02;1;0.99;0.94;0.89;0.88;0.8;0.78","ANDREA BACIGALUPO;ANGELO MICHELE CARELLA;GIORGIO CIPRANDI;LORENZO MORETTA;GIORGIO WALTER CANONICA;DOMENICO FRANCO MERLO;ALDO PAGANO;PAOLO BRUZZI;MARIA CRISTINA MINGARI;FULVIO BRAIDO;TERESA LAMPARELLI;FRANCO PATRONE;PAOLA QUEIROLO;ALBERTO BALLESTRERO;MARIA TERESA VAN LINT;PAOLO ROMANO;ANTONIO DAGA;BIANCA BRUZZONE;PAOLA GHIORZO;ALESSANDRO POGGI","21;15;15;10;9;7;7;7;7;7;7;7;7;7;7;6;6;6;6;6","GIORGIO CIPRANDI;ANDREA CARIATI;SAMIR GIUSEPPE SUKKAR;PAOLO ROMANO;ANGELO MICHELE CARELLA;ANDREA BACIGALUPO;ACHILLE ZAPPA;ELISA PIROMALLI;LORENZO MORETTA;GIORGIO WALTER CANONICA;STEFANO SCABINI;GABRIELE ZOPPOLI;MARIA CRISTINA MINGARI;A. SOBRERO;UMBERTO ROSSI;FULVIO BRAIDO;SARA SEITUN;ALDO PAGANO;ANDREA DE MARIA;PIER LUIGI VENTURINI","3.77;3.33;3.2;2.87;2.02;1.75;1.53;1.33;1.3;1.3;1.27;1.26;1.02;1;0.99;0.94;0.89;0.88;0.8;0.78","ERIC VAN CUTSEM;JOSEP TABERNERO;ALBERTO SOBRERO;SALVATORE SIENA;ALFREDO FALCONE;THIERRY ANDRÉ;AXEL GROTHEY;FRANK CIHON;MARC YCHOU;TAKAYUKI YOSHINO;HEINZ‐JOSEF LENZ;ANTOINE ADENIS;CARLO BARONE;DANIEL J. SARGENT;DIRK LAURENT;LAURENT MINEUR;OLIVIER BOUCHÉ;RICHARD M. GOLDBERG;YVES HUMBLET;LISA CUPIT","3918;3901;3884;2561;2559;2540;2535;2535;2535;2535;2533;2518;2518;2518;2518;2518;2518;2518;2516;2480","ALBERTO SOBRERO;CLAUDIO VISCOLI;PAOLO PELOSI;SIMONA COCO;GIAN PAOLO TONINI;ANDREA BACIGALUPO;PAOLA QUEIROLO;MARIA TERESA VAN LINT;MARIA CRISTINA MINGARI;MARIA TERESA VAN LINT SUP SUP;ANGELO MICHELE CARELLA;MASSIMO VITALE;PIETRO DULBECCO;ROBERTO BENELLI;TERESA LAMPARELLI;FILIPPO BALLERINI;ROSI ONETO;DANIELA PENDE;ALIDA DOMINIETTO;ANNA GHISO","3884;1802;1187;948;883;882;667;645;536;499;476;432;419;419;388;373;373;362;357;357","ANDREA BACIGALUPO;GIORGIO CIPRANDI;ANGELO MICHELE CARELLA;ALDO PAGANO;FULVIO BRAIDO;MARIA TERESA VAN LINT;TERESA LAMPARELLI;PAOLA QUEIROLO;MARIA CRISTINA MINGARI;GIORGIO WALTER CANONICA;BIANCA BRUZZONE;LUCIA DEL MASTRO;MAURO TRUINI;PAOLO BRUZZI;GIOVANNA BIANCHI‐SCARRÀ;ALBERTO SOBRERO;ANDREA CARIATI;ANDREA DE MARIA;ANTONIO DAGA;MASSIMO COSTANTINI","21;14;13;7;7;7;7;7;7;6;6;6;6;6;5;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;ENGINEERING;POLITICAL SCIENCE;SOCIOLOGY;PSYCHOLOGY;MATERIALS SCIENCE;PHILOSOPHY;ECONOMICS;BUSINESS;ART;ENVIRONMENTAL SCIENCE","283;145;49;26;25;10;9;8;8;7;5;5;4;3;2;1","INTERNAL MEDICINE;IMMUNOLOGY;GENETICS;SURGERY;ONCOLOGY;BIOCHEMISTRY;PATHOLOGY;CANCER RESEARCH;GASTROENTEROLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;RADIOLOGY;PHARMACOLOGY;MOLECULAR BIOLOGY;PALEONTOLOGY;DERMATOLOGY;FAMILY MEDICINE;NURSING;OPTICS","209;81;80;68;66;61;57;55;50;35;28;27;21;17;16;16;15;15;15;15","CANCER;GENE;CHEMOTHERAPY;TRANSPLANTATION;STEM CELL;DISEASE;POPULATION;RECEPTOR;BONE MARROW;ENZYME;IMMUNE SYSTEM;CONFIDENCE INTERVAL;IN VITRO;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;COHORT;LYMPHOMA;RETROSPECTIVE COHORT STUDY;APOPTOSIS;LEUKEMIA;LUNG;STAGE (STRATIGRAPHY)","84;58;35;32;29;26;26;26;20;17;17;16;15;14;14;13;13;13;12;12;12;12","BREAST CANCER;COLORECTAL CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;GENE EXPRESSION;HAEMATOPOIESIS;CYCLOPHOSPHAMIDE;HAZARD RATIO;PHENOTYPE;PROSTATE CANCER;CLINICAL ENDPOINT;CYTOTOXIC T CELL;MUTATION;MYELODYSPLASTIC SYNDROMES;SPIROMETRY;TRANSCRIPTION FACTOR;CD8;IMMUNOTHERAPY;METASTASIS;NEUROBLASTOMA;RNA;VIRAL LOAD","25;19;19;12;12;11;11;8;8;7;7;7;7;7;7;6;6;6;6;6;6","ANTIRETROVIRAL THERAPY;FLUDARABINE;TRANSCRIPTOME;HEMATOPOIETIC CELL;BUSULFAN;IMATINIB MESYLATE;INTERLEUKIN 12;INTERLEUKIN 21;METASTATIC BREAST CANCER;NILOTINIB;ONCOGENE;REGORAFENIB;TOTAL BODY IRRADIATION;ALTERNATIVE SPLICING;BRONCHODILATION;CD38;COLONOSCOPY;GERMLINE MUTATION;HISTONE DEACETYLASE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;PTCH1;RNA INTERFERENCE;SINGLE-NUCLEOTIDE POLYMORPHISM;THIOTEPA","6;6;6;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ITALY;ANTINEOPLASTIC AGENTS;ADOLESCENT;YOUNG ADULT;HIV INFECTIONS;ANIMALS;ASTHMA;AGED, 80 AND OVER;BREAST NEOPLASMS;NEUROBLASTOMA;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;CELL LINE, TUMOR","222;138;128;106;97;96;81;53;42;41;39;34;32;32;31;31;31;28;25;23","HEMATOPOIETIC STEM CELL BIOLOGY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ASTHMA;LYMPHOID NEOPLASMS;NATURAL KILLER CELLS IN IMMUNITY;NEUROBLASTOMA RESEARCH AND TREATMENT;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;REGULATION OF RNA PROCESSING AND FUNCTION;EFFICACY AND RESISTANCE IN CML TREATMENT;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;MOLECULAR MECHANISMS OF DNA DAMAGE RESPONSE;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;INTEGRATION OF PALLIATIVE CARE IN END-OF-LIFE;ACUTE MYELOID LEUKEMIA;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GLIOMAS","14;11;11;8;8;8;7;6;5;5;5;4;4;3;3;3;3;3;3;3","HEMATOPOIETIC CELL TRANSPLANTATION;METASTATIC COLORECTAL CANCER;REGIMEN;NK CELL ACTIVATION;NK CELL DEVELOPMENT;NK CELL THERAPY;ASTHMA;NEUROBLASTOMA;CLINICAL ENDPOINT;NK CELL RECOGNITION;ANTIRETROVIRAL THERAPY;CANCER INCIDENCE;TREATMENT;FOLLICULAR LYMPHOMA;MANTLE CELL LYMPHOMA;NK CELL RECEPTORS;SINGLE CENTER;ALLERGEN IMMUNOTHERAPY;BREAST CANCER SCREENING;CANCER","12;10;10;9;9;9;8;8;7;7;6;6;6;5;5;5;5;4;4;4","STEM CELL;BREAST CANCER;CELL TRANSPLANTATION;COLORECTAL CANCER;CANCER PATIENTS;METASTATIC COLORECTAL;PROSTATE CANCER;STEM CELLS;MYELOID LEUKEMIA;PHASE II;PHASE III;CANCER MCRC;HEMATOPOIETIC STEM;MULTIPLE MYELOMA;ALLERGIC RHINITIS;ALLOGENEIC HEMATOPOIETIC;BONE MARROW;CHRONIC MYELOID;FIRST-LINE TREATMENT;HEMATOPOIETIC CELL;II STUDY;MARROW TRANSPLANTATION;MELANOMA CELLS;METASTATIC BREAST;NK CELLS;RECTAL CANCER;RETROSPECTIVE STUDY;ALLOGENEIC STEM;CANCER CELLS;CANCER THERAPY","15;14;14;10;8;7;7;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3","STEM CELL;CELL TRANSPLANTATION;BREAST CANCER;NK CELLS;BONE MARROW;HEMATOPOIETIC STEM;PROSTATE CANCER;CELL LINES;SEMANTIC WEB;CANCER CELLS;MEDIAN AGE;OPTIMAL HRQOL;PATIENTS TREATED;PERIPHERAL BLOOD;CANCER PATIENTS;GENE EXPRESSION;UVEAL MELANOMA;DATA MODEL;GALLBLADDER CANCER;LAIR EXPRESSION;MEDIAN FOLLOW-UP;MELANOMA CELLS;PALLIATIVE CARE;POSTN EXPRESSION;PRIMARY ENDPOINT;STATISTICALLY SIGNIFICANT;STEM CELLS;WEB INTERFACE;BODY IRRADIATION;CLINICAL TRIALS","23;20;19;14;13;13;13;11;11;10;10;10;9;9;8;8;8;7;7;7;7;7;7;7;7;7;7;7;6;6",125,0.37,4,4,2,2,1.75,4.5,3.75,1,1.5,5,1,1,4,0,1,2,2,3,2,0,0,88,88,2,0,3,0,0,0,0,0,0,0,0,0,3,0,0,5,4.66666666666667,1.54,2.33333333333333,0,3,2,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CHIARUGI LUCA;RUZZON TIZIANA;FANZIO PAOLA;FIRPO GIUSEPPE;MUSSI VALENTINA;REPETTO LUCA;SCARUFFI PAOLA;STIGLIANI SARA;TONIN GIAN PAOLO;TONINI GIAN PAOLO","2;2;1;1;1;1;1;1;1;1","OMEGA SRL;IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO - IST - ISTITUTO NATIONZALE PER LA RICERCA SUL CANCRO;IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO - IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO;IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO - IST - ISTITUTO NAZIONZALE PER LA RICERCA SUL CANCRO;IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO IST ISTITUTO NAZIONZALE PER LA RICERCA SUL CANCR;UNIVERSITA DEGLI STUDI DI GENOVA","2;1;1;1;1;1","34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;41 ENVIRONMENTAL SCIENCES;31 BIOLOGICAL SCIENCES;40 ENGINEERING;4008 ELECTRICAL ENGINEERING","2;2;2;1;1;1",NA,NA,NA,NA,"B81B1/00;G01N1/38;G01N1/40;G01N30/02;G01N33/487","1;1;1;1;1","G01N1/2226;G01N2001/2241;G01N33/0011;G01N15/12;G01N33/48721","2;2;2;1;1",23,7.09,414.64,4.8,7,0.3,58.83,0,0,6,0,10,0,1,6,0,17,5,0,0,0,0,0,0,19,4,0,22,1,0,0,0,0,0,0,0,0,"Italy;United States","4;3","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;3204 IMMUNOLOGY;3208 MEDICAL PHYSIOLOGY;44 HUMAN SOCIETY;4403 DEMOGRAPHY","23;15;10;6;2;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;LUNG;HEMATOLOGY;LUNG CANCER;PATIENT SAFETY;CONTRACEPTION/REPRODUCTION;GENETICS;LYMPHOMA;BIOENGINEERING;BIOMEDICAL IMAGING;BRAIN DISORDERS;BREAST CANCER;HUMAN GENOME;NEUROSCIENCES;ACUTE RESPIRATORY DISTRESS SYNDROME;AGING;ASSISTIVE TECHNOLOGY","20;18;13;10;8;7;5;4;3;3;3;2;2;2;2;2;2;1;1;1","CANCER;RESPIRATORY;REPRODUCTIVE HEALTH AND CHILDBIRTH","17;2;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","17;3;2;2;2;1;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA;MELANOMA;MYELOMA;OVARIAN CANCER;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;RESPIRATORY SYSTEM","8;4;2;2;2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;1.2 CANCER INITIATION: ALTERATIONS IN CHROMOSOMES;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","18;3;1;1;1;1;1",1,3137774,209184.93,5,15,11,1,21,417500.642652795,0.807184386253168,"BELGIAN FEDERAL SCIENCE POLICY OFFICE;CAB INTERNATIONAL;GHENT UNIVERSITY;INSTITUT PASTEUR;INSTITUTE OF AGRICULTURAL AND FOOD BIOTECHNOLOGY;INSTITUTE OF BIOCHEMISTRY AND PHYSIOLOGY OF MICROORGANISMS;LEIBNIZ INSTITUTE DSMZ – GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES;NATIONAL RESEARCH INSTITUTE FOR AGRICULTURE, FOOD AND ENVIRONMENT;OSPEDALE POLICLINICO SAN MARTINO;ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES;SPANISH NATIONAL RESEARCH COUNCIL;UNIVERSITY OF GOTHENBURG;UNIVERSITY OF MINHO;UNIVERSITY OF TURIN;UNIVERSITY OF VALENCIA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-CSA-INFRA - COMBINATION OF CP AND CSA (FUNDING SCHEME);FP7-INFRASTRUCTURES - SPECIFIC PROGRAMME ""CAPACITIES"": RESEARCH INFRASTRUCTURES (PROGRAMME);FP7-INFRASTRUCTURES-2012-1-RTD (CALL FOR PROPOSAL)","1;1;1","31 BIOLOGICAL SCIENCES;44 HUMAN SOCIETY;4407 POLICY AND ADMINISTRATION","1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"B12 ENGINEERING","1","1 NO POVERTY","1",25,"PUBLIC LIBRARY OF SCIENCE","25","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;40 ENGINEERING;4202 EPIDEMIOLOGY;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;44 HUMAN SOCIETY;4905 STATISTICS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;4001 AEROSPACE ENGINEERING;4003 BIOMEDICAL ENGINEERING;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4303 HISTORICAL STUDIES;4403 DEMOGRAPHY","18;17;9;6;4;4;4;4;2;2;2;1;1;1;1;1;1;1;1","GENETICS;CANCER;CLINICAL RESEARCH;BIOTECHNOLOGY;NEUROSCIENCES;RARE DISEASES;NEUROBLASTOMA;PEDIATRIC;HUMAN GENOME;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TOBACCO;TOBACCO SMOKE AND HEALTH;AGING;EYE DISEASE AND DISORDERS OF VISION;HEMATOLOGY;OSTEOPOROSIS;PREVENTION","10;6;6;5;4;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","4;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","5","BIOMEDICAL;CLINICAL","6;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE","6;4;3","MELANOMA;NEUROBLASTOMA;EYE CANCER;LEUKEMIA / LEUKAEMIA","4;2;1;1",NA,NA
"IRCCS_SANMARTINO",2013,448,11.5044642857143,3.06026785714286,0.326768781911014,0.372767857142857,0.352678571428571,0.287946428571429,0.455357142857143,14,251,71,46,40,0.56,0.16,0.1,0.09,28.03,0.803358831563829,0.348214285714286,0.872767857142857,6.15267175572518,0.457596515219639,0.38664343786295,0.42618128332414,0.401805157593123,"ANDREA BACIGALUPO;ANGELO MICHELE CARELLA;CLAUDIO VISCOLI;ANTONIO DI BIAGIO;GIORGIO CIPRANDI;ALBERTO SOBRERO;PAOLO BRUZZI;GÈRARD SOCIÉ;DOMENICO FRANCO MERLO;BIANCA BRUZZONE;GIANMARIO SAMBUCETI;MANLIO FERRARINI;SALVATORE SIENA;RENZO CORVÒ;MARCO GOBBI;ERIC VAN CUTSEM;ALFREDO FALCONE;MARC YCHOU;FORTUNATO MORABITO;MYRIAM LABOPIN","22;14;14;13;12;10;10;9;9;9;9;9;9;9;9;9;8;8;8;8","ANGELO MICHELE CARELLA;PAOLO ROMANO;SAMIR GIUSEPPE SUKKAR;ANDREA CARIATI;GIORGIO CIPRANDI;ANNA RUBARTELLI;UMBERTO LEONE ROBERTI MAGGIORE;ANDREA BACIGALUPO;SARA STIGLIANI;MARA BOSCHETTI;RANIERI CANCEDDA;MATTIA ROCCO;GIANNI TESTINO;FABRIZIO MONTECUCCO;SIMONE FERRERO;SONIA CARTA;MICHELE MUSSAP;ANTONIO CUROTTO;B. PARODI;NICOLA CANNATA","3.07;2.9;2.62;2;1.93;1.59;1.32;1.29;1.29;1.28;1.16;1.13;1.12;1.12;1.12;1.01;1;1;1;1","ANDREA BACIGALUPO;ANGELO MICHELE CARELLA;CLAUDIO VISCOLI;ANTONIO DI BIAGIO;GIORGIO CIPRANDI;ALBERTO SOBRERO;PAOLO BRUZZI;DOMENICO FRANCO MERLO;BIANCA BRUZZONE;GIANMARIO SAMBUCETI;MANLIO FERRARINI;RENZO CORVÒ;MARCO GOBBI;MASSIMO COSTANTINI;LUCIA DEL MASTRO;ANNA RUBARTELLI;RANIERI CANCEDDA;FRANCESCO BOCCARDO;GIOVANNA CUTRONA;PAOLO ROMANO","22;14;14;13;12;10;10;9;9;9;9;9;9;8;8;8;8;7;7;7","ANGELO MICHELE CARELLA;PAOLO ROMANO;SAMIR GIUSEPPE SUKKAR;ANDREA CARIATI;GIORGIO CIPRANDI;ANNA RUBARTELLI;UMBERTO LEONE ROBERTI MAGGIORE;ANDREA BACIGALUPO;SARA STIGLIANI;MARA BOSCHETTI;RANIERI CANCEDDA;MATTIA ROCCO;GIANNI TESTINO;FABRIZIO MONTECUCCO;SIMONE FERRERO;SONIA CARTA;MICHELE MUSSAP;ANTONIO CUROTTO;B. PARODI;UO ALCOLOGIA","3.07;2.9;2.62;2;1.93;1.59;1.32;1.29;1.29;1.28;1.16;1.13;1.12;1.12;1.12;1.01;1;1;1;1","CLAUDIO VISCOLI;PAOLA QUEIROLO;ANDREA BACIGALUPO;PAOLO A. ASCIERTO;MAŁGORZATA MIKULSKA;CATHERINE CORDONNIER;CHRISTINA ORASCH;DAN ENGELHARD;DAVID M. LIVERMORE;DIANA AVERBUCH;G. A. KLYASOVA;INGE C. GYSSENS;MURAT AKOVA;OSCAR MARCHETTI;WINFRIED V. KERN;MARIA CRISTINA MINGARI;ANGELA ZUBEL;ANNIE ST‐PIERRE;AXEL HAUSCHILD;CARLA M.L. VAN HERPEN","1035;1026;882;851;747;670;670;670;670;670;670;670;670;670;670;623;613;613;613;613","PAOLA QUEIROLO;CLAUDIO VISCOLI;ANDREA BACIGALUPO;MAŁGORZATA MIKULSKA;MARIA CRISTINA MINGARI;ALBERTO SOBRERO;GIANMARIO SAMBUCETI;ANTONIO DAGA;ALESSANDRO POGGI;ULRICH PFEFFER;MICHELE CILLI;DAVIDE MAGGI;ADRIANA AMARO;SIMONA BOCCARDO;ANNA MARIA ORENGO;DOMENICO FRANCO MERLO;LAURA EMIONITE;RENZO CORDERA;RANIERI CANCEDDA;SANDRA SALVI","1015;940;882;732;482;430;353;334;333;320;314;292;284;284;280;277;270;268;264;264","ANDREA BACIGALUPO;ANGELO MICHELE CARELLA;GIORGIO CIPRANDI;PAOLO BRUZZI;ANTONIO DI BIAGIO;FRANCESCO BOCCARDO;ALBERTO SOBRERO;CLAUDIO VISCOLI;BIANCA BRUZZONE;DOMENICO FRANCO MERLO;GIOVANNA CUTRONA;LUCIA DEL MASTRO;MANLIO FERRARINI;ALESSANDRO POGGI;ANNA RUBARTELLI;RANIERI CANCEDDA;SAMIR GIUSEPPE SUKKAR;MARCO GOBBI;ANTONIO DAGA;MATTEO LAMBERTINI","22;13;11;10;10;10;9;9;8;8;7;7;7;7;7;7;7;7;7;6","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;POLITICAL SCIENCE;ECONOMICS;ENGINEERING;MATERIALS SCIENCE;GEOGRAPHY;BUSINESS;PHILOSOPHY;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY","385;187;47;34;19;16;16;14;13;12;12;9;7;5;5;2;2;2","INTERNAL MEDICINE;GENETICS;SURGERY;IMMUNOLOGY;ONCOLOGY;GASTROENTEROLOGY;PATHOLOGY;BIOCHEMISTRY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;CELL BIOLOGY;ENDOCRINOLOGY;RADIOLOGY;MOLECULAR BIOLOGY;OPTICS;NURSING;INTENSIVE CARE MEDICINE;PEDIATRICS;CARDIOLOGY;PALEONTOLOGY","308;109;109;99;98;68;64;61;56;53;42;39;36;25;25;24;23;23;22;20","CANCER;GENE;CHEMOTHERAPY;POPULATION;TRANSPLANTATION;DISEASE;COHORT;ANTIBODY;STEM CELL;ADVERSE EFFECT;LEUKEMIA;CONFIDENCE INTERVAL;LYMPHOMA;BONE MARROW;CELL CULTURE;IN VITRO;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;REGIMEN;CLINICAL TRIAL;RECEPTOR","105;74;51;51;41;33;29;25;25;24;21;20;20;19;19;19;19;19;19;18;18","BREAST CANCER;COLORECTAL CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;CLINICAL ENDPOINT;GENE EXPRESSION;NEUTROPENIA;RITUXIMAB;CYCLOPHOSPHAMIDE;CUMULATIVE INCIDENCE;GENOTYPE;PHENOTYPE;VIRAL LOAD;CHRONIC LYMPHOCYTIC LEUKEMIA;CYTOTOXIC T CELL;IMMUNOTHERAPY;HAEMATOPOIESIS;HAZARD RATIO;NEUROBLASTOMA;PLACEBO","45;23;21;17;16;14;14;14;12;10;10;10;10;9;9;9;8;8;8;8","KRAS;ANTIRETROVIRAL THERAPY;FLUDARABINE;FEBRILE NEUTROPENIA;OXALIPLATIN;REGORAFENIB;ESTROGEN RECEPTOR;IGHV@;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;METASTATIC BREAST CANCER;EPIRUBICIN;TAMOXIFEN;TRASTUZUMAB;CAPECITABINE;DNA METHYLATION;FERTILITY PRESERVATION;IPILIMUMAB;MAMMOGRAPHY;SINGLE-NUCLEOTIDE POLYMORPHISM;TRANSACTIVATION","9;8;8;7;7;7;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4","HUMANS;FEMALE;;MALE;MIDDLE AGED;ADULT;AGED;ITALY;AGED, 80 AND OVER;TREATMENT OUTCOME;HIV INFECTIONS;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ANTINEOPLASTIC AGENTS;RETROSPECTIVE STUDIES;MELANOMA;ADOLESCENT;ANIMALS;YOUNG ADULT;ASTHMA","263;179;170;158;131;106;104;62;54;53;51;50;46;45;40;39;37;36;35;33","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ACUTE MYELOID LEUKEMIA;LYMPHOID NEOPLASMS;HEMATOPOIETIC STEM CELL BIOLOGY;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ASTHMA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;MOLECULAR MECHANISMS OF INFLAMMASOME ACTIVATION AND REGULATION;NATURAL KILLER CELLS IN IMMUNITY;NEUROBLASTOMA RESEARCH AND TREATMENT;INTEGRATION OF PALLIATIVE CARE IN END-OF-LIFE;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;EFFICACY AND RESISTANCE IN CML TREATMENT;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF LUNG CANCER;IMMUNOBIOLOGY OF DENDRITIC CELLS;MACROPHAGE ACTIVATION AND POLARIZATION;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH","13;12;12;11;10;8;8;8;8;8;7;6;6;6;5;5;5;5;5;5","REGIMEN;HEMATOPOIETIC CELL TRANSPLANTATION;TREATMENT;CLINICAL ENDPOINT;HIV;METASTATIC COLORECTAL CANCER;BREAST CANCER;CUMULATIVE INCIDENCE;DISCONTINUATION;NEUROBLASTOMA;ASTHMA;PROGRESSION-FREE SURVIVAL;REGORAFENIB;ANTIRETROVIRAL THERAPY;CANCER CELL METABOLISM;IGHV@;IMATINIB MESYLATE;INFLAMMATION;NK CELL RECOGNITION;POSITIVE END-EXPIRATORY PRESSURE","19;17;17;16;13;11;10;10;9;8;7;7;7;6;6;6;6;6;6;6","BREAST CANCER;STEM CELL;CELL TRANSPLANTATION;PHASE II;CANCER PATIENTS;ACUTE LEUKEMIA;COLORECTAL CANCER;HEMATOPOIETIC STEM;CHRONIC LYMPHOCYTIC;II STUDY;LYMPHOCYTIC LEUKEMIA;PHASE III;METASTATIC COLORECTAL;ALLOGENEIC STEM;AORTIC VALVE;BONE MARROW;OBSERVATIONAL STUDY;ALLOGENEIC HEMATOPOIETIC;APLASTIC ANEMIA;CELL LINES;CORRECT STUDY;ELDERLY PATIENTS;MARROW TRANSPLANTATION;MYELOID LEUKEMIA;PROSTATE CANCER;APPETITE CONTROL;COMPLETE REMISSION;FONDAZIONE ITALIANA;HUMAN IMMUNODEFICIENCY;III CORRECT","26;19;18;13;11;9;9;9;8;8;8;8;7;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4","PUBMED SCOPUS;PANCREATIC CANCER;CELL LINES;NK CELLS;METASTATIC PANCREATIC;CLIN ONCOL;PHASE III;GOOGLE SCHOLARGEM;ADVANCED PANCREATIC;DOIJCOCROSSREF PUBMED;ONCOL -DOIJCOCROSSREF;BREAST CANCER;HR CI;NATURAL KILLER;SCHOLARGEM VERSUSGEM;VERSUS GEMCITABINE;BONE MARROW;PERFORMANCE STATUS;CLINICAL TRIALS;NK CELL;RISK FACTORS;SLEEP QUALITY;STEM CELLS;CLINICAL PRACTICE;KILLER CELLS;STEM CELL;LYMPH NODES;MEDIAN AGE;RENAL DYSFUNCTION;AAA PATIENTS","43;29;28;26;25;24;21;18;17;17;17;16;15;15;15;15;14;14;13;13;13;13;13;12;12;12;11;11;11;10",148,0.33,6.06,5,3,1,1,4,3,1,1,5.25,1,1,3.5,3,1.25,1,1,3,2,0,0,74.25,74.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,5.72,935.56,4.46,10,0.36,84.18,0,0,7,2,9,0,0,10,0,19,7,0,0,0,0,0,0,24,3,1,26,2,0,0,0,0,0,0,0,0,"United States;Germany;United Kingdom;Austria;Belgium;France;Italy;Netherlands","7;3;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;3204 IMMUNOLOGY;3208 MEDICAL PHYSIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","27;14;7;7;3;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;AGING;BREAST CANCER;TRANSPLANTATION;LUNG;STEM CELL RESEARCH;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;CARDIOVASCULAR;DIGESTIVE DISEASES;LYMPHOMA;ORPHAN DRUG;PREVENTION;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;ACUTE RESPIRATORY DISTRESS SYNDROME","25;19;18;14;8;6;5;5;5;4;4;3;3;3;3;3;3;3;3;2","CANCER;RESPIRATORY;BLOOD;CARDIOVASCULAR;NEUROLOGICAL","16;3;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;4.4 POPULATION SCREENING;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","14;2;2;2;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;LUNG CANCER;MELANOMA;PROSTATE CANCER;MYELOMA;STOMACH CANCER","6;5;3;2;2;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","15;4;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,63,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;AMERICAN CHEMICAL SOCIETY;THE CAMBRIDGE STRUCTURAL DATABASE","60;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3105 GENETICS;4203 HEALTH SERVICES AND SYSTEMS;49 MATHEMATICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3204 IMMUNOLOGY;3107 MICROBIOLOGY;4905 STATISTICS;3207 MEDICAL MICROBIOLOGY;34 CHEMICAL SCIENCES;4202 EPIDEMIOLOGY;52 PSYCHOLOGY;3402 INORGANIC CHEMISTRY;3403 MACROMOLECULAR AND MATERIALS CHEMISTRY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","70;46;20;16;13;12;7;6;4;4;4;3;3;2;2;2;2;1;1;1","GENETICS;CANCER;RARE DISEASES;CLINICAL RESEARCH;PREVENTION;HUMAN GENOME;NEUROSCIENCES;PEDIATRIC;LUNG;NEUROBLASTOMA;BIOTECHNOLOGY;BREAST CANCER;GENETIC TESTING;OVARIAN CANCER;ASTHMA;DIGESTIVE DISEASES;HEPATITIS;HEPATITIS - B;LIVER DISEASE;LUNG CANCER","18;15;11;8;6;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2","CANCER;RESPIRATORY;GENERIC HEALTH RELEVANCE;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","11;2;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","12;4;4;2;1;1","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY;HEALTH SERVICES & SYSTEMS","9;3;2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","21;11;2","BREAST CANCER;OVARIAN CANCER;NEUROBLASTOMA;LUNG CANCER;NOT SITE-SPECIFIC CANCER;SKIN CANCER;THYROID CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;GENITAL SYSTEM, FEMALE;HEAD AND NECK CANCER;KIDNEY CANCER;LIVER CANCER;MELANOMA;NERVOUS SYSTEM;ORAL CAVITY AND LIP CANCER;PROSTATE CANCER","6;5;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SANMARTINO",2014,505,13.3623762376238,3.02574257425742,0.330497382198953,0.368316831683168,0.35049504950495,0.237623762376238,0.469306930693069,5,264,104,47,39,0.52,0.21,0.09,0.08,37.54,0.993460293899794,0.374257425742574,0.889108910891089,5.81116471399034,0.461349833427828,0.45702491522925,0.443112443112443,0.43019801980198,"ANDREA BACIGALUPO;ANTONIO DI BIAGIO;CLAUDIO VISCOLI;SIMONE FERRERO;GIORGIO WALTER CANONICA;PAOLO PELOSI;ALESSANDRO RAMBALDI;ANGELO MICHELE CARELLA;FRANCESCO GROSSI;PAOLA QUEIROLO;VALENTINO REMORGIDA;PIER LUIGI VENTURINI;GIANMARIO SAMBUCETI;MARCO GOBBI;ALBERTO F. SOBRERO;LORENZO MORETTA;FABRIZIO MONTECUCCO;FABIO CICERI;ALBERTO BOSI;SILVIA MORBELLI","30;20;18;17;14;13;13;11;11;11;11;11;10;10;10;9;9;9;9;9","SIMONE FERRERO;ANDREA BACIGALUPO;GIORGIO CIPRANDI;VALENTINO REMORGIDA;PIER LUIGI VENTURINI;AURORA PARODI;ANTONIO DI BIAGIO;CLAUDIO VISCOLI;GIORGIO WALTER CANONICA;PAOLO PELOSI;UMBERTO LEONE ROBERTI MAGGIORE;PAOLO ROMANO;C. CAMPISI;SILVIA MORBELLI;ANNA RUBARTELLI;L BONELLI;P. L. VENTURINI;GIANMARIO SAMBUCETI;CAROLINA SCALA;VALERIO DEL BONO","3.16;2.59;2.22;2.18;2.06;1.55;1.54;1.51;1.47;1.44;1.44;1.33;1.32;1.26;1.26;1.19;1.14;1.11;1.09;1.04","ANDREA BACIGALUPO;ANTONIO DI BIAGIO;CLAUDIO VISCOLI;SIMONE FERRERO;GIORGIO WALTER CANONICA;PAOLO PELOSI;ANGELO MICHELE CARELLA;FRANCESCO GROSSI;PAOLA QUEIROLO;VALENTINO REMORGIDA;PIER LUIGI VENTURINI;GIANMARIO SAMBUCETI;MARCO GOBBI;ALBERTO F. SOBRERO;FABRIZIO MONTECUCCO;SILVIA MORBELLI;ALBERTO SOBRERO;BIANCA BRUZZONE;ALESSIO SIGNORI;ULRICH PFEFFER","30;20;18;17;14;13;11;11;11;11;11;10;10;10;9;9;8;8;8;8","SIMONE FERRERO;ANDREA BACIGALUPO;GIORGIO CIPRANDI;VALENTINO REMORGIDA;PIER LUIGI VENTURINI;AURORA PARODI;ANTONIO DI BIAGIO;CLAUDIO VISCOLI;GIORGIO WALTER CANONICA;PAOLO PELOSI;UMBERTO LEONE ROBERTI MAGGIORE;PAOLO ROMANO;C. CAMPISI;SILVIA MORBELLI;ANNA RUBARTELLI;L BONELLI;P. L. VENTURINI;GIANMARIO SAMBUCETI;CAROLINA SCALA;VALERIO DEL BONO","3.16;2.59;2.22;2.18;2.06;1.55;1.54;1.51;1.47;1.44;1.44;1.33;1.32;1.26;1.26;1.19;1.14;1.11;1.09;1.04","GIORGIO WALTER CANONICA;PETER SCHMID‐GRENDELMEIER;ANDREA BACIGALUPO;ALEXANDER KAPP;ALEXANDER NAST;ALLEN P. KAPLAN;AMIR HAMZAH ABDUL LATIFF;ANA M. GIMÉNEZ‐ARNAU;BETTINA WEDI;CARSTEN BINDSLEV‐JENSEN;CLIVE GRATTAN;ELIAS TOUBI;F. ESTELLE R. SIMONS;GORDON SUSSMAN;JEAN‐LOUIS HÉBERT;KIRAN GODSE;LUÍS FELIPE ENSINA;MARCUS MAURER;MARGARIDA GONÇALO;MARIO SÁNCHEZ‐BORGES","2390;1794;1486;1246;1246;1246;1246;1246;1246;1246;1246;1246;1246;1246;1246;1246;1246;1246;1246;1246","GIORGIO WALTER CANONICA;ANGELO MICHELE CARELLA;SILVANA CHIARA;PAOLA QUEIROLO;ANDREA BACIGALUPO;GIOVANNI PASSALACQUA;MARIA CRISTINA MINGARI;DANIELA PENDE;CLAUDIO VISCOLI;ULRICH PFEFFER;ANDREA A. BACIGALUPO;FRANCESCO GROSSI;PAOLO PELOSI;LILIANA VARESCO;FRANCESCA VIAZZI;LAURA EMIONITE;VALERIO DEL BONO;MARIA TERESA VAN LINT;ANNA RUBARTELLI;SIMONE FERRERO","1842;1052;1012;996;985;576;575;574;532;436;379;356;345;340;339;334;334;316;305;304","ANDREA BACIGALUPO;ANTONIO DI BIAGIO;CLAUDIO VISCOLI;SIMONE FERRERO;GIORGIO WALTER CANONICA;PAOLO PELOSI;MARCO GOBBI;ANGELO MICHELE CARELLA;ALBERTO F. SOBRERO;FRANCESCO GROSSI;PAOLA QUEIROLO;VALENTINO REMORGIDA;ALBERTO SOBRERO;GIORGIO CIPRANDI;ILARIA BAIARDINI;PIER LUIGI VENTURINI;SILVIA MORBELLI;GIANMARIO SAMBUCETI;LILIANA VARESCO;LUCIA DEL MASTRO","27;19;15;15;13;12;11;10;10;10;9;9;8;8;8;8;7;7;7;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;ENGINEERING;ECONOMICS;POLITICAL SCIENCE;HISTORY;MATERIALS SCIENCE;SOCIOLOGY;BUSINESS;GEOGRAPHY;PHILOSOPHY;ENVIRONMENTAL SCIENCE;ART;GEOLOGY","444;175;58;38;20;19;18;17;8;8;7;7;7;5;5;4;2;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;ONCOLOGY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;CELL BIOLOGY;RADIOLOGY;ENDOCRINOLOGY;PEDIATRICS;PHARMACOLOGY;CARDIOLOGY;OPTICS;ANESTHESIA;INTENSIVE CARE MEDICINE;NURSING","342;129;108;104;98;86;72;68;61;60;43;43;34;31;28;26;26;23;23;22","CANCER;GENE;CHEMOTHERAPY;POPULATION;TRANSPLANTATION;DISEASE;RECEPTOR;ADVERSE EFFECT;IMMUNE SYSTEM;CLINICAL TRIAL;COHORT;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;REGIMEN;LEUKEMIA;LUNG CANCER;STEM CELL;HUMAN IMMUNODEFICIENCY VIRUS (HIV);ALLERGY;BONE MARROW;LYMPHOMA","118;69;63;53;41;39;31;28;27;26;23;23;23;23;23;22;21;21;19;18;18;18","COLORECTAL CANCER;BREAST CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CLINICAL ENDPOINT;HAZARD RATIO;CYCLOPHOSPHAMIDE;BEVACIZUMAB;INTERIM ANALYSIS;MUTATION;VIRAL LOAD;HAEMATOPOIESIS;IMMUNOTHERAPY;TOLERABILITY;GENOTYPE;HUMAN LEUKOCYTE ANTIGEN;METASTASIS;NEUROBLASTOMA;ALLERGEN;CHRONIC LYMPHOCYTIC LEUKEMIA;PHASES OF CLINICAL RESEARCH;PHENOTYPE;RITUXIMAB","36;35;22;17;17;16;13;13;13;13;11;11;11;10;10;10;10;9;8;8;8;8","ANTIRETROVIRAL THERAPY;OXALIPLATIN;FLUDARABINE;KRAS;IRINOTECAN;AFLIBERCEPT;ALLERGEN IMMUNOTHERAPY;IGHV@;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IPILIMUMAB;DIFFUSING CAPACITY;ESTROGEN RECEPTOR;IMATINIB MESYLATE;INTERLEUKIN 21;MAMMOGRAPHY;PEMETREXED;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;ANAPLASTIC LYMPHOMA KINASE;AROMATASE;AXILLA;BUSULFAN;CETUXIMAB;COMET ASSAY;CRIZOTINIB;DIFFUSE ALVEOLAR DAMAGE;FEBRILE NEUTROPENIA;HBSAG;INTERLEUKIN 12;MASTECTOMY;MISSENSE MUTATION;NILOTINIB;SENTINEL LYMPH NODE;TOTAL BODY IRRADIATION;TRANSACTIVATION;VEMURAFENIB","13;11;10;9;8;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ANTINEOPLASTIC AGENTS;ITALY;TREATMENT OUTCOME;BREAST NEOPLASMS;LUNG NEOPLASMS;AGED, 80 AND OVER;ADOLESCENT;MELANOMA;YOUNG ADULT;ANIMALS;HIV INFECTIONS;CARCINOMA, NON-SMALL-CELL LUNG;RETROSPECTIVE STUDIES","306;207;195;176;158;139;119;61;61;60;51;51;47;46;42;42;41;39;34;34","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;HEMATOPOIETIC STEM CELL BIOLOGY;ADVANCEMENTS IN LUNG CANCER RESEARCH;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;ACUTE MYELOID LEUKEMIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;NEUROBLASTOMA RESEARCH AND TREATMENT;NATURAL KILLER CELLS IN IMMUNITY;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;LYMPHOID NEOPLASMS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MANAGEMENT OF VALVULAR HEART DISEASE;COLORECTAL CANCER RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;MOLECULAR RESEARCH ON BREAST CANCER","19;17;15;12;12;9;9;9;8;7;7;6;6;6;6;5;5;5;5;5","REGIMEN;CLINICAL ENDPOINT;HEMATOPOIETIC CELL TRANSPLANTATION;FOLFIRI;INTERIM ANALYSIS;ANTIRETROVIRAL THERAPY;HIV;TOLERABILITY;DISCONTINUATION;METASTATIC COLORECTAL CANCER;TREATMENT;NEUROBLASTOMA;DIAGNOSIS;NK CELL DEVELOPMENT;NK CELL RECOGNITION;TREATMENT OUTCOMES;ASTHMA;BIOMARKER ANALYSIS;BREAST CANCER;CUMULATIVE INCIDENCE","23;17;15;13;13;12;11;11;10;10;10;9;8;8;8;8;7;7;7;7","STEM CELL;BREAST CANCER;CELL TRANSPLANTATION;COLORECTAL CANCER;LUNG CANCER;METASTATIC COLORECTAL;CANCER PATIENTS;CHRONIC LYMPHOCYTIC;HEMATOPOIETIC STEM;PHASE III;CANCER MCRC;CELL LUNG;LYMPHOCYTIC LEUKEMIA;NON-SMALL CELL;RISK FACTORS;SECOND-LINE TREATMENT;AFLIBERCEPT SAFETY;ALLERGIC RHINITIS;CLINICAL OUTCOME;GLOBAL AFLIBERCEPT;MYELOID LEUKEMIA;PATIENTS TREATED;ACUTE LEUKEMIA;ADVANCED MELANOMA;ALLOGENEIC STEM;DRY EYE;HEPATOCELLULAR CARCINOMA;LEUKEMIA PATIENTS;MARROW TRANSPLANTATION;MULTICENTER STUDY","20;17;17;16;13;13;8;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5","PUBMED SCOPUS;CROSSREF PUBMED;CIK CELLS;NK CELLS;STEM CELL;CELL TRANSPLANTATION;TARGET CELLS;HR CI;ADVERSE EVENTS;CELL LINES;GENE EXPRESSION;GRAFT-VERSUS-HOST DISEASE;PRIMARY ENDPOINT;HEMATOPOIETIC STEM;BREAST CANCER;LUNG CANCER;PATIENTS RECEIVING;GROWTH FACTOR;MEDIAN PFS;CHRONIC GVHD;KILLER CELLS;MULTIVARIATE ANALYSIS;PROGRESSION-FREE SURVIVAL;SIGNIFICANT DIFFERENCE;TARGET CELL;TUMOR SIZE;CIK-MEDIATED CYTOTOXICITY;CLINICAL TRIALS;HAZARD RATIO;MARROW TRANSPLANT","106;69;44;36;35;32;30;28;26;25;24;22;22;20;19;18;18;17;17;16;16;16;16;16;16;16;15;15;15;15",193,0.38,5.5,4,2,1,2,2,4,1,1,5,1,1,4,1.75,2,1,2,3,2,0,0,73,73,2,0,0,0,0,0,0,1,1,0,0,0,1,1,0,6,7,0.92,2.5,0,2,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"TONINI GIAN PAOLO;CHIARUGI LUCA;FANZIO PAOLA;FIRPO GIUSEPPE;MAGNANI MAURO;MANNESCHI CHIARA;MENOTTA MICHELE;MUSSI VALENTINA;REPETTO LUCA;RUZZON TIZIANA","2;1;1;1;1;1;1;1;1;1","IRCCS AZIENDA OSPEDALIERA SAN MARTINO-IST-ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO;IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO IST INSTITUTO NAZIONALE PER LA RICERCA SUL CANCRO;OMEGA SRL;UNIVERSITA DEGLI STUDI DI GENOVA;UNIVERSITA DEGLI STUDI DI URBINO ""CARLO BO""","1;1;1;1;1","34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;40 ENGINEERING;4018 NANOTECHNOLOGY;51 PHYSICAL SCIENCES","2;1;1;1;1","BIOENGINEERING;BIOTECHNOLOGY;NANOTECHNOLOGY","1;1;1",NA,NA,"G01N30/02;G01N33/487","1;1","G01N1/2226;G01N15/12;G01N2001/2241;G01N27/4473;G01N33/0011;G01N33/48721","1;1;1;1;1;1",30,5.5,290.24,4.59,13,0.43,67.43,0,2,10,0,6,0,1,11,0,23,7,0,0,0,0,0,0,26,3,1,29,0,0,1,0,0,0,0,0,0,"United States;Italy;Germany;Japan","7;5;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;4205 NURSING","29;18;13;7;5;5;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LUNG;ORPHAN DRUG;GENETICS;LUNG CANCER;PEDIATRIC;BREAST CANCER;PREVENTION;STEM CELL RESEARCH;TRANSPLANTATION;CHILDHOOD LEUKEMIA;LYMPHOMA;PATIENT SAFETY;PEDIATRIC CANCER;AGING;COMPARATIVE EFFECTIVENESS RESEARCH","28;25;19;16;10;6;6;5;5;5;4;4;4;4;3;3;3;3;2;2","CANCER;BLOOD;INFECTION;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","22;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.2 END OF LIFE CARE","18;5;4;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;HEAD AND NECK CANCER;MYELOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;HODGKIN'S DISEASE;LARYNGEAL CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER;SARCOMA","6;6;4;4;2;2;2;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;1.4 CANCER PROGRESSION AND METASTASIS;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;6.2 SURVEILLANCE;6.6 END-OF-LIFE CARE","18;5;3;2;2;2;1;1;1",2,1060587.5,384962.5,4,2.5,1.5,1,130,448593.702176605,1.12574028023512,"OSPEDALE POLICLINICO SAN MARTINO;ISTITUTO GIANNINA GASLINI;UNIVERSITY OF BERN;UNIVERSITY OF GENEVA","2;1;1;1","SWISS NATIONAL SCIENCE FOUNDATION;TELETHON FOUNDATION","1;1","COALITION S","1","PROJECT FUNDING (FUNDING INSTRUMENT);PROJECTS (FUNDING INSTRUMENT HIERARCHY);TELETHON GRANT PROJECTS - 2014 (PROGRAM)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;51 PHYSICAL SCIENCES;5106 NUCLEAR AND PLASMA PHYSICS;5107 PARTICLE AND HIGH ENERGY PHYSICS","1;1;1;1;1","ARTHRITIS;BRAIN DISORDERS;GENETICS","1;1;1","INFLAMMATORY AND IMMUNE SYSTEM","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;B09 PHYSICS","1;1","7 AFFORDABLE AND CLEAN ENERGY","1",34,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;THE CAMBRIDGE STRUCTURAL DATABASE","31;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4206 PUBLIC HEALTH;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3105 GENETICS;3204 IMMUNOLOGY;49 MATHEMATICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;4905 STATISTICS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;40 ENGINEERING;4202 EPIDEMIOLOGY;4205 NURSING;46 INFORMATION AND COMPUTING SCIENCES;4612 SOFTWARE ENGINEERING;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","34;19;13;8;5;4;4;3;3;3;2;2;1;1;1;1;1;1;1;1","CANCER;BREAST CANCER;AGING;PREVENTION;CLINICAL RESEARCH;GENETICS;RARE DISEASES;BIOMEDICAL IMAGING;ESTROGEN;BIOTECHNOLOGY;BRAIN CANCER;BRAIN DISORDERS;CONTRACEPTION/REPRODUCTION;GENETIC TESTING;INFECTIOUS DISEASES;NEUROBLASTOMA;NEUROSCIENCES;OVARIAN CANCER;PEDIATRIC RESEARCH INITIATIVE","9;5;4;4;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","7;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;5.1 PHARMACEUTICALS;6.4 SURGERY","5;1;1;1","BIOMEDICAL;CLINICAL","4;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","10;2;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;OVARIAN CANCER;NEUROBLASTOMA;NOT SITE-SPECIFIC CANCER","8;2;2;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SANMARTINO",2015,593,13.6981450252951,3.18212478920742,0.314255431902491,0.355817875210793,0.360876897133221,0.311973018549747,0.510961214165261,3,325,120,60,42,0.55,0.2,0.1,0.07,36.63,0.982984322820716,0.3929173693086,0.90893760539629,6.09090909090908,0.504333356297119,0.478932090890602,0.460677496038035,0.425537757437071,"ANDREA BACIGALUPO;ANGELO MICHELE CARELLA;SIMONE FERRERO;GIORGIO CIPRANDI;LUCIA DEL MASTRO;GIANMARIO SAMBUCETI;GIORGIO WALTER CANONICA;FRANCESCO GROSSI;ALBERTO SOBRERO;PAOLO PELOSI;MATTEO LAMBERTINI;P. PRONZATO;MARCO GOBBI;CLAUDIO VISCOLI;ANNALISA RACCA;AURORA PARODI;ANGELA ALAMA;FRANCESCA POGGIO;LORENZO MORETTA;PAOLO BRUZZI","29;22;21;21;20;18;17;16;15;15;15;14;14;14;13;13;13;12;12;12","GIORGIO CIPRANDI;SIMONE FERRERO;AURORA PARODI;PAOLO PELOSI;GIORGIO WALTER CANONICA;ANNALISA RACCA;FRANCESCO DRAGO;UMBERTO LEONE ROBERTI MAGGIORE;ANDREA BACIGALUPO;VALENTINO REMORGIDA;GIANMARIO SAMBUCETI;CLAUDIO VISCOLI;MATTIA ROCCO;GIULIA CICCARESE;FRANCESCO GROSSI;IRENE SCHIAVETTI;F. SOZZI;EMANUELE COZZANI;ROBERTO PONTREMOLI;FRANCO FRATI","5.34;3.46;2.43;2.26;2.06;2.04;1.75;1.72;1.67;1.63;1.59;1.56;1.54;1.51;1.44;1.41;1.34;1.32;1.29;1.29","ANDREA BACIGALUPO;ANGELO MICHELE CARELLA;SIMONE FERRERO;GIORGIO CIPRANDI;LUCIA DEL MASTRO;GIANMARIO SAMBUCETI;GIORGIO WALTER CANONICA;FRANCESCO GROSSI;ALBERTO SOBRERO;PAOLO PELOSI;MATTEO LAMBERTINI;P. PRONZATO;MARCO GOBBI;CLAUDIO VISCOLI;ANNALISA RACCA;AURORA PARODI;ANGELA ALAMA;FRANCESCA POGGIO;PAOLO BRUZZI;MARIA GIOVANNA DAL BELLO","29;22;21;21;20;18;17;16;15;15;15;14;14;14;13;13;13;12;12;12","GIORGIO CIPRANDI;SIMONE FERRERO;AURORA PARODI;PAOLO PELOSI;GIORGIO WALTER CANONICA;ANNALISA RACCA;FRANCESCO DRAGO;UMBERTO LEONE ROBERTI MAGGIORE;ANDREA BACIGALUPO;VALENTINO REMORGIDA;GIANMARIO SAMBUCETI;CLAUDIO VISCOLI;MATTIA ROCCO;GIULIA CICCARESE;FRANCESCO GROSSI;F. SOZZI;EMANUELE COZZANI;ROBERTO PONTREMOLI;P. PRONZATO;CARLO GENOVA","5.34;3.46;2.43;2.26;2.06;2.04;1.75;1.72;1.67;1.63;1.59;1.56;1.54;1.51;1.44;1.34;1.32;1.29;1.29;1.24","DIK HEG;PETER JÜNI;BERNARDO CORTESE;PAOLO CALABRÒ;ALESSANDRA REPETTO;ALESSANDRO LUPI;ANDREA GAGNOR;ANDREA SANTARELLI;ANTONIO ZINGARELLI;ARTURO AUSIELLO;CARLO BRIGUORI;ENRICO FRIGOLI;FERDINANDO VARBELLA;GENNARO SARDELLA;GIOVANNI ESPOSITO;GIUSEPPE ANDÒ;MARCO VALGIMIGLI;MARTINA ROTHENBÜHLER;NICOLETTA DE CESARE;PAOLO RUBARTELLI","1607;1607;1473;1473;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472","ANTONIO ZINGARELLI;GIORGIO WALTER CANONICA;ALBERTO SOBRERO;ANGELO MICHELE CARELLA;ANDREA BACIGALUPO;SILVANA CHIARA;DANIELA PENDE;ANDREA A. BACIGALUPO;LUCIA DEL MASTRO;VIVIANA GISMONDI;LAURA EMIONITE;CLAUDIA BIGHIN;SVEVA BOLLINI;CLAUDIO VISCOLI;SIMONA ZUPO;SIMONE FERRERO;MARIA CRISTINA MINGARI;FRANCESCO GROSSI;ALESSIO NENCIONI;RAFFAELLA MEAZZA","1472;1298;1289;1245;1077;919;605;603;523;507;506;435;433;426;413;403;369;367;366;356","ANDREA BACIGALUPO;SIMONE FERRERO;GIORGIO CIPRANDI;ANGELO MICHELE CARELLA;LUCIA DEL MASTRO;FRANCESCO GROSSI;GIORGIO WALTER CANONICA;ALBERTO SOBRERO;MATTEO LAMBERTINI;MARCO GOBBI;P. PRONZATO;GIANMARIO SAMBUCETI;PAOLO PELOSI;ANGELA ALAMA;ANNALISA RACCA;FRANCESCA POGGIO;CARLO GENOVA;MARIA GIOVANNA DAL BELLO;CLAUDIO VISCOLI;FRANCESCO DRAGO","28;21;21;20;20;16;16;15;15;15;14;14;14;13;13;12;12;12;12;11","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;MATHEMATICS;ENGINEERING;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY;GEOLOGY;HISTORY;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY","531;225;64;46;37;31;20;19;14;14;12;7;7;4;4;2;2;2","INTERNAL MEDICINE;SURGERY;ONCOLOGY;IMMUNOLOGY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;CELL BIOLOGY;PHARMACOLOGY;RADIOLOGY;PEDIATRICS;CARDIOLOGY;INTENSIVE CARE MEDICINE;PSYCHIATRY;DERMATOLOGY;ENDOCRINOLOGY;PALEONTOLOGY","416;138;131;128;112;98;88;77;77;67;43;39;38;37;35;33;26;25;25;25","CANCER;GENE;CHEMOTHERAPY;POPULATION;DISEASE;CONFIDENCE INTERVAL;TRANSPLANTATION;LEUKEMIA;COHORT;STEM CELL;ADVERSE EFFECT;CLINICAL TRIAL;IMMUNE SYSTEM;BONE MARROW;MYELOID LEUKEMIA;IN VITRO;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;RETROSPECTIVE COHORT STUDY;ALLERGY;ALTERNATIVE MEDICINE","130;83;75;62;58;45;45;33;31;29;27;27;27;25;25;24;24;24;24;22;22","BREAST CANCER;HAZARD RATIO;CLINICAL ENDPOINT;COLORECTAL CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CYCLOPHOSPHAMIDE;PLACEBO;GENE EXPRESSION;BEVACIZUMAB;CHRONIC LYMPHOCYTIC LEUKEMIA;GENOTYPE;MUTATION;NEUROBLASTOMA;NEUTROPENIA;PHENOTYPE;CISPLATIN;CYTOTOXIC T CELL;MICRORNA;PHASES OF CLINICAL RESEARCH;EPIDERMAL GROWTH FACTOR RECEPTOR;GRAFT-VERSUS-HOST DISEASE;HAEMATOPOIESIS;IMMUNOTHERAPY;VIRAL LOAD","56;31;29;27;27;21;18;15;12;12;12;12;12;12;12;11;11;10;10;9;9;9;9;9","OXALIPLATIN;FLUDARABINE;METASTATIC BREAST CANCER;TRASTUZUMAB;GEFITINIB;RIBAVIRIN;ANTIRETROVIRAL THERAPY;THIOTEPA;BUSULFAN;FAMILY PLANNING;IRINOTECAN;KRAS;REGORAFENIB;VINORELBINE;AFLIBERCEPT;ALLERGEN IMMUNOTHERAPY;ANTHRACYCLINE;DNA METHYLATION;ERLOTINIB;ESTROGEN RECEPTOR;EXHALED NITRIC OXIDE;IGHV@;SINGLE-NUCLEOTIDE POLYMORPHISM","9;8;8;8;7;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","HUMANS;FEMALE;;MALE;MIDDLE AGED;AGED;ADULT;BREAST NEOPLASMS;ITALY;TREATMENT OUTCOME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED, 80 AND OVER;ANIMALS;YOUNG ADULT;ANTINEOPLASTIC AGENTS;ADOLESCENT;NEUROBLASTOMA;RETROSPECTIVE STUDIES;BIOMARKERS, TUMOR;LUNG NEOPLASMS","339;249;233;208;180;150;137;91;88;69;68;62;52;50;48;45;43;41;40;40","HEMATOPOIETIC STEM CELL BIOLOGY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;NEUROBLASTOMA RESEARCH AND TREATMENT;NATURAL KILLER CELLS IN IMMUNITY;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;ASTHMA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;ACUTE MYELOID LEUKEMIA;HEPATITIS C INFECTION AND TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;LYMPHOID NEOPLASMS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;MOLECULAR RESEARCH ON BREAST CANCER;DIAGNOSIS AND MANAGEMENT OF FOOD ALLERGY;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;UTERINE CONDITIONS AND TREATMENTS","17;15;15;14;12;12;11;10;10;9;9;9;8;8;7;7;7;6;6;6","CLINICAL ENDPOINT;HEMATOPOIETIC CELL TRANSPLANTATION;TREATMENT;BREAST CANCER;REGIMEN;NEUROBLASTOMA;METASTATIC COLORECTAL CANCER;DIAGNOSIS;ASTHMA;NK CELL RECOGNITION;FOLFIRI;MALIGNANT PLEURAL MESOTHELIOMA;DISCONTINUATION;HISTOLOGY;NK CELL ACTIVATION;NK CELL RECEPTORS;UNIVARIATE ANALYSIS;ALLERGEN IMMUNOTHERAPY;CANCER RISK;CANCER THERAPY","29;20;19;18;17;13;12;11;10;10;9;9;8;8;8;8;8;7;7;7","BREAST CANCER;STEM CELL;METASTATIC COLORECTAL;CANCER PATIENTS;CELL TRANSPLANTATION;COLORECTAL CANCER;MYELOID LEUKEMIA;PHASE III;ACUTE MYELOID;LUNG CANCER;ACUTE LEUKEMIA;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;CELL LUNG;CORD BLOOD;NON-SMALL CELL;RETROSPECTIVE STUDY;BONE MARROW;MARROW TRANSPLANTATION;CLINICAL OUTCOME;HEMATOPOIETIC STEM;METASTATIC BREAST;ALLOGENEIC STEM;AORTIC VALVE;CELL LINES;DE NOVO;MULTIPLE MYELOMA;PHASE II;PILOT STUDY;PLEURAL MESOTHELIOMA","39;20;18;16;15;15;13;13;12;12;11;11;10;9;9;9;9;8;8;7;7;7;6;6;6;6;6;6;6;6","BREAST CANCER;HR CI;MEDIAN AGE;ADVERSE EVENTS;CELL LINES;PROGRESSION-FREE SURVIVAL;NK CELLS;HAZARD RATIO;STEM CELL;OVARIAN FUNCTION;SURVIVAL OS;GENOVA ITALY;MULTIVARIATE ANALYSIS;CANCER PATIENTS;CONFIDENCE INTERVAL;RESEARCH FUNDING;RESPONSE RATE;STATISTICALLY SIGNIFICANT;CLINICAL TRIALS;GENOA ITALY;MEDIAN FOLLOW-UP;ODDS RATIO;AOU SAN;CLINICAL BENEFIT;IRCCS AOU;LUNG CANCER;RATIO HR;BRENTUXIMAB VEDOTIN;DISEASE PROGRESSION;PATIENTS PTS","63;45;40;36;34;34;26;25;25;23;23;22;22;21;21;21;21;21;20;20;20;20;19;19;19;19;19;18;18;18",259,0.44,7.12,7,2,2,1,5,3,1,1,7,1,1,6,1.25,1.5,1,4,5,2.5,0,0,84,84.5,1,0,0,0,0,1,1,0,0,0,0,0,0,2,0,0,3,0.32,3,0,2,2,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CHIARUGI LUCA;RUZZON TIZIANA;TONIN GIAN PAOLO","2;2;2","OMEGA SRL;IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO - IST - ISTITUTO NAZIONZALE PER LA RICERCA SUL CANCRO;IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO IST ISTITUTO NAZ PER LA RICERCA SUL CANCRO;IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO IST ISTITUTO NAZIONZALE PER LA RICERCA SUL CANCR;IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO-IST-ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO","2;1;1;1;1","40 ENGINEERING;46 INFORMATION AND COMPUTING SCIENCES;4605 DATA MANAGEMENT AND DATA SCIENCE","1;1;1",NA,NA,NA,NA,"G01N1/38;G01N1/40","2;2","G01N1/2226;G01N2001/2241;G01N33/0011","2;2;2",29,5.07,1378.52,4.21,16,0.55,99.93,1,0,7,0,12,0,1,8,0,22,7,0,0,0,0,0,0,24,5,0,29,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan;Switzerland;Belgium;Germany","8;2;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;48 LAW AND LEGAL STUDIES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3506 MARKETING;4205 NURSING;4206 PUBLIC HEALTH;4806 PRIVATE LAW AND CIVIL OBLIGATIONS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","25;15;9;5;3;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;BREAST CANCER;HEMATOLOGY;RARE DISEASES;PATIENT SAFETY;LUNG;LUNG CANCER;AGING;CHILDHOOD LEUKEMIA;DIGESTIVE DISEASES;ESTROGEN;HIV/AIDS;LYMPHOMA;ORPHAN DRUG;PEDIATRIC;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;ASTHMA","26;18;16;6;6;6;5;4;3;2;2;2;2;2;2;2;2;2;2;1","CANCER;INFECTION;RESPIRATORY","14;2;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS","22;4;2","BREAST CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;PANCREATIC CANCER;STOMACH CANCER","6;6;4;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","15;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;THE CAMBRIDGE STRUCTURAL DATABASE;SPRINGER NATURE","13;8;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;34 CHEMICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3204 IMMUNOLOGY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;3407 THEORETICAL AND COMPUTATIONAL CHEMISTRY;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY;44 HUMAN SOCIETY;4404 DEVELOPMENT STUDIES;46 INFORMATION AND COMPUTING SCIENCES;52 PSYCHOLOGY","27;12;10;4;3;2;1;1;1;1;1;1;1;1;1;1;1","GENETICS;RARE DISEASES;CANCER;BIOTECHNOLOGY;CLINICAL RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;NEUROSCIENCES;HEMATOLOGY;LYMPHOMA;PREVENTION;BIODEFENSE;CARDIOVASCULAR;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEART DISEASE;HUMAN GENOME;INFECTIOUS DISEASES;LUNG;LUNG CANCER;NEUROBLASTOMA","8;6;5;4;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER","6","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","4;2;1","BIOMEDICAL;CLINICAL","4;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","9;2","NEUROBLASTOMA;ORAL CAVITY AND LIP CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NOT SITE-SPECIFIC CANCER","7;4;3;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SANMARTINO",2016,643,14.0622083981337,3.10575427682737,0.321982974461693,0.343701399688958,0.345256609642302,0.357698289269051,0.561430793157076,4,367,139,45,44,0.57,0.22,0.07,0.07,27.86,0.857632214095975,0.382581648522551,0.905132192846034,5.82433712121214,0.531926648715175,0.492191020497884,0.477343783459677,0.464810393318096,"CAROLINA SCALA;ALFREDO FALCONE;PAOLO BRUZZI;SIMONE FERRERO;UMBERTO LEONE ROBERTI MAGGIORE;PAOLO PELOSI;FABRIZIO MONTECUCCO;GIORGIO WALTER CANONICA;ANGELO MICHELE CARELLA;ANNALISA RACCA;LUCIA DEL MASTRO;E. TAFI;GIORGIO CIPRANDI;ANDREA BACIGALUPO;GIANMARIO SAMBUCETI;ALBERTO ZANIBONI;PAOLA QUEIROLO;AURORA PARODI;SILVIA MORBELLI;ERIC VAN CUTSEM","24;21;21;21;21;19;19;18;17;17;17;16;16;16;15;14;14;14;13;13","CAROLINA SCALA;UMBERTO LEONE ROBERTI MAGGIORE;SIMONE FERRERO;PAOLO PELOSI;GIORGIO CIPRANDI;ANNALISA RACCA;FABRIZIO MONTECUCCO;GIULIA CICCARESE;PAOLO BRUZZI;E. TAFI;FRANCESCO DRAGO;AURORA PARODI;LUCIA DEL MASTRO;CARLO ENRICO TRAVERSO;GIORGIO WALTER CANONICA;MATTEO LAMBERTINI;ROBERTO FANCELLU;CLAUDIO VISCOLI;ASMA KHALIL;LORENZO BALL","3.85;3.22;3.12;2.91;2.66;2.64;2.62;2.58;2.53;2.47;2.36;2.33;1.83;1.7;1.68;1.57;1.52;1.41;1.4;1.35","CAROLINA SCALA;PAOLO BRUZZI;SIMONE FERRERO;UMBERTO LEONE ROBERTI MAGGIORE;PAOLO PELOSI;FABRIZIO MONTECUCCO;GIORGIO WALTER CANONICA;ANGELO MICHELE CARELLA;ANNALISA RACCA;LUCIA DEL MASTRO;E. TAFI;GIORGIO CIPRANDI;ANDREA BACIGALUPO;GIANMARIO SAMBUCETI;PAOLA QUEIROLO;AURORA PARODI;SILVIA MORBELLI;CLAUDIO VISCOLI;GIULIA CICCARESE;FLAVIO NOBILI","24;21;21;21;19;19;18;17;17;17;16;16;16;15;14;14;13;13;12;12","CAROLINA SCALA;UMBERTO LEONE ROBERTI MAGGIORE;SIMONE FERRERO;PAOLO PELOSI;GIORGIO CIPRANDI;ANNALISA RACCA;FABRIZIO MONTECUCCO;GIULIA CICCARESE;PAOLO BRUZZI;E. TAFI;FRANCESCO DRAGO;AURORA PARODI;LUCIA DEL MASTRO;CARLO ENRICO TRAVERSO;GIORGIO WALTER CANONICA;MATTEO LAMBERTINI;ROBERTO FANCELLU;CLAUDIO VISCOLI;LORENZO BALL;GABRIELLA PIATTI","3.85;3.22;3.12;2.91;2.66;2.64;2.62;2.58;2.53;2.47;2.36;2.33;1.83;1.7;1.68;1.57;1.52;1.41;1.35;1.33","ALBERTO SOBRERO;ALFREDO FALCONE;ROBERTO LABIANCA;ERIC VAN CUTSEM;PAULO M. HOFF;JOSEP TABERNERO;TAKAYUKI YOSHINO;AXEL GROTHEY;FORTUNATO CIARDIELLO;G. BODOKY;KEI MURO;JEAN‐YVES DOUILLARD;DIRK ARNOLD;MICHEL DUCREUX;RAMÓN SALAZAR;WERNER SCHEITHAUER;A. ROTH;AL B. BENSON;ALBERTO BARDELLI;ANDRÉ D’HOORE","3056;3033;2987;2984;2972;2961;2949;2914;2891;2887;2887;2884;2883;2883;2883;2883;2882;2882;2882;2882","ALBERTO SOBRERO;SIMONE FERRERO;GIORGIO WALTER CANONICA;CLAUDIO VISCOLI;PAOLO BRUZZI;PAOLO PELOSI;GIANMARIO SAMBUCETI;ANGELO MICHELE CARELLA;ANDREA BACIGALUPO;FRANCESCA VIAZZI;FLAVIO NOBILI;GIORGIO CIPRANDI;AMBRA BUSCHIAZZO;PAOLO DURANDO;ROBERTO PONTREMOLI;MARIA CRISTINA MINGARI;AURORA PARODI;GIOVANNI PASSALACQUA;MAURIZIO CUTOLO;FABRIZIO MONTECUCCO","3056;840;745;743;672;522;452;424;364;348;326;326;320;320;288;285;265;262;262;261","CAROLINA SCALA;SIMONE FERRERO;PAOLO BRUZZI;UMBERTO LEONE ROBERTI MAGGIORE;PAOLO PELOSI;ANNALISA RACCA;ANGELO MICHELE CARELLA;E. TAFI;GIORGIO WALTER CANONICA;LUCIA DEL MASTRO;GIORGIO CIPRANDI;GIANMARIO SAMBUCETI;FABRIZIO MONTECUCCO;AURORA PARODI;FRANCESCO DRAGO;GIULIA CICCARESE;CLAUDIO VISCOLI;SILVIA MORBELLI;PAOLA QUEIROLO;GIOVANNI PASSALACQUA","23;22;21;21;18;17;17;16;16;16;16;15;13;12;12;12;11;11;11;11","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;MATHEMATICS;ECONOMICS;MATERIALS SCIENCE;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;BUSINESS;ART;GEOGRAPHY;ENVIRONMENTAL SCIENCE;GEOLOGY","592;211;63;63;36;34;26;23;18;14;14;9;8;6;5;4;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;IMMUNOLOGY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;CANCER RESEARCH;RADIOLOGY;CARDIOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;PALEONTOLOGY;GYNECOLOGY;INTENSIVE CARE MEDICINE;ANESTHESIA;PEDIATRICS;OPTICS;PSYCHIATRY","448;149;138;116;113;112;93;76;71;71;51;50;44;36;35;32;32;29;29;28;28","CANCER;CHEMOTHERAPY;GENE;POPULATION;DISEASE;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;COHORT;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;TRANSPLANTATION;ALTERNATIVE MEDICINE;ALLERGY;ANTIBODY;INCIDENCE (GEOMETRY);PREGNANCY;STEM CELL;REGIMEN;RECEPTOR","149;87;84;64;63;46;40;39;36;36;35;35;30;26;25;25;25;25;24;23","BREAST CANCER;COLORECTAL CANCER;HAZARD RATIO;CLINICAL ENDPOINT;PLACEBO;IMMUNOTHERAPY;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;CYCLOPHOSPHAMIDE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;FETUS;GENE EXPRESSION;ALLERGEN;BEVACIZUMAB;NEUTROPENIA;UNIVARIATE ANALYSIS;MICRORNA;MUTATION;MYELODYSPLASTIC SYNDROMES;GENOTYPE;VIRAL DISEASE","54;30;29;27;21;16;16;16;15;15;14;13;12;12;12;12;10;10;10;9;9","INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MAMMOGRAPHY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ANTIRETROVIRAL THERAPY;DNA METHYLATION;EPIRUBICIN;FAMILY PLANNING;FLUDARABINE;HERPESVIRIDAE;KLEBSIELLA PNEUMONIAE;OXALIPLATIN;CETUXIMAB;GERMLINE MUTATION;IRINOTECAN;NILOTINIB;PAZOPANIB;RIBAVIRIN;CHROMOPHOBE CELL;FEBRILE NEUTROPENIA;FRACTIONAL FLOW RESERVE;IGHV@;IPILIMUMAB;KRAS;MASTECTOMY;REGORAFENIB;SENTINEL LYMPH NODE;VENTRICULOMEGALY","7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;BREAST NEOPLASMS;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;YOUNG ADULT;ANIMALS;RISK FACTORS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PROGNOSIS;ADOLESCENT;BIOMARKERS;CELL PROLIFERATION","356;270;255;231;168;153;135;114;70;66;58;56;49;48;43;42;39;37;34;31","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;MOLECULAR RESEARCH ON BREAST CANCER;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;LYMPHOID NEOPLASMS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ASTHMA;HEMATOPOIETIC STEM CELL BIOLOGY;MANAGEMENT OF VALVULAR HEART DISEASE;CANCER IMMUNOTHERAPY;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;NATURAL KILLER CELLS IN IMMUNITY;NEUROBLASTOMA RESEARCH AND TREATMENT;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;HEPATITIS C INFECTION AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;AGE-RELATED MACULAR DEGENERATION RESEARCH","22;16;15;12;10;10;10;9;8;8;8;7;7;7;7;6;6;6;5;5","CLINICAL ENDPOINT;REGIMEN;BREAST CANCER;METASTATIC COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL;TREATMENT;REFRACTORY (PLANETARY SCIENCE);RADIOTHERAPY;UNIVARIATE ANALYSIS;DIAGNOSIS;NEOADJUVANT THERAPY;ASTHMA;DISCONTINUATION;ALLERGEN IMMUNOTHERAPY;MELANOMA;NEUROBLASTOMA;PROSTHETIC VALVES EVALUATION;STROKE (ENGINE);CONTACT ALLERGY;HEMATOPOIETIC CELL TRANSPLANTATION","27;25;16;16;16;15;14;12;12;11;11;9;9;8;8;8;8;8;7;7","BREAST CANCER;CANCER PATIENTS;METASTATIC COLORECTAL;STEM CELL;COLORECTAL CANCER;PHASE III;CELL TRANSPLANTATION;ALLERGIC RHINITIS;MYELOID LEUKEMIA;PATIENTS PTS;PATIENTS TREATED;AORTIC VALVE;KIDNEY DISEASE;PHASE II;RECOURSE TRIAL;TYPE DIABETES;LUNG CANCER;PHASE STUDY;POOLED ANALYSIS;RANDOMIZED PHASE;RETROSPECTIVE ANALYSIS;RETROSPECTIVE STUDY;RISK FACTORS;ACUTE MYELOID;ADJUVANT CHEMOTHERAPY;ASTHMA CONTROL;CANCER MCRC;CELL LUNG;CHRONIC LYMPHOCYTIC;CLINICAL OUTCOMES","34;24;18;18;17;17;14;11;11;10;9;8;8;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6;6","HR CI;BREAST CANCER;ADVERSE EVENTS;PUBMED SCOPUS;SURVIVAL OS;PATIENTS TREATED;CLINICAL TRIALS;MEDIAN AGE;MULTIVARIATE ANALYSIS;RISK FACTORS;GENOA ITALY;LUNG CANCER;PROGRESSION-FREE SURVIVAL;CANCER PATIENTS;AOU SAN;CONSULTANCY HONORARIA;GROWTH FACTOR;IRCCS AOU;SURVIVAL PFS;CLINICAL PRACTICE;CROSSREF PUBMED;NK CELLS;CONGENITAL CMV;DISEASE CONTROL;STATISTICALLY SIGNIFICANT;ANGLE CLOSURE;ANTI-APOA- IGG;CMV INFECTION;DISEASE PROGRESSION;HR CI-","60;53;39;30;30;29;27;27;27;26;23;23;23;22;20;20;20;20;20;19;19;19;18;18;18;17;17;17;17;17",252,0.39,7.56,6,2,1,1,2,2,1,1,6,1,1,5,0,1.5,1,3,4,2,0,0,72,71.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,5.18,513.03,4.03,21,0.64,99.58,0,0,9,0,15,0,3,6,0,27,5,0,0,0,0,0,0,30,3,0,31,1,0,1,0,0,0,0,0,0,"United States;Italy;Germany;Japan;United Kingdom","8;4;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3207 MEDICAL MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;44 HUMAN SOCIETY","30;22;13;5;4;3;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;HEMATOLOGY;BREAST CANCER;ORPHAN DRUG;DIGESTIVE DISEASES;LUNG;LYMPHOMA;NEUROSCIENCES;GENETICS;KIDNEY DISEASE;LUNG CANCER;PEDIATRIC;PREVENTION;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;BRAIN DISORDERS","30;25;24;11;8;7;5;4;3;3;3;3;2;2;2;2;2;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","17;1;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","25;6;3;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;KIDNEY CANCER;MELANOMA;LUNG CANCER;BLADDER CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER;PANCREATIC CANCER","7;5;5;3;3;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","20;4;2;2;1",1,577925,288962.5,3,2,2,1,11,412054.935509938,1.56047154053441,"OSPEDALE POLICLINICO SAN MARTINO;UNIVERSITY OF GENEVA","1;1","SWISS NATIONAL SCIENCE FOUNDATION","1","COALITION S","1","PROJECT FUNDING (FUNDING INSTRUMENT);PROJECTS (FUNDING INSTRUMENT HIERARCHY)","1;1","51 PHYSICAL SCIENCES;5106 NUCLEAR AND PLASMA PHYSICS;5107 PARTICLE AND HIGH ENERGY PHYSICS","1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"B09 PHYSICS","1",NA,NA,29,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;TAYLOR & FRANCIS GROUP","22;5;2","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;3101 BIOCHEMISTRY AND CELL BIOLOGY;42 HEALTH SCIENCES;3207 MEDICAL MICROBIOLOGY;34 CHEMICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;36 CREATIVE ARTS AND WRITING;40 ENGINEERING;47 LANGUAGE, COMMUNICATION AND CULTURE;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3206 MEDICAL BIOTECHNOLOGY;3401 ANALYTICAL CHEMISTRY;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;3605 SCREEN AND DIGITAL MEDIA;4003 BIOMEDICAL ENGINEERING;4018 NANOTECHNOLOGY","20;19;6;6;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","GENETICS;CANCER;HUMAN GENOME;LUNG;RARE DISEASES;BREAST CANCER;CLINICAL RESEARCH;HIV/AIDS;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;BIOTECHNOLOGY;BRAIN CANCER;BRAIN DISORDERS;INFECTIOUS DISEASES;LUNG CANCER;NANOTECHNOLOGY;NEUROSCIENCES;OVARIAN CANCER;PREVENTION;REGENERATIVE MEDICINE","10;5;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;GENERIC HEALTH RELEVANCE","3;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","5;1","BIOMEDICAL;CLINICAL","3;1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","6;1","LUNG CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;BREAST CANCER;BRAIN TUMOR;GENITAL SYSTEM, FEMALE","4;3;3;2;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SANMARTINO",2017,679,15.139911634757,3.34904270986745,0.298592788038698,0.338733431516937,0.344624447717231,0.303387334315169,0.614138438880707,8,370,136,72,40,0.54,0.2,0.11,0.06,28.4,0.96339761602111,0.384388807069219,0.916053019145803,5.81561996779386,0.543348332072291,0.46110908279583,0.418970884453397,0.447986150816339,"FRANCESCO GROSSI;LUCIA DEL MASTRO;ANTONIO DI BIAGIO;PAOLO PELOSI;CARLO GENOVA;GIORGIO CIPRANDI;VALERIO GAETANO VELLONE;FABRIZIO MONTECUCCO;MAURIZIO CUTOLO;FILIPPO MONTEMURRO;FEDERICA BIELLO;CLAUDIO VISCOLI;GIANMARIO SAMBUCETI;PAOLO BRUZZI;SIMONE FERRERO;MARIA GIOVANNA DAL BELLO;EMANUELE ANGELUCCI;FLAVIO NOBILI;ROBERTO LABIANCA;MASSIMO BRECCIA","28;22;21;19;19;17;17;16;15;14;14;14;13;13;13;13;13;13;13;13","GIORGIO CIPRANDI;FABRIZIO MONTECUCCO;PAOLO PELOSI;VALERIO GAETANO VELLONE;PAOLO ROMANO;FRANCESCO GROSSI;CARLO ENRICO TRAVERSO;ALESSANDRO BAGNIS;AURORA PARODI;SIMONE FERRERO;LUCIA DEL MASTRO;FRANCESCO DRAGO;ALBERTO SOBRERO;ANTONIO DI BIAGIO;CARLO GENOVA;RENZO CORVÒ;GIULIA CICCARESE;ALBERTO SULLI;GIOVANNI PASSALACQUA;UMBERTO LEONE ROBERTI MAGGIORE","3.66;2.23;2.1;2.09;2.03;1.99;1.79;1.65;1.61;1.6;1.59;1.57;1.55;1.53;1.53;1.53;1.4;1.37;1.37;1.34","FRANCESCO GROSSI;LUCIA DEL MASTRO;ANTONIO DI BIAGIO;PAOLO PELOSI;CARLO GENOVA;GIORGIO CIPRANDI;VALERIO GAETANO VELLONE;FABRIZIO MONTECUCCO;MAURIZIO CUTOLO;FILIPPO MONTEMURRO;FEDERICA BIELLO;CLAUDIO VISCOLI;GIANMARIO SAMBUCETI;PAOLO BRUZZI;SIMONE FERRERO;MARIA GIOVANNA DAL BELLO;EMANUELE ANGELUCCI;FLAVIO NOBILI;MICHELINO DE LAURENTIIS;ALBERTO SULLI","28;22;21;19;19;17;17;16;15;14;14;14;13;13;13;13;13;13;12;12","GIORGIO CIPRANDI;FABRIZIO MONTECUCCO;PAOLO PELOSI;VALERIO GAETANO VELLONE;PAOLO ROMANO;FRANCESCO GROSSI;CARLO ENRICO TRAVERSO;ALESSANDRO BAGNIS;AURORA PARODI;SIMONE FERRERO;LUCIA DEL MASTRO;FRANCESCO DRAGO;ALBERTO SOBRERO;ANTONIO DI BIAGIO;CARLO GENOVA;RENZO CORVÒ;GIULIA CICCARESE;ALBERTO SULLI;GIOVANNI PASSALACQUA;UMBERTO LEONE ROBERTI MAGGIORE","3.66;2.23;2.1;2.09;2.03;1.99;1.79;1.65;1.61;1.6;1.59;1.57;1.55;1.53;1.53;1.53;1.4;1.37;1.37;1.34","PAOLA QUEIROLO;MARIO MANDALÁ;PAOLO A. ASCIERTO;ANA ARANCE;MICHELE DEL VECCHIO;GEORGINA V. LONG;PIOTR RUTKOWSKI;HELEN GOGAS;JAMES LARKIN;VANNA CHIARION‐SILENI;MICHELE MAIO;ANILA QURESHI;IVÁN MÁRQUEZ‐RODAS;JEFFREY S. WEBER;MARCUS O. BUTLER;MARK R. MIDDLETON;MICHAEL SCHENKER;STÉPHANE DALLE;VEERLE DE PRIL;VICTORIA ATKINSON","2422;2398;2387;2351;2351;2309;2309;1944;1944;1944;1915;1911;1911;1911;1911;1911;1911;1911;1911;1911","PAOLA QUEIROLO;GIANNI PASSALACQUA;DANIELE REVERBERI;PAOLO BRUZZI;CLAUDIO VISCOLI;LAURA EMIONITE;AURORA PARODI;PAOLO PELOSI;MAURIZIO CUTOLO;DOMENICO FRANCO MERLO;MAŁGORZATA MIKULSKA;CLAUDIA LO SICCO;ROBERTA TASSO;VALERIA FONTANA;FLAVIO NOBILI;DANIELA PENDE;DIEGO FERONE;GIANMARIO SAMBUCETI;SILVIA MORBELLI;FRANCESCA GUALANDI","2422;1533;707;559;556;519;493;487;466;456;454;451;451;442;411;409;406;404;374;363","FRANCESCO GROSSI;ANTONIO DI BIAGIO;LUCIA DEL MASTRO;CARLO GENOVA;PAOLO PELOSI;GIORGIO CIPRANDI;CLAUDIO VISCOLI;ERIKA RIJAVEC;FEDERICA BIELLO;FABRIZIO MONTECUCCO;MARIA GIOVANNA DAL BELLO;PAOLO BRUZZI;MAURIZIO CUTOLO;GIULIA BARLETTA;MARIA TERESA VAN LINT;SIMONE FERRERO;FLAVIO NOBILI;ALBERTO BALLESTRERO;GIANMARIO SAMBUCETI;ALBERTO F. SOBRERO","28;21;21;19;18;17;14;14;14;14;13;13;12;12;12;12;11;11;11;11","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;ART;GEOGRAPHY;BUSINESS;ENVIRONMENTAL SCIENCE;HISTORY","622;216;73;46;41;33;31;22;13;12;12;10;5;4;3;2;2;2","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;IMMUNOLOGY;BIOCHEMISTRY;GENETICS;GASTROENTEROLOGY;RADIOLOGY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;PALEONTOLOGY;DERMATOLOGY;ENDOCRINOLOGY;CELL BIOLOGY;INTENSIVE CARE MEDICINE;CARDIOLOGY;NUCLEAR MEDICINE;PEDIATRICS;PHARMACOLOGY","477;176;167;118;113;89;86;84;73;72;69;41;39;39;37;37;34;34;33;30","CANCER;CHEMOTHERAPY;DISEASE;GENE;POPULATION;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;TRANSPLANTATION;CLINICAL TRIAL;COHORT;RETROSPECTIVE COHORT STUDY;LUNG CANCER;RECEPTOR;ALTERNATIVE MEDICINE;REGIMEN;IMMUNE SYSTEM;STAGE (STRATIGRAPHY);ALLERGY;ANTIBODY;PROPORTIONAL HAZARDS MODEL","178;75;62;61;58;51;43;41;39;36;36;36;33;30;28;28;27;27;26;24;24","BREAST CANCER;CLINICAL ENDPOINT;HAZARD RATIO;IMMUNOTHERAPY;COLORECTAL CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;ALLERGEN;PROSTATE CANCER;VIRAL LOAD;CYCLOPHOSPHAMIDE;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;TOLERABILITY;TYPE 2 DIABETES;PHASES OF CLINICAL RESEARCH;PLACEBO;ADJUVANT THERAPY;CUMULATIVE INCIDENCE;GENE EXPRESSION;MYELODYSPLASTIC SYNDROMES","53;44;37;35;34;23;15;15;15;13;13;12;12;12;11;11;10;10;10;10","NIVOLUMAB;METASTATIC BREAST CANCER;OXALIPLATIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ANTIRETROVIRAL THERAPY;NEOADJUVANT THERAPY;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;ACROMEGALY;ANDROGEN RECEPTOR;HORMONE RECEPTOR;MAMMOGRAPHY;TRASTUZUMAB;ALLERGEN IMMUNOTHERAPY;ANDROGEN DEPRIVATION THERAPY;ERLOTINIB;ESTROGEN RECEPTOR;FLUDARABINE;IMATINIB MESYLATE;NILOTINIB;ANTHRACYCLINE;BRENTUXIMAB VEDOTIN;DASATINIB;FLUORESCENCE IN SITU HYBRIDIZATION;GEFITINIB;GERMLINE MUTATION;HOUSE DUST MITE;IPILIMUMAB;KRAS;RUXOLITINIB;TAMOXIFEN;TAXANE","23;16;14;12;9;8;7;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ITALY;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;YOUNG ADULT;AGED, 80 AND OVER;LUNG NEOPLASMS;HIV INFECTIONS;RISK FACTORS;BREAST NEOPLASMS;ANIMALS;ADOLESCENT;FOLLOW-UP STUDIES;ANTINEOPLASTIC AGENTS","345;311;233;210;182;151;151;111;72;68;55;52;50;47;45;44;42;40;37;36","CANCER IMMUNOTHERAPY;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;LYMPHOID NEOPLASMS;NATURAL KILLER CELLS IN IMMUNITY;ACUTE MYELOID LEUKEMIA;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ASTHMA;MOLECULAR RESEARCH ON BREAST CANCER;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;HEMATOPOIETIC STEM CELL BIOLOGY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;HEPATITIS C INFECTION AND TREATMENT;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE","20;19;14;14;12;12;11;11;9;9;8;8;7;7;7;7;7;7;6;6","CLINICAL ENDPOINT;REGIMEN;BREAST CANCER;TREATMENT;NEOADJUVANT THERAPY;HEMATOPOIETIC CELL TRANSPLANTATION;PROGRESSION-FREE SURVIVAL;TOLERABILITY;DISCONTINUATION;EXPANDED ACCESS;NK CELL ACTIVATION;ADJUVANT THERAPY;CUMULATIVE INCIDENCE;HIV;NK CELL RECOGNITION;REFRACTORY (PLANETARY SCIENCE);TUMOR MICROENVIRONMENT;BIOMARKERS FOR IMMUNOTHERAPY;FOLFOX;METASTATIC BREAST CANCER","44;28;20;20;18;15;13;12;11;11;11;10;10;10;10;10;10;9;9;9","BREAST CANCER;LUNG CANCER;PATIENTS PTS;CANCER PATIENTS;CELL LUNG;STEM CELL;CELL TRANSPLANTATION;NON-SMALL CELL;EXPANDED ACCESS;COLON CANCER;METASTATIC BREAST;MYELOID LEUKEMIA;PROSTATE CANCER;PATIENTS TREATED;SYSTEMIC SCLEROSIS;HEMATOPOIETIC STEM;PHASE III;ACCESS PROGRAM;ACUTE MYELOID;CANCER MBC;PHASE II;ACUTE LEUKEMIA;ALLERGIC RHINITIS;ALZHEIMERS DISEASE;CELL CARCINOMA;COLORECTAL CANCER;TOSCA TRIAL;TYPE DIABETES;ADVANCED NON-SMALL;CANCER NSCLC","35;26;22;20;18;17;16;15;13;12;12;12;12;11;10;9;9;8;8;8;8;7;7;7;7;7;7;7;6;6","HR CI;ADVERSE EVENTS;BREAST CANCER;NK CELLS;GENOA ITALY;SURVIVAL OS;CONFIDENCE INTERVAL;LUNG CANCER;STATISTICALLY SIGNIFICANT;PATIENTS TREATED;SPEAKERS BUREAU;CLINICAL BENEFIT;MEDIAN FOLLOW-UP;CLINICAL TRIAL;MEDIAN AGE;PROGRESSION-FREE SURVIVAL;CLINICAL PRACTICE;CLINICAL TRIALS;SAN MARTINO;COLON CANCER;COMPLETE RESPONSE;CONSULTING FEE;HAZARD RATIO;MEDIAN OS;MULTIVARIATE ANALYSIS;STAGE III;CELL LUNG;GASTRIC ACIDITY;RESEARCH FUNDING;ENTITY RESPONSIBLE","75;38;37;36;34;34;32;32;32;31;31;30;29;28;27;27;25;25;25;24;23;23;23;23;23;23;22;22;22;21",310,0.46,8,6.75,2,1,1,4,2.75,1,1,7,1,1,6,2,2,1.75,3.5,5,3,0,0,66,66,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,5.11,846.81,4.51,20,0.54,98.08,0,0,8,0,16,0,1,12,0,28,9,0,0,0,0,0,0,32,3,2,36,0,0,1,0,0,0,0,0,0,"Italy;United States;Germany;Belgium;Sweden;Switzerland;Turkey","15;12;3;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4205 NURSING;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","34;17;14;6;5;4;3;3;2;2;2;2","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;LUNG;ORPHAN DRUG;PEDIATRIC;DIGESTIVE DISEASES;LYMPHOMA;PREVENTION;AGING;BRAIN DISORDERS;CARDIOVASCULAR;ENDOMETRIOSIS;HEALTH SERVICES;HEART DISEASE;LUNG CANCER;NEURODEGENERATIVE","34;26;21;13;9;9;6;5;5;4;4;4;3;3;3;3;3;3;3;3","CANCER;CARDIOVASCULAR;NEUROLOGICAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;RESPIRATORY","15;2;2;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT);6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION);7.1 INDIVIDUAL CARE NEEDS","25;3;2;2;2;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;MELANOMA;COLON AND RECTAL CANCER;PROSTATE CANCER;BREAST CANCER;NOT SITE-SPECIFIC CANCER","6;6;4;3;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","15;1;1;1;1",1,3607596,277507.38,4,13,7,1,40,203417.67948718,3.33795961939874,"DEUTSCHE ARTHROSE-HILFE;ELI LILLY (UNITED STATES);ERASMUS MC;GOETHE UNIVERSITY FRANKFURT;KU LEUVEN;LIFETEC GROUP (NETHERLANDS);ORTHOPAEDIC RESEARCH;OSPEDALE POLICLINICO SAN MARTINO;REUMANEDERLAND;ROYAL COLLEGE OF SURGEONS IN IRELAND;ROYAL VETERINARY COLLEGE;TRINITY COLLEGE DUBLIN;UNIVERSITY HOSPITAL COLOGNE","1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.1.3. - EXCELLENT SCIENCE - MARIE SKŁODOWSKA-CURIE ACTIONS (PROGRAMME);H2020-MSCA-ITN-2016 (CALL FOR PROPOSAL);MSCA-ITN-ETN - EUROPEAN TRAINING NETWORKS (FUNDING SCHEME)","1;1;1","40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","1;1","AGING;ARTHRITIS;BIOENGINEERING;REGENERATIVE MEDICINE","1;1;1;1","MUSCULOSKELETAL","1",NA,NA,NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,37,"PUBLIC LIBRARY OF SCIENCE;KARGER PUBLISHERS;SPRINGER NATURE","35;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;44 HUMAN SOCIETY;52 PSYCHOLOGY;3105 GENETICS;3107 MICROBIOLOGY;34 CHEMICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;37 EARTH SCIENCES;4406 HUMAN GEOGRAPHY;48 LAW AND LEGAL STUDIES;5202 BIOLOGICAL PSYCHOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3008 HORTICULTURAL PRODUCTION;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","34;11;6;5;5;5;4;2;2;2;2;2;2;2;2;1;1;1;1;1","RARE DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;CANCER;CLINICAL RESEARCH;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;WEST NILE VIRUS;AUTOIMMUNE DISEASE;BIOTECHNOLOGY;BREAST CANCER;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIABETES;DIGESTIVE DISEASES;GENETICS;HIV/AIDS;HUMAN GENOME;KIDNEY DISEASE;NEUROSCIENCES;OBESITY;PEDIATRIC","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","INFECTION;CANCER;CARDIOVASCULAR;CONGENITAL;METABOLIC AND ENDOCRINE;STROKE","6;3;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;7.3 MANAGEMENT AND DECISION MAKING","2;1;1","CLINICAL;HEALTH SERVICES & SYSTEMS","5;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH;HEALTH SERVICES RESEARCH","15;2;2;1","ESOPHAGEAL / OESOPHAGEAL CANCER;LARYNGEAL CANCER;PHARYNGEAL CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;BREAST CANCER;KIDNEY CANCER;ORAL CAVITY AND LIP CANCER","3;3;3;2;2;1;1;1","3 GOOD HEALTH AND WELL BEING","3"
"IRCCS_SANMARTINO",2018,829,14.6477683956574,2.89505428226779,0.345416666666667,0.311218335343788,0.324487334137515,0.36670687575392,0.585042219541616,7,407,185,71,65,0.49,0.22,0.09,0.08,29.93,0.981205316020701,0.408926417370326,0.936067551266586,5.67474048442904,0.517912651751233,0.481931887884364,0.448923577144224,0.499918808102951,"MAURIZIO CUTOLO;ANTONIO DI BIAGIO;FRANCESCO GROSSI;FABRIZIO MONTECUCCO;CLAUDIO VISCOLI;FLAVIO NOBILI;LUCIA DEL MASTRO;BARBARA RUARO;EDOARDO G. GIANNINI;ALBERTO SULLI;GIORGIO CIPRANDI;EMANUELE ANGELUCCI;MICAELA BERGAMASCHI;CARMEN PIZZORNI;MARIA TERESA VAN LINT;VANESSA SMITH;DIDIER BLAISE;ARNON NAGLER;SABRINA PAOLINO;MOHAMAD MOHTY","30;29;25;23;22;21;20;19;18;18;18;17;17;17;17;16;15;15;15;14","GIORGIO CIPRANDI;MAURIZIO CUTOLO;ANTONIO DI BIAGIO;SIMONE FERRERO;FABRIZIO MONTECUCCO;AURORA PARODI;FABIO BARRA;FRANCESCO DRAGO;DAVIDE FRUMENTO;BARBARA RUARO;MATTEO GELARDI;LORENZO FERRO DESIDERI;ALBERTO SULLI;CARMEN PIZZORNI;FRANCESCO GROSSI;CLAUDIO VISCOLI;LAMBERTO FELLI;RENZO CORVÒ;SABRINA PAOLINO;PAOLO PELOSI","4.64;3.51;3.46;3.21;2.57;2.44;2.15;2.02;2;1.98;1.92;1.92;1.9;1.88;1.82;1.8;1.76;1.76;1.7;1.66","MAURIZIO CUTOLO;ANTONIO DI BIAGIO;FRANCESCO GROSSI;FABRIZIO MONTECUCCO;CLAUDIO VISCOLI;FLAVIO NOBILI;LUCIA DEL MASTRO;BARBARA RUARO;EDOARDO G. GIANNINI;ALBERTO SULLI;GIORGIO CIPRANDI;EMANUELE ANGELUCCI;MICAELA BERGAMASCHI;CARMEN PIZZORNI;MARIA TERESA VAN LINT;SABRINA PAOLINO;RENZO CORVÒ;AURORA PARODI;SILVIA MORBELLI;MATTEO BAUCKNEHT","30;29;25;23;22;21;20;19;18;18;18;17;17;17;17;15;14;14;13;12","GIORGIO CIPRANDI;MAURIZIO CUTOLO;ANTONIO DI BIAGIO;SIMONE FERRERO;FABRIZIO MONTECUCCO;AURORA PARODI;FABIO BARRA;FRANCESCO DRAGO;DAVIDE FRUMENTO;BARBARA RUARO;LORENZO FERRO DESIDERI;ALBERTO SULLI;CARMEN PIZZORNI;FRANCESCO GROSSI;CLAUDIO VISCOLI;LAMBERTO FELLI;RENZO CORVÒ;SABRINA PAOLINO;PAOLO PELOSI;EMANUELE ANGELUCCI","4.64;3.51;3.46;3.21;2.57;2.44;2.15;2.02;2;1.98;1.92;1.9;1.88;1.82;1.8;1.76;1.76;1.7;1.66;1.6","FRANCESCO GROSSI;MARINA CHIARA GARASSINO;SILVIA NOVELLO;EDWARD B. GARON;EMILIO ESTEBAN;M. CATHERINE PIETANZA;MANUEL DÓMINE;MARTIN RECK;MAXIMILIAN J. HOCHMAIR;MICHAEL BOYER;NIR PELED;ROSS JENNENS;STEVEN POWELL;SUSANNA Y. CHENG;ENRIQUETA FELIP;JING YANG;RINA HUI;SHIRISH M. GADGEEL;BELÉN RUBIO‐VIQUEIRA;FLÁVIA DE ANGELIS","5942;5340;5315;5263;5263;5263;5263;5263;5263;5263;5263;5263;5263;5263;5259;5259;5259;5259;5254;5254","FRANCESCO GROSSI;CLAUDIO VISCOLI;FLAVIO NOBILI;MAURIZIO CUTOLO;GIORGIO CIPRANDI;ANNA RUBARTELLI;LUCIA DEL MASTRO;GABRIELLA PIETRA;CARLO GENOVA;ANTONIO DI BIAGIO;SONIA CARTA;MARIA TERESA VAN LINT;FABRIZIO MONTECUCCO;BARBARA RUARO;DANIELE ROBERTO GIACOBBE;BENJAMIN J. SWARTZWELTER;C. PRESTON NEFF;CARLO MARCHETTI;CHARLES A. DINARELLO;FABIA GAMBONI","5942;1861;735;710;653;570;564;517;512;500;474;463;449;446;409;407;407;407;407;407","ANTONIO DI BIAGIO;MAURIZIO CUTOLO;FRANCESCO GROSSI;FABRIZIO MONTECUCCO;CLAUDIO VISCOLI;GIORGIO CIPRANDI;LUCIA DEL MASTRO;BARBARA RUARO;ALBERTO SULLI;MARIA TERESA VAN LINT;MICAELA BERGAMASCHI;CARMEN PIZZORNI;EMANUELE ANGELUCCI;FLAVIO NOBILI;SABRINA PAOLINO;RENZO CORVÒ;AURORA PARODI;EDOARDO G. GIANNINI;MARCO GOBBI;SILVIA MORBELLI","29;29;25;23;19;18;18;18;18;17;17;16;16;16;14;14;13;13;13;12","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;ECONOMICS;MATERIALS SCIENCE;POLITICAL SCIENCE;PHILOSOPHY;SOCIOLOGY;BUSINESS;ART;HISTORY;GEOGRAPHY","760;277;99;68;51;44;40;32;26;23;15;12;12;4;3;3;2","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GENETICS;PATHOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;CANCER RESEARCH;RADIOLOGY;INTENSIVE CARE MEDICINE;ENDOCRINOLOGY;CELL BIOLOGY;CARDIOLOGY;PSYCHIATRY;PEDIATRICS;OPTICS;PHARMACOLOGY;NEUROSCIENCE;NURSING;PHYSICAL THERAPY","583;189;172;145;139;135;111;105;86;76;64;57;55;53;50;48;42;41;40;32;32;32","CANCER;DISEASE;GENE;CHEMOTHERAPY;POPULATION;CONFIDENCE INTERVAL;COHORT;TRANSPLANTATION;ADVERSE EFFECT;CLINICAL TRIAL;RECEPTOR;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;VIRUS;IMMUNE SYSTEM;IN VITRO;REGIMEN;LUNG CANCER;RETROSPECTIVE COHORT STUDY","183;115;97;93;77;50;46;46;44;35;35;34;33;31;30;29;28;28;27;27","BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;IMMUNOTHERAPY;HAZARD RATIO;MUTATION;CYCLOPHOSPHAMIDE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DEMENTIA;VIRAL LOAD;PLACEBO;TOLERABILITY;ALLELE;NEUTROPENIA;PHASES OF CLINICAL RESEARCH;PHENOTYPE;RITUXIMAB;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;TYPE 2 DIABETES;UNIVARIATE ANALYSIS","62;41;35;34;32;22;21;21;18;17;16;15;14;14;13;13;13;12;12;12;12","NIVOLUMAB;METASTATIC BREAST CANCER;ANTIRETROVIRAL THERAPY;PEMBROLIZUMAB;OXALIPLATIN;CETUXIMAB;GERMLINE MUTATION;TRASTUZUMAB;RUXOLITINIB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KRAS;MICRONUCLEUS;MICROSATELLITE;RIBAVIRIN;ANDROGEN DEPRIVATION THERAPY;ANTHRACYCLINE;BUSULFAN;FLUDARABINE;HERPESVIRIDAE;MAMMOGRAPHY;THIOTEPA","17;15;11;10;9;8;8;8;7;6;6;6;6;6;5;5;5;5;5;5;5","HUMANS;FEMALE;;MALE;MIDDLE AGED;AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;BREAST NEOPLASMS;AGED, 80 AND OVER;TREATMENT OUTCOME;YOUNG ADULT;BIOMARKERS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;HIV INFECTIONS;FOLLOW-UP STUDIES;ADOLESCENT;ANIMALS;ANTINEOPLASTIC AGENTS","473;338;330;304;253;220;199;127;100;87;84;73;68;60;58;57;55;54;50;47","PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;CANCER IMMUNOTHERAPY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;HEPATITIS C INFECTION AND TREATMENT;LYMPHOID NEOPLASMS;HEMATOPOIETIC STEM CELL BIOLOGY;NATURAL KILLER CELLS IN IMMUNITY;EFFICACY AND RESISTANCE IN CML TREATMENT;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;GLIOMAS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MOLECULAR RESEARCH ON BREAST CANCER;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;NEUROBLASTOMA RESEARCH AND TREATMENT;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ASTHMA","22;19;16;15;15;14;13;11;10;10;10;9;9;9;9;8;8;8;7;7","TREATMENT;CLINICAL ENDPOINT;REGIMEN;HEMATOPOIETIC CELL TRANSPLANTATION;BREAST CANCER;DISCONTINUATION;HEPATITIS C;TOLERABILITY;CANCER RISK;HEMATOLOGY;PROGRESSION-FREE SURVIVAL;STROKE (ENGINE);CONCOMITANT;LIVER DISEASE;UNIVARIATE ANALYSIS;INTERQUARTILE RANGE;METASTATIC COLORECTAL CANCER;NK CELL ACTIVATION;NEURORADIOLOGY;NK CELL DEVELOPMENT","41;36;28;21;20;16;15;15;14;14;13;13;12;12;12;11;11;11;10;10","BREAST CANCER;LUNG CANCER;STEM CELL;CLINICAL PRACTICE;PATIENTS TREATED;COLORECTAL CANCER;MYELOID LEUKEMIA;SYSTEMIC SCLEROSIS;CANCER PATIENTS;ITALIAN SOCIETY;CELL LUNG;CELL TRANSPLANTATION;ACUTE LEUKEMIA;CELL CARCINOMA;METASTATIC COLORECTAL;SCLEROSIS PATIENTS;ALZHEIMERS DISEASE;MULTICENTER STUDY;MULTIPLE SCLEROSIS;CHRONIC MYELOID;EUROPEAN SOCIETY;KIDNEY DISEASE;MARROW TRANSPLANTATION;NON-SMALL CELL;PHASE II;PROSTATE CANCER;ACUTE MYELOID;CHRONIC KIDNEY;MAGNETIC RESONANCE;OBSERVATIONAL STUDY","39;19;17;16;16;15;15;15;14;14;13;13;11;11;11;11;10;10;10;9;9;9;9;9;9;9;8;8;8;8","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;BREAST CANCER;RESEARCH FUNDING;ADVISORY BOARD;HR CI;HONORARIA MEMBERSHIP;MULTIVARIATE ANALYSIS;PATIENTS TREATED;MEDIAN AGE;SURVIVAL OS;STATISTICALLY SIGNIFICANT;MEDIAN FOLLOW-UP;SSC PATIENTS;ADVERSE EVENTS;CONSULTANCY HONORARIA;STEM CELL;NK CELLS;BOARD SPEAKERS;CONFIDENCE INTERVAL;PROGRESSION-FREE SURVIVAL;CLINICAL PRACTICE;SIGNIFICANTLY LOWER;CELL TRANSPLANTATION;CHRONIC GVHD;CLINICAL TRIAL;MONTHS NA;PUBMED SCOPUS;DE NOVO","156;156;125;97;83;77;72;65;47;47;45;43;42;41;41;39;35;35;33;32;30;30;29;29;27;27;27;25;25;24",387,0.47,7,8,2,1,1,1,2,0,1,8.5,1,1,7.75,1,2.5,2,3.5,6,3,0,0,63,62,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,3,0.13,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"LAVIERI ROSA;MONTI GIACOMO;RUBARTELLI ANNA","1;1;1","IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO-IST-ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","2;1",NA,NA,"5.1 PHARMACEUTICALS","1","A61K31/4439;A61K45/06;A61P29/00","1;1;1","A61K31/4439;A61K45/06;A61P29/00","1;1;1",49,4.86,793.2,5.73,24,0.49,122.12,0,0,14,1,19,0,0,15,0,36,13,0,0,0,0,0,0,42,6,1,49,0,0,0,0,0,0,0,0,0,"United States;Japan;United Kingdom;Switzerland;Australia;Finland;Germany;Italy","18;4;4;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3215 REPRODUCTIVE MEDICINE;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4205 NURSING","47;25;17;5;5;5;3;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;DIGESTIVE DISEASES;AUTOIMMUNE DISEASE;BRAIN DISORDERS;HEMATOLOGY;LUNG;NEUROSCIENCES;BIOMEDICAL IMAGING;BREAST CANCER;ENDOMETRIOSIS;INFECTIOUS DISEASES;INFLAMMATORY BOWEL DISEASE;LYMPHOMA;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;NUTRITION","43;29;18;13;12;7;6;5;5;5;5;3;3;3;3;3;3;3;3;3","CANCER;CARDIOVASCULAR;INFECTION;NEUROLOGICAL;EYE;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;RESPIRATORY","14;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.4 SURGERY","29;5;3;3;2;1;1","BREAST CANCER;MELANOMA;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;ANAL CANCER;BLADDER CANCER;COLON AND RECTAL CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;PROSTATE CANCER;SKIN CANCER","4;4;3;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;3.3 CHEMOPREVENTION;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","10;2;2;1;1;1",2,4673446,339458.81,5.5,13.5,8.5,1,135,325869.196153846,2.54396552292909,"OSPEDALE POLICLINICO SAN MARTINO;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS;ENGINEERING (ITALY);FRAUNHOFER SOCIETY;HANNOVER MEDICAL SCHOOL;HEBREW UNIVERSITY OF JERUSALEM;HEIDELBERG UNIVERSITY;HOSPITAL CLÍNIC DE BARCELONA;IMEC;INNATE PHARMA (FRANCE);INSTITUT PASTEUR;MEDICAL UNIVERSITY OF VIENNA;MILTENYI BIOTEC (GERMANY);NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS;NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH;OSLO UNIVERSITY HOSPITAL;PIRKANMAA HOSPITAL DISTRICT;POMPEU FABRA UNIVERSITY;RECHTS DER ISAR HOSPITAL","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","H2020-EU.1.3. - EXCELLENT SCIENCE - MARIE SKŁODOWSKA-CURIE ACTIONS (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-MSCA-ITN-2017 (CALL FOR PROPOSAL);MSCA-ITN - MARIE SKŁODOWSKA-CURIE INNOVATIVE TRAINING NETWORKS (ITN) (FUNDING SCHEME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","2;1;1;1","ATHEROSCLEROSIS;CANCER;CARDIOVASCULAR;CLINICAL RESEARCH;HEART DISEASE;NEUROSCIENCES;PATIENT SAFETY;STROKE","1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES","1;1;1;1","NOT SITE-SPECIFIC CANCER","1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1;1","A01 CLINICAL MEDICINE","2","3 GOOD HEALTH AND WELL BEING","1",29,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;SPRINGER NATURE;KARGER PUBLISHERS;MENDELEY DATA;SAGE JOURNALS;TAYLOR & FRANCIS GROUP","9;8;4;4;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3105 GENETICS;3207 MEDICAL MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;34 CHEMICAL SCIENCES;42 HEALTH SCIENCES;3203 DENTISTRY;3206 MEDICAL BIOTECHNOLOGY;3215 REPRODUCTIVE MEDICINE;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;40 ENGINEERING;4007 CONTROL ENGINEERING, MECHATRONICS AND ROBOTICS;4202 EPIDEMIOLOGY;44 HUMAN SOCIETY;4407 POLICY AND ADMINISTRATION","37;11;7;4;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;GENETICS;RARE DISEASES;BRAIN CANCER;BRAIN DISORDERS;CANCER;HIV/AIDS;INFECTIOUS DISEASES;ORPHAN DRUG;GENETIC TESTING;IMMUNIZATION;NEURODEGENERATIVE;NEUROSCIENCES;PREVENTION;VACCINE RELATED;ARTHRITIS;AUTOIMMUNE DISEASE;CHRONIC LIVER DISEASE AND CIRRHOSIS;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;DIGESTIVE DISEASES","8;7;5;3;3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1","GENERIC HEALTH RELEVANCE;CANCER;INFECTION;NEUROLOGICAL;INFLAMMATORY AND IMMUNE SYSTEM","4;3;3;2;1","5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT","7;6;3;2;2;1","BIOMEDICAL;CLINICAL","9;3","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","11;8","BRAIN TUMOR;MELANOMA;NOT SITE-SPECIFIC CANCER;CERVICAL CANCER;LIVER CANCER;NEUROBLASTOMA","3;3;3;2;1;1","3 GOOD HEALTH AND WELL BEING","2"
"IRCCS_SANMARTINO",2019,904,14.6935840707965,2.98340707964602,0.335187245087134,0.331858407079646,0.357300884955752,0.301991150442478,0.627212389380531,6,441,201,93,61,0.49,0.22,0.1,0.07,24.07,0.989697876519276,0.445796460176991,0.962389380530973,5.83218192285551,0.519137824111341,0.462049028677151,0.462119094213028,0.439110308753414,"MAURIZIO CUTOLO;SILVIA MORBELLI;FLAVIO NOBILI;FRANCESCO GROSSI;EMANUELE ANGELUCCI;VANESSA SMITH;SABRINA PAOLINO;ROBERTO M. LEMOLI;CARMEN PIZZORNI;ALBERTO SULLI;SIMONE FERRERO;ANTONIO DI BIAGIO;LUCIA DEL MASTRO;MARIO AMORE;MATTEO LAMBERTINI;CARLO GENOVA;ALESSIO SIGNORI;MARIA PIA SORMANI;MICAELA BERGAMASCHI;AURORA PARODI","28;28;27;26;25;24;23;21;21;19;19;18;18;17;17;17;16;16;16;16","SIMONE FERRERO;MAURIZIO CUTOLO;AURORA PARODI;ALBERTO SULLI;FABIO BARRA;SABRINA PAOLINO;MATTEO LAMBERTINI;VANESSA SMITH;CHIARA ROBBA;CARMEN PIZZORNI;EMANUELE ANGELUCCI;MARIA PIA SORMANI;MARIO AMORE;SILVIA MORBELLI;CARLO ENRICO TRAVERSO;FRANCESCO GROSSI;EMANUELE COZZANI;GIANLUCA SERAFINI;FLAVIO NOBILI;CAROLINA SCALA","3.42;3.23;3.14;2.99;2.88;2.82;2.59;2.5;2.41;2.38;2.27;2.26;2.23;2.18;2.17;2.08;1.98;1.87;1.83;1.8","MAURIZIO CUTOLO;SILVIA MORBELLI;FLAVIO NOBILI;FRANCESCO GROSSI;EMANUELE ANGELUCCI;SABRINA PAOLINO;ROBERTO M. LEMOLI;CARMEN PIZZORNI;ALBERTO SULLI;SIMONE FERRERO;ANTONIO DI BIAGIO;LUCIA DEL MASTRO;MARIO AMORE;MATTEO LAMBERTINI;CARLO GENOVA;ALESSIO SIGNORI;MARIA PIA SORMANI;MICAELA BERGAMASCHI;AURORA PARODI;FABRIZIO MONTECUCCO","28;28;27;26;25;23;21;21;19;19;18;18;17;17;17;16;16;16;16;15","SIMONE FERRERO;MAURIZIO CUTOLO;AURORA PARODI;ALBERTO SULLI;FABIO BARRA;SABRINA PAOLINO;MATTEO LAMBERTINI;CHIARA ROBBA;CARMEN PIZZORNI;EMANUELE ANGELUCCI;MARIA PIA SORMANI;MARIO AMORE;SILVIA MORBELLI;CARLO ENRICO TRAVERSO;FRANCESCO GROSSI;EMANUELE COZZANI;GIANLUCA SERAFINI;FLAVIO NOBILI;CAROLINA SCALA;GIACOMO BREGNI","3.42;3.23;3.14;2.99;2.88;2.82;2.59;2.41;2.38;2.27;2.26;2.23;2.18;2.17;2.08;1.98;1.87;1.83;1.8;1.78","CLAUDIO VISCOLI;MATTEO BASSETTI;JOHAN MAERTENS;CORNELIUS J. CLANCY;ELIO CASTAGNOLA;LIVIO PAGANO;ADILIA WARRIS;ANDREAS H. GROLL;ANGELA M. CALIENDO;BARBARA D. ALEXANDER;BART JAN KULLBERG;BRIAN T. FISHER;C ORLA MORRISEY;CAROL A. KAUFFMAN;CATHERINE F. DECKER;CHRISTOPHER C. KIBBLER;CLAUS PETER HEUßEL;CORNELIA SCHAEFER PROKOP;DAVID A. STEVENS;DAVID R. ANDES","2790;2111;1876;1850;1833;1832;1830;1830;1830;1830;1830;1830;1830;1830;1830;1830;1830;1830;1830;1830","CLAUDIO VISCOLI;SILVIA MORBELLI;FLAVIO NOBILI;DARIO ARNALDI;DANIELE ROBERTO GIACOBBE;CLAUDIA TRENKWALDER;MATTEO LAMBERTINI;CHIARA ROBBA;ALBERTO SOBRERO;MAŁGORZATA MIKULSKA;CARLO GENOVA;MARIO AMORE;MARIA PIA SORMANI;PAOLA QUEIROLO;GIANLUCA SERAFINI;MICAELA BERGAMASCHI;FRANCESCA VIAZZI;ROBERTO PONTREMOLI;MARIA GIOVANNA DAL BELLO;FABIO BENFENATI","2790;1355;1342;1025;784;739;604;575;509;478;466;432;425;420;410;410;409;398;388;386","MAURIZIO CUTOLO;SILVIA MORBELLI;EMANUELE ANGELUCCI;FLAVIO NOBILI;SABRINA PAOLINO;CARMEN PIZZORNI;SIMONE FERRERO;ALBERTO SULLI;ANTONIO DI BIAGIO;LUCIA DEL MASTRO;ROBERTO M. LEMOLI;CARLO GENOVA;MARIO AMORE;MATTEO LAMBERTINI;ELISA ALESSANDRI;MICAELA BERGAMASCHI;MASSIMO PATANÈ;AURORA PARODI;CHIARA ROBBA;GIANLUCA SERAFINI","29;25;25;24;21;20;19;18;17;17;17;16;16;16;15;15;14;14;14;13","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;MATHEMATICS;ENGINEERING;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;HISTORY;GEOLOGY;ART;ENVIRONMENTAL SCIENCE","837;284;91;73;67;65;44;32;20;19;19;16;12;6;5;4;3;2;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;IMMUNOLOGY;GENETICS;BIOCHEMISTRY;GASTROENTEROLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;CANCER RESEARCH;PSYCHIATRY;NEUROSCIENCE;CELL BIOLOGY;CARDIOLOGY;INTENSIVE CARE MEDICINE;PHYSICAL THERAPY;ENDOCRINOLOGY;PALEONTOLOGY;PEDIATRICS","643;210;199;161;137;131;115;111;99;84;77;72;57;52;50;50;47;43;40;39","CANCER;DISEASE;GENE;CHEMOTHERAPY;POPULATION;COHORT;CLINICAL TRIAL;TRANSPLANTATION;CONFIDENCE INTERVAL;RECEPTOR;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;IMMUNE SYSTEM;REGIMEN;LUNG CANCER;MULTIPLE SCLEROSIS;ANTIBODY;IN VITRO;ALTERNATIVE MEDICINE","213;116;112;92;76;63;50;50;47;40;39;39;35;33;32;30;30;29;29;28","BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;IMMUNOTHERAPY;CYCLOPHOSPHAMIDE;HAZARD RATIO;MUTATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DEMENTIA;PHENOTYPE;GENE EXPRESSION;METASTASIS;UNIVARIATE ANALYSIS;RITUXIMAB;PROSTATE CANCER;VIRAL LOAD;PARKINSON'S DISEASE;PHASES OF CLINICAL RESEARCH;TOLERABILITY;CHRONIC LYMPHOCYTIC LEUKEMIA","67;39;38;36;27;26;25;21;18;17;16;16;16;15;14;14;13;13;13;12","NIVOLUMAB;FLUDARABINE;ANTIRETROVIRAL THERAPY;DNA METHYLATION;KRAS;OXALIPLATIN;TRASTUZUMAB;ANDROGEN RECEPTOR;BUSULFAN;KARYOTYPE;PEMBROLIZUMAB;THIOTEPA;ANDROGEN DEPRIVATION THERAPY;DEMENTIA WITH LEWY BODIES;IBRUTINIB;METASTATIC BREAST CANCER;EPIRUBICIN;GERMLINE MUTATION;IMMUNE CHECKPOINT;MAMMOGRAPHY;PLACENTA;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SENTINEL LYMPH NODE;TOTAL BODY IRRADIATION","26;14;10;10;10;9;9;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;TREATMENT OUTCOME;BREAST NEOPLASMS;YOUNG ADULT;ANIMALS;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LUNG NEOPLASMS;BRAIN;PROSPECTIVE STUDIES;CARCINOMA, NON-SMALL-CELL LUNG","484;393;343;304;255;220;214;155;103;88;79;76;74;60;58;57;55;53;49;42","PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;CANCER IMMUNOTHERAPY;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ACUTE MYELOID LEUKEMIA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;HEMATOPOIETIC STEM CELL BIOLOGY;LYMPHOID NEOPLASMS;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;MOLECULAR RESEARCH ON BREAST CANCER;ASTHMA;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;EFFICACY AND RESISTANCE IN CML TREATMENT","27;24;21;19;18;14;14;14;14;13;12;10;10;10;10;9;9;9;8;8","CLINICAL ENDPOINT;REGIMEN;BREAST CANCER;TREATMENT;METASTATIC COLORECTAL CANCER;DISCONTINUATION;BIOMARKERS FOR IMMUNOTHERAPY;NEUROIMAGING;UNIVARIATE ANALYSIS;HEMATOPOIETIC CELL TRANSPLANTATION;REFRACTORY (PLANETARY SCIENCE);TOLERABILITY;INTERQUARTILE RANGE;TREATMENT OUTCOMES;ASTHMA;CANCER RISK;CUMULATIVE INCIDENCE;PROGRESSION-FREE SURVIVAL;RADIOTHERAPY;NEURORADIOLOGY","40;32;27;27;18;17;15;15;15;14;14;14;13;13;11;11;11;11;11;10","BREAST CANCER;CANCER PATIENTS;LUNG CANCER;SYSTEMIC SCLEROSIS;MULTIPLE SCLEROSIS;COLORECTAL CANCER;STEM CELL;CELL TRANSPLANTATION;CELL LUNG;MYELOID LEUKEMIA;PATIENTS TREATED;METASTATIC COLORECTAL;OBSERVATIONAL STUDY;PARKINSONS DISEASE;NON-SMALL CELL;PHASE III;RETROSPECTIVE STUDY;SCLEROSIS PATIENTS;ACUTE MYELOID;CELL CARCINOMA;PATIENTS PTS;PHASE II;ALZHEIMERS DISEASE;CHRONIC LYMPHOCYTIC;LYMPH NODE;LYMPHOCYTIC LEUKEMIA;PROGNOSTIC FACTORS;STEM CELLS;COHORT STUDY;PROSTATE CANCER","41;25;25;22;21;18;18;17;16;16;16;14;14;14;13;13;12;12;11;10;10;10;9;9;9;9;9;9;8;8","ADVISORY CONSULTANCY;ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;SPEAKER BUREAU;ACCOMMODATION EXPENSES;TRAVEL ACCOMMODATION;SPEAKERS BUREAU;EXPERT TESTIMONY;BUREAU EXPERT;PUBMED SCOPUS;CONSULTANCY MEMBERSHIP;RESEARCH GRANT;GRANT FUNDING;BREAST CANCER;FUNDING INSTITUTION;ARTICLECROSSREF GOOGLE;SSC PATIENTS;CONSULTANCY HONORARIA;CONSULTANCY SPEAKER;HR CI;HONORARIA MEMBERSHIP;NOVARTIS HONORARIA;SURVIVAL OS;CROSSREF PUBMED;PATIENTS TREATED;CONSULTANCY RESEARCH;ADVERSE EVENTS;ADVISORY BOARD;PFIZER HONORARIA","334;239;239;166;121;117;117;112;111;109;94;93;90;88;77;72;70;68;67;67;67;63;60;60;58;57;50;49;48;46",447,0.49,9.25,8,1,1.5,0,2,2.5,1,1,9,1,1,7.25,3,3,2,3,6,3,0,0,54,54,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,4,0.15,7,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CANTONI CLAUDIA;MORETTA ALESSANDRO;MORETTA LORENZO;VITALE MASSIMO","1;1;1;1","DEL ZOTTO GENNY;INNATE PHARMA;IRCCS OSPEDALE POLICLINICO SAN MARTINO;MORETTA LAURA;MORETTA STEFANO;OSPEDALE PEDIATRICO BAMBINO GESÙ;UNIV DEGLI STUDI GENOVA","1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1","CANCER;PREVENTION","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","1;1","A61P35/00;C07K16/18","1;1","A61K2039/505;A61P35/00;C07K16/18","1;1;1",44,5.25,724.16,5.05,22,0.5,76.64,1,1,11,0,13,0,0,18,0,30,14,0,0,0,0,0,0,40,4,0,44,0,0,0,0,0,0,0,0,0,"Italy;United States;Netherlands;Belgium;Japan;Germany;India","13;10;6;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3208 MEDICAL PHYSIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3215 REPRODUCTIVE MEDICINE;39 EDUCATION;3904 SPECIALIST STUDIES IN EDUCATION;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;51 PHYSICAL SCIENCES","43;19;16;6;4;4;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;BRAIN DISORDERS;DIGESTIVE DISEASES;NEUROSCIENCES;AGING;CARDIOVASCULAR;PREVENTION;BREAST CANCER;HEART DISEASE;NEURODEGENERATIVE;LUNG;LYMPHOMA;PEDIATRIC;PEDIATRIC CANCER;TRANSPLANTATION","40;28;18;15;9;8;6;6;6;5;5;5;4;4;4;3;3;3;3;3","CANCER;CARDIOVASCULAR;NEUROLOGICAL;RENAL AND UROGENITAL;BLOOD;EYE;ORAL AND GASTROINTESTINAL;SKIN;STROKE","14;5;3;2;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","27;3;3;2;2;1;1;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;COLON AND RECTAL CANCER;BLOOD CANCER;ENDOMETRIAL CANCER;GALLBLADDER CANCER;KIDNEY CANCER;LUNG CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;SKIN CANCER","4;3;3;2;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK;3.3 CHEMOPREVENTION;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","11;5;2;1;1;1;1",2,26145996,408531.19,5,34.5,8,1,92,273534.600320513,3.30488354650835,"OSPEDALE POLICLINICO SAN MARTINO;UNIVERSITY OF FLORENCE;ANTONI VAN LEEUWENHOEK HOSPITAL;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;AZIENDA OSPEDALIERA UNIVERSITARIA SENESE;BIOBANKING AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE - ERIC;BIOGEM;CENTER FOR ADVANCED STUDIES RESEARCH AND DEVELOPMENT IN SARDINIA;CHARITÉ - UNIVERSITY MEDICINE BERLIN;CSC - IT CENTER FOR SCIENCE (FINLAND);DIAMOND LIGHT SOURCE;DÉLÉGATION PARIS 11;EU-OPENSCREEN ERIC;EUROPEAN ADVANCED TRANSLATIONAL RESEARCH INFRASTRUCTURE - ERIC;EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK - ERIC;EUROPEAN MARINE BIOLOGY RESOURCE CENTER - ERIC;EUROPEAN MOLECULAR BIOLOGY LABORATORY;FLANDERS MARINE INSTITUTE;FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;FORSCHUNGSZENTRUM JÜLICH","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;ITALIAN ASSOCIATION FOR CANCER RESEARCH","1;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","1;1;1","H2020-EU.1.4.1.1. - DEVELOPING NEW WORLD-CLASS RESEARCH INFRASTRUCTURES (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;46 INFORMATION AND COMPUTING SCIENCES;4610 LIBRARY AND INFORMATION STUDIES","1;1;1;1;1;1","BRAIN DISORDERS;CANCER;CLINICAL RESEARCH;GENETICS;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD);RARE DISEASES;VACCINE RELATED","1;1;1;1;1;1;1","CANCER","1","1.5 RESOURCES AND INFRASTRUCTURE (UNDERPINNING);2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","1;1;1","MELANOMA","1","1.4 CANCER PROGRESSION AND METASTASIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1;1","A01 CLINICAL MEDICINE;B11 COMPUTER SCIENCE AND INFORMATICS","1;1",NA,NA,34,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;AMERICAN CHEMICAL SOCIETY","21;12;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;40 ENGINEERING;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;34 CHEMICAL SCIENCES;4008 ELECTRICAL ENGINEERING;49 MATHEMATICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;3103 ECOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3208 MEDICAL PHYSIOLOGY;3209 NEUROSCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;38 ECONOMICS;3801 APPLIED ECONOMICS","45;14;5;4;4;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1","RARE DISEASES;LUNG;OBESITY;CANCER;ACUTE RESPIRATORY DISTRESS SYNDROME;CLINICAL RESEARCH;NEUROSCIENCES;BIOENGINEERING;BIOTECHNOLOGY;BRAIN DISORDERS;CARDIOVASCULAR;DIGESTIVE DISEASES;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;BREAST CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DENTAL/ORAL AND CRANIOFACIAL DISEASE","9;8;6;5;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1","RESPIRATORY;CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;ORAL AND GASTROINTESTINAL","7;4;3;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES","12;3;3;2;1","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS","14;5;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","14;11","BREAST CANCER;HEAD AND NECK CANCER;LIVER CANCER;LUNG CANCER;NASAL CAVITY AND PARANASAL SINUS CANCER;NEUROBLASTOMA;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER","1;1;1;1;1;1;1;1;1",NA,NA
"IRCCS_SANMARTINO",2020,1288,16.4479813664596,3.05357142857143,0.327485380116959,0.328416149068323,0.34472049689441,0.309782608695652,0.657608695652174,15,685,274,96,53,0.53,0.21,0.07,0.04,26.7,1.05962721777241,0.415372670807453,0.962732919254658,6.75943505441077,0.575201287767769,0.493454355820498,0.47765976417092,0.485598911564626,"MATTEO BASSETTI;SIMONE FERRERO;MATTEO LAMBERTINI;FABIO BARRA;MATILDE INGLESE;FLAVIO NOBILI;EMANUELE ANGELUCCI;ANTONIO DI BIAGIO;AURORA PARODI;CHIARA ROBBA;PAOLO PELOSI;CARLO ENRICO TRAVERSO;MAŁGORZATA MIKULSKA;ALESSIO SIGNORI;VALERIO GAETANO VELLONE;FABRIZIO MONTECUCCO;MAURIZIO CUTOLO;ANTONIO UCCELLI;DANIELE ROBERTO GIACOBBE;LUCIA DEL MASTRO","44;41;38;36;34;32;31;30;29;28;25;25;24;24;24;23;23;23;23;23","SIMONE FERRERO;FABIO BARRA;MATTEO LAMBERTINI;MATTEO BASSETTI;AURORA PARODI;CAROLINA SCALA;CARLO ENRICO TRAVERSO;GIANNI TESTINO;VALERIO GAETANO VELLONE;MATILDE INGLESE;CHIARA ROBBA;ANTONIO DI BIAGIO;DANIELE ROBERTO GIACOBBE;ALBERTO TAGLIAFICO;MARIO AMORE;ITALO PORTO;MAURIZIO CUTOLO;PAOLO BRUZZI;GIANLUCA SERAFINI;MARIA PIA SORMANI","7.11;5.96;5.3;5.03;4.38;3.61;3.56;3.5;3.34;3.31;3.21;3.16;2.96;2.62;2.52;2.51;2.46;2.35;2.29;2.19","MATTEO BASSETTI;SIMONE FERRERO;MATTEO LAMBERTINI;FABIO BARRA;MATILDE INGLESE;FLAVIO NOBILI;EMANUELE ANGELUCCI;ANTONIO DI BIAGIO;AURORA PARODI;CHIARA ROBBA;PAOLO PELOSI;CARLO ENRICO TRAVERSO;MAŁGORZATA MIKULSKA;VALERIO GAETANO VELLONE;FABRIZIO MONTECUCCO;MAURIZIO CUTOLO;ANTONIO UCCELLI;DANIELE ROBERTO GIACOBBE;LUCIA DEL MASTRO;MARIO AMORE","44;41;38;36;34;32;31;30;29;28;25;25;24;24;23;23;23;23;23;22","SIMONE FERRERO;FABIO BARRA;MATTEO LAMBERTINI;MATTEO BASSETTI;AURORA PARODI;CAROLINA SCALA;CARLO ENRICO TRAVERSO;GIANNI TESTINO;VALERIO GAETANO VELLONE;MATILDE INGLESE;CHIARA ROBBA;ANTONIO DI BIAGIO;DANIELE ROBERTO GIACOBBE;ALBERTO TAGLIAFICO;MARIO AMORE;ITALO PORTO;MAURIZIO CUTOLO;PAOLO BRUZZI;GIANLUCA SERAFINI;MARIA PIA SORMANI","7.11;5.96;5.3;5.03;4.38;3.61;3.56;3.5;3.34;3.31;3.21;3.16;2.96;2.62;2.52;2.51;2.46;2.35;2.29;2.19","MATTEO BASSETTI;ROBERTO M. LEMOLI;MARIO AMORE;GIANLUCA SERAFINI;ROMAN HÁJEK;ANDREA AGUGLIA;ANDREA AMERIO;PAOLO PELOSI;HARTMUT DÖHNER;COURTNEY D. DINARDO;JALAJA POTLURI;MARINA KONOPLEVA;ANDREW H. WEI;ANTHONY LETAI;BRIAN A. JONAS;BRIAN LEBER;DAVID LAVIE;ELIZABETH A. KOLLER;JACQUELINE S. GARCIA;JIANXIANG WANG","3214;2404;2377;2291;2054;2013;2009;1952;1855;1783;1783;1783;1749;1749;1749;1749;1749;1749;1749;1749","MATTEO BASSETTI;MARIO AMORE;GIANLUCA SERAFINI;ROBERTO M. LEMOLI;ANDREA AGUGLIA;ANDREA AMERIO;PAOLO PELOSI;DANIELE ROBERTO GIACOBBE;MATTEO LAMBERTINI;CHIARA ROBBA;B PARMIGIANI;EMANUELE ANGELUCCI;MAŁGORZATA MIKULSKA;ANTONIO DI BIAGIO;CARLO GENOVA;ANTONIO VENA;PAOLO BRUZZI;MATILDE INGLESE;LUCIA TARAMASSO;LAURA MAGNASCO","3109;2197;2111;1866;1833;1708;1698;1283;1260;1079;1067;1066;1056;1026;986;976;964;914;808;768","SIMONE FERRERO;MATTEO BASSETTI;MATTEO LAMBERTINI;FABIO BARRA;FLAVIO NOBILI;MATILDE INGLESE;PAOLO PELOSI;EMANUELE ANGELUCCI;ANTONIO DI BIAGIO;CHIARA ROBBA;AURORA PARODI;MAURIZIO CUTOLO;GIUSEPPE FORNARINI;LUCIA DEL MASTRO;CARLO ENRICO TRAVERSO;MAŁGORZATA MIKULSKA;DANIELE ROBERTO GIACOBBE;FABIO BENFENATI;MARIO AMORE;GIANLUCA SERAFINI","41;39;38;36;30;29;29;29;28;28;25;24;22;22;22;21;21;20;20;19","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;BUSINESS;ART;GEOGRAPHY;HISTORY;GEOLOGY","1204;361;117;114;110;84;57;53;53;47;34;27;18;16;11;7;6;5","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;GENETICS;BIOCHEMISTRY;PSYCHIATRY;RADIOLOGY;INTENSIVE CARE MEDICINE;CANCER RESEARCH;CARDIOLOGY;NEUROSCIENCE;ENDOCRINOLOGY;PALEONTOLOGY;VIROLOGY;FAMILY MEDICINE;OPTICS","918;301;258;222;184;152;150;148;146;130;116;102;89;84;81;79;77;75;65;65","CANCER;DISEASE;POPULATION;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;COHORT;RETROSPECTIVE COHORT STUDY;OUTBREAK;TRANSPLANTATION;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;ANTIBODY;CLINICAL TRIAL;STAGE (STRATIGRAPHY);IMMUNE SYSTEM;ADVERSE EFFECT;MULTIPLE SCLEROSIS","289;247;132;104;100;97;96;66;62;62;55;55;52;50;48;46;44;41;40;39","INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;HAZARD RATIO;COLORECTAL CANCER;2019-20 CORONAVIRUS OUTBREAK;IMMUNOTHERAPY;CLINICAL ENDPOINT;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CYCLOPHOSPHAMIDE;DEMENTIA;PROSTATE CANCER;UNIVARIATE ANALYSIS;VIRAL LOAD;MUTATION;CUMULATIVE INCIDENCE;NEURORADIOLOGY;PARKINSON'S DISEASE;GENE EXPRESSION;PROGRESSION-FREE SURVIVAL;METASTASIS","115;104;69;51;49;46;40;32;28;22;21;21;21;19;18;16;16;15;15;14","CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;ANTIRETROVIRAL THERAPY;METASTATIC BREAST CANCER;FLUDARABINE;TRASTUZUMAB;DEMENTIA WITH LEWY BODIES;OXALIPLATIN;KRAS;PEMBROLIZUMAB;FERTILITY PRESERVATION;GERMLINE MUTATION;IPILIMUMAB;BUSULFAN;ESTROGEN RECEPTOR;MISSENSE MUTATION;THIOTEPA;ANTHRACYCLINE;CETUXIMAB;TOTAL BODY IRRADIATION","113;20;18;15;14;12;10;10;9;9;8;8;8;7;7;7;7;6;6;6",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ITALY;ADULT;RETROSPECTIVE STUDIES;COVID-19;CORONAVIRUS INFECTIONS;PNEUMONIA, VIRAL;AGED, 80 AND OVER;TREATMENT OUTCOME;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;YOUNG ADULT;PANDEMICS;RISK FACTORS;PROSPECTIVE STUDIES","721;545;346;312;249;215;196;191;120;97;88;84;83;80;78;69;60;58;57;50","IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;CANCER IMMUNOTHERAPY;CORONAVIRUS DISEASE 2019;HEMATOPOIETIC STEM CELL BIOLOGY;RENAL CELL CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;MOLECULAR RESEARCH ON BREAST CANCER;ACUTE MYELOID LEUKEMIA;HER2 SIGNALING IN BREAST CANCER TREATMENT;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;BRAIN-COMPUTER INTERFACES IN NEUROSCIENCE AND MEDICINE;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE","37;28;28;20;20;17;17;15;13;12;12;12;11;11;11;10;10;10;10;10","PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;TREATMENT;BREAST CANCER;REGIMEN;INTERQUARTILE RANGE;UNIVARIATE ANALYSIS;HEMATOPOIETIC CELL TRANSPLANTATION;NEUROIMAGING DATA ANALYSIS;BIOMARKERS FOR IMMUNOTHERAPY;CUMULATIVE INCIDENCE;STROKE (ENGINE);TUMOR MICROENVIRONMENT;DEPRESSION (ECONOMICS);NEURORADIOLOGY;ADJUVANT THERAPY;DIAGNOSIS;PROGRESSION-FREE SURVIVAL;DISCONTINUATION","68;48;40;33;31;27;22;21;20;20;18;18;18;17;16;16;15;15;15;14","BREAST CANCER;CANCER PATIENTS;MULTIPLE SCLEROSIS;COVID- PANDEMIC;PATIENTS TREATED;CELL TRANSPLANTATION;CELL CARCINOMA;COLORECTAL CANCER;STEM CELL;METASTATIC RENAL;PATIENTS UNDERGOING;RENAL CELL;LUNG CANCER;MULTICENTER STUDY;OBSERVATIONAL STUDY;PROSTATE CANCER;COLON CANCER;CLINICAL PRACTICE;RISK FACTORS;COHORT STUDY;HEART FAILURE;RETROSPECTIVE STUDY;BRAIN INJURY;EUROPEAN SOCIETY;MAGNETIC RESONANCE;MULTIPLE MYELOMA;MYELOID LEUKEMIA;PATIENTS PTS;ALZHEIMERS DISEASE;CHECKPOINT INHIBITORS","66;34;33;30;26;24;22;20;20;16;15;15;14;14;14;14;13;12;12;11;11;11;10;10;10;10;10;10;9;9","SPEAKERS BUREAU;ADVISORY COMMITTEES;ENTITYS BOARD;HR CI;RESEARCH FUNDING;PERSONAL FEES;BREAST CANCER;CONSULTANCY HONORARIA;PATIENTS TREATED;MEDIAN AGE;COVID- PANDEMIC;HAZARD RATIO;CONFIDENCE INTERVAL;INTENSIVE CARE;MULTIPLE SCLEROSIS;ADVERSE EVENTS;HONORARIA RESEARCH;MEDIAN FOLLOW-UP;PATIENTS UNDERGOING;SURVIVAL OS;INCLUDED PATIENTS;CLINICAL PRACTICE;INCREASED RISK;MULTIVARIATE ANALYSIS;FUNDING SPEAKERS;CARE UNIT;LOGISTIC REGRESSION;RISK FACTORS;SIGNIFICANT DIFFERENCE;ACUTE RESPIRATORY","155;142;142;142;135;128;115;99;70;66;55;52;51;48;48;47;47;47;43;43;42;41;41;41;40;39;37;37;37;36",658,0.51,11.07,11,2,1.5,0,2,2,1,1,12,2,1,11,1,1,2,5,9,5,0,0,59,59,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,3.33,454.62,6.17,37,0.54,62.78,0,0,15,1,22,0,2,29,0,49,20,0,0,0,0,0,0,65,4,0,69,0,0,0,0,0,0,0,0,0,"Italy;United States;Germany;Netherlands;Japan;Switzerland;Canada;United Kingdom","15;10;6;3;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;4403 DEMOGRAPHY;3105 GENETICS;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;3209 NEUROSCIENCES;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE","66;42;23;6;6;5;3;2;2;2;2;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;PREVENTION;LUNG;HEMATOLOGY;INFECTIOUS DISEASES;NEUROSCIENCES;CARDIOVASCULAR;DIGESTIVE DISEASES;BRAIN DISORDERS;PNEUMONIA;PNEUMONIA & INFLUENZA;AUTOIMMUNE DISEASE;EMERGING INFECTIOUS DISEASES;GENETICS;HEART DISEASE;KIDNEY DISEASE","64;44;26;23;17;16;12;11;10;8;7;6;5;5;5;4;4;4;4;4","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;NEUROLOGICAL;RENAL AND UROGENITAL;RESPIRATORY;BLOOD;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","23;9;6;3;3;3;2;2;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES;3.4 VACCINES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.4 SURGERY;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","42;9;5;3;3;2;1;1;1;1;1;1;1;1;1","BREAST CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;LUNG CANCER;MELANOMA;ORAL CAVITY AND LIP CANCER;BLADDER CANCER;HEAD AND NECK CANCER;KIDNEY CANCER;LARYNGEAL CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","5;5;5;4;4;2;2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.2 SURVEILLANCE","15;4;4;2;2;1;1;1;1;1;1",10,8605763,649340,4.7,4.6,2.9,0.3,8.55555555555556,743257.005082418,1.73291336804445,"OSPEDALE POLICLINICO SAN MARTINO;BELGIAN FEDERAL SCIENCE POLICY OFFICE;BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS;CENTRO DE COMPUTAÇÃO GRÁFICA;CENTRUM MEDYCZNE KSZTAŁCENIA PODYPLOMOWEGO;CHARITÉ - UNIVERSITY MEDICINE BERLIN;DÉLÉGATION PARIS 11;EUROPEAN SOCIETY OF CARDIOLOGY;HASSELT UNIVERSITY;HEIDELBERG UNIVERSITY;INSTITUT PASTEUR;INSTITUTE OF AGRICULTURAL AND FOOD BIOTECHNOLOGY;INSTITUTE OF BIOCHEMISTRY AND PHYSIOLOGY OF MICROORGANISMS;JAGIELLONIAN UNIVERSITY;NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS;NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE;NATIONAL RESEARCH COUNCIL;NATIONAL RESEARCH INSTITUTE FOR AGRICULTURE, FOOD AND ENVIRONMENT;QUEEN'S UNIVERSITY BELFAST;ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES","10;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ITALIAN ASSOCIATION FOR CANCER RESEARCH;EUROPEAN COMMISSION","7;3","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;COALITION S;EC & ERC - EUROPEAN UNION","7;3;3","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);H2020-EU.1.4.1.1. - DEVELOPING NEW WORLD-CLASS RESEARCH INFRASTRUCTURES (PROGRAMME);H2020-SC1-PHE-CORONAVIRUS-2020 (CALL FOR PROPOSAL);IA - INNOVATION ACTION (FUNDING SCHEME)","2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3106 INDUSTRIAL BIOTECHNOLOGY;3204 IMMUNOLOGY;46 INFORMATION AND COMPUTING SCIENCES;4610 LIBRARY AND INFORMATION STUDIES","8;5;3;2;2;2;1;1;1;1;1","CANCER;BREAST CANCER;BIOTECHNOLOGY;CLINICAL RESEARCH;GENETICS;PREVENTION;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COLO-RECTAL CANCER;DIGESTIVE DISEASES;PATIENT SAFETY;AGING;ATHEROSCLEROSIS;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;HUMAN GENOME","7;4;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE","7;1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.1 PHARMACEUTICALS","4;2;1;1;1;1","BREAST CANCER;COLON AND RECTAL CANCER","4;2","1.4 CANCER PROGRESSION AND METASTASIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;1.1 NORMAL FUNCTIONING;1.2 CANCER INITIATION: ALTERATIONS IN CHROMOSOMES;1.3 CANCER INITIATION: ONCOGENES AND TUMOR SUPPRESSOR GENES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2;2;2;2;1;1;1;1;1","A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;C23 EDUCATION","7;1;1","3 GOOD HEALTH AND WELL BEING;12 RESPONSIBLE CONSUMPTION AND PRODUCTION;9 INDUSTRY, INNOVATION AND INFRASTRUCTURE","3;1;1",69,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;SPRINGER NATURE;KARGER PUBLISHERS;SAGE JOURNALS","35;22;8;3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3101 BIOCHEMISTRY AND CELL BIOLOGY;34 CHEMICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3209 NEUROSCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;3105 GENETICS;4204 MIDWIFERY;40 ENGINEERING;44 HUMAN SOCIETY;4403 DEMOGRAPHY;52 PSYCHOLOGY;3106 INDUSTRIAL BIOTECHNOLOGY;3210 NUTRITION AND DIETETICS","85;25;14;13;12;9;9;6;6;5;5;5;4;4;3;3;2;2;1;1","GENETICS;CANCER;BIOTECHNOLOGY;CLINICAL RESEARCH;NEUROSCIENCES;PREVENTION;BIODEFENSE;BRAIN DISORDERS;EMERGING INFECTIOUS DISEASES;HUMAN GENOME;NEURODEGENERATIVE;VACCINE RELATED;BREAST CANCER;EPILEPSY;LUNG;AGING;BEHAVIORAL AND SOCIAL SCIENCE;LUNG CANCER;BASIC BEHAVIORAL AND SOCIAL SCIENCE;CARDIOVASCULAR","17;12;7;7;7;7;5;5;5;5;5;5;4;4;4;3;3;3;2;2","NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;CANCER;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM;MUSCULOSKELETAL;RESPIRATORY;STROKE","10;9;7;5;5;5;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);5.2 CELLULAR AND GENE THERAPIES","13;7;4;3;1;1;1","BIOMEDICAL;CLINICAL;POPULATION & SOCIETY","19;6;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","22;18;6","BREAST CANCER;MELANOMA;LUNG CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;ORAL CAVITY AND LIP CANCER","6;5;3;1;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SANMARTINO",2021,1248,17.6322115384615,2.97596153846154,0.336025848142165,0.297275641025641,0.337339743589744,0.290865384615385,0.713141025641026,8,580,273,124,49,0.46,0.22,0.1,0.04,16.53,1.07191211482994,0.445512820512821,0.965544871794872,7.37610186092064,0.574542198185101,0.540316509694364,0.459536535495211,0.513571807146278,"MATTEO BASSETTI;PAOLO PELOSI;ITALO PORTO;CHIARA ROBBA;MATTEO LAMBERTINI;AURORA PARODI;SILVIA MORBELLI;ANDREA AMERIO;DANIELE ROBERTO GIACOBBE;LUCA CARMISCIANO;FLAVIO NOBILI;EMANUELE COZZANI;MAŁGORZATA MIKULSKA;MATTEO BAUCKNEHT;MARIA PIA SORMANI;LUCIA DEL MASTRO;GIANLUCA SERAFINI;MATILDE INGLESE;MARIO AMORE;ANDREA AGUGLIA","49;43;41;40;39;38;37;29;29;28;27;26;26;26;26;26;26;25;24;24","AURORA PARODI;EMANUELE COZZANI;PAOLO PELOSI;CHIARA ROBBA;ITALO PORTO;MATTEO BASSETTI;MATTEO LAMBERTINI;SILVIA MORBELLI;ANTONIO DI BIAGIO;MARTINA BURLANDO;ANDREA AMERIO;GIANLUCA SERAFINI;MAURIZIO CUTOLO;FABRIZIO MONTECUCCO;MARIO AMORE;ANDREA AGUGLIA;LUCA CARMISCIANO;ANGELO CAGNACCI;MATTEO PARDINI;EMANUELE GOTELLI","6.33;4.63;3.9;3.74;3.73;3.59;3.31;3.15;3.04;3.03;3;2.89;2.79;2.77;2.6;2.49;2.43;2.35;2.29;2.27","MATTEO BASSETTI;PAOLO PELOSI;ITALO PORTO;CHIARA ROBBA;MATTEO LAMBERTINI;AURORA PARODI;SILVIA MORBELLI;ANDREA AMERIO;DANIELE ROBERTO GIACOBBE;LUCA CARMISCIANO;FLAVIO NOBILI;EMANUELE COZZANI;MAŁGORZATA MIKULSKA;MATTEO BAUCKNEHT;MARIA PIA SORMANI;LUCIA DEL MASTRO;GIANLUCA SERAFINI;MATILDE INGLESE;MARIO AMORE;ANDREA AGUGLIA","49;43;41;40;39;38;37;29;29;28;27;26;26;26;26;26;26;25;24;24","AURORA PARODI;EMANUELE COZZANI;PAOLO PELOSI;CHIARA ROBBA;ITALO PORTO;MATTEO BASSETTI;MATTEO LAMBERTINI;SILVIA MORBELLI;ANTONIO DI BIAGIO;MARTINA BURLANDO;ANDREA AMERIO;GIANLUCA SERAFINI;MAURIZIO CUTOLO;FABRIZIO MONTECUCCO;MARIO AMORE;ANDREA AGUGLIA;LUCA CARMISCIANO;ANGELO CAGNACCI;MATTEO PARDINI;EMANUELE GOTELLI","6.33;4.63;3.9;3.74;3.73;3.59;3.31;3.15;3.04;3.03;3;2.89;2.79;2.77;2.6;2.49;2.43;2.35;2.29;2.27","PAOLO PELOSI;MATTEO BASSETTI;MARIA PIA SORMANI;DANIELE ROBERTO GIACOBBE;IOLE BRUNETTI;LUCA CARMISCIANO;MARCO SALVETTI;CHIARA ROBBA;IRENE SCHIAVETTI;MARIO ALBERTO BATTAGLIA;CINZIA CORDIOLI;FABIO SILVIO TACCONE;MAŁGORZATA MIKULSKA;ANTONIO UCCELLI;ANTONIO VENA;MAURO ODDO;LORENZO BALL;GIANCARLO COMI;MATILDE INGLESE;ÉLIE AZOULAY","2513;2252;1440;1390;1253;1242;1239;1212;1199;1194;1112;934;886;849;833;821;804;799;797;773","PAOLO PELOSI;MATTEO BASSETTI;MARIA PIA SORMANI;DANIELE ROBERTO GIACOBBE;IOLE BRUNETTI;CHIARA ROBBA;MAŁGORZATA MIKULSKA;ANTONIO VENA;MATILDE INGLESE;SILVIA MORBELLI;ANDREA AMERIO;MATTEO LAMBERTINI;LORENZO BALL;ALICE LARONI;CHIARA DENTONE;NICOLÒ PATRONITI;ANTONIO UCCELLI;DENISE BATTAGLINI;LUCIA DEL MASTRO;CATERINA LAPUCCI","2266;2052;1383;1283;1087;988;795;794;710;678;672;667;640;638;637;560;557;536;510;500","PAOLO PELOSI;MATTEO BASSETTI;ITALO PORTO;CHIARA ROBBA;MATTEO LAMBERTINI;AURORA PARODI;SILVIA MORBELLI;ANDREA AMERIO;GIANLUCA SERAFINI;DANIELE ROBERTO GIACOBBE;MATTEO BAUCKNEHT;LUCIA DEL MASTRO;FLAVIO NOBILI;ANDREA AGUGLIA;EMANUELE COZZANI;MARIA PIA SORMANI;MAŁGORZATA MIKULSKA;DENISE BATTAGLINI;MAURIZIO CUTOLO;MATILDE INGLESE","49;41;39;38;36;34;33;28;26;26;26;25;25;24;24;23;23;22;22;21","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;ECONOMICS;MATHEMATICS;SOCIOLOGY;POLITICAL SCIENCE;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;HISTORY;ART;ENVIRONMENTAL SCIENCE;GEOLOGY","1163;330;125;110;107;92;62;53;48;44;35;26;24;15;12;8;4;4;4","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;IMMUNOLOGY;GENETICS;PSYCHIATRY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;CARDIOLOGY;RADIOLOGY;CANCER RESEARCH;NEUROSCIENCE;VIROLOGY;PEDIATRICS;PALEONTOLOGY;DERMATOLOGY;OPTICS","888;263;225;221;190;142;137;128;125;123;121;115;107;85;80;78;75;70;60;60","DISEASE;CANCER;COHORT;POPULATION;CONFIDENCE INTERVAL;GENE;RETROSPECTIVE COHORT STUDY;CHEMOTHERAPY;OUTBREAK;LUNG;TRANSPLANTATION;ADVERSE EFFECT;INCIDENCE (GEOMETRY);PROPORTIONAL HAZARDS MODEL;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;ANTIBODY;MULTIPLE SCLEROSIS;COHORT STUDY;PROSPECTIVE COHORT STUDY","264;251;109;107;99;98;86;70;64;55;54;51;51;51;45;45;44;41;40;40","INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;HAZARD RATIO;2019-20 CORONAVIRUS OUTBREAK;IMMUNOTHERAPY;COLORECTAL CANCER;CLINICAL ENDPOINT;PROSTATE CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DEMENTIA;MUTATION;PARKINSON'S DISEASE;RITUXIMAB;NEURORADIOLOGY;UNIVARIATE ANALYSIS;ALZHEIMER'S DISEASE;CUMULATIVE INCIDENCE;EJECTION FRACTION;METASTASIS;TOLERABILITY","144;76;57;56;38;35;32;27;22;21;19;17;16;15;14;13;13;13;13;13","CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;KRAS;NIVOLUMAB;PROSTATECTOMY;DEMENTIA WITH LEWY BODIES;METASTATIC BREAST CANCER;OXALIPLATIN;ANTHRACYCLINE;TAMOXIFEN;TRASTUZUMAB;GERMLINE MUTATION;HORMONE RECEPTOR;NEOADJUVANT THERAPY;OCRELIZUMAB;SINGLE-NUCLEOTIDE POLYMORPHISM;DIFFUSING CAPACITY;FERTILITY PRESERVATION;HEMATOPOIETIC CELL;RIBAVIRIN","143;13;12;12;11;9;9;9;8;8;8;7;7;7;7;7;6;6;6;6",";HUMANS;FEMALE;MALE;COVID-19;MIDDLE AGED;AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;SARS-COV-2;TREATMENT OUTCOME;BREAST NEOPLASMS;PROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MULTIPLE SCLEROSIS;AGED, 80 AND OVER;PROGNOSIS;ANIMALS;BRAIN","613;602;251;218;180;164;152;148;144;142;91;80;67;55;54;52;49;48;45;37","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CORONAVIRUS DISEASE 2019;CANCER IMMUNOTHERAPY;CORONAVIRUS DISEASE 2019 RESEARCH;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MANAGEMENT OF VALVULAR HEART DISEASE;HEPATOCELLULAR CARCINOMA;NATURAL KILLER CELLS IN IMMUNITY;ASTHMA;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;HEMATOPOIETIC STEM CELL BIOLOGY;MOLECULAR RESEARCH ON BREAST CANCER;PROSTATE CANCER RESEARCH AND TREATMENT","28;27;23;21;20;16;15;15;15;14;14;12;12;11;11;11;10;10;10;10","PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;STROKE (ENGINE);BREAST CANCER;INTERQUARTILE RANGE;CONCOMITANT;REGIMEN;TREATMENT;TRANSCATHETER AORTIC-VALVE REPLACEMENT;BIOMARKERS FOR IMMUNOTHERAPY;NEURORADIOLOGY;UNIVARIATE ANALYSIS;DISCONTINUATION;TOLERABILITY;CUMULATIVE INCIDENCE;DIAGNOSTIC CRITERIA;NEUROIMAGING DATA ANALYSIS;POSITIVE END-EXPIRATORY PRESSURE;METASTATIC COLORECTAL CANCER","68;56;35;26;24;21;20;20;19;18;16;15;15;14;14;13;13;13;13;12","BREAST CANCER;MULTIPLE SCLEROSIS;CANCER PATIENTS;COVID- PANDEMIC;MULTICENTER STUDY;OBSERVATIONAL STUDY;PATIENTS TREATED;LUNG CANCER;COVID- PATIENTS;PROSTATE CANCER;CELL TRANSPLANTATION;CELL CARCINOMA;COLORECTAL CANCER;HEPATOCELLULAR CARCINOMA;ITALIAN SOCIETY;ALZHEIMERS DISEASE;BRAIN INJURY;COHORT STUDY;CRITICALLY ILL;EUROPEAN SOCIETY;HEART FAILURE;INTENSIVE CARE;STEM CELL;PHASE II;RETROSPECTIVE STUDY;URIC ACID;PATIENTS UNDERGOING;TRAUMATIC BRAIN;ACUTE RESPIRATORY;RISK FACTORS","57;35;29;26;22;21;20;18;17;17;16;14;14;14;14;13;13;13;13;13;13;13;13;12;12;12;11;11;10;10","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;HR CI;RESEARCH FUNDING;CONSULTANCY HONORARIA;HONORARIA MEMBERSHIP;BREAST CANCER;COVID- PANDEMIC;COVID- PATIENTS;PATIENTS TREATED;SARS-COV- INFECTION;HAZARD RATIO;RISK FACTORS;MEDIAN AGE;PUBMED SCOPUS;SURVIVAL OS;CONFIDENCE INTERVAL;CORONAVIRUS DISEASE;INTENSIVE CARE;SAN MARTINO;CLINICAL PRACTICE;ADVERSE EVENTS;DISEASE COVID-;CANCER PATIENTS;ITALY SEARCH;MILAN ITALY;STATISTICALLY SIGNIFICANT;PATIENTS UNDERGOING;MEDIAN FOLLOW-UP","224;224;159;144;126;113;106;94;83;75;71;70;65;62;61;59;59;58;56;56;53;52;51;51;48;48;48;47;45;44",687,0.55,10.25,11,2,1,0,2,1,1,1,12,1,1,10,1,2,2,5,7,4,0,0,37.5,37,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,53,3.73,2347.4,5.42,23,0.43,80.25,0,0,10,1,20,0,0,22,0,32,17,0,0,0,0,0,0,50,3,0,47,4,0,2,0,0,0,0,0,0,"Italy;United States;Switzerland;Germany;Japan;United Kingdom","14;8;4;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","50;21;18;6;6;6;4;3;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;PREVENTION;HEMATOLOGY;INFECTIOUS DISEASES;BRAIN DISORDERS;CARDIOVASCULAR;HEART DISEASE;KIDNEY DISEASE;LUNG;NEUROSCIENCES;BREAST CANCER;LYMPHOMA;PEDIATRIC;VACCINE RELATED;CHILDHOOD LEUKEMIA;EMERGING INFECTIOUS DISEASES","45;33;19;15;11;10;8;6;5;5;5;5;5;5;4;4;4;4;3;3","CANCER;CARDIOVASCULAR;INFECTION;RENAL AND UROGENITAL;METABOLIC AND ENDOCRINE;RESPIRATORY;NEUROLOGICAL;STROKE","16;5;4;4;2;2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;7.1 INDIVIDUAL CARE NEEDS;2.4 SURVEILLANCE AND DISTRIBUTION;3.4 VACCINES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;7.3 MANAGEMENT AND DECISION MAKING","32;4;4;2;2;1;1;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BLADDER CANCER;MELANOMA;BLOOD CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;KIDNEY CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;STOMACH CANCER","4;4;4;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","14;1;1;1;1;1",3,1.2e+07,250000,4,16.6666666666667,6.66666666666667,0.333333333333333,14.3333333333333,736380.158928571,1.69477678732658,"OSPEDALE POLICLINICO SAN MARTINO;AMSTERDAM UMC LOCATION VUMC;BARCELONA SUPERCOMPUTING CENTER;BIOBANKING AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE - ERIC;CENTER FOR ADVANCED STUDIES RESEARCH AND DEVELOPMENT IN SARDINIA;CENTRE FOR GENOMIC REGULATION;CONSORTIUM OF EUROPEAN SOCIAL SCIENCE DATA ARCHIVES - ERIC;EMPIRICA - COMMUNICATION AND TECHNOLOGY RESEARCH;ERASMUS MC;EU-OPENSCREEN ERIC;EURO-BIOIMAGING ERIC;EUROPEAN ADVANCED TRANSLATIONAL RESEARCH INFRASTRUCTURE - ERIC;EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK - ERIC;EUROPEAN MOLECULAR BIOLOGY LABORATORY;EUROPEAN UNIVERSITY INSTITUTE;EÖTVÖS LORÁND UNIVERSITY;FINNISH INSTITUTE FOR HEALTH AND WELFARE;FRAUNHOFER SOCIETY;GESUNDHEIT ÖSTERREICH;INFRAFRONTIER","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ITALIAN ASSOCIATION FOR CANCER RESEARCH;EUROPEAN COMMISSION","2;1","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;COALITION S;EC & ERC - EUROPEAN UNION","2;1;1","HORIZON-INFRA-2021-EMERGENCY-01 (CALL FOR PROPOSAL);HORIZON-RIA - HORIZON  RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME);HORIZON.1.3 - RESEARCH INFRASTRUCTURES (PROGRAMME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;46 INFORMATION AND COMPUTING SCIENCES;4604 CYBERSECURITY AND PRIVACY","2;2;1;1;1","CANCER;CLINICAL RESEARCH;PREVENTION;BIODEFENSE;BREAST CANCER;CONTRACEPTION/REPRODUCTION;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;VACCINE RELATED","2;2;2;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE;INFECTION","2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2","BREAST CANCER;LUNG CANCER;OVARIAN CANCER","1;1;1","1.4 CANCER PROGRESSION AND METASTASIS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1","A01 CLINICAL MEDICINE;A05 BIOLOGICAL SCIENCES","2;1","3 GOOD HEALTH AND WELL BEING","1",82,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;ZENODO;SPRINGER NATURE;AMERICAN CHEMICAL SOCIETY;AMERICAN ASSOCIATION FOR CANCER RESEARCH;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","40;22;10;4;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;34 CHEMICAL SCIENCES;4202 EPIDEMIOLOGY;51 PHYSICAL SCIENCES;44 HUMAN SOCIETY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3203 DENTISTRY;3208 MEDICAL PHYSIOLOGY","94;27;22;15;14;13;10;10;6;6;5;4;4;4;4;4;3;2;2;2","CLINICAL RESEARCH;CANCER;GENETICS;RARE DISEASES;NEUROSCIENCES;PREVENTION;BRAIN DISORDERS;MENTAL HEALTH;NEURODEGENERATIVE;BREAST CANCER;HEMATOLOGY;AGING;BIOTECHNOLOGY;LYMPHOMA;OVARIAN CANCER;BIOENGINEERING;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INFECTIOUS DISEASES;SUICIDE","24;22;20;16;13;12;7;7;7;6;6;5;5;5;5;4;4;4;4;4","CANCER;MENTAL HEALTH;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;RESPIRATORY;CARDIOVASCULAR;EYE;INFECTION;ORAL AND GASTROINTESTINAL","17;6;5;5;5;4;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS;6.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","20;7;7;5;4;4;3;2;1;1;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY;HEALTH SERVICES & SYSTEMS","23;18;2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","34;5","BREAST CANCER;OVARIAN CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;KIDNEY CANCER;NON-HODGKIN'S LYMPHOMA","6;5;4;3;3;1;1;1;1","3 GOOD HEALTH AND WELL BEING","5"
"IRCCS_SANMARTINO",2022,1275,18.6854901960784,3.02039215686275,0.33108283562711,0.27921568627451,0.312156862745098,0.243921568627451,0.738039215686275,7,570,252,118,49,0.45,0.2,0.09,0.04,10.43,1.16845659631601,0.450980392156863,0.965490196078431,6.85908852802522,0.574917033861261,0.537128626047915,0.492365424430642,0.500966962127317,"MATTEO LAMBERTINI;MATTEO BASSETTI;AURORA PARODI;CHIARA ROBBA;CARLO TERRONE;LUCIA DEL MASTRO;EMANUELE ANGELUCCI;ANDREA AMERIO;GIUSEPPE FORNARINI;PAOLO PELOSI;ITALO PORTO;SILVIA MORBELLI;MATILDE INGLESE;MARTA PONZANO;DENISE BATTAGLINI;GUGLIELMO MANTICA;LORENZO BALL;DANIELE ROBERTO GIACOBBE;GIANCARLO ICARDI;ALESSIO SIGNORI","48;46;41;36;35;33;31;30;30;26;26;26;25;24;24;23;23;23;22;22","AURORA PARODI;MATTEO LAMBERTINI;MATTEO BASSETTI;EMANUELE COZZANI;CHIARA ROBBA;EMANUELE ANGELUCCI;GIULIA CICCARESE;ANDREA AMERIO;CARLO TERRONE;FRANCESCO DRAGO;CLAUDIA MASSAROTTI;ITALO PORTO;MARTA PONZANO;GUGLIELMO MANTICA;GIANCARLO ICARDI;ASTRID HERZUM;GABRIELE GAGGERO;ALESSANDRO POGGI;MATILDE INGLESE;CARLO ENRICO TRAVERSO","7.05;3.57;3.24;3.13;3.05;2.71;2.49;2.46;2.4;2.22;2.1;2.05;2.04;1.99;1.83;1.81;1.8;1.8;1.79;1.75","MATTEO LAMBERTINI;MATTEO BASSETTI;AURORA PARODI;CHIARA ROBBA;CARLO TERRONE;LUCIA DEL MASTRO;EMANUELE ANGELUCCI;ANDREA AMERIO;GIUSEPPE FORNARINI;PAOLO PELOSI;ITALO PORTO;SILVIA MORBELLI;MATILDE INGLESE;MARTA PONZANO;DENISE BATTAGLINI;GUGLIELMO MANTICA;LORENZO BALL;DANIELE ROBERTO GIACOBBE;GIANCARLO ICARDI;MATTEO BAUCKNEHT","48;46;41;36;35;33;31;30;30;26;26;26;25;24;24;23;23;23;22;22","AURORA PARODI;MATTEO LAMBERTINI;MATTEO BASSETTI;EMANUELE COZZANI;CHIARA ROBBA;EMANUELE ANGELUCCI;GIULIA CICCARESE;ANDREA AMERIO;CARLO TERRONE;FRANCESCO DRAGO;CLAUDIA MASSAROTTI;ITALO PORTO;MARTA PONZANO;GUGLIELMO MANTICA;GIANCARLO ICARDI;ASTRID HERZUM;GABRIELE GAGGERO;ALESSANDRO POGGI;MATILDE INGLESE;CARLO ENRICO TRAVERSO","7.05;3.57;3.24;3.13;3.05;2.71;2.49;2.46;2.4;2.22;2.1;2.05;2.04;1.99;1.83;1.81;1.8;1.8;1.79;1.75","MAURIZIO CUTOLO;GILBERTO FILACI;ALBA GRIFONI;ALESSANDRO SETTE;ALISON TARKE;JENNIFER M. DAN;JOÃO EURICO FONSECA;ANNAMARIA IAGNOCCO;ALEJANDRO BALSA;ALEXANDRE SEPRIANO;ALFONS A DEN BROEDER;ANDREA RUBBERT‐ROTH;ANDREAS KERSCHBAUMER;ANJA STRANGFELD;ANNETTE H M VAN DER HELM–VAN MIL;AXEL FINCKH;CHRISTOPHER J EDWARDS;CĂTĂLIN CODREANU;DANIEL ALETAHA;DÉSIRÉE VAN DER HEIJDE","937;845;833;833;831;792;784;779;777;777;777;777;777;777;777;777;777;777;777;777","MAURIZIO CUTOLO;GILBERTO FILACI;MATTEO BASSETTI;LUCIA DEL MASTRO;PAOLA QUEIROLO;MATTEO LAMBERTINI;EMANUELE ANGELUCCI;DANIELE ROBERTO GIACOBBE;PAOLO PELOSI;LUCA BONI;ANTONIO UCCELLI;FRANCESCO SPAGNOLO;AURORA PARODI;DIEGO FRANCIOTTA;GABRIELE ZOPPOLI;IOLE BRUNETTI;MARIA PIA SORMANI;CHIARA ROBBA;MATILDE INGLESE;LORENZO BALL","920;844;672;645;544;529;422;405;385;359;341;326;311;300;285;270;266;259;235;232","MATTEO LAMBERTINI;MATTEO BASSETTI;AURORA PARODI;CARLO TERRONE;PAOLO PELOSI;LUCIA DEL MASTRO;GIUSEPPE FORNARINI;EMANUELE ANGELUCCI;CHIARA ROBBA;ANDREA AMERIO;MATILDE INGLESE;ITALO PORTO;GUGLIELMO MANTICA;SILVIA MORBELLI;DENISE BATTAGLINI;MATTEO BAUCKNEHT;DANIELE ROBERTO GIACOBBE;DARIO ARNALDI;MAURIZIO CUTOLO;GIANCARLO ICARDI","42;41;38;33;32;31;30;30;30;29;25;25;23;22;22;22;22;19;19;19","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;ECONOMICS;SOCIOLOGY;MATHEMATICS;POLITICAL SCIENCE;PHILOSOPHY;MATERIALS SCIENCE;GEOGRAPHY;BUSINESS;GEOLOGY;HISTORY;ART;ENVIRONMENTAL SCIENCE","1206;343;106;103;101;78;67;42;42;33;30;21;15;11;9;4;4;3;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GENETICS;GASTROENTEROLOGY;BIOCHEMISTRY;PSYCHIATRY;CARDIOLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;PEDIATRICS;CANCER RESEARCH;NEUROSCIENCE;PALEONTOLOGY;VIROLOGY;DERMATOLOGY;OPTICS","944;283;253;241;198;159;156;137;133;127;113;91;86;85;79;69;63;63;62;62","CANCER;DISEASE;POPULATION;COHORT;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;ADVERSE EFFECT;PROPORTIONAL HAZARDS MODEL;RANDOMIZED CONTROLLED TRIAL;ANTIBODY;INCIDENCE (GEOMETRY);TRANSPLANTATION;IMMUNE SYSTEM;PROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;VACCINATION;LOGISTIC REGRESSION","311;247;149;124;119;107;94;73;70;62;61;61;59;56;55;50;50;48;48;47","INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;IMMUNOTHERAPY;HAZARD RATIO;CLINICAL ENDPOINT;COLORECTAL CANCER;2019-20 CORONAVIRUS OUTBREAK;PROSTATE CANCER;CYCLOPHOSPHAMIDE;PLACEBO;MUTATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;GENE EXPRESSION;DEMENTIA;NEURORADIOLOGY;BLADDER CANCER;METASTASIS;CANCER CELL;CUMULATIVE INCIDENCE;PERCUTANEOUS CORONARY INTERVENTION;PHENOTYPE","135;99;58;53;48;42;32;32;29;27;20;19;18;17;17;16;16;15;15;15;15","CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;PEMBROLIZUMAB;METASTATIC BREAST CANCER;FLUDARABINE;KRAS;NEOADJUVANT THERAPY;TRASTUZUMAB;CETUXIMAB;FERTILITY PRESERVATION;IPILIMUMAB;OXALIPLATIN;PROSTATECTOMY;TAXANE;TRANSCRIPTOME;AXITINIB;CARBOPLATIN;CYSTECTOMY;GERMLINE MUTATION;OCRELIZUMAB;TRIPLE-NEGATIVE BREAST CANCER","133;24;18;13;10;10;10;10;9;9;8;8;8;8;8;7;7;7;7;7;7","HUMANS;;COVID-19;FEMALE;RETROSPECTIVE STUDIES;MALE;AGED;ADULT;TREATMENT OUTCOME;BREAST NEOPLASMS;SARS-COV-2;PROSPECTIVE STUDIES;MIDDLE AGED;ITALY;MULTIPLE SCLEROSIS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASMS;STROKE;ANIMALS;BRAIN","665;588;180;148;140;124;84;79;78;72;69;67;64;61;55;47;41;38;35;35","CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;RENAL CELL CARCINOMA;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;HEMATOPOIETIC STEM CELL BIOLOGY;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CORONAVIRUS DISEASE 2019;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;CANCER IMMUNOTHERAPY;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;FERTILITY PRESERVATION IN CANCER PATIENTS;IMPACT OF COVID-19 ON MENTAL HEALTH;PROSTATE CANCER RESEARCH AND TREATMENT;ACUTE MYELOID LEUKEMIA;BRAIN-COMPUTER INTERFACES IN NEUROSCIENCE AND MEDICINE;MOLECULAR MECHANISMS OF AMYLOIDOSIS;NATURAL KILLER CELLS IN IMMUNITY","31;23;22;19;18;18;17;17;17;16;15;14;14;12;12;12;10;10;10;10","CLINICAL ENDPOINT;PANDEMIC;TREATMENT;STROKE (ENGINE);2019-20 CORONAVIRUS OUTBREAK;BREAST CANCER;NEOADJUVANT THERAPY;REGIMEN;VACCINES;INTERQUARTILE RANGE;CONCOMITANT;METASTATIC COLORECTAL CANCER;HEMATOPOIETIC CELL TRANSPLANTATION;NEURORADIOLOGY;CUMULATIVE INCIDENCE;BIOMARKERS FOR IMMUNOTHERAPY;DISCONTINUATION;IMMUNE CHECKPOINT BLOCKADE;TUMOR MICROENVIRONMENT;CARDIAC IMAGING","49;41;36;29;26;25;22;20;19;18;17;17;16;16;15;14;14;14;14;13","BREAST CANCER;MULTIPLE SCLEROSIS;CANCER PATIENTS;CELL CARCINOMA;PROSTATE CANCER;COHORT STUDY;RENAL CELL;COLORECTAL CANCER;RETROSPECTIVE STUDY;CELL TRANSPLANTATION;CLINICAL PRACTICE;MULTICENTER STUDY;PATIENTS TREATED;ITALIAN SOCIETY;LUNG CANCER;COVID- PANDEMIC;METASTATIC RENAL;PATIENTS UNDERGOING;SARS-COV- INFECTION;STEM CELL;INTENSIVE CARE;METASTATIC COLORECTAL;ABSTRACT P--;CLINICAL TRIAL;OBSERVATIONAL STUDY;PHASE III;PILOT STUDY;BLADDER CANCER;BLASTIC PLASMACYTOID;CELL NEOPLASM","64;35;29;26;25;21;18;17;17;16;16;15;15;14;14;13;13;13;13;13;12;12;11;11;11;11;11;10;10;10","BREAST CANCER;HR CI;PATIENTS TREATED;ADVERSE EVENTS;MEDIAN AGE;RISK FACTORS;STATISTICALLY SIGNIFICANT;SURVIVAL OS;CONFIDENCE INTERVAL;COVID- PANDEMIC;SARS-COV- INFECTION;MEDIAN FOLLOW-UP;PATIENTS RECEIVING;PRIMARY ENDPOINT;CLINICAL PRACTICE;LOGISTIC REGRESSION;PATIENTS UNDERGOING;HAZARD RATIO;CANCER PATIENTS;ODDS RATIO;STEM CELL;CELL CARCINOMA;RETROSPECTIVE STUDY;CLINICAL OUTCOMES;CLINICAL TRIALS;INTENSIVE CARE;INTERVAL CI;MULTIPLE SCLEROSIS;MULTIVARIATE ANALYSIS;PROGRESSION-FREE SURVIVAL","125;89;88;77;74;67;61;59;58;57;56;53;52;50;49;48;47;44;41;41;39;36;36;35;35;35;35;35;35;35",652,0.51,11,12,1,1,0,3,1,1,1,15,1,1,12,1,1,2,6,9,4,0,0,20,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,47,3.7,3717.74,3.97,25,0.53,109.21,0,0,6,1,16,0,1,22,1,31,16,0,0,0,0,0,0,45,2,0,44,0,1,2,0,0,0,0,0,0,"Italy;United States;Belgium;Brazil;Germany;Netherlands;Switzerland;United Kingdom","18;14;3;2;2;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;52 PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4206 PUBLIC HEALTH;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4207 SPORTS SCIENCE AND EXERCISE","44;21;18;10;7;5;3;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;LUNG;CARDIOVASCULAR;BRAIN DISORDERS;DIGESTIVE DISEASES;NEUROSCIENCES;PREVENTION;AUTOIMMUNE DISEASE;RARE DISEASES;AGING;HEART DISEASE;LUNG CANCER;NEURODEGENERATIVE;BREAST CANCER;COLO-RECTAL CANCER;BEHAVIORAL AND SOCIAL SCIENCE;DENTAL/ORAL AND CRANIOFACIAL DISEASE","46;29;20;15;11;8;7;7;7;7;6;6;5;5;5;5;4;4;3;3","CANCER;CARDIOVASCULAR;NEUROLOGICAL;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY;STROKE;INFECTION;MENTAL HEALTH;REPRODUCTIVE HEALTH AND CHILDBIRTH","19;7;4;3;3;2;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;6.4 SURGERY;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES;8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)","25;4;3;2;2;1;1;1;1;1;1;1","LUNG CANCER;BREAST CANCER;COLON AND RECTAL CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;BRAIN TUMOR;HEAD AND NECK CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;SARCOMA;STOMACH CANCER","7;4;4;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.2 SURVEILLANCE","14;4;2;2;1;1;1;1",1,5980347,498362.25,6,12,7,1,0,586539.283928571,2.17376744394715,"ANDALUSIAN SCHOOL OF PUBLIC HEALTH;CENTRAL CLINICAL HOSPITAL;CLEVELAND CLINIC;EUROPEAN SOCIETY OF ANAESTHESIOLOGY;HOSPITAL UNIVERSITARIO DE LA PRINCESA;INSTITUT MIHAJLO PUPIN;INSTITUTE OF RESEARCH AND INNOVATION PARC TAULI;LEIPZIG UNIVERSITY;MADRID HEALTH SERVICE;OSPEDALE POLICLINICO SAN MARTINO;TU DRESDEN;UNIVERSITY OF GENOA","1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","HORIZON-HLTH-2021-DISEASE-04 (CALL FOR PROPOSAL);HORIZON-RIA - HORIZON  RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME);HORIZON.2.1 - HEALTH (PROGRAMME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1","ASSISTIVE TECHNOLOGY;BIOENGINEERING;CLINICAL RESEARCH;LUNG;PATIENT SAFETY","1;1;1;1;1","GENERIC HEALTH RELEVANCE;RESPIRATORY","1;1",NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,61,"FRONTIERS;ZENODO;TAYLOR & FRANCIS GROUP;PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;KARGER PUBLISHERS","43;10;3;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;52 PSYCHOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;4207 SPORTS SCIENCE AND EXERCISE;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;34 CHEMICAL SCIENCES;5202 BIOLOGICAL PSYCHOLOGY;3105 GENETICS;3207 MEDICAL MICROBIOLOGY;40 ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4003 BIOMEDICAL ENGINEERING;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY","93;28;20;12;10;8;6;6;5;5;4;4;4;3;3;3;3;2;2;1","CLINICAL RESEARCH;PREVENTION;CANCER;NEUROSCIENCES;RARE DISEASES;PATIENT SAFETY;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AUTOIMMUNE DISEASE;PEDIATRIC;INFECTIOUS DISEASES;GENETICS;NEURODEGENERATIVE;AGING;BEHAVIORAL AND SOCIAL SCIENCE;DIABETES;HEMATOLOGY;LYMPHOMA;EMERGING INFECTIOUS DISEASES;IMMUNIZATION","39;20;18;15;15;14;11;10;8;8;7;6;6;5;5;5;5;5;4;4","NEUROLOGICAL;CANCER;INFECTION;METABOLIC AND ENDOCRINE;CARDIOVASCULAR;MENTAL HEALTH;MUSCULOSKELETAL;RESPIRATORY;SKIN;EAR;REPRODUCTIVE HEALTH AND CHILDBIRTH","11;10;5;5;2;2;2;2;2;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.7 PHYSICAL;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;3.4 VACCINES;6.4 SURGERY;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);5.2 CELLULAR AND GENE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING","10;6;6;5;3;3;3;2;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","33;17;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","31;11;4","NOT SITE-SPECIFIC CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;HODGKIN'S DISEASE;BREAST CANCER;ENDOMETRIAL CANCER;KIDNEY CANCER;NEUROBLASTOMA;OVARIAN CANCER;PROSTATE CANCER","6;5;4;2;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING;7 AFFORDABLE AND CLEAN ENERGY;8 DECENT WORK AND ECONOMIC GROWTH","3;1;1"
"IRCCS_SANMARTINO",2023,1328,19.6686746987952,2.90888554216867,0.343774268703081,0.239457831325301,0.268072289156627,0.213855421686747,0.724397590361446,8,621,280,84,76,0.47,0.21,0.06,0.06,4.31,0.984238649955231,0.503012048192771,0.980421686746988,6.40037272868464,0.562942988390695,0.510994247591817,0.457302648719062,0.487096876085789,"GIUSEPPE FORNARINI;MATTEO LAMBERTINI;MATTEO BASSETTI;CARLO TERRONE;CHIARA ROBBA;ROBERTO M. LEMOLI;LUCIA DEL MASTRO;ITALO PORTO;STEFANO TAPPERO;PAOLO PELOSI;UGO DE GIORGI;SEBASTIANO BUTI;ALBERTO BRIGANTI;FELIX K.‐H. CHUN;MAURIZIO CUTOLO;FRED SAAD;DANIELE ROBERTO GIACOBBE;ANTONIO VENA;SILVIA MORBELLI;AURORA PARODI","42;41;39;38;36;33;33;30;29;27;27;26;26;24;24;24;24;24;24;24","ROCCO VERGALLO;MATTEO LAMBERTINI;CHIARA ROBBA;PAOLO PELOSI;AURORA PARODI;MATTEO BASSETTI;MAURIZIO CUTOLO;ANTONIO DI BIAGIO;DANIELE ROBERTO GIACOBBE;EDOARDO G. GIANNINI;CARLO TERRONE;GIUSEPPE FORNARINI;VANESSA SMITH;ITALO PORTO;FRANCESCA VIAZZI;EMANUELE COZZANI;PASQUALE ESPOSITO;EMANUELE ANGELUCCI;ELISA PELOSIN;LUCIA DEL MASTRO","4.29;3.63;3.43;3.1;2.87;2.81;2.54;2.35;2.22;2.17;2.09;2.08;2.02;2.01;1.94;1.89;1.86;1.86;1.85;1.85","GIUSEPPE FORNARINI;MATTEO LAMBERTINI;MATTEO BASSETTI;CARLO TERRONE;CHIARA ROBBA;ROBERTO M. LEMOLI;LUCIA DEL MASTRO;ITALO PORTO;STEFANO TAPPERO;PAOLO PELOSI;MAURIZIO CUTOLO;DANIELE ROBERTO GIACOBBE;ANTONIO VENA;SILVIA MORBELLI;AURORA PARODI;FEDERICA GRILLO;FRANCESCO SPAGNOLO;FABIO GUOLO;MAŁGORZATA MIKULSKA;MATTEO BAUCKNEHT","42;41;39;38;36;33;33;30;29;27;24;24;24;24;24;23;23;22;22;22","ROCCO VERGALLO;MATTEO LAMBERTINI;CHIARA ROBBA;PAOLO PELOSI;AURORA PARODI;MATTEO BASSETTI;MAURIZIO CUTOLO;ANTONIO DI BIAGIO;DANIELE ROBERTO GIACOBBE;EDOARDO G. GIANNINI;CARLO TERRONE;GIUSEPPE FORNARINI;ITALO PORTO;FRANCESCA VIAZZI;EMANUELE COZZANI;PASQUALE ESPOSITO;EMANUELE ANGELUCCI;ELISA PELOSIN;LUCIA DEL MASTRO;GIANNI TESTINO","4.29;3.63;3.43;3.1;2.87;2.81;2.54;2.35;2.22;2.17;2.09;2.08;2.01;1.94;1.89;1.86;1.86;1.85;1.85;1.83","MATTEO BASSETTI;MAŁGORZATA MIKULSKA;DANIELE ROBERTO GIACOBBE;LUCIA DEL MASTRO;ANTONIO VENA;GIUSEPPE FORNARINI;JAN J. DE WAELE;ALEXIS TABAH;PAOLO PELOSI;ANNE LEDTISCHKE;HAIBO QIU;MACKENZIE FINNIS;YOSHIRO HAYASHI;CHIARA ROBBA;SARA LONARDI;UGO DE GIORGI;BIANCA BRUZZONE;VALENTINA GUARNERI;MURAT AKOVA;CARMEN DI GRAZIA","691;328;319;311;295;262;246;243;219;218;218;218;218;206;205;201;168;168;167;163","MATTEO BASSETTI;DANIELE ROBERTO GIACOBBE;LUCIA DEL MASTRO;MAŁGORZATA MIKULSKA;ANTONIO VENA;GIUSEPPE FORNARINI;PAOLO PELOSI;CHIARA ROBBA;BIANCA BRUZZONE;CARMEN DI GRAZIA;ROBERTO M. LEMOLI;ITALO PORTO;MATTEO LAMBERTINI;CHIARA DENTONE;ANNA MARIA RAIOLA;CHIARA GHIGGI;EMANUELE ANGELUCCI;FEDERICA MAGNÈ;CHIARA SEPULCRI;LUCA BONI","672;319;311;308;280;262;186;173;168;163;155;153;148;142;140;138;137;136;135;134","GIUSEPPE FORNARINI;MATTEO LAMBERTINI;MATTEO BASSETTI;CARLO TERRONE;LUCIA DEL MASTRO;CHIARA ROBBA;ITALO PORTO;PAOLO PELOSI;ROBERTO M. LEMOLI;DANIELE ROBERTO GIACOBBE;AURORA PARODI;FRANCESCO SPAGNOLO;SILVIA MORBELLI;LUCA BONI;ANTONIO VENA;STEFANO TAPPERO;CARLO GENOVA;MAURIZIO CUTOLO;MAŁGORZATA MIKULSKA;FEDERICA GRILLO","44;39;36;35;32;32;30;30;25;24;23;23;22;22;22;22;21;21;21;20","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;PHYSICS;ENGINEERING;ECONOMICS;SOCIOLOGY;MATHEMATICS;POLITICAL SCIENCE;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOLOGY;ART;GEOGRAPHY;HISTORY;ENVIRONMENTAL SCIENCE","1223;385;114;108;104;102;59;44;33;32;31;27;24;15;7;5;5;4;3","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;GENETICS;IMMUNOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PSYCHIATRY;CARDIOLOGY;CANCER RESEARCH;RADIOLOGY;INTENSIVE CARE MEDICINE;PEDIATRICS;PALEONTOLOGY;NEUROSCIENCE;DERMATOLOGY;OPTICS;NURSING","971;303;292;226;175;175;135;131;130;121;111;108;107;101;80;79;71;60;55;53","CANCER;DISEASE;GENE;POPULATION;CHEMOTHERAPY;COHORT;CONFIDENCE INTERVAL;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;PROPORTIONAL HAZARDS MODEL;TRANSPLANTATION;IMMUNE SYSTEM;OBSERVATIONAL STUDY;MYOCARDIAL INFARCTION;PREGNANCY;ANTIBODY;INCIDENCE (GEOMETRY);ODDS RATIO;PROSPECTIVE COHORT STUDY;VACCINATION","338;218;128;120;112;105;102;83;79;67;62;62;52;51;50;45;45;42;42;39;39;39","BREAST CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;HAZARD RATIO;IMMUNOTHERAPY;COLORECTAL CANCER;PROSTATE CANCER;GENE EXPRESSION;MUTATION;2019-20 CORONAVIRUS OUTBREAK;CYCLOPHOSPHAMIDE;PROGRESSION-FREE SURVIVAL;DEMENTIA;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PERCUTANEOUS CORONARY INTERVENTION;TOLERABILITY;PARKINSON'S DISEASE;PHENOTYPE;PLACEBO;UNIVARIATE ANALYSIS","104;72;63;62;61;51;37;28;25;24;24;24;21;21;19;19;17;17;17;17","CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;PEMBROLIZUMAB;METASTATIC BREAST CANCER;ANTIRETROVIRAL THERAPY;DNA METHYLATION;KRAS;PROSTATECTOMY;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;ALPHA (FINANCE);ANDROGEN DEPRIVATION THERAPY;CARBOPLATIN;FLUDARABINE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MAMMOGRAPHY;MASTECTOMY;NEOADJUVANT THERAPY;SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS;TAMOXIFEN;TRANSCRIPTOME","72;32;19;15;14;13;13;13;11;9;8;8;8;8;8;8;8;8;8;8;8","HUMANS;;RETROSPECTIVE STUDIES;FEMALE;MALE;COVID-19;ADULT;TREATMENT OUTCOME;AGED;ITALY;PROSPECTIVE STUDIES;MIDDLE AGED;BREAST NEOPLASMS;ANIMALS;NEOPLASM RECURRENCE, LOCAL;BRAIN;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;SARS-COV-2;PROGNOSIS;STROKE","666;626;170;134;128;94;90;79;73;68;68;60;54;44;44;42;40;40;37;34","RENAL CELL CARCINOMA;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CANCER IMMUNOTHERAPY;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;CORONAVIRUS DISEASE 2019;CORONAVIRUS DISEASE 2019 RESEARCH;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;MOLECULAR RESEARCH ON BREAST CANCER;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;LYMPHOID NEOPLASMS;ASTHMA;HEMATOPOIETIC STEM CELL BIOLOGY;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PROSTATE CANCER RESEARCH AND TREATMENT","27;24;22;22;21;19;16;15;15;14;14;13;12;12;12;12;11;11;11;11","CLINICAL ENDPOINT;TREATMENT;BREAST CANCER;PANDEMIC;DISCONTINUATION;PROGRESSION-FREE SURVIVAL;STROKE (ENGINE);2019-20 CORONAVIRUS OUTBREAK;REGIMEN;INTERQUARTILE RANGE;MELANOMA;TOLERABILITY;CARDIAC IMAGING;METASTATIC PROSTATE CANCER;UNIVARIATE ANALYSIS;BIOMARKERS FOR IMMUNOTHERAPY;IMMUNE CHECKPOINT BLOCKADE;NEOADJUVANT THERAPY;RENAL CELL CARCINOMA;TUMOR MICROENVIRONMENT","69;44;32;31;28;27;25;22;21;20;20;19;18;18;18;17;16;16;16;16","BREAST CANCER;CELL CARCINOMA;PROSTATE CANCER;CANCER PATIENTS;RENAL CELL;MULTIPLE SCLEROSIS;COHORT STUDY;OBSERVATIONAL STUDY;PHASE II;CELL TRANSPLANTATION;COLORECTAL CANCER;METASTATIC RENAL;MYELOID LEUKEMIA;PATIENTS UNDERGOING;RETROSPECTIVE STUDY;ALZHEIMERS DISEASE;STEM CELL;ACUTE MYELOID;IMMUNE CHECKPOINT;ITALIAN ASSOCIATION;MULTIPLE MYELOMA;PATIENTS PTS;PATIENTS TREATED;HEPATOCELLULAR CARCINOMA;PROSPECTIVE OBSERVATIONAL;COVID- PANDEMIC;SQUAMOUS CELL;BRAIN INJURY;CHECKPOINT INHIBITORS;LUNG CANCER","74;41;29;28;27;22;21;19;19;17;17;17;16;16;16;15;15;14;14;14;14;14;14;13;13;12;12;11;11;11","HR CI;BREAST CANCER;PATIENTS TREATED;PUBMED SCOPUS;MEDIAN AGE;RISK FACTORS;ADVERSE EVENTS;CLINICAL PRACTICE;PRIMARY ENDPOINT;MONTHS CI;SURVIVAL OS;MEDIAN FOLLOW-UP;PATIENTS RECEIVING;CROSSREF PUBMED;PROGRESSION-FREE SURVIVAL;CLINICAL TRIALS;CONFIDENCE INTERVAL;ADULT PATIENTS;HAZARD RATIO;STEM CELL;PATIENTS RECEIVED;STATISTICALLY SIGNIFICANT;CELL LINES;CLINICAL OUTCOMES;SIGNIFICANT DIFFERENCES;SURVIVAL PFS;DE NOVO;RETROSPECTIVE STUDY;CELL TRANSPLANTATION;INTERVAL CI","123;118;93;83;82;77;68;68;68;65;63;61;61;54;51;48;48;47;47;47;45;44;41;40;40;40;39;39;38;38",602,0.45,9.86,11,1,2,0,2,0,1,1,13,1,1,11,1,1,2,5,8,5,0,0,9,9,2,0,0,3,0,0,0,0,0,0,0,0,2,0,1,0,3,0.23,2.33333333333333,1,2,2,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"DECUZZI PAOLO;PRIMAVERA ROSITA;THAKOR AVNESH S;DE PASCALE ANGELO;DEPASCALE ANGELO;POGGI ALESSANDRO","2;2;2;1;1;1","IRCCS OSPEDALE POLICLINICO SAN MARTINO;FONDAZIONE ST ITALIANO TECNOLOGIA;UNIV LELAND STANFORD JUNIOR","3;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;3211 ONCOLOGY AND CARCINOGENESIS;4003 BIOMEDICAL ENGINEERING","2;2;1;1","BIOENGINEERING;BIOTECHNOLOGY;CANCER;DIABETES","1;1;1;1",NA,NA,"A61K;A61K38/28;A61K47/54;A61K47/62;A61K47/68;A61K47/69;A61K9/14;A61P3/10;A61P35/00","1;1;1;1;1;1;1;1;1","A61K38/28;A61K47/54;A61K47/62;A61K47/6927;A61K9/0021;A61K9/5031;A61P3/10;A61K47/6803;A61K47/6849;A61P35/00","2;2;2;2;2;2;2;1;1;1",28,3.36,11981.5,2.59,7,0.25,48.36,0,0,7,1,5,0,0,15,0,19,9,0,0,0,0,0,0,22,6,0,28,0,0,0,0,0,0,0,0,0,"Italy;United States;Netherlands;Belgium;France","13;6;5;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","26;13;9;3;3;3;3;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;NEUROSCIENCES;BRAIN DISORDERS;BREAST CANCER;NEURODEGENERATIVE;PREVENTION;RARE DISEASES;AGING;AUTOIMMUNE DISEASE;GENETICS;LUNG;PATIENT SAFETY;BIOMEDICAL IMAGING;HEMATOLOGY;LUNG CANCER;UTERINE CANCER;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING","28;19;13;8;6;5;5;5;5;4;4;4;4;4;3;3;3;3;2;2","CANCER;NEUROLOGICAL;SKIN;CARDIOVASCULAR;STROKE","12;5;2;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","15;3;3;2;1;1;1;1;1;1","BREAST CANCER;ENDOMETRIAL CANCER;LUNG CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;MELANOMA;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER","6;3;3;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;3.3 CHEMOPREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","9;2;1;1;1",1,0,0,2,1,1,0,1,530747.800595238,2.50213001073323,"OSPEDALE POLICLINICO SAN MARTINO","1","ITALIAN ASSOCIATION FOR CANCER RESEARCH","1","ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","1",NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","BRAIN CANCER;BRAIN DISORDERS;CANCER;GENE THERAPY;GENETICS;IMMUNIZATION;NEUROSCIENCES;ORPHAN DRUG;RARE DISEASES;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION","1;1","5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES","1;1","BRAIN TUMOR","1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","1","A01 CLINICAL MEDICINE","1",NA,NA,62,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;ZENODO;AMERICAN CHEMICAL SOCIETY;TAYLOR & FRANCIS GROUP;KARGER PUBLISHERS;SPRINGER NATURE","34;17;4;3;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3207 MEDICAL MICROBIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;51 PHYSICAL SCIENCES;52 PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;44 HUMAN SOCIETY;4608 HUMAN-CENTRED COMPUTING;3212 OPHTHALMOLOGY AND OPTOMETRY;37 EARTH SCIENCES;40 ENGINEERING;47 LANGUAGE, COMMUNICATION AND CULTURE;49 MATHEMATICAL SCIENCES","84;26;14;9;6;6;6;5;4;4;4;3;3;3;3;2;2;2;2;2","CLINICAL RESEARCH;CANCER;BRAIN DISORDERS;PREVENTION;NEUROSCIENCES;LUNG;NEURODEGENERATIVE;AGING;INFECTIOUS DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;BIOTECHNOLOGY;EMERGING INFECTIOUS DISEASES;PNEUMONIA & INFLUENZA;RARE DISEASES;REHABILITATION;VACCINE RELATED;BIODEFENSE;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES","25;14;12;10;9;7;7;6;6;5;4;4;4;4;4;4;4;3;3;3","NEUROLOGICAL;CANCER;INFECTION;CARDIOVASCULAR;MENTAL HEALTH;MUSCULOSKELETAL;INJURIES AND ACCIDENTS;RENAL AND UROGENITAL","10;6;6;3;2;2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.4 VACCINES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS;2.4 SURVEILLANCE AND DISTRIBUTION;5.1 PHARMACEUTICALS;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.3 MANAGEMENT AND DECISION MAKING","9;3;3;3;3;3;2;2;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY;HEALTH SERVICES & SYSTEMS","19;9;2;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE;HEALTH SERVICES RESEARCH","29;10;7;1","BREAST CANCER;LUNG CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;KIDNEY CANCER;LIVER CANCER","3;3;3;3;3;2;2;1;1","3 GOOD HEALTH AND WELL BEING;2 ZERO HUNGER","6;1"
"IRCCS_SANMARTINO",2024,1133,19.5428067078553,2.77228596646072,0.360713148678765,0.249779346866726,0.285966460723742,0.161518093556929,0.620476610767873,7,583,199,63,51,0.51,0.18,0.06,0.05,1.28,1.34002795383291,0.455428067078552,0.98676081200353,5.27356218006625,0.557759716770605,0.507814854873313,0.473852319338237,0.466358427027321,"MATTEO LAMBERTINI;MATTEO BASSETTI;GIUSEPPE FORNARINI;LUCIA DEL MASTRO;CHIARA ROBBA;FRANCESCA VIAZZI;ALESSIO SIGNORI;ITALO PORTO;MATTEO BAUCKNEHT;AURORA PARODI;DENISE BATTAGLINI;ANTONIO DI BIAGIO;SILVIA MORBELLI;ROCCO VERGALLO;PIETRO AMERI;EVA BLONDEAUX;SEBASTIANO BUTI;DIEGO FERONE;MAŁGORZATA MIKULSKA;CARLO TERRONE","40;35;35;34;30;28;25;25;24;24;24;23;23;22;21;20;19;19;18;18","ROCCO VERGALLO;MATTEO BASSETTI;AURORA PARODI;CHIARA ROBBA;FRANCESCA VIAZZI;DANIELA PEDICINO;MATTEO LAMBERTINI;DENISE BATTAGLINI;MATTEO BAUCKNEHT;MATTEO FORMICA;LUCIA DEL MASTRO;EMANUELE ANGELUCCI;LEONARDA GALIUTO;FEDERICO CARBONE;EMANUELE COZZANI;GIUSEPPE FORNARINI;DANIELE ROBERTO GIACOBBE;GIANCARLO ICARDI;SILVIA MORBELLI;ALBERTO IZZOTTI","8.89;3.54;2.88;2.65;2.56;2.5;2.45;2.41;2.25;2.12;2.12;2.1;2;1.89;1.88;1.84;1.78;1.75;1.74;1.72","MATTEO LAMBERTINI;MATTEO BASSETTI;GIUSEPPE FORNARINI;LUCIA DEL MASTRO;CHIARA ROBBA;FRANCESCA VIAZZI;ITALO PORTO;MATTEO BAUCKNEHT;AURORA PARODI;DENISE BATTAGLINI;ANTONIO DI BIAGIO;SILVIA MORBELLI;ROCCO VERGALLO;PIETRO AMERI;EVA BLONDEAUX;DIEGO FERONE;MAŁGORZATA MIKULSKA;CARLO TERRONE;MARTINA BURLANDO;FABRIZIO MONTECUCCO","40;35;35;34;30;28;25;24;24;24;23;23;22;21;20;19;18;18;18;17","ROCCO VERGALLO;MATTEO BASSETTI;AURORA PARODI;CHIARA ROBBA;FRANCESCA VIAZZI;MATTEO LAMBERTINI;DENISE BATTAGLINI;MATTEO BAUCKNEHT;MATTEO FORMICA;LUCIA DEL MASTRO;EMANUELE ANGELUCCI;FEDERICO CARBONE;EMANUELE COZZANI;GIUSEPPE FORNARINI;DANIELE ROBERTO GIACOBBE;GIANCARLO ICARDI;SILVIA MORBELLI;ALBERTO IZZOTTI;PIETRO AMERI;DIEGO FERONE","8.89;3.54;2.88;2.65;2.56;2.45;2.41;2.25;2.12;2.12;2.1;1.89;1.88;1.84;1.78;1.75;1.74;1.72;1.71;1.69","GIUSEPPE FORNARINI;ALEXANDRA DRAKAKI;AUDE FLÉCHON;BEGOÑA P. VALDERRAMA;BLANCA HOMET MORENO;CHRISTOF VULSTEKE;DANIEL CASTELLANO;EIJI KIKUCHI;GOPA IYER;IGNACIO DURÁN;JEAN H. HOFFMAN-CENSITS;JENS BEDKE;JIAN‐RI LI;MAHMUT GÜMÜŞ;MICHIEL S. VAN DER HEIJDEN;NATALIYA MAR;SANG JOON SHIN;SE HOON PARK;SEEMA RAO GORLA;SHILPA GUPTA","188;156;156;156;156;156;156;156;156;156;156;156;156;156;156;156;156;156;156;156","GIUSEPPE FORNARINI;MATTEO LAMBERTINI;FRANCESCO SPAGNOLO;DIEGO FERONE;FRANCESCA VIAZZI;CHIARA ROBBA;MARCO CANEPA;PIETRO AMERI;PASQUALE ESPOSITO;SILVIA MORBELLI;ANTONIO VENA;FEDERICO MASSA;MARTINA BURLANDO;FEDERICO CARBONE;FLAVIO NOBILI;GUGLIELMO MANTICA;LUCA LIBERALE;DENISE BATTAGLINI;FABRIZIO MONTECUCCO;SIMONE FERRERO","188;77;61;59;54;52;38;38;36;36;35;33;33;31;30;30;28;27;27;27","MATTEO LAMBERTINI;GIUSEPPE FORNARINI;LUCIA DEL MASTRO;MATTEO BASSETTI;CHIARA ROBBA;FRANCESCA VIAZZI;AURORA PARODI;ITALO PORTO;DENISE BATTAGLINI;ROCCO VERGALLO;MATTEO BAUCKNEHT;EVA BLONDEAUX;PIETRO AMERI;DIEGO FERONE;ANTONIO DI BIAGIO;MARTINA BURLANDO;MAŁGORZATA MIKULSKA;FEDERICO CARBONE;ANGELO SCHENONE;CARLO TERRONE","40;35;32;32;28;26;24;23;23;22;22;20;19;18;18;18;18;17;16;16","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;PSYCHOLOGY;PHYSICS;ENGINEERING;MATHEMATICS;SOCIOLOGY;POLITICAL SCIENCE;MATERIALS SCIENCE;ECONOMICS;PHILOSOPHY;BUSINESS;HISTORY;GEOGRAPHY;GEOLOGY;ART;ENVIRONMENTAL SCIENCE","1051;292;117;111;91;82;65;42;37;33;31;29;20;10;8;7;7;6;4","INTERNAL MEDICINE;ONCOLOGY;SURGERY;PATHOLOGY;GENETICS;INTENSIVE CARE MEDICINE;IMMUNOLOGY;RADIOLOGY;BIOCHEMISTRY;CARDIOLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;CANCER RESEARCH;GASTROENTEROLOGY;NEUROSCIENCE;DERMATOLOGY;PEDIATRICS;GYNECOLOGY;ANESTHESIA;PALEONTOLOGY","769;212;209;177;135;127;122;109;108;108;94;90;70;69;67;59;58;56;51;51","CANCER;DISEASE;GENE;COHORT;CHEMOTHERAPY;POPULATION;RETROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;CLINICAL TRIAL;OBSERVATIONAL STUDY;RECEPTOR;ALTERNATIVE MEDICINE;TRANSPLANTATION;HORMONE;PROSPECTIVE COHORT STUDY;ADVERSE EFFECT;PROPORTIONAL HAZARDS MODEL;PREGNANCY;MYOCARDIAL INFARCTION;QUALITY OF LIFE (HEALTHCARE)","258;159;85;84;73;73;68;67;50;49;38;38;34;34;33;32;30;30;29;28;28","BREAST CANCER;IMMUNOTHERAPY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);HAZARD RATIO;COLORECTAL CANCER;PROSTATE CANCER;CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;MULTICENTER STUDY;GENE EXPRESSION;PHENOTYPE;PARKINSON'S DISEASE;DEMENTIA;PLACEBO;TOLERABILITY;MICRORNA;BLADDER CANCER;LIVER TRANSPLANTATION;PROSTATE;CYCLOPHOSPHAMIDE;GROWTH HORMONE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;KIDNEY TRANSPLANTATION;METASTASIS;PROGRESSION-FREE SURVIVAL;REFLUX;TYPE 2 DIABETES;VIRAL LOAD","93;45;36;34;31;29;27;17;17;15;14;13;12;12;12;11;10;10;10;9;9;9;9;9;9;9;9;9","CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;METASTATIC BREAST CANCER;PROSTATECTOMY;PEMBROLIZUMAB;ACROMEGALY;ANTIRETROVIRAL THERAPY;HORMONE RECEPTOR;SYSTEMIC THERAPY;ANDROGEN DEPRIVATION THERAPY;DNA METHYLATION;ENDOVASCULAR ANEURYSM REPAIR;FERTILITY PRESERVATION;MAMMOGRAPHY;TRIPLE-NEGATIVE BREAST CANCER;CEREBRAL AUTOREGULATION;DEMENTIA WITH LEWY BODIES;DNA MISMATCH REPAIR;GERD;HEMATOPOIETIC CELL;IPILIMUMAB;KRAS;MICROVESICLES;REM SLEEP BEHAVIOR DISORDER;SECUKINUMAB;TRASTUZUMAB;USTEKINUMAB","36;22;16;12;11;8;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5",";HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;RETROSPECTIVE STUDIES;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;PROSPECTIVE STUDIES;YOUNG ADULT;ANIMALS;QUALITY OF LIFE;ADOLESCENT;BREAST NEOPLASMS;CHILD;PROGNOSIS;RISK FACTORS","656;460;248;217;195;170;166;105;97;64;56;43;40;39;28;26;26;26;25;25","ADVANCEMENTS IN PROSTATE CANCER RESEARCH;RENAL CELL CARCINOMA;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;CANCER IMMUNOTHERAPY;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;PROSTATE CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ASTHMA;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GLIOMAS;MANAGEMENT OF VALVULAR HEART DISEASE;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS","17;17;16;16;15;14;14;12;11;11;11;10;10;10;10;10;9;9;9;9","TREATMENT;BREAST CANCER;CLINICAL ENDPOINT;STROKE (ENGINE);2019-20 CORONAVIRUS OUTBREAK;INTERQUARTILE RANGE;METASTATIC PROSTATE CANCER;PROSTATE CANCER;CARDIAC IMAGING;PSORIASIS;TOLERABILITY;DELPHI METHOD;DIAGNOSIS;METASTATIC BREAST CANCER;PREGNANCY;ASTHMA;CANCER SUSCEPTIBILITY;INFARCTION TREATMENT;METASTATIC COLORECTAL CANCER;PANDEMIC","44;34;26;20;18;18;17;17;16;13;13;12;12;11;11;10;10;10;10;10","BREAST CANCER;COHORT STUDY;PROSTATE CANCER;MULTIPLE SCLEROSIS;CANCER PATIENTS;RETROSPECTIVE STUDY;COLORECTAL CANCER;CELL CARCINOMA;JOURNAL SCAN;WEEKLY JOURNAL;CRITICALLY ILL;PATIENTS TREATED;LUNG CANCER;SYSTEMIC SCLEROSIS;HEART FAILURE;ILL PATIENTS;METASTATIC BREAST;RENAL CELL;EUROPEAN SOCIETY;MEET-URO STUDY;OBSERVATIONAL STUDY;ABSTRACT PO--;CLINICAL OUTCOMES;ITALIAN SOCIETY;KIDNEY DISEASE;METASTATIC COLORECTAL;METASTATIC RENAL;MULTICENTER STUDY;NEOADJUVANT CHEMOTHERAPY;PROSPECTIVE STUDY","71;26;23;21;20;18;17;15;14;14;13;13;12;12;11;11;11;11;10;10;10;9;9;9;9;9;9;9;9;9","BREAST CANCER;HR CI;PATIENTS TREATED;CAMURUS AB;CLINICAL PRACTICE;BLOOD PRESSURE;RISK FACTORS;PATIENTS UNDERGOING;HEART FAILURE;GENETIC TESTING;CANCER PATIENTS;CROSSREF PUBMED;MEDIAN AGE;PUBMED SCOPUS;ADVERSE EVENTS;CLINICAL TRIALS;CONFIDENCE INTERVAL;INCREASED RISK;INTENSIVE CARE;CLINICAL OUTCOMES;RETROSPECTIVE STUDY;ALL-CAUSE MORTALITY;GENETIC COUNSELING;MULTIVARIATE ANALYSIS;COHORT STUDY;KIDNEY DISEASE;MEDIAN FOLLOW-UP;HAZARD RATIO;INCLUDED PATIENTS;LUNG CANCER","76;66;53;51;47;42;41;39;38;35;34;32;32;32;30;28;28;27;27;26;26;25;25;24;23;23;23;22;22;22",13,0.01,9.65,17,0,0,0,1,0,0,0,17,1,0,17,0,0,1,7,11,3,0,0,3,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,"ZENODO;AMERICAN ASSOCIATION FOR CANCER RESEARCH;FRONTIERS","2;1;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY","4;4;2;2;1","CANCER;LUNG;LUNG CANCER","1;1;1","CANCER;NEUROLOGICAL","2;2","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1","BIOMEDICAL;CLINICAL","1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","3;1","BREAST CANCER;LUNG CANCER","1;1",NA,NA
